‹Æ�шꗗ

2026”N‹Æ�Ñ
�y‰¢•¶Œ´’˜�z
Nakanishi H, Ogino H, Murakami K, Ogura Y, Tamiya H, Kajimoto T, Morita Y, Mitsuhashi A, Ozaki R, Fukuya A, Kagawa K, Hanibuchi M, Nishioka Y. Severe neutropenia and thrombocytopenia induced by tepotinib in a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation. Int Cancer Conf J, in press.

Mouri A, Kenmotsu H, Kagamu H, Azuma K, Saito R, Akamatsu H, Yonesaka K, Kakegawa M, Nagashima H, Takahashi S, Fujita M, Yanagitani N, Ninomiya K, Nishioka Y, Mori K, Kitano S, Tamada K, Yamamoto N, Gemma A, Mitsudomi T. Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC. Clin Cancer Res, in press.

Okuda R, Nishioka Y, Kondoh Y, Tsubouchi K, Okamoto M, Nishiyama O, Sato S, Keiji Oishi K, Ishikawa N, Chiba H, Miyazaki Y, Homma S, Ogura T, Inoue Y, Azuma A. Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical Trial. Am J Respir Crit Care Med 212(8):1770-1777, 2026.

Takeuchi E, Ogino H, Kondo K, Okano Y, Takahashi H, Nii K, Matsumura Y, Ishida T, Ichihara S, Kunishige M, Kadota N, Machida H, Hatakeyama N, Naruse K, Sato S, Nokihara H, Shinohara T, Nishioka Y. Tumor Necrosis on Routine Pretreatment CT as a Potential Prognostic Marker in Advanced NSCLC Treated With Immune Checkpoint Inhibitor Monotherapy: A Two-Center Retrospective Study. Thorac Cancer 17(14):e70363, 2026.

Minote K, Murakami K, Shinya T, Yoshimoto T, Mitsuhashi R, Otomi Y, Bando Y, Takizawa H, Nishioka Y, Harada M. A case of intrapulmonary schwannoma in a patient with rectal carcinoma: A case report and literature review. Radiol Case Rep 21(8):3025-3031, 2026.

Kayal Y, Farhoud M, Odeh M, Barash U, Naroditsky I, Bassal R, Nishioka Y, Sanderson RD, Ilan N, Vlodavsky I. Heparanase 2 (Hpa2) protects the exocrine pancreas from damages of Western diet and pancreatic cancer. Int J Biol Sci 22(10):4997-5014, 2026.

Gomez AC, Koyama K, Gamboa A, Guan X, Liu X, Parimon T, Jiang D, Liang J, Noble PW, Chen P, Stripp BR, Yao C. Cellular Heterogeneity of HTII-280-Labeled Epithelial Cells in Healthy and Fibrotic Human Lungs. Am J Respir Crit Care Med 212(3):651-654, 2026.

Ishida M, Yamada T, Katayama Y, Kawachi H, Sawada R, Nakamura R, Hirai S, Matsui Y, Morimoto K, Onoi K, Nakamura-Sasada A, Horinaka M, Sakai T, Sakakida T, Doi T, Yasumoto K, Goto Y, Furuya N, Taniguchi H, Ogino H, Takayuki N, Chihara Y, Fukuda K, Taniguchi H, Uehara H, Yano S, Tokuda S, Takayama K. AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ Precis Oncol 10(1):142, 2026.

Tsugitomi R, Takagi K, Saito G, Tachihara M, Ashinuma H, Shukuya T, Takemoto S, Sakata S, Mouri A, Miwa H, Tamura Y, Tokito T, Tsukita Y, Kogure Y, Masuda T, Tanaka H, Kubo S, Sasaki T, Oba T, Mamesaya N, Yamanaka T, Nagashima H, Tamiya M, Kanemura H, Tozuka T, Furuta M, Kawachi H, Ninomiya T, Nagai Y, Ogino H, Ito K, Ishihara M, Suzuki T. Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting. Lung Cancer 214:109309, 2026.

Yoshida A, Abe S, Izumi T, Itakura S, Yamada K, Wada T, Yamamoto T, Sato C, Mitsuhashi A, Ogino H, Sato S, Shinohara T, Hanibuchi M, Kaneko MK, Kato Y, Nishioka Y. Cancer-specific anti-human podoplanin antibody chLpMab-2f exerts antitumor effects against pleural mesothelioma. Cancer Sci 117(4):917-928, 2026.

Mouri A, Kagamu H, Tamada K, Nishio M, Akamatsu H, Goto Y, Hayashi H, Miura S, Gemma A, Yoshino I, Misumi T, Saito R, Yanagitani N, Masaki F, Nokihara H, Nishino K, Seike M, Hase T, Hataji O, Takeoka H, Kawashima Y, Kuroki H, Sugimoto M, Kuriki H, Mitsudomi T. Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab. Cancer Sci 117(4):904-916, 2026.

Tachibana S, Ogawa H, Ichimura-Shimizu M, Takayama T, Bando H, Sato S, Inoue K, Kurano M, Nishioka Y, Tsuneyama K. Lysophosphatidic acid (LPA)/LPA1 axis induces goblet cell hyperplasia via activation of pulmonary neuroendocrine cells in a chronic mouse model of asthma. Allergol Int 75(2):307-318, 2026.

Ikeda S, Ogura T, Misumi T, Nishioka Y, Hashimoto S, Ichikado K, Fukuizumi A, Takata S, Itoh T, Sato Y, Okishio K, Yatera K, Sakamoto N, Kato M, Kikuchi R, Honda T, Hashimoto N, Murakami K, Isshiki T, Yamane M, Karayama M, Miyamoto A, Ishida Y, Inomata M, Nishikiori H, Yamaguchi K, Amimoto H, Tamura K, Yanagihara T, Tanino Y, Koyama J, Tsurumaki N, Waseda Y, Kishaba T, Ozasa H, Matsumoto M, Kinoshita Y, Nakamura Y, Yamauchi H, Kishi K. Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan. Eur J Cancer 235:116232, 2026.

Fukuya A, Sakaguchi S, Hanibuchi M, Kusunose K, Kadota M, Murakami K, Sato S, Yagi K, Sata M, Nishioka Y. Evaluation of the Performance of a Demand Oxygen Delivery System with a Built-in Reservoir. Respir Care 71(2):176-182, 2026.

�yŠw‰ï”­•\-�‘�ÛŠw‰ï�A�‘�ÛƒVƒ“ƒ|ƒWƒEƒ€�z
Seidai Sato, Takushi Yamamoto, Yuki Morimoto, Hiroki Bando, Nguyen Cam Yen, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Takeshi Imakura, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. Mass spectrometry imaging of nintedanib and nerandomilast in normal and fibrotic mouse lungs and extrapulmonary organs. The ERS Congress 2026. Barcelona, Spain. 2026”N9ŒŽ8“ú.

Aito Yoshida, Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, Yasuhiko Nishioka. Regulation of Monocyte-to-Fibrocyte Differentiation in Lung Cancer. The ERS Congress 2026. Barcelona, Spain. 2026”N9ŒŽ8“ú.

Atsushi Mitsuhashi, Kazuya Koyama, Aito Yoshida, Yuki Tsukazaki, Hiroshi Kawano, Hirokazu Ogino, Yasuhiko Nishioka. Tumor extracellular matrix profiling identifies predictive biomarkers and novel therapeutic targets to overcome immune exclusion in lung carcinoma. The ERS Congress 2026. Barcelona, Spain. 2026”N9ŒŽ7“ú.

Claudia Valenzuela, Marlies S. Wijsenbeek, Ayodeji Adegunsoye, Min Cao, Man Pyo Chung, Yasuhiko Nishioka, Markus Polke, Hui Gu, Kamila Sroka-Saidi, Gerrit Weimann. Effect of nerandomilast in patients with pulmonary fibrosis by forced vital capacity (FVC) at baseline: pooled data from the FIBRONEER trials. The ERS Congress 2026. Barcelona, Spain. 2026”N9ŒŽ7“ú.

Marlies S. Wijsenbeek, Jaclyn Smith, Ayodeji Adegunsoye, Luo Fengming, Steven D. Nathan, Yasuhiko Nishioka, Anna Podolanczuk, Christopher J. Ryerson, Ulrich Hirt, Mihaela Dumistracael, Ante Jelaska, Richard Vinisko, Nina Patel, Surinder S. Birring, Lorcan McGarvey, Philip Molyneaux. Late Breaking Abstract - Selective TRPA-1 antagonist in patients with chronic cough and idiopathic pulmonary fibrosis: A phase IIa/IIb randomized, double-blind, placebo-controlled study (BI 1839100). The ERS Congress 2026. Barcelona, Spain. 2026”N9ŒŽ7“ú.

Kazuya Koyama, Alicia Gambola, Hadis Najibi, Changfu Yao, Barry Stripp. AT2 Cell Senescence Increases Susceptibility to ARDS-Like Injury in a Sin3a-Deficient Mouse Model. The ERS Congress 2026. Barcelona, Spain. 2026”N9ŒŽ6“ú.

Aito Yoshida, Atsushi Mitsuhashi, Hirokazu Ogino, Yasuhiko Nishioka. Cancer therapeutic strategy targeting the master regulator of monocyte-to-fibrocyte differentiation. 12th Joint Meeting on Immunology, Seoul National University, KAIST, Gifu University and Tokushima University. Tokushima. 2026”N7ŒŽ23“ú.

�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. ”x�üˆÛ�ǂɑ΂·‚é�R�üˆÛ‰»–òŠJ”­�Fƒgƒ‰ƒ“ƒXƒŒ�[ƒVƒ‡ƒiƒ‹ƒŠƒT�[ƒ`‚©‚瓾‚½Šw‚т𖢗ˆ‚É. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï(‰ï’·�u‰‰). “Œ‹ž. 2026”N9ŒŽ19“ú.

�²“¡�³‘å. ”x�üˆÛ�ǂ̕a‘Ô‘½—l�«‚©‚ç�l‚¦‚é�R�üˆÛ‰»–ò‚Ì�ì—p‹@�˜‚ÆŽ¡—Ã�í—ª. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï(ƒR�[ƒq�[ƒuƒŒƒCƒNƒZƒ~ƒi�[). “Œ‹ž. 2026”N9ŒŽ19“ú.

‰¬–ì�L˜a.�@‚ª‚ñŽ¡—Ã‚ðŽ©•ª‚炵‚­‘I‚Ô‚½‚ß‚É�`‹¤“¯ˆÓŽvŒˆ’è�iSDM�j‚ð’m‚Á‚Ä‚­‚¾‚³‚¢�`. “¿“‡Œ§–¯‚ª‚ñƒtƒH�[ƒ‰ƒ€. “¿“‡. 2026”N9ŒŽ6“ú.

�¼‰ªˆÀ•F. �i•à‚·‚éŠÔŽ¿�«”x‰Š�f—Ã�`�R�üˆÛ‰»–ò‚̃Gƒrƒfƒ“ƒX‚Æ�V‚½‚È“WŠJ�`. ƒ�ƒfƒBƒJƒ‹ƒm�[ƒg�~“ú–{ŒÄ‹zŠíŠw‰ï ˜AŒgƒEƒFƒrƒi�[ ‘æ3‰ñ ŒÄ‹zŠí޾г‚ð’m‚낤�I Web. 2026”N8ŒŽ25“ú.

�¼‰ªˆÀ•F. ŒÄ‹zŠí޾г‚ɑ΂·‚é�R�üˆÛ‰»–òŠJ”­‚̃gƒ‰ƒ“ƒXƒŒ�[ƒVƒ‡ƒiƒ‹ƒŠƒT�[ƒ`. ‘æ42‰ñ“ú–{DDSŠw‰ïŠw�p�W‰ï(“Á•Ê�u‰‰). “¿“‡. 2026”N7ŒŽ31“ú.

‹g“c•É�l, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ƒAƒKƒ‹ƒUƒ“ƒ_ƒ“ ƒoƒ„ƒ‹ƒ}�[, ’Ë�è—C‹M, �X“c—D, Š�–{’B–ç, �¼–{—˜‰ÁŽq, �û•£�¹‹B, �¼‰ªˆÀ•F. Žîᇓà fibrocyte ‚Ì•ª‰»�§Œä‹@�\‚̉𖾂Æ�üˆÛ‰»—}�§‚ð‰î‚µ‚½�V‹K–Ɖu—Ö@‰ž—p‚ÌŒŸ“¢. ‘æ35‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). ŽRŒ`. 2026”N7ŒŽ31“ú.

ŽO‹´“ÕŽu, �¬ŽRˆë–ç, ‹g“c•É�l, ‰¬–ì�L˜a, ’Ë�è—C‹M, �X“c—D, Š�–{’B–ç, �û•£�¹‹B, �¼‰ªˆÀ•F. ‚ª‚ñŠÔŽ¿‚É‚¨‚¯‚éƒ}ƒgƒŠƒ\�[ƒ€“]Š·‹@�˜‚Ì“¯’è‚Æ‚ª‚ñ–Ɖu”r�œ�Ž•ž‚Ö‚ÌŽ¡—Éž—p. ‘æ35‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). ŽRŒ`. 2026”N7ŒŽ30“ú.

�²“¡�³‘å. ŽÀ‘H�I‚т܂ñ�«”x޾г‚ÌMDD �Ç—á1. ‘æ74‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï(‰ï’·Šé‰æ). �L“‡. 2026”N7ŒŽ19“ú.

�¼‰ªˆÀ•F. “ú–{ŒÄ‹zŠíŠw‰ï‚ÌŠˆ“®‚ƌċzŠíŠO‰ÈƒTƒ}�[ƒXƒN�[ƒ‹‚Ö‚ÌŽx‰‡. “ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ï ‘æ14‰ñŒÄ‹zŠíŠO‰ÈƒTƒ}�[ƒXƒN�[ƒ‹(“Á•Ê�u‰‰). “Œ‹ž. 2026”N7ŒŽ12“ú.

ŽO‹´“ÕŽu, ‹g“c•É�l, ’Ë�è—C‹M, ‰¬–ì�L˜a, �¼‰ªˆÀ•F. Žîᇃ}ƒgƒŠƒ\�[ƒ€‰ð�͂ɂæ‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‘Ï�«ˆöŽq‚Ì“¯’è‚Æ�Ž•ž‚ÉŒü‚¯‚½Ž¡—Ã’T�õ. ‘æ30‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv�j. �L“‡. 2026”N7ŒŽ1“ú.

�²“¡�³‘å, ŽR–{‘ìŽu, �X–{—FŽ÷, �Ⓦ�OŠî, �¼‰ªˆÀ•F. Ž¿—Ê•ª�̓Cƒ��[ƒWƒ“ƒO‚ð—p‚¢‚½ƒjƒ“ƒeƒ_ƒjƒu‚ƃlƒ‰ƒ“ƒhƒ~ƒ‰ƒXƒg‚Ì‘ŸŠí•Ê‹Ç�Ý•ª•z‚Ƒؗ¯ŽžŠÔ‚ÌŒŸ“¢. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). �_ŒË. 2026”N4ŒŽ19“ú.

‹g“c•É�l, ŽO‹´“ÕŽu, ’Ë�è—C‹M, �X“c—D, Š�–{’B–ç, �¼–{—˜‰ÁŽq, ‰¬–ì�L˜a, �û•£�¹‹B, �¼‰ªˆÀ•F. Žîᇓàfibrocyte‚̃}ƒXƒ^�[ƒŒƒMƒ…ƒŒ�[ƒ^�[’T�õ‚Æ�V‹K–Ɖu—Ö@Šm—§‚ÉŒü‚¯‚½ŒŸ“¢. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). �_ŒË. 2026”N4ŒŽ19“ú.

’r“cŒd, �¬‘qûüŽu, ŽOŠp�r—T, �¼‰ªˆÀ•F, ‹´–{�¬�C, ˆê–å˜a�Æ, •Ÿ�ò�Ê, �‚“c�²�D, ˆÉ“¡‘ñ, �²“¡—I�é, ‰«‰–‹¦ˆê, –˜a”Ž, �â–{Œ›•ä, ‰Á“¡Œ³�N, ‹e’r—º‘¾, –{‘½—²�s, ‹´–{’¼�ƒ, ‹e’r�’Žj, ŠÝˆê”n. ŠÔŽ¿�«”x‰Š�‡•¹”ñ�¬�×–E”xŠàгŽÒ‚É‚¨‚¯‚éˆâ“`ŽqŒŸ�¸‚Æ•W“IŽ¡—ÂɊւ·‚é‘S�‘Œ¤‹†. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). �_ŒË. 2026”N4ŒŽ19“ú.

‰¬–ì�L˜a. ƒ^ƒ‹ƒ‰ƒ^ƒ}ƒu‚ª‚à‚½‚ç‚·Œø‰Ê‚Æ—LŠQŽ–�ۂ̃�ƒJƒjƒYƒ€‚ɂ‚¢‚Ä. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[). �_ŒË. 2026”N4ŒŽ19“ú.

�¼‰ªˆÀ•F, –k‘º‰p–ç, ‰ªŒ³�¹Ž÷, ’Ø“à˜a�Æ, �¼ŽR—�, •xˆäŒ[‰î, �â–{�W, �{“c—²•¶, ‹ß“¡�N”Ž, �¬‘qûüŽu, ŒK–¼�³—², “c’†—Ç�Æ, Klaus B Rohr, Œá�ȈÀ—Ç‘¾. “Á”­�«”x�üˆÛ�ǂɂ¨‚¯‚鑿III‘ŠFIBRONEER-IPFŽŽŒ±‹y‚Ñ�i�s�«”x�üˆÛ�ǂɂ¨‚¯‚鑿III‘ŠFIBRONEER-ILDŽŽŒ±‚Ì“ú–{�l�W’c•¹�‡‰ð�Í. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). �_ŒË. 2026”N4ŒŽ18“ú.

‹ß“¡�N”Ž, –k‘º‰p–ç, •ЉªŒ’‰î, ûü–ì’qŽk, �à‘OŒ\�W, ‰Á“¡Œ³�N, ‰ªŒ³�¹Ž÷, ŒK–¼�³—², �¬‘qûüŽu, �¼‰ªˆÀ•F, “c’†—Ç�Æ, Klaus B Rohr, Œá�ȈÀ—Ç‘¾. “ú–{�l�i�s�«”x�üˆÛ�Ç�iPPF�jгŽÒ‚ł̃lƒ‰ƒ“ƒhƒ~ƒ‰ƒXƒg‚Ì—LŒø�«‹y‚шÀ‘S�«�F‘æIII‘ŠFIBRONEER-ILDŽŽŒ±ƒTƒuƒOƒ‹�[ƒv‰ð�Í. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). �_ŒË. 2026”N4ŒŽ18“ú.

�¬‘qûüŽu, ‰ªŒ³�¹Ž÷, –k‘º‰p–ç, ’Ø“à˜a�Æ, �{“c—²•¶, �¼ŽR—�, •xˆäŒ[‰î, �â–{�W, ‹ß“¡�N”Ž, �¼‰ªˆÀ•F, Klaus B Rohr, Œá�ȈÀ—Ç‘¾. “ú–{�l“Á”­�«”x�üˆÛ�Ç�iIPF�jгŽÒ‚É‚¨‚¯‚éƒlƒ‰ƒ“ƒhƒ~ƒ‰ƒXƒg‚Ì—LŒø�«‹y‚шÀ‘S�«�F‘æIII‘ŠFIBRONEER- IPFŽŽŒ±ƒTƒuƒOƒ‹�[ƒv‰ð�Í. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). �_ŒË. 2026”N4ŒŽ18“ú.

‰¬–ì�L˜a, �¼–{—˜‰ÁŽq, �ª–{�ô‹v, ’|“à‰hŽ¡, ’JŒûа˜a, ‹g‘º�²�h, Žë–ì—F‰Ô—¢, �XŒËãÄŠî, �¼‰ª’¼�Æ, –L“c—DŽq, ŽR–{�_�¶, Ž›àV�‰, �¼‰ªˆÀ•F. �‚—î�i“WŒ^�¬�×–E”xŠàгŽÒ‚ɑ΂·‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò•¹—pŒø‰Ê‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). �_ŒË. 2026”N4ŒŽ18“ú.

�X“c—D. ”x‚ª‚ñ‚ɑ΂·‚é�Å�V‚̖Ɖu—Ö@�D“¿“‡‘åŠw•a‰@‚ª‚ñ�f—ØAŒgƒZƒ“ƒ^�[ƒtƒH�[ƒ‰ƒ€(Žs–¯�u�À). “¿“‡. 2026”N2ŒŽ11“ú.

‰¬–ì�L˜a. –Ɖu‚͂ǂ̂悤‚É‚µ‚Ä‚ª‚ñ‚ð“|‚·‚Ì‚©�`‚ª‚ñ–Ɖu—Ö@‚ªŒø‚­Žd‘g‚Ý�`. “¿“‡‘åŠw•a‰@‚ª‚ñ�f—ØAŒgƒZƒ“ƒ^�[ƒtƒH�[ƒ‰ƒ€(Žs–¯�u�À). “¿“‡. 2026”N2ŒŽ11“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
Atsushi Mitsuhashi, Aito Yoshida, Kazuya Koyama, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka. Identification of Fibrocyte Surface Antigen for AntibodyBased Therapies to Overcome Cancer Immune Exclusion. ‘æ85‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‹ž“s. 2026”N9ŒŽ2“ú.

‹g“c•É�l, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ƒAƒKƒ‹ƒUƒ“ƒ_ƒ“ ƒoƒ„ƒ‹ƒ}�[, ’Ë�è—C‹M, �X“c—D, Š�–{’B–ç, �¼–{—˜‰ÁŽq, �û•£�¹‹B, �¼‰ªˆÀ•F. ’P‹…‚©‚ç fibrocyte •ª‰»‚ðŽi‚éƒ}ƒXƒ^�[ƒŒƒMƒ…ƒŒ�[ƒ^�[‚ð•W“I‚Æ‚µ‚½”x‚ª‚ñŽ¡—Ã�í—ª. ‘æ85‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‹ž“s. 2026”N9ŒŽ24“ú.

“yŽtŒbŽq, �²“¡�³‘å, �¬�씎‹v, ‘º�ã�s�l, ŽR‰º—Y–ç, �¬ŽRˆë–ç, ‰Í–ì�O, ŽsŒ´�¹–ç, ˆé‘º—S‘¾, ˆÀ‘î�Ž”Ž, Œ´“cŽÑŠó, �¡‘qŒ’, �”�¯�r˜Y, �¼‰ªˆÀ•F. ƒI�[ƒgƒ^ƒLƒVƒ“‘jŠQ�ì—p‚ð—L‚·‚é2ccPA‚Ì”x�üˆÛ�ǂɂ¨‚¯‚é�R�üˆÛ‰»�ì—p‚ÌŒŸ“¢. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ20“ú.

‘º�ã�s�l, �²“¡�³‘å, �¬�씎‹v, ŽsŒ´�¹–ç, ˆÀ‘î�Ž”Ž, Œ´“cŽÑŠó, Yen Nguyen Cam, ˆé‘º—S‘¾, Phuong Trang Thi Hong, Danzan Nandin-Erdene, ŽR‰º—Y–ç, �Ⓦ�OŠî, “yŽtŒbŽq, “à“¡�L�m, ‰Í–ì�O, Œ´�’, ˆî‘º“T�º, ˜@Œ©œ¨Ži, �¼‰ªˆÀ•F. �V‹K‰Â—n�«ƒGƒ|ƒLƒVƒqƒhƒ�ƒ‰�[ƒ[‘jŠQ�ÜSMTP-44D‚Ì�R�üˆÛ‰»�ì—p‚ÌŒŸ“¢. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ20“ú.

“à“¡�L�m, ‰Í–ì�O, ŽsŒ´�¹–ç, ˆé‘º—S‘¾, ˆÀ‘î�Ž”Ž, Œ´“cŽÑŠó, �¡‘qŒ’, ‘º�ã�s�l, ŽR‰º—Y–ç, �Ⓦ�OŠî, “yŽtŒbŽq, �²“¡�³‘å, �¡�d”V, �¼‰ªˆÀ•F. Fibrocyte‚¨‚æ‚Ñ�üˆÛ‰è�×–E‚É‚¨‚¯‚éƒCƒ“ƒeƒOƒŠƒ“ƒVƒOƒiƒ‹�§Œä‚É‚æ‚é�R�üˆÛ‰»Œø‰Ê. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ20“ú.

ŽsŒ´�¹–ç, •�ˆä—æ�¶�m, ”“Œ’m�G, ”‹–{‘�, •x‹MŒ´�~, �ù–쌳, ŽR–ì‘וF, �²“¡�³‘å, •ЉªŒ’‰î, –Ø‘º’qŽ÷, �¼‰ªˆÀ•F, ‹ß“¡�N”Ž. ”x‹@”\‚̕ۂ½‚ꂽŠÔŽ¿�«”x޾г‚ÌŽ¾Š³�i�s‚ÆKL-6‚¨‚æ‚ÑSP-D‚Ƃ̊֘A. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ20“ú.

–öŒ´–LŽj, ‰ªŒ³�¹Ž÷, –؉º‹`�W, �²“¡�³‘å, �¼‰ªˆÀ•F, ûM“c’¼Ž÷, “¡“c�¹Ž÷. PPFE‚Ì’e�«�üˆÛ’¾’…‚ÉŠÖ‚í‚鉊�Ç”½‰ž�«�üˆÛ‰è�×–Eƒjƒbƒ`‚Ì“¯’è. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ20“ú.

–؉º‹`�W, –öŒ´–LŽj, ‰ªŒ³�¹Ž÷, �²“¡�³‘å, ûM“c’¼Ž÷, �¼‰ªˆÀ•F, �Έ䊰, “¡“c�¹Ž÷. PPFE‚Ì•a•Ï‹«ŠE‚ÉŒ`�¬‚³‚ê‚é�ã”ç?ŠÔŽ¿ƒŠƒ‚ƒfƒŠƒ“ƒO�\‘¢‚Ì‹óŠÔ“I‰ð�Í. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ20“ú.

�‚ŒF�«ˆê˜N, Ž›�è‘×�O, Š�–{—Y‰î, ‰““c‰xŽq, Ž›�è”ü‰À, Œ÷“�‚µ‚Ì‚Ô, �Î�ìŒá—˜”ü, ŒKŒ´�®”ü, �H“cŒ[Žj, ”n�ê’q�®, •õ‰º�¹“¹, ‹v“c�„Žu, �¼‰ªˆÀ•F. ‚т܂ñ�«”x�œ‰»�Ç‚ÆCiOP‚̃�ƒJƒjƒYƒ€‚ÌŠÖ˜A‚ɂ‚¢‚Ä. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ19“ú.

�¬ŽRˆë–ç, Yao Changfu, Stripp Barry, �¼‰ªˆÀ•F. 2Œ^”x�ã”ç�×–E‚Ì�üˆÛ�«�×–E˜V‰»‚ÍDnase113’ቺ‚ÆNET’~�Ï‚ð‰î‚µ‚ÄLPS—U”­”x�áŠQ‚ð‘�ˆ«‚³‚¹‚é. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ19“ú.

ˆé‘º—S‘¾, �¼–{—˜‰ÁŽq, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. ”x�_Œo“à•ª”åŠà‚ɑ΂·‚éƒAƒ€ƒ‹ƒrƒVƒ“—Ö@‚É”º‚¤–ò�Ü�«”x�áŠQ”­�ÇƒŠƒXƒN‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ19“ú.

�¡‘qŒ’, •Ÿ‰Æ–ƒ”ü, �âŒû‹Å, �û•£�¹‹B, “í�£Œ«–ç, –å“c�@”V, ‘º�ã�s�l, �²“¡�³‘å, �²“c�­—², �¼‰ªˆÀ•F. ŠÔŽ¿�«”x޾ггŽÒ‚̘J�쎞’áŽ_‘fŒŒ�ǂɑ΂·‚郊ƒU�[ƒo�[ƒ^ƒ“ƒN“à‘ ŒÄ‹z“¯’²Ž®Ž_‘f‹Ÿ‹‹‘•’u‚Ì—L—p�«. ‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2026”N9ŒŽ19“ú.

‹g“c•É�l, ŽO‹´“ÕŽu, ’Ë�è—C‹M, ‰¬–ì�L˜a, �¼‰ªˆÀ•F. Žîᇓà fibrocyte ‚Ì•ª‰»ƒ�ƒJƒjƒYƒ€‰ð–¾‚Æ�V‹K–Ɖu—Ö@‰ž—p‚ÉŒü‚¯‚½ŒŸ“¢. ‘æ30‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �L“‡. 2026”N7ŒŽ1“ú.

ƒoƒgƒ€ƒ“ƒN ƒEƒ‹ƒWƒTƒCƒnƒ“, ‹gŠÛ“N˜Y, �¼‰º—m•ã, “àŽRŒ\Ži, �¼‰ªˆÀ•F, •Ћ˖L‰ë. ƒ~ƒgƒRƒ“ƒhƒŠƒA BIG3-PHB2 •¡�‡‘Ì‚ª TNBC ‚ð‹ì“®‚µ�A‚»‚±‚ð•W“I‚Æ‚µ‚½ƒyƒvƒ`ƒh‘n–ò stERAP ŠJ”­. ‘æ30‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �L“‡. 2026”N7ŒŽ1“ú.

‰Í–ì�O, ŽR‰º—Y–ç, “à“¡�L�m, �¡‘qŒ’, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. Alvocidib‚ÌCD80‚ð•W“I‚Æ‚µ‚½�RƒŠƒEƒ}ƒ`�ì—p‚ÌŒŸ“¢. ‘æ70‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. •Ÿ‰ª. 2026”N4ŒŽ24“ú.

‹g“c�„, ŽRú±”Ž‹P, �‚�¼’¼Žq, ˆä�ã�³—², ’JŒû‹`“T, –ì�葾Šó, Œö•¶‹`—Y, �¼Œ³—F�ô, Œ´“c‰ëŽj, ‰Í–ì�O, �¼‰ªˆÀ•F, �¼–ìˆêŽO, ˜a�ò—B�M, Jemima Albayda. �œŠi‹Ø’´‰¹”g‰æ‘œ‚̃eƒNƒXƒ`ƒƒ�[‰ð�͂ɂæ‚鋨‰Š�f’f‚Ì—L—p�«. ‘æ70‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. •Ÿ‰ª. 2026”N4ŒŽ23“ú.

’Ë�è—C‹M, ŽO‹´“ÕŽu, Š�–{’B–ç, �¼–{—˜‰ÁŽq, �X“c—D, ‹g“c•É�l, ‰¬–ì�L˜a, �û•£�¹‹B, �¼‰ªˆÀ•F. ”ñ�¬�×–E”xŠà‘g�D‚É‚¨‚¯‚éƒRƒ‰�[ƒQƒ“�\‘¢‚̖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŒø‰Ê—\‘ªˆöŽq‚Æ‚µ‚Ă̌Ÿ“¢. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2026”N4ŒŽ19“ú.

ˆä�ã�ƒ�l, “c“‡Š°”V, Œ´—I, ‹àŽq–Ò, �¼‰ªˆÀ•F, —é–Ø‘ñŽ™. —Õ�°ŒÄ‹z‹@”\�u�K‰ï�‰ŠúŒ¤�CˆãƒR�[ƒX‚͌ċzŠí“à‰Èˆã‘�‰Á‚ÉŠñ—^‚Å‚«‚é‚©. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2026”N4ŒŽ19“ú.

�¡‘qŒ’, �¬ŽRˆë–ç, �²“¡�³‘å, ˆé‘º—S‘¾, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, “yŽtŒbŽq, �Ⓦ�OŠî, ‰Í–ì�O, �¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`‚É‚¨‚¯‚錌�´ƒyƒ“ƒgƒ‰ƒLƒVƒ“2‚ÆŠÔŽ¿�«”x޾г�‡•¹‚ÌŠÖ˜A�F’PŽ{�ÝŒã•ûŽ‹“IŒŸ“¢. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2026”N4ŒŽ19“ú.

ŽO‹´“ÕŽu, �¬ŽRˆë–ç, ‹g“c•É�l, ’Ë�è—C‹M, �X“c—D, Š�–{’B–ç, �¼–{—˜‰ÁŽq, ‰¬–ì�L˜a, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹¹•”Žîᇂɂ¨‚¯‚é�×–EŠOŠîŽ¿�¬•ª‰ð�͂ɂæ‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‘Ï�«‹@�˜‚Ì’T�õ. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2026”N4ŒŽ19“ú.

“yŽtŒbŽq, �û•£�¹‹B, “à“¡�L�m, �Ⓦ�OŠî, ŽR‰º—Y–ç, �¡‘qŒ’, ‰Í–ì�O, �²“¡�³‘å, �¼‰ªˆÀ•F. “Á”­�«”x�üˆÛ�Ç�E�i�s�«�üˆÛ‰»‚𔺂¤ŠÔŽ¿�«”x޾г‚Ì‹}�«‘�ˆ«Œã‚É‚¨‚¯‚éƒjƒ“ƒeƒ_ƒjƒu‚É‚æ‚é�Ä‘�ˆ«—\–hŒø‰Ê‚Ì—\‘ªˆöŽq‚ÌŒŸ“¢. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2026”N4ŒŽ18“ú.

å×–Ø–FŽ÷, –Ø“‡‹MŽu, •�ˆä—æ�¶�m, ŽR–ì‘וF, ‹ß“¡�N”Ž, •ЉªŒ’‰î, –Ø‘º’qŽ÷, �¼‰ªˆÀ•F, �û•£�¹‹B, –k‰ª—TŽq. �R�üˆÛ‰»–ò“Š—^’†‚ÌIPFгŽÒ‚É‚¨‚¯‚éSVC‚ÆFVC‚ÌŒ¸�­—ʂ̌Ÿ“¢. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2026”N4ŒŽ18“ú.

Hirokazu Ogino, Rikako Matsumoto, Teruhisa Nemoto, Eiji Takeuchi, Hirokazu Taniguchi, Shunya Tanaka, Yukari Kano, Shoki Morito, Naoya Nishioka, Yuko Toyoda, Hitomi Kagawa, Midori Terazawa, Tatsuya Kajimoto, Yutaka Morita, Atsushi Mitsuhashi, Yuki Tsukazaki, Yasuhiko Nishioka. A multicenter retrospective study on the impact of immune checkpoint inhibitors on brain metastases in ES-SCLC. ‘æ23‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. ‰¡•l. 2026”N3ŒŽ27“ú.

Rikako Matsumoto, Hirokazu Ogino, Teruhisa Nemoto, Eiji Takeuchi, Hirokazu Taniguchi, Akihiro Yoshimura, Yukari Kano, Shoki Morito, Yuki Takahashi, Yuko Toyoda, Hiroki Yamamoto, Midori Terazawa, Tatsuya Kajimoto, Yutaka Morita, Atsushi Mitsuhashi, Yuki Tsukazaki1, Yasuhiko Nishioka. A multicenter retrospective study on the efficacy of chemoimmunotherapy for liver metastases in small cell lung cancer. ‘æ23‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. ‰¡•l. 2026”N3ŒŽ27“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
�²“¡�³‘å, Šì‘½‘åŽ÷, —é�]—ÁŽq, �X“c—D, ˆÀ‘î�Ž”Ž, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, ‰Í–ì�O, �¼‰ªˆÀ•F. ƒŠƒcƒLƒVƒ}ƒu•s‰žŒã‚ɃgƒVƒŠƒYƒ}ƒu‚ðŠÜ‚ÞŽ¡—ª‘tŒø‚µ‚½TAFRO�ÇŒóŒQ‚Ì1—á. ‘æ37‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. “‡�ª. 2026”N10ŒŽ4“ú.

‰Í–ì�O, ˆÀ‘î�Ž”Ž, �¡‘qŒ’, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. ƒOƒ‹ƒRƒRƒ‹ƒ`ƒRƒCƒh”ñ“Š—^‰º‚ɃAƒjƒtƒ�ƒ‹ƒ}ƒu‚ð‘�Šú“±“ü‚µ‚½SLE‚Ì3—á. ‘æ37‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. “‡�ª. 2026”N10ŒŽ3“ú.

Œ´“cŽÑŠó, �X“c—D, “yŽtŒbŽq, ‰¬–ì�L˜a, �û•£�¹‹B, ’¹‰H”Ž–¾, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. Œ´“cŽÑŠó, �X“c—D, “yŽtŒbŽq, ‰¬–ì�L˜a, �û•£�¹‹B, ’¹‰H”Ž–¾, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. “–‰@‚ł̔xŠà�Ç—á‚ɑ΂·‚é•“I‚ª‚ñƒQƒmƒ€ƒvƒ�ƒtƒ@ƒCƒŠƒ“ƒOŒŸ�¸‚ÌŽg—pŽÀ�Ñ. ‘æ273‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2026”N7ŒŽ19“ú.

š �d“¹‘å, �X“c—D, Ž›àV�‰, —é�]—ÁŽq, ’Ë�è—C‹M, “yŽtŒbŽq, “à“¡�L“ñ, •Ÿ‰Æ–ƒ”ü, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒIƒVƒ�ƒ‹ƒ`ƒjƒu‚É‚æ‚èŽîá‡�k�¬Œø‰Ê‚ª“¾‚ç‚ꂽEGFRˆâ“`Žq•ψٗz�«”x�G•½�ã”çŠà‚Ì2—á. ‘æ64‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �L“‡. 2026”N7ŒŽ19“ú.

ŽsŒ´�¹–ç, �X“c—D, ’|Œ´Œb”ü, ŽR‰º—Y–ç, “¡–{Œ[‰î, “yŽtŒbŽq, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, ’¹‰H”Ž, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. ƒVƒF�[ƒOƒŒƒ“•a‚É�‡•¹‚µ‚½‹¹‘BŒ´”­MALT ƒŠƒ“ƒpŽî‚Ì2—á. ‘æ74‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �L“‡. 2026”N7ŒŽ19“ú.

–{“c‚³‚­‚ç, �X“c—D, —é�]—ÁŽq, “yŽtŒbŽq, •Ÿ‰Æ–ƒ”ü, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒyƒ€ƒuƒ�ƒŠƒYƒ}ƒu•s‰žŒã‚Ƀ^ƒ‹ƒ‰ƒ^ƒ}ƒu‚ª’˜Œø‚µ‚½�¬�×–E”xŠà‚Ì1—á. ‘æ74‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�^‘æ64‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �L“‡. 2026”N7ŒŽ18“ú.

ˆ¢•”‹»�¶, �X“c—D, Œ´“cŽÑŠó, “yŽtŒbŽq, •Ÿ‰Æ–ƒ”ü, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒXƒeƒ�ƒCƒh’ï�R�«–ƉuŠÖ˜A”x�áŠQ‚Ƀ~ƒRƒtƒFƒm�[ƒ‹Ž_ƒ‚ƒtƒFƒ`ƒ‹‚ª—LŒø‚Å‚ ‚Á‚½1—á. ‘æ74‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �L“‡. 2026”N7ŒŽ18“ú.

‹ß“¡Œ\‘å, ŽR‰º—Y–ç, “yŽtŒbŽq, ’†“à—F�‡�], •Ÿ‰Æ–ƒ”ü, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒgƒVƒŠƒYƒ}ƒu“Š—^’†‚ÉŒŒ‹…æÃ�H�ÇŒóŒQ‚ð”­�Ç‚µ‚½ŠÖ�ßƒŠƒEƒ}ƒ`‚Ì1—á. ‘æ134‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2026”N6ŒŽ7“ú.

�X“c—D, ŽR‰º—Y–ç, “¡–{Œ[‰î, •Ÿ‰Æ–ƒ”ü, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, ’¹‰H”Ž–¾, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. ”xŒ´”­ŠÌ—l‘BŠà‚Ì1—á. ‘æ134‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2026”N6ŒŽ7“ú.

š �d“¹‘å, •Ÿ‰Æ–ƒ”ü, �âŒû‹Å, ŽR‰º—Y–ç, “yŽtŒbŽq, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒŠƒU�[ƒo�[ƒ^ƒ“ƒN“à‘ Ž_‘f‹Ÿ‹‹ƒVƒXƒeƒ€‚Ì�«”\•]‰¿. ‘æ272‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2026”N3ŒŽ8“ú.
2025”N‹Æ�Ñ
�y‰¢•¶‘��à�z
Mitsuhashi A, Nishioka Y. Fibrocytes in tumor microenvironment:Identification of their fraction and novel therapeutic strategy. Cancer Sci 116(1):21-28, 2025.
�y‰¢•¶Œ´’˜�z
Bando N, Ogino H, Murakami K, Wadatsu M, Tsukazaki Y, Yabuki Y, Kajimoto T, Matsumoto R, Harada S, Morita Y, Ozaki R, Mitsuhashi A, Sato S, Sakaguchi S, Hanibuchi M, Nishioka Y. A Case of Thymic Carcinoma Harboring an FGFR3 S249C Mutation with Durable Disease Control on Lenvatinib. Int Cancer Conf J 15(1):160-165, 2025.

Iwama E, Sakai K, Harada T, Kanda S, Sugawara S, Yokoyama T, Taniguchi H, Tanaka K, Toyozawa R, Koyama K, Zenke Y, Kida G, Nishioka Y, Yokouchi H, Hirose M, Nishio K, Yamamoto N, Ohe Y, Okamoto I. Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations. Lung Cancer 208:108756, 2025.

Zenke Y, Shiraishi Y, Goto Y, Azuma K, Okishio K, Ogino H, Horio Y, Oizumi S, Hayama M, Nii M, Harada M, Mann H, Olivo YS, Jiang H, Senan S. Durvalumab post concurrent chemoradiotherapy in Japanese patients with limited-stage small-cell lung cancer in the phase 3 ADRIATIC trial. Cancer Sci 116(11):3171-3184, 2025.

Mitsuhashi A, Koyama K, Ogino H, Matsuo R, Nguyen NT, Yabuki Y, Ozaki R, Tsukazaki Y, Morita Y, Yoshida A, Murakami K, Sato S, Kawano H, Nokihara H, Inagaki Y, Shinohara T, Hanibuchi M, Takizawa H, Nishioka Y. Clock pathway inhibitor overcomes tumor immune-exclusion via regulation of fibrocyte differentiation. NPJ Precis Oncol 9(1):274, 2025.

Nakanishi K, Ogino H, Murakami K, Saijo Y, Naito N, Matsumoto R, Morita Y, Tsukazaki Y, Ozaki R, Yabuki Y, Bando N, Mitsuhashi A, Sato S, Hanibuchi M, Nishioka Y. A favorable anti-tumor efficacy of sotorasib in a patient with KRAS G12C-mutated pulmonary large-cell neuroendocrine carcinoma. Int Cancer Conf J 14(4):374-380, 2025.

Takagi K, Saito G, Tanaka H, Kubo S, Shukuya T, Tsugitomi R, Sasaki T, Oba T, Mamesaya N, Yamanaka T, Tachihara M, Gyotoku H, Nagashima H, Tamiya M, Kanemura H, Tozuka T, Furuta M, Sakata S, Mouri A, Miwa H, Kawachi H, Ninomiya T, Nagai Y, Ogino H, Ito K, Tamura Y, Tokito T, Ishihara M, Ashinuma H, Tsukita Y, Kogure Y, Masuda T, Suzuki T. Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings. ESMO Open 10(6):105301, 2025.

Nishimura H, Kawano H, Sato S, Imakura T, Yamashita Y, Murakami K, Haji K, Bando H, Naito N, Kagawa K,Isomura Y, Koyama K,Ogawa H, Nishimura Y, Nishioka Y. Analysis of the anti-fibrotic potential of a JAK inhibitor in a bleomycin-induced pulmonary fibrosis model. J Med Invest 72(3,4):298-307, 2025.

Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H. Glioma-neuronal circuit remodeling induces regional immunosuppression. Nat Commun 16:4770, 2025.

Yagi I, Yagi S, Nakanishi K, Tezuka K, Matsuyama K, Aibara Y, Ishida T, Yoneda H, Yamamoto M, Ise T, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Kitagawa T, Nishioka Y, Sata M. Critical Limb Threatening Ischemia Due to Severe Polyarteritis Nodosa. Intern Med 64(9):1355-1358, 2025.

Yabuki Y, Mitsuhashi A, Ogino H, Yoshida A, Nguyen TN, Yoneda H, Ozaki R, Tsukazaki Y, Morita Y, Nokihara H, Sato S, Shinohara T, Hanibuchi M, Nishioka Y. Hypoxia inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-ƒÁ-induced chemokines in tumor cells. Int J Cancer 156(9):1814-1825, 2025.

Terasaki Y, Nishioka Y, Kajimoto Y, Toyoda Y, Hebisawa A, Johkoh T, Egashira R, Hisada T, Mineshita M, Baba T, Fujikura Y, Kato M, Ichikado K, Inoue Y, Izumi S, Hasegawa Y, Handa T, Hidaka K, Hisata S, Honjo C, Kishimoto T, Okamoto M, Yamasue M, Terasaki M, Suda T. Diffuse pulmonary ossification and its association with cicatricial organising pneumonia in idiopathic and secondary forms. Sci Rep 15(1):12442, 2025.

Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, Jung J, Okada K, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Liu J, Wu SH, Ramos E, Yamamichi A, Watchmaker PB, Ogino H, Saijo A, Du A, Grishanina NR, Woo J, Diaz A, Hervey-Jumper SL, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H. Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature 639(8054):463-473, 2025.

Okuda R, Ogura T, Hisata S, Baba T, Kondoh Y, Suda T, Johkoh T, Iwasawa T, Tomioka H, Bando M, Azuma A, Inoue Y, Ishikawa N, Arai N, Takihara T, Hamaguchi M, Arai T, Nakamura Y, Miyamoto A, Tomii K, Miyazaki Y, Chiba H, Ishii H, Hamada N, Terasaki Y, Fukuoka J, Sakai F, Egashira R,Fujimoto K, Sumikawa H, Suzuki T, Sakamoto S, Nishioka Y, Hattori N, Hashimoto N, Morita S, Ichihara N, Miyata H, Hagiwara K, Kobayashi K, Nukiwa T.JIPS registry collaborators. Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030). Respir Investig 63(3):365-372, 2025.

Sugasaki M, Nakamura S, Arai S, Teramoto K, Urushihara M, Inoue Y, Nakao T, Nishioka Y, Sata M. Congenital hypofibrinogenemia with a novel mutation BƒÀCys76Phe. J Med Invest 72(1,2):182-184, 2025.

Nii K, Ogino H, Bando H, Yamamoto Y, Fujita K, Yoneda H, Naito N, Mitsuhashi A, Morita Y, Tsukazaki Y, Yabuki Y, Ozaki R, Sato S, Hanibuchi M, Izumi Y, Nishioka Y. Immune checkpoint inhibitor-associated paraneoplastic cerebellar degeneration in a case of extensive-stage small-cell lung cancer with pre-existing anti-SOX1 antibody. J Med Invest 72(1,2):172-176, 2025.

Yamashita Y, Sato S, Nii K, Mori K, Haji K, Naito N, Ogino H, Kawawno H, Hanibuchi M, Endo I, Nishioka Y. Isolated Adrenocorticotropic Hormone Deficiency Presenting With Arthritis: A Case Report. Mod Rheumatol Case Rep 9(1):10-14,2025.
�y˜a•¶’˜�‘�z
�²“¡�³‘å, –L“c—DŽq, �¼‰ªˆÀ•F. “Á”­�«Ž÷Ž}�ó”x�œ‰»�ǂ̗Õ�°. ŒÄ‹zŠí޾г�Å�V‚ÌŽ¡—à 2025-2026, Œ·ŠÔ�º•F, �¼‰ªˆÀ•F, –˜a”Ž•Ò�W, pp53-56, 2025. “ì�]“°.
�y˜a•¶‘��à�z
‰Í–ì�O. Œ°”÷‹¾“I‘½”­ŒŒŠÇ‰Š‚Ì�f’fŽž‚ÉEBV‚Ì�ÄŠˆ�«‰»‚ð’æ‚µ�AƒŠƒcƒLƒVƒ}ƒu‚ɂĊ°‰ð“±“ü—Ö@‚ð�s‚Á‚½‚P—á. “¿“‡Œ§ˆãŽt‰ï•ñ 654(—ߘa7”N11ŒŽ�†):3-5, 2025.

�¼‰ªˆÀ•F. “¿“‡‘åŠwŒÄ‹zŠí�EäPŒ´•a“à‰ÈŠw•ª–ì‚̋ߋµ. ˆÉ—\˜H 55:8-9, 2025.

‰¬–ì�L˜a. •“IƒQƒmƒ€ƒvƒ�ƒtƒ@ƒCƒŠƒ“ƒO‚É‚æ‚è�f’f‚µ“¾‚½EGFR exon19Œ‡Ž¸•ψٗz�«”x‘B‚ª‚ñ‚̈ê—á. “¿“‡Œ§ˆãŽt‰ï•ñ 652:2-4, 2025.

�V‰Æ�’‹`, Œ´“c‰ëŽj, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. ‰æ‘œ�f’f“¹�ê�`ŽÀ‚Í‚±‚¤‚¾‚Á‚½. “ú–{ˆãŽ–�V•ñ 5287:1-2, 2025.

�û•£�¹‹B. ‚µ‚¢‚½‚¯�Í”|ŽÒ‚É”­�Ç‚µ‚½ƒAƒŒƒ‹ƒM�[�«‹CŠÇŽx”xƒAƒXƒyƒ‹ƒMƒ‹ƒX�Ç‚Ì1—á. “¿“‡Œ§ˆãŽt‰ï•ñ 650:2-5, 2025.

�Ⓦ�OŠî. ƒyƒvƒ`ƒhŽó—e‘Ì•úŽË�«ŠjŽí—Ö@‚ª‘tŒø‚µ‚½�¶‰º—tŒ´”­�i�sŠú”ñ’èŒ^ƒJƒ‹ƒ`ƒmƒCƒh‚Ì1—á. “¿“‡Œ§ˆãŽt‰ï•ñ 648:2-4, 2025.

���ì�k‘¢. ƒXƒeƒ�ƒCƒhƒpƒ‹ƒX—Ö@Œã‚É‘�ˆ«‚µ�A“ñ“x–ڂ̃pƒ‹ƒX—Ö@‚ª‘tŒø‚µ‚½COVID-19”x‰Š‚Ì‚P—á. “¿“‡Œ§ˆãŽt‰ï•ñ 646:2-4, 2025.

�²“¡�³‘å. ”ñŒ‹Šj�«�RŽ_‹Û�ǂƂ̊ӕʂð—v‚µ‚½�¬�lT�×–E”’ŒŒ•aƒŠƒ“ƒpŽî‚Ì1—á. “¿“‡Œ§ˆãŽt‰ï•ñ 644:7-9, 2025.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Yasuhiko Nishioka. Therapeutic Advances in IPF/PPF. The 29th Congress of the Asian Pacific Society of Respirology (APSR 2025)�iScientific Session�j. Manila, Philippines. 2025”N11ŒŽ11“ú.

Keiko Haji, Seidai Sato, Hirohisa Ogawa, Yuta Isomura, Noriko Bando, Ryoko Suzue, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Yuya Yamashita, Kojin Murakami, Hiroki Bando, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, Katsutoshi Kobayashi, Toshiro Morohoshi, Yasuhiko Nishioka. The novel autotaxin inhibitor, 2-carba cyclic phosphatidic acid, ameliorates bleomycin-induced lung fibrosis in mice. The ERS Congress 2025. Amsterdam, Netherlands. 2025”N9ŒŽ30“ú.

Nandin-Erdene Danzan, Hiroshi Kawano, Yuya Yamashita, Kojin Murakami, Nobuhito Naito, Keiko Haji, Hiroki Bando,Trang Thi Hong Phuong, Agarzandan Bayarmaa, Seidai Sato, Yasuhiko Nishioka. The Development of a Novel Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs (tsDMARDS) Targeted for CD80. The 27th Asia-Pacific League of Associations for Rheumatology Congress (APLAR 2025). Fukuoka, Japan. 2025”N9ŒŽ6“ú.

Yuya Yamashita, Hiroshi Kawano, Noriko Bando, Ryoko Suzue, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Keiko Haji, Hiroki Bando, Nobuhito Naito, Seidai Sato, Yasuhiko Nishioka. Therapeutic Potential of Polo-like Kinase Inhibition in Rheumatoid Arthritis. The 27th Asia-Pacific League of Associations for Rheumatology Congress (APLAR 2025). Fukuoka, Japan. 2025”N9ŒŽ6“ú.

Takushi Yamamoto, Seidai Sato, Yasuhiko Nishioka. Analysis of local distribution and residence time of Nintedanib in fibrotic lung tissue using mass spectrometry imaging. The 10th Asia-Oceania Mass Spectrometry Conference (AOMSC2025). Okinawa, Japan. 2025”N6ŒŽ24“ú.

Seidai Sato, Takushi Yamamoto, Yuki Morimoto, Yuta Isomura, Ryoko Suzue, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Yuya Yamashita, Kojin Murakami, Hiroki Bando, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. Analysis of Local Distribution and Residence Time of Nerandomilast in Lung Tissue Using Mass Spectrometry Imaging. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ19“ú.

Yuta Isomura, Masaki Hanibuchi, Seidai Sato, Atsushi Mitsuhashi, Tatsuya Kajimoto, Atsuro Saijo, Yasuhiko Nishioka . Serial Changes of Fractional Exhaled Nitric Oxide and Periostin in the Treatment Course of Cough Variant Asthma. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ19“ú.

Kojin Murakami, Seidai Sato, Yuta Isomura, Phuong Trang, Noriko Bando, Ryoko Suzue, Nandin-Erdene Danzan, Yuya Yamashita, Hiroki Bando, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Noriaki Inamura, Keiji Hasumi, Yasuhiko Nishioka. SMTP-44D, a Novel Soluble Epoxide Hydrolase Inhibitor, Ameliorates Bleomycin-induced Pulmonary Fibrosis in Mice. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ19“ú.

Nobuhito Naito, Hiroshi Kawano, Yuta Isomura, Phuong Trang, Noriko Bando, Ryoko Suzue, Nandin-Erdene Danzan, Yuya Yamashita, Hiroki Bando, Keiko Haji, Kozo Kagawa, Seidai Sato, Shigeyuki Kon, Yasuhiko Nishioka. The Antifibrotic Effects of ƒ¿9 Integrin-targeted Therapy Through Inhibition of Fibrocyte and Fibroblast Activity. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ19“ú.

Wataru Inoue, Tomoya Tateishi, Haruhiko Furusawa, Shinya Fujii, Takayuki Takimoto, Hiroshi Ishii, Naoki Tode, Yasuhiro Kondoh, Tsuneyuki Oda, Takafumi Suda, Yasushi Horimasu, Keishi Sugino, Tomohiro Handa, Koji Sakamoto, Hiromi Tomioka, Yuki Shundo, Kazuya Ichikado, Yuko Waseda, Noriho Sakamoto, Atsushi Miyamoto, Naoki Arai, Hiromichi Hara, Keisuke Tomii, Susumu Sakamoto, Hiroyoshi Yamauchi, Kazuhiro Yatera, Seidai Sato, Seishu Hashimoto, Kojiro Honda, Tomoo Kishaba, Hirokazu Kimura, Yoshinori Tanino, Motoyasu Kato, Koichiro Kamio, Yusuke Nakamura, Hiroaki Saito, Masayoshi Kobayashi, Tomoyuki Ogata, Satoshi Watanabe, Yasunari Miyazaki. A Prospective Cohort Study of Idiopathic Pleuroparenchymal Fibroelastosis in Japan. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ19“ú.

Yasuhiro Kondoh, Okuda Ryo, Kazuya Tsubouchi, Masaki Okamoto, Osamu Nishiyama, Seidai Sato, Keiji Oishi, Nobuhisa Ishikawa, Hirofumi Chiba, Yasunari Miyazaki, Sakae Homma, Yasuhiko Nishioka, Takashi Ogura, Yoshikazu Inoue, Arata Azuma. TAS-115 (Pamufetinib) in Patients With Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype: Results of Phase 2b Randomized Clinical Trial. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ18“ú.

Masaaki Iwabayashi, Hiromi Tomioka, Okuda Ryo, Nobuhisa Ishikawa, Naoki Arai, Takahisa Takihara, Megumi Hamaguchi, Yuriko Takeda, Kunihiko Kobayashi, Toshihiro Nukiwa, Yasuhiro Kondoh, Takafumi Suda, Mikio Toyoshima MD, Hamamtsu Rosai, Keisuke Tomii, Motoyasu Kato, Takuji Suzuki, Michiko Kagajo, Yasuo Shimizu, Yasuhiko Nishioka, Kojiro Honda, Kodai Kawamura, Shinyu Izumi, Toru Arai, Akina Nigi, Hirofumi Chiba, Yoshinori Tanino, Kazunori Tobino, Takashi Ogura. Impact of Cough in Patients With Idiopathic Interstitial Pneumonia. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ18“ú.

Shotaro Tachibana, Hirohisa Ogawa, Mayuko Shimizu, Hiroki Bando, Seidai Sato, Takahiro Takayama, Koichi Inoue, Makoto Kurano, Yasuhiko Nishioka, Koichi Tsuneyama. Role of the Lysophosphatidic Acid 1 Receptor in Goblet Cell Hyperplasia in Chronic Bronchial Asthma. ATS2025 International Conference. San Francisco, CA, USA. 2025”N5ŒŽ18“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. IPF�EPPF‚ɑ΂·‚é�R�üˆÛ‰»–ò‚ÌŠî‘b‚Æ—Õ�°. ‘æ73‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[). •ÄŽq. 2025”N12ŒŽ20“ú.

ŽO‹´“ÕŽu, ‹g“c•É�l, �¬ŽRˆë–ç, ‰¬–ì�L˜a, �¼‰ªˆÀ•F. Žîᇓàfibrocyte‚Ì“¯’è‚Æ‚ª‚ñ”÷�¬ŠÂ‹«‚É‚¨‚¯‚é‹@”\‚̉ð–¾. ‘æ48‰ñ“ú–{•ªŽq�¶•¨Šw‰ï”N‰ï�iƒVƒ“ƒ|ƒWƒEƒ€�j. ‰¡•l. 2025”N12ŒŽ3“ú.

‰¬–ì�L˜a. Œ§–¯‚ÌŠF‚³‚ñ‚É’m‚Á‚Ä‚¨‚¢‚Ä‚¢‚½‚¾‚«‚½‚¢“¿“‡Œ§‚ª�„�i‚·‚邪‚ñ‘Î�ô‚ɂ‚¢‚Ä. “¿“‡Œ§–¯‚ª‚ñƒtƒH�[ƒ‰ƒ€. “¿“‡. 2025”N11ŒŽ2“ú.

‰¬–ì�L˜a. ’m‚Á‚Ä‚¨‚«‚½‚¢”x‚ª‚ñ‚̃Cƒ�ƒn�`—\–h�E‘�Šú”­Œ©�E�Å“KŽ¡—Âɂ‚¢‚Ä�`. —ߘa7”N“x”x‚ª‚ñ�u‰‰‰ï(Žs–¯�u�À). “¿“‡. 2025”N10ŒŽ10“ú.

�¼‰ªˆÀ•F. äPŒ´•a‚É”º‚¤ŠÔŽ¿�«”x޾г‚ÌŠî‘b‚Æ—Õ�°. ‘æ36‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï(ƒCƒuƒjƒ“ƒOƒZƒ~ƒi�[). �‚�¼. 2025”N10ŒŽ4“ú.

�¼‰ªˆÀ•F, ŽO‹´“ÕŽu, ‹àŽq”ü‰Ø, ‰Á“¡�K�¬. ”x‚ª‚ñ‚ÌŽîᇔ÷�¬ŠÂ‹«‚ð•W“I‚Æ‚µ‚½‚ª‚ñ–Ɖu—Ö@‚ÌŠJ”­. ‘æ84‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‹à‘ò. 2025”N9ŒŽ25“ú.

�²“¡�³‘å. �¬Œ÷‚ÆŽ¸”s‚©‚çŠw‚ÔILD Ž¡—ÖòŠJ”­‚Ì�V�í—ª�F‘w•ʉ»‚Æ•W“I‘I‘ð‚Ì�lŽ@. ‘æ5‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). “Œ‹ž. 2025”N9ŒŽ20“ú.

�¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�f—ÂÌ�Å‘O�ü. ‘æ72‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘Žx•”�¶ŠU‹³ˆç�u‰‰‰ï. �‚’m. 2025”N5ŒŽ25“ú.

�²“¡�³‘å, ŽR–{‘ìŽu, �X–{—FŽ÷, ˆé‘º—S‘¾, �Ⓦ‹IŽq, ‘º�ã�s�l, �Ⓦ�OŠî, “yŽtŒbŽq, ���ì�k‘¢, �¼‰ªˆÀ•F. Ž¿—Ê•ª�̓Cƒ��[ƒWƒ“ƒO‚ð—p‚¢‚½ƒjƒ“ƒeƒ_ƒjƒu‚Ì‘ŸŠí•Ê‘g�D“à•ª•z‚Ƒؗ¯ŽžŠÔ‚ÌŒŸ“¢. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ŽáŽèŒÄ‹zŠíŒ¤‹†�Å‘O�üƒVƒ“ƒ|ƒWƒEƒ€). “Œ‹ž. 2025”N4ŒŽ11“ú.

•Ÿ‰Æ–ƒ”ü, �âŒû‹Å, �û•£�¹‹B, “í�£Œ«–ç, –å“c�@”V, ‘º�ã�s�l, �²“¡�³‘å, �²“c�­—², �¼‰ªˆÀ•F. ŠÔŽ¿�«”x޾г‚É‚¨‚¯‚é˜J�쎞’áŽ_‘fŒŒ�ǂɑ΂·‚郊ƒU�[ƒo�[ƒ^ƒ“ƒN“à‘ ŒÄ‹z“¯’²Ší‚Ì—LŒø�«‚Ì•]‰¿. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). “Œ‹ž. 2025”N4ŒŽ11“ú.

ˆé‘º—S‘¾, �²“¡�³‘å, ‰¬–ì�L˜a, ‰Í–ì�O, �û•£�¹‹B, �¼‰ªˆÀ•F. ”ñHIVƒjƒ…�[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚É‚¨‚¯‚錌’†ƒÀ-D-glucan’l‚ÉŠÖ˜A‚·‚éˆöŽq‚¨‚æ‚ÑŽ¡—ÃŒo‰ß’†‚Ì�„ˆÚ‚ÌŒŸ“¢. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). “Œ‹ž. 2025”N4ŒŽ11“ú.

‰¬–ì�L˜a. ”x‚ª‚ñ‚ɑ΂·‚é�WŠw“IŽ¡—ÂÌ�Å‘O�ü. “¿“‡‘åŠw•a‰@‚ª‚ñ�f—ØAŒgƒZƒ“ƒ^�[ƒtƒH�[ƒ‰ƒ€(Žs–¯�u�À). “¿“‡. 2025”N2ŒŽ1“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ’Ë�è—C‹M, �X“c—D, Œ¬Œ´�_, �û•£�¹‹B, �¼‰ªˆÀ•F. �×–EŠOŠîŽ¿�¬•ª‰ð�͂ɂæ‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‘Ï�«‹@�˜‚̉ð–¾. ‘æ66‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2025”N11ŒŽ8“ú.

âV“¡—Ç‘¾, –Ñ—˜“Ä�l, çÝŽ��L’m, “ŒŒöˆê, �Ô�¼�O˜N, •Ä�ã�m—Y, Š|�ì–¢ŠóŽq, ’·“‡�L‘Š, �‚‹´‘�, “¡“c�¹Ž÷, úå’J“TŽq, “ñ‹{‹Mˆê˜Y, �¼‰ªˆÀ•F, �·Œ[‘¾, –k–쎠‹v, ‹Ê“c�kŽ¡, Še–±”Ž, ŽR–{�M”V, Œ·ŠÔ�º•F, Œõ•y“O�Æ. �Ø�œ•s”\‡VŠú”ñ�¬�×–E”xŠà‚ɑ΂·‚鉻Šw•úŽË�ü—Ö@ŒãDurvalumab‚̃oƒCƒIƒ}�[ƒJ�[Œ¤‹†�iDual-Bio study) . ‘æ66‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2025”N11ŒŽ8“ú.

‰¬–ì�L˜a, �¼–{—˜‰ÁŽq, ’Ë�è—C‹M, �X“c—D, Š�–{’B–ç, ŽO‹´“ÕŽu, �û•£�¹‹B, �¼‰ªˆÀ•F. ”xŠà‚ɑ΂·‚éƒAƒ€ƒ‹ƒrƒVƒ““Š—^‚É”º‚¤–ò�Ü�«”x�áŠQ‚Ì”­�ǂɊ֘A‚·‚郊ƒXƒNˆöŽq‚ɂ‚¢‚Ä. ‘æ66‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2025”N11ŒŽ7“ú.

�X“c—D, ƒAƒKƒ‹ƒUƒ“ƒ_ƒ“ ƒoƒ„ƒ‹ƒ}�[, ŽO‹´“ÕŽu, ‹g“c•É�l, ‰¬–ì�L˜a, ’Ë�è—C‹M, �¼–{—˜‰ÁŽq, Œ¬Œ´�_, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹¹–Œ’†”çŽî‚ɑ΂·‚鎞Œvˆâ“`Žq‘jŠQ–ò‚ÌŒŒŠÇ�V�¶�§Œä‚ð‰î‚µ‚½Ž¡—ÃŒø‰Ê‚ÌŒŸ“¢. ‘æ66‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. “Œ‹ž. 2025”N11ŒŽ7“ú.

�¼–{—˜‰ÁŽq, ‰¬–ì�L˜a, ’Ë�è—C‹M, �X“c—D, Š�–{’B–ç, ŽO‹´“ÕŽu, �û•£�¹‹B, �¼‰ªˆÀ•F. ”xŠà‚ɑ΂·‚éƒAƒ€ƒ‹ƒrƒVƒ“‚É‚æ‚é–ò�Ü�«”x�áŠQ”­�ÇƒŠƒXƒN‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢. ‘æ63‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‰¡•l. 2025”N10ŒŽ18“ú.

‹g“c•É�l, ˆ¢•”�^Ž¡, ŽO‹´“ÕŽu, ŽR–{�‚�¬, �ì“cŒh, �²“¡’qŒb”ü, ‰¬–ì�L˜a, ‹àŽq”ü‰Ø, ‰Á“¡�K�¬, �¼‰ªˆÀ•F. ‚ª‚ñ“ÁˆÙ“I�Rƒqƒgƒ|ƒhƒvƒ‰ƒjƒ“�R‘Ì chLpMab-2f ‚Í‹¹–Œ’†”çŽî‚ɑ΂µ‚Ä�RŽîᇌø‰Ê‚ð”­Šö‚·‚é. ‘æ84‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‹à‘ò. 2025”N9ŒŽ27“ú.

Batmunkh Ulziisaikhan, ‹gŠÛ“N˜Y, �¼‰º—m•ã, “àŽRŒ\Ži, �¼‰ªˆÀ•F, ŽO�D�N—Y, �ùŽO“¿, •Ћ˖L‰ë Mitochondrial BIG3-PHB2 complex as a potential therapeutic target in Triple-Negative Breast Cancer. ‘æ84‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‹à‘ò. 2025”N9ŒŽ27“ú.

ƒAƒKƒ‹ƒUƒ“ƒ_ƒ“ ƒoƒ„ƒ‹ƒ}�[, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ‹g“c•É�l, ’Ë�è—C‹M, ”ö�è—Ì•F, �X“c—D, �û•£�¹‹B, �¼‰ªˆÀ•F. ŽžŒvˆâ“`Žq‘jŠQ–ò‚É‚æ‚鋹–Œ’†”çŽî‚ɑ΂·‚錌ŠÇ�V�¶—}�§�ì—p‚ÌŒŸ“¢. ‘æ84‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‹à‘ò. 2025”N9ŒŽ27“ú.

He Fengyu, “àŽRŒ\Ži, ‹gŠÛ“N˜Y, �¼‰º—m•ã, �¼‰ªˆÀ•F, •Ћ˖L‰ë. The critical role of the BIG3-PHB2 complex as a novel therapeutic target in prostate cancer. ‘æ84‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‹à‘ò. 2025”N9ŒŽ26“ú.

ŽO‹´“ÕŽu, ‹g“c•É�l, ‰¬–ì�L˜a, ”ö�è—Ì•F, ’Ë�è—C‹M, �X“c—D, ƒAƒKƒ‹ƒUƒ“ƒ_ƒ“ ƒoƒ„ƒ‹ƒ}�[, �¼–{—˜‰ÁŽq, Œ¬Œ´�_, �û•£�¹‹B, �¼‰ªˆÀ•F. �×–EŠOŠîŽ¿�¬•ª‰ð�͂ɂæ‚邪‚ñ–Ɖu”r�œ—U“±‹@�˜‚Ì’T�õ. ‘æ84‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‹à‘ò. 2025”N9ŒŽ25“ú.

�¡‘qŒ’, �¬ŽRˆë–ç, �²“¡�³‘å, ˆé‘º—S‘¾, —é�]—ÁŽq, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, “yŽtŒbŽq, �Ⓦ�OŠî, ‰Í–ì�O, �¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`ŠÖ˜AŠÔŽ¿�«”x޾г‚É‚¨‚¯‚錌�´ƒyƒ“ƒgƒ‰ƒLƒVƒ“2 ‚Ì�f’f“I—L—p�«‚ÌŒŸ“¢. ‘æ5‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï. “Œ‹ž. 2025”N9ŒŽ21“ú.

“yŽtŒbŽq, �¼‘º�t‰À, ‰Í–ì�O, �²“¡�³‘å, �¡‘qŒ’, ŽR‰º—Y–ç, �Ⓦ�OŠî, “à“¡�L�m, �¬�씎‹v, �¼‰ªˆÀ•F. TGF-ƒÀ/JAK2 Œo˜H‚ð•W“I‚Æ‚µ‚½JAK ‘jŠQ–ò‚Ì”x�üˆÛ�Ç—}�§Œø‰Ê‚ÌŒŸ“¢. ‘æ5‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï. “Œ‹ž. 2025”N9ŒŽ20“ú.

Šâ—Ñ�³–¾, •y‰ª—mŠC, ‰œ“c—Ç, �Î�ì’¨‹v, �rˆä’¼Ž÷, ‘ꌴ�’‹v, à_Œûˆ¤, •�“c—T—¢Žq, �¬—Ñ�‘•F, ŠÑ˜a•q”Ž, ‹ß“¡�N”Ž, �{“c—²•¶, –L“ˆŠ²�¶, •xˆäŒ[‰î, ‰Á“¡Œ³�N, —é–Ø‘ñŽ™, ‰Á‰ê�é”ü’qŽq, �´�…‘×�¶, �¼‰ªˆÀ•F, –{‘½�h“ñ˜Y, �쑺�G‘å, �ò�M—L, �Vˆä“O, �m‹V–¾”[, �ç—t�O•¶, ’J–ìŒ÷“T, ”ò–ì˜a‘¥, �¬‘q�‚Žu. “Á”­�«ŠÔŽ¿�«”x‰Š‚É‚¨‚¯‚éŠP‚Ì—Õ�°“IˆÓ‹`. ‘æ5‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï. “Œ‹ž. 2025”N9ŒŽ20“ú.

ŽO‹´“ÕŽu, ‹g“c•É�l, ‰¬–ì�L˜a, ”ö�è—Ì•F, ’Ë�è—C‹M, �¼‰ªˆÀ•F. –Ɖu”r�œ‚ð�\’z‚·‚é�×–EŠOŠîŽ¿�¬•ª“¯’è‚É‚æ‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‘Ï�«‹@�˜‚̉ð�Í. ‘æ29‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ŽD–y. 2025”N7ŒŽ4“ú.

‹g“c•É�l, ˆ¢•”�^Ž¡, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ‰Á“¡�K�¬, �¼‰ªˆÀ•F. ‚ª‚ñ“ÁˆÙ“I�Rƒqƒg podoplanin �R‘̂̋¹–Œ’†”çŽîŽ¡—ÂɌü‚¯‚½Šî‘b“IŒŸ“¢. ‘æ29‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ŽD–y. 2025”N7ŒŽ4“ú.

Bayarmaa Agarzandan, Atsushi Mitsuhashi, Hirokazu Ogino, Aito Yoshida, Yuki Tsukazaki, Ryohiko Ozaki, Yutaka Morita, Masaki Hanibuchi, Yasuhiko Nishioka. The anti-angiogenic effects of clock gene inhibitors in malignant pleural mesothelioma. ‘æ34‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. ’W˜H�D2025”N6ŒŽ19“ú.

ŽRú±”Ž‹P, ‹g“c�„, �¼Œ³—F�ô, �‚�¼’¼Žq, ‹ààV—TŽ÷, Œö•¶‹`—Y, ‘å�è—T—º, ‰Í–ì�O, �¼–ìˆêŽO, �¼‰ªˆÀ•F, Œ´“c‰ëŽj, ˜a�ò—B�M. ‹Ø‰Š‚É‚¨‚¯‚é’´‰¹”g‰æ‘œ‚ÆMRI‰æ‘œ‚Ì“¯Žž’è—Ê•ª�Í. ‘æ66‰ñ“ú–{�_ŒoŠw‰ïŠw�p‘å‰ï. ‘å�ã. 2025”N5ŒŽ22“ú.

“à“¡�L�m, ‰Í–ì�O, ‘º�ã�s�l, ŽR‰º—Y–ç, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. ƒCƒ“ƒeƒOƒŠƒ“ƒ¿9‘jŠQ—Ö@‚Ífibrocyte‚Ì—V‘–‚ð—}�§‚·‚é. ‘æ69‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. •Ÿ‰ª. 2025”N4ŒŽ24“ú.

�û•£�¹‹B, ’†�£�Ÿ‘¥, ‰F“s‹{�³“o, “‡“c‹v•v, Œá�ȉë•F, Žè’Ë•qŽj, ‰¬–ì�L˜a, �²“¡�³‘å, —t‹v‹MŽi, �¼‰ªˆÀ•F. “¿“‡Žs‚É‚¨‚¯‚éCOPDŒŸ�f‚Ì—L—p�«‚ÌŒŸ“¢. ‘æ122‰ñ“ú–{“à‰ÈŠw‰ï‘�‰ï�E�u‰‰‰ï. ‘å�ã. 2025”N4ŒŽ19“ú.

�¼–{—˜‰ÁŽq, ‰¬–ì�L˜a, �X“c—D, ’Ë�è—C‹M, ”ö�è—Ì•F, ŽO‹´“ÕŽu, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. �i“WŒ^�¬�×–E”xŠà‚ɑ΂·‚鉻Šw–Ɖu—Ö@‚̉“Šu“]ˆÚ�§ŒäŒø‰Ê‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2025”N4ŒŽ11“ú.

�¼–{—˜‰ÁŽq, ‰¬–ì�L˜a, ’Ëú±—C‹M, �X“c—D, ”ö�è—Ì•F, ŽO‹´“ÕŽu, �û•£�¹‹B, �¼‰ªˆÀ•F. �i“WŒ^�¬�×–E”xŠà‚É‚¨‚¯‚鉻Šw–Ɖu—Ö@‚̉“Šu“]ˆÚ�§ŒäŒø‰Ê‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢. ‘æ22‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. �_ŒË. 2025”N3ŒŽ8“ú.

”ö�è—Ì•F, ‰¬–ì�L˜a, �X“c—D, �¼–{—˜‰ÁŽq, ’Ë�è—C‹M, ŽO‹´“ÕŽu, Œ¬Œ´�_, �¼‰ªˆÀ•F. �i“WŒ^�¬�×–E”xŠà‚É‚¨‚¯‚é“ñŽŸ‰»Šw—Ö@‚ð–W‚°‚éˆöŽq‚ÌŒŸ“¢. ‘æ22‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. �_ŒË. 2025”N3ŒŽ8“ú.

’|“à‰hŽ¡, ‰¬–ì�L˜a, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, �V‹����D, �¼‘º—LŒå, ŽsŒ´�¹–ç, š �d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨�¶, �¬�£ŒjŽj, Œ¬Œ´�_, ŽÂŒ´•×, �¼‰ªˆÀ•F. �DŽ_‹…‘�‰Á‚Í”ñ�¬�×–E”xŠàгŽÒ‚̖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽ¡—ÃŒø‰Ê—\‘ªƒoƒCƒIƒ}�[ƒJ�[. ‘æ22‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. �_ŒË. 2025”N3ŒŽ8“ú.

‰¬–ì�L˜a, �¼žŠ“Ö˜Y, �¼‰ªˆÀ•F, Nicholas A Butowski, Susan M Chang, Mitchel S Berger, ‰ª“c�G•ä. ƒ}ƒ‹ƒ`ƒyƒvƒ`ƒhƒ�ƒNƒ`ƒ“‚Æ�RCD27ƒAƒSƒjƒXƒg�R‘Ì•¹—p—Ö@‚͒ራ�«“x�_ŒoäPŽîгŽÒ––�½ŒŒ‚É‚¨‚¢‚Äeffector memory T�×–E‚ð—U“±‚·‚é. ‘æ22‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. �_ŒË. 2025”N3ŒŽ6“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
Šì‘½‘åŽ÷, ŽR‰º—Y–ç, “yŽtŒbŽq, �X�ʉÔ, •Ä“c�_�l, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. JAK‘jŠQ–òŽg—p’†‚É”­�Ç‚µ‚½”xMycobacterium avium complex�Ç‚Ì2—á. ‘æ76‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï. •ÄŽq. 2025”N12ŒŽ20“ú.

‹{–{Œ›�Æ, ŽR‰º—Y–ç, “yŽtŒbŽq, ’Ë�è—C‹M, ���ì�k‘¢, ‹{–{’¼‹P, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, ’¹‰H”Ž–¾, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾ŒŸ�¸‚Å�f’f‚µ“¾‚½”xŒ´”­�‚ˆ«�«“x‘ÙŽ™Œ^‘BŠà‚̈ê—á. ‘æ34‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. •ÄŽq. 2025”N12ŒŽ20“ú.

�¼‘ºˆèŠC, ŽR‰º—Y–ç, “yŽtŒbŽq, Š�–{’B–ç, �X“c—D, •Ÿ‰Æ–ƒ”ü, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ”ì‘å�«�œŠÖ�ß�Ç‚ð�‡•¹‚µ‚½KRAS G12C•ψٗz�«”x‘BŠà‚̈ê—á. ‘æ73‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. •ÄŽq. 2025”N12ŒŽ20“ú.

Œ´“cŽÑŠó, ŽR‰º—Y–ç, “yŽtŒbŽq, ’†�¼éD“l, ���ì�k‘¢, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ‚×ƒŠƒ€ƒ}ƒu‚©‚çƒAƒjƒtƒ�ƒ‹ƒ}ƒu‚ւ̃XƒCƒbƒ`‚ª—LŒø‚Å‚ ‚Á‚½‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX‚Ì1—á. ‘æ133‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2025”N11ŒŽ30“ú.

�¼–{—˜‰ÁŽq, ‰¬–ì�L˜a, ŽR‰º—Y–ç, Š�–{’B–ç, �X“c—D, ŽO‹´“ÕŽu, ’Ëú±—C‹M, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. �i“WŒ^�¬�×–E”xŠà‚ɑ΂·‚鉻Šw–Ɖu—Ö@‚ÌŠÌ“]ˆÚ�§ŒäŒø‰Ê‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢. ‘æ133‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2025”N11ŒŽ30“ú.

Š�–{’B–ç, ‰Í–ì�O, �¡‘qŒ’, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. �…áv�«—Þ“Vávጂð�‡•¹‚µ‚½IgG4ŠÖ˜A޾г‚Ì1—á. ‘æ36‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚�¼. 2025”N10ŒŽ5“ú.

‰Í–ì�O, �¡‘qŒ’, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. TAFRO�ÇŒóŒQ‚Ì2—á. ‘æ36‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚�¼. 2025”N10ŒŽ4“ú.

‹{–{Œ›�Æ, �û•£�¹‹B, ŽR‰º—Y–ç, �X“c—D, �¡‘qŒ’, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾ŒŸ�¸Œã‚̌ċzŠíŠ´�õ�ǂɑ΂·‚é—\‘ªˆöŽq‚̉ð�͂Ɨ\–h“I�R‹Û–ò“Š—^‚̈Ӌ`. ‘æ271‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2025”N7ŒŽ27“ú.

’†“à—F�‡�], ŽR‰º—Y–ç, “yŽtŒbŽq, ’†�¼éD“l, �¼–{—˜‰ÁŽq, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. �RARS �R‘Ì—z�«”畆‹Ø‰Š‚É”º‚¤‹}‘¬�i�s�«ŠÔŽ¿�«”x‰Š‚É3 �Ü•¹—p—Ö@‚ª‘tŒø‚µ‚½2�Ç—á. ‘æ72‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �¼ŽR. 2025”N7ŒŽ26“ú.

’|“à‰hŽ¡, ‰¬–ì�L˜a, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, �V‹����D, �¼‘º—LŒå, ŽsŒ´�¹–ç, š �d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨�¶, �¬�£ŒjŽj, Œ¬Œ´�_, ŽÂŒ´•×, �¼‰ªˆÀ•F. “Š—^Œã‚Ì––�½ŒŒ�DŽ_‹…‘�‰Á‚Í”ñ�¬�×–E”xŠàгŽÒ‚̖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽ¡—ÃŒø‰Ê—\‘ªƒoƒCƒIƒ}�[ƒJ�[. ‘æ72‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �¼ŽR. 2025”N7ŒŽ26“ú.

Šì‘½‘åŽ÷, ŽR‰º—Y–ç, “yŽtŒbŽq, ‹ß“¡Œ\‘å, ‹{–{’¼Ž÷, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, ’¹‰H”Ž–¾, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. Šw�ZŒŸ�f‚ðŒ_‹@‚É�f’f‚µ‚¦‚½Žá”N”­�Çlymphoepithelial carcinoma‚̈ê—á. ‘æ63‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �¼ŽR. 2025”N7ŒŽ25“ú.

�¼‘ºˆèŠC, ŽR‰º—Y–ç, “yŽtŒbŽq, —é�]—ÁŽq, •Ÿ‰Æ–ƒ”ü, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. Pembrolizumab‚É‚æ‚é–ò�Ü�«–³è÷—±‹…�ǂ̈ê—á. ‘æ63‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �¼ŽR. 2025”N7ŒŽ25“ú.

ŽR‰º—Y–ç, ‘º�ã�s�l, ˆÉ“¡ˆê‹P, ‹{–{Œ›�Æ, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �û•£�¹‹B, �¼‰ªˆÀ•F. ‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX‚É”º‚¤ŒŒ�ð�«”÷�¬ŒŒŠÇ�ǂɑ΂µ‚ÄŒŒŸ÷ŒðŠ·‚ÆƒŠƒcƒLƒVƒ}ƒu‚ðŠÜ‚ß‚½�WŠw“IŽ¡—ª‘tŒø‚µ‚½1—á. ‘æ132‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2025”N5ŒŽ25“ú.

‹ß“¡Œ\‘å, ‘º�ã�s�l, �Ⓦ�OŠî, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �û•£�¹‹B, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š•¹‘¶Šà�«‹¹�…‚ɑ΂·‚é50%ƒuƒhƒE“œ‰t‚ð—p‚¢‚½‹¹–Œ–ü’…�p‚Ì—LŒø�«‚ƈÀ‘S�«‚ÌŒŸ“¢. ‘æ132‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2025”N5ŒŽ25“ú.

‰““¡—T”ü, –ØŒ´’¼‹P, ŽR–{—Y‹M, ”ö�è—Ì•F, “¡“c�_Ži, �¼ˆä�®Žq, �¼‰ªˆÀ•F, ˜a�ò—B�M. ƒjƒ{ƒ‹ƒ}ƒu�EƒCƒsƒŠƒ€ƒ}ƒu•¹—p—Ö@’†‚É‘½”­�«’†�•�_Œo•a•Ï‚ð’æ‚µ‚½–ƉuŠÖ˜A—LŠQŽ–�Û‚Ì1—á. ‘æ132‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2025”N5ŒŽ25“ú.

‘º�ã�s�l, �Ⓦ�OŠî, “yŽtŒbŽq, •Ÿ‰Æ–ƒ”ü, “à“¡�L�m, ”ö�è—Ì•F, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �âŒû‹Å, �û•£�¹‹B, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�‡•¹”xŠà‚ÌŠà�«‹¹�…‚ɑ΂·‚é50�“ƒuƒhƒE“œ‰t‚ð—p‚¢‚½‹¹–Œ–ü’…�p‚ÌŒŸ“¢. ‘æ270‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2025”N2ŒŽ16“ú�D
2024”N‹Æ�Ñ
�y‰¢•¶‘��à�z
Nishioka Y, Araya J, Tanaka Y, Kumanogoh A. Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease. Inflamm Regen 44(1):34, 2024.

Hanibuchi M, Ogino H, Sato S, Nishioka Y. Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives. J Med Invest 71(1,2):9-22, 2024.
�y‰¢•¶Œ´’˜�z
Soboh S, Vorontsova A, Farhoud M, Barash U, Naroditsky I, Gross-Cohen M, Weissmann M, Nishioka Y, Woolf AS, Roberts NA, Shaked Y, Ilan N, Vlodavsky I. Tumor- and host-derived heparanase-2 (Hpa2) attenuates tumorigenicity: role of Hpa2 in macrophage polarization and BRD7 nuclear localization. Cell Death Dis 15(12):894, 2024.

Kondoh Y, Furukawa T, Hozumi H, Suda T, Egashira R, Jokoh T, Fukuoka J, Kuwana M, Teramachi R, Fujisawa T, Hasegawa Y, Ogura T, Miyazaki Y, Oyama S, Teramukai S, Horiguchi G, Naito A, Inoue Y, Ichikado K, Bando M, Tomioka H, Nishioka Y, Chiba H, Ebina M, Nakanishi Y, Satoh K, Shiratori Y, Hashimoto N, Ishii M. The providing multidisciplinary ILD diagnoses (PROMISE) study - study design of the national registry of Japan facilitating interactive online multidisciplinary discussion diagnosis. BMC Pulm Med 24(1):511, 2024.

Hanibuchi M, Miki M, Hiraoka K, Nakamura M, Tsujimoto Y, Yamamura T, Murakami K, Ogino H, Sato S, Nishioka Y. A case of pulmonary Mycobacterium heckeshornense infection coexisted with lung cancer. J Med Invest 71(3.4):327-331, 2024.

Jenkins RG, Cottin V, Nishioka Y, Noth I, White ES, Ittrich C, Diefenbach C, Rohr KB, Selman M, Maher TM, on behalf of the INMARK trial investigators. Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis. ERJ Open Res 10(6):00558-2023, 2024.

Tsukazaki Y, Ogino H, Okano Y, Kakiuchi S, Harada S, Toyoda Y, Matsumura Y, Ichihara S, Imakura T, Matsumoto R, Ozaki R, Ogawa E, Morita Y, Mitsuhashi A, Yabuki Y, Yoneda H, Hanibuchi M, Hase K, Takeuchi E, Haku T, Nishioka Y. Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer. Int J Clin Oncol 29(10):1451-1460. 2024.

Maher TM, Jenkins RG, Cottin V, Nishioka Y, Noth I, Selman M, Song JW, Ittrich C, Diefenbach C, Stowasser S, White ES; on behalf of the INMARK trial investigators. Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. ERJ Open Res 10(4):00335-2023, 2024.

Miyamoto K, Ogino H, Kakimoto T, Matsumura Y, Haji K, Mitsuhashi A, Morita Y, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Bando Y, Nokihara N, Nishioka Y. Transformation of epidermal growth factor receptor mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review. Respir Med Case Rep 51:102076, 2024.

Inoue Y, Kitamura H, Okamoto M, Ogura T, Nishioka Y, Kuwana M, Taniguchi A, Ito T, Rohr KB, Suda T. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial. Respir Investig 62(4):589-596, 2024.

Matsumura Y, Sato S, Haji K, Masuda T, Yoneda H, Ogino H, Ogawa H, Hanibuchi M, Hattori N, Nishioka Y. A case of pleural mesothelioma with immunohistochemicalstaining positive for Krebs von den Lungen-6. Respir Med Case Rep 50:102040, 2024.

Ueno M, Egashira R, Hashisako M, Fujimoto K, Fukuda T, Hayashida Y, Sumikawa H, Tominaga J, Tanaka T, Terasaki Y, Fukuoka J, Nishioka Y, Aoki T, Gabata T, Hatabu H, Johkoh T. Idiopathic dendriform pulmonaryossification as the phenotype of interstitial lung abnormalities: CT-pathologic correlation and prevalence. Jpn J Radiol 42(9):993-1002, 2024.

Sugasaki M, Nakamura S, Teramoto K, Urushihara M, Inoue Y, Nakao T, Nishioka Y, Sata M. Lupus anticoagulant hypoprothrombinemia syndrome with multiple and high-titer antiphospholipid antibodies strongly interfered with coagulation assays. Blood Coagul Fibrinolysis 35(3):149-153, 2024.

Bando M, Homma S, Date H, Kishi K, Yamauchi H, Sakamoto S, Miyamoto A, Goto Y, Nakayama T, Azuma A, Kondoh Y, Johkoh T, Nishioka Y, Fukuoka J, Miyazaki Y, Yoshino I, Suda T; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition. Respir Investig 62(3):402-418, 2024.

Mima M, Sato S, Shinya T, Naito N, Shoji T, Harada S, Suzue R, Murakami K, Koyama K, Nishioka Y. Characteristics of chest high-resolution computed tomography in patients with anti-aminoacyl-tRNA synthetase antibody-positive interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 41(1):e2024005, 2024.

Kozai H, Ogino H, Mitsuhashi A, Nguyen N, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Shinohara T, Nokihara H, Nishioka Y. Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thorac Cancer 15(5):369-378, 2024.

Yoneda H, Mitsuhashi A, Yoshida A, Ogino H, Itakura S, Nguyen N, Nokihara H, Sato S, Shinohara T, Hanibuchi M, Abe S, Kaneko Mika, Kato Y, Nishioka Y. Anti-podoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells. Cancer Sci 115(2):357-368, 2024.

Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol 26(2):335-347, 2024.

Takeuchi E, Ogino H, Kondou K, Okano Y, Ichihara S, Kunishige M, Kadota N, Machida H, Hatakeyama N, Naruse K, Nokihara H, Shinohara T, Nishioka Y. An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thorac Cancer 15(3):248-257, 2024.
�y˜a•¶‘��à�z
“yŽtŒbŽq, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š‚Æ”x�üˆÛ�Ç. ‰Š�ǂƖƉu 32(6):61-66, 2024.

�¡‘qŒ’, �²“¡�³‘å, �¼‰ªˆÀ•F. IPAF‚Ì—Õ�°“I“Á’¥‚Ɖۑè. ŒÄ‹zŠí“à‰È 46(2):163-169, 2024.

�²“¡�³‘å, �¼‰ªˆÀ•F. ˆâ“`�«ŠÔŽ¿�«”x޾г‚ƉƑ°�«ŠÔŽ¿�«”x‰Š‚Ì—Õ�°‘œ. ŒÄ‹zŠí“à‰È 46(1):1-7, 2024.

ŒK–¼�³—², �¼‰ªˆÀ•F, ‹ß“¡�N”Ž. Phosphodiesterase 4B‘jŠQ–ònerandomilast�F�V‹K”x�üˆÛ�ÇŽ¡—Öò‚Æ‚µ‚Ă̓W–]. “úŒÄ‹zŽ� 13(4):131-139, 2024.

�V‰Æ�’‹`, Œ´“c‰ëŽj, �¼‰ªˆÀ•F. ƒEƒCƒ‹ƒXŠ´�õ�ǂ̋¹•”‰æ‘œ�f’f. Žl�‘ˆãŽ� 80(1,2):17-22, 2024.

�¼‰ªˆÀ•F. ”x�üˆÛ�ǂɑ΂·‚é�R�üˆÛ‰»–òŠJ”­�F‚ª‚ñ‚Æ�üˆÛ‰»”x‚Ì�Ú“_‚𑨂¦‚½ƒgƒ‰ƒ“ƒXƒŒ�[ƒVƒ‡ƒiƒ‹ƒŠƒT�[ƒ`. ˆãŠw‚Ì‚ ‚ä‚Ý 288(2):148-161, 2024.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Kojin Murakami, Seidai Sato, Yuta Isomura, Trang Thi Hong Phuong, Noriko Bando, Ryoko Suzue, Nandin-Erdene Danzan, Yuya Yamashita, Hiroki Bando, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Noriaki Inamura, Kenji Hasumi, Yasuhiko Nishioka. SMTP-44D, a soluble epoxide hydrolase inhibitor, attenuated the progression of pulmonary fibrosis in vivo and in vitro. The ERS Congress 2024. Vienna, Austria. 2024”N9ŒŽ9“ú.

S Hisata, Y Tanino, R Okuda, T Ogura, T Isshiki, Y Horimasu, N Hamada , N Arai, Y Tsubata, T Suda, Y Horio, N Ishikawa, Y Kondoh, M Toyoshima, H Ishii, M Abe, M Kato, M Tanigawa, H Tomioka, H Chiba, T Arai, Yasuhiko Nishioka, N Hattori, T Hoshino, Y Shimizu, K Sakamoto, S Ishikawa, M Mieno, T Baba, Y Miyazaki, T Nukiwa, K Kobayashi, T Suzuki, K Hagiwara. Effect of telomere length and TERT/TERC rare variants on survival in Japanese patients with idiopathic interstitial pneumonias�FGenetic predisposition study from the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry (NEJ036A). The ERS Congress 2024. Vienna, Austria. 2024”N9ŒŽ9“ú.

Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yuko Toyoda, Yugo Matsumura, Seiya Ichihara, Takeshi Imakura, Rikako Matsumoto, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Kayoko Hase, Eiji Takeuchi, Takashi Haku, Yasuhiko Nishioka. The Conflicting Impacts of G-CSF on the Therapeutic Efficacy of Chemoimmunotherapy for Extensive Stage Small Cell Lung Cancer. 2024 World Conference on Lung Cancer. San Diego, CA, USA. 2024”N9ŒŽ7-10“ú.

Hirokazu Ogino, Nguyen Thi Na, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi, Yasuhiko Nishioka. The potential of fluoropyrimidine to be an immunologically optimal partner of immunotherapy for thoracic malignancies. 2024 World Conference on Lung Cancer. San Diego, CA, USA. 2024”N9ŒŽ7-10“ú.

Nobuaki Mamesaya, Kento Takagi, Go Saito, Hiroshi Tanaka, Sousuke Kubo, Takehito Shukuya, Ryosuke Tsugitomi, Takaaki Sasaki, Tomohiro Oba, Taro Yamanaka, Motoko Tachihara, Hiroshi Gyotoku, Hiromi Nagashima, Motohiro Tamiya, Hiroaki Kanemura, Takehiro Tozuka, Megumi Furuta, Shinya Sakata, Atsuto Mouri, Hideki Miwa, Hayato Kawachi, Takashi inomiya, Yoshiaki Nagai, Hirokazu Ogino, Kentaro Ito, Yosuke Tamura, Takaaki Tokito, Masashi Ishihara, Takuji Suzuki. Real-World Data on the Efficacy and Safety of Lenvatinib in Patients with Previously Treated Thymic Carcinoma. 2024 World Conference on Lung Cancer. San Diego, CA, USA. 2024”N9ŒŽ7-10“ú.

Keiko Haji, Seidai Sato, Hirohisa Ogawa, Yuta Isomura, Noriko Bando, Ryoko Suzue, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Yuya Yamashita, Kojin Murakami, Hiroki Bando, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, Katsutoshi Kobayashi, Toshiro Morohoshi, Yasuhiko Nishioka. The effect of novel autotaxin inhibitor, 2-carba cyclic phosphatidic acid, in lung fibrosis. ATS 2024. San Diego, CA, USA. 2024”N5ŒŽ19“ú.

Seidai Sato, Takushi Yamamoto, Yuki Morimoto, Yuta Isomura, Noriko Bando, Ryoko Suzue, Trang Thi Hong Phuong, Nandin-Erdene Danzan, Yuya Yamashita, Kojin Murakami, Hiroki Bando, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. Analysis of Local Distribution and Residence Time of Nintedanib in Fibrotic Lung Tissue Using Mass Spectrometry Imaging. ATS 2024. San Diego, CA, USA. 2024”N5ŒŽ19“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. �R�üˆÛ‰»–ò‚ÌŠî‘b‚Æ—Õ�°. ‘æ71‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[). �‚’m. 2024”N11ŒŽ29“ú.

Yoshitaka Zenke, Isamu Okamoto, Yuichiro Ohe, Koichi Azuma, Kyoichi Okishio, Hirokazu Ogino, Yoshitsugu Horio, Satoshi Oizumi, Manabu Hayama, Masatoshi Sugeno, Masaya Harada, Yuka Olivo, Haiyi Jiang, Suresh Senan. Durvalumab consolidation treatment�itx�jin limited-stage SCLC�FADRIATIC Japanese subgroup analysis. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(Presidential Session). ‰¡•l. 2024”N11ŒŽ2“ú.

’‡’nˆê˜Y, �•�£�_Žj, –…”ö’¼, —t‹v‹MŽi, ˆÉ“¡Œ’ˆê˜Y, –{ŠÔ—Tˆê˜Y, •P˜H‘å•ã, �Ÿ�ì�’, ‰z’q�é�º, �¬“c�®œA, ‹à“c�D˜a, ŽÂŒ´•×, �㌎–«�K, �²“¡�³“¹, ŽR“Y‰ëŒÈ, �¼‰ªˆÀ•F, �¬—Ñ�‘•F, âE•”ˆÐ, ’Ã’[—R‰À—¢. “ú–{�l�‚—î”xŠàгŽÒ‚ɑ΂·‚é�V‹K—LŠQŽ–�Û—\‘ªƒVƒXƒeƒ€LACTA-score‚ÌŠJ”­�FENSURE-GAŽŽŒ±‚æ‚è. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). ‰¡•l. 2024”N11ŒŽ1“ú.

�¬ŽRŒšˆê, �‚–ØŒ«�l, âV“¡�‡, ‹v•Û‘n‰î, �²�X–Ø�‚–¾, ‘å�ê’q�L, “¤�â�L�º, ‹Ê‰ª–¾—m, ’·“‡�L‘Š, “c‹{Šî—T, ‹à‘º’ˆ�¹, ŒË’Ë–Ò‘å, ŒÃ“cŒb, ‰Í“à—E�l, “ñ‹{�’, ’·ˆä—Ç�º, ‰¬–ì�L˜a, ˆÉ“¡Œ’‘¾˜Y, �ÎŒ´�¹Žu, —é–Ø‘ñŽ™. ŽÀ—Õ�°‚ł̊ùŽ¡—Ã�i�s�Ä”­‹¹‘BŠàгŽÒ‚ɑ΂·‚郌ƒ“ƒoƒ`ƒjƒu‚Ì—LŒø�«‚¨‚æ‚шÀ‘S�«‚ÌŒŸ“¢�F�‚—îŽÒ‚É‚¨‚¯‚é‰ð�Í. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). ‰¡•l. 2024”N11ŒŽ1“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, –—m•½, ”ö�è—Ì•F, ’Ë�è—C‹M, �û•£�¹‹B, Œ¬Œ´�_, �¼‰ªˆÀ•F. Fibrocyte •ª‰»�§Œä‚É‚æ‚é–Æ‰u”r�œ�Ž•ž‚Æ�V‹K•¡�‡‚ª‚ñ–Ɖu—Ö@‚Ö‚Ì“WŠJ. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). ‰¡•l. 2024”N10ŒŽ31“ú.

‰¬–ì�L˜a. ‚ª‚ñ–ò•¨—Ö@‚ɂ‚¢‚Ä�`�Å�V‚̘b‘è‚ð’†�S‚É�`. “¿“‡Œ§–¯‚ª‚ñƒtƒH�[ƒ‰ƒ€. “¿“‡. 2024”N10ŒŽ19“ú.

�¼‰ªˆÀ•F. ’m‚Á‚Ä‚¨‚«‚½‚¢”x‚Ì•a‹C�I�uCOPD�v‚Æ�uŠÔŽ¿�«”x‰Š�v. ‘æ11‰ñ“¿“‡ŽsˆãŽt‰ïCOPDŽs–¯ŒöŠJ�u�À. “¿“‡. 2024”N10ŒŽ14“ú.

�²“¡�³‘å. ”x�üˆÛ�ÇŒ¤‹†‚Ì�Å‘O�ü �`�¡�A’�–Ú‚·‚ׂ«•W“IŒó•âˆöŽq‚ɂ‚¢‚Ä�`. ‘æ44‰ñ“ú–{ƒTƒ‹ƒRƒCƒh�[ƒVƒX�^“÷‰èŽî�«Ž¾Š³Šw‰ï‘�‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[). �_ŒË. 2024”N10ŒŽ11“ú�D

�¼‰ªˆÀ•F. ”x‚ª‚ñ‚ɑ΂·‚錌ŠÇ�V�¶‘jŠQ–ò‚Æ�üˆÛ�×–E. ‘æ92‰ñŒÄ‹zŠí�‡“¯–k—¤’n•û‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[). ‹à‘ò. 2024”N5ŒŽ25“ú.

’Ëú±—C‹M, ”ò”~—º, ŽO‹´“ÕŽu, ”ö�è—Ì•F, –—m•½, •Ä“c�_�l, ‰¬–ì�L˜a, �û•£�¹‹B, �¬�씎‹v, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. �üˆÛ�×–E‚ÌŽîᇓà�Z��‚¨‚æ‚Ñ‚»‚ê‚ð—U“±‚·‚é‘–‰»ˆöŽq‚ª”ñ�¬�×–E”xŠà‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ẳð�Í. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ7“ú�D

’|“à‰hŽ¡, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, �¼‘º—LŒå, ŽsŒ´�¹–ç, š �d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨�¶, ‰¬–ì�L˜a, Œ¬Œ´�_, ŽÂŒ´•×, �¼‰ªˆÀ•F. �DŽ_‹…‚Í”ñ�¬�×–E”xŠàгŽÒ‚ɑ΂·‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŒø‰Ê—\‘ªƒoƒCƒIƒ}�[ƒJ�[. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ7“ú�D

�¼‰ªˆÀ•F. �«—ˆŒv‰æˆÏˆõ‰ï‚ÌŠˆ“®•ñ��. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•Ê•ñ��). ‰¡•l. 2024”N4ŒŽ7“ú�D

�‚‘ºŒ\, “¡Œ´Œcˆê, ‰Pˆäˆê—T, ’†‘ºŒdˆê, �‚‹´‘�, ŽRŒûŠo”Ž, ŽsŒ´‰pŠî, “n•”‘�, “¡–{�Lˆê, ’|“c—²”V, ûüú±�r˜a, �¼‰ªˆÀ•F, �¬—Ñ�‘•F, âE•”ˆÐ, ’Ã’[—R‰À—¢. �‚—îŽÒ‹@”\•]‰¿‚ð—p‚¢‚½ƒ‰ƒ“ƒ_ƒ€‰»‘æIII‘ŠŽŽŒ±�iENSURE-GAŽŽŒ±�j�FQOLƒf�[ƒ^‚̉ð�ÍŒ‹‰Ê. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ7“ú�D

�²“¡Œ÷, �¼‰ªˆÀ•F. �­�l�”‚ÌŠw•”�¶‚ɑ΂·‚é”x‹æˆæ‰ð–U‚̓ljeŽÀ�K. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2024”N4ŒŽ6“ú.

ˆ¢•”‚ ‚©‚Ë. ŒÄ‹zŠíŠ´�õ�ǂ̌»�ó‚Æ“W–]. ‘æ268‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï Žs–¯ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€. “¿“‡. 2024”N3ŒŽ10“ú.

�²“¡�³‘å. �¬�l‚Ì�d�Çšb‘§‚Æ�¶•¨Šw“I�»�܂ɂ‚¢‚Ä. —ߘa5”N“x“¿“‡Œ§ƒAƒŒƒ‹ƒM�[޾г Œ§–¯ŒöŠJ�u�À. “¿“‡. 2024”N2ŒŽ23“ú.

�¼‰ªˆÀ•F. ’m‚Á‚Ä‚¨‚«‚½‚¢”x‚Ì•a‹C�`ŠÔŽ¿�«”x‰Š‚Æ‚Í�H�`. —ߘa5”N“x“¿“‡Œ§—§ŽO�D•a‰@Œ§–¯ŒöŠJ�u�À. “¿“‡. 2024”N1ŒŽ27“ú.

�¼‰ªˆÀ•F. Žîᇔ÷�¬ŠÂ‹«‚Ìfibrocyte�`‹@”\‰ð�Í‚©‚ç•W“IŽ¡—ÂÖ�`. “ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ï ‘æ19‰ñƒgƒ‰ƒ“ƒXƒŒ�[ƒVƒ‡ƒiƒ‹ƒŠƒT�[ƒ`ƒ��[ƒNƒVƒ‡ƒbƒv. “Œ‹ž. 2024”N1ŒŽ26“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
’Ë�è—C‹M, ‰¬–ì�L˜a, ‰ª–ì‹`•v, Š`“à‘�Ži, –L“c—DŽq, �¼–{—˜‰ÁŽq, ”ö�è—Ì•F, �X“c—D, ŽO‹´“ÕŽu, –—m•½, �û•£�¹‹B, ’·’J‰Á—eŽq, ’|“à‰hŽ¡, —t‹v‹MŽi, �¼‰ªˆÀ•F. G-CSF‚ª�i“WŒ^�¬�×–E”xŠà‚É‚¨‚¯‚鉻Šw–Ɖu—Ö@‚ÌŽ¡—ÃŒø‰Ê‚É‹y‚Ú‚·‰e‹¿‚ðŒŸ“¢‚µ‚½‘½Ž{�Ý‹¤“¯Œã•ûŽ‹“I‰ð�Í. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‰¡•l. 2024”N11ŒŽ2“ú.

–—m•½, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ”ö�è—Ì•F, ’Ë�è—C‹M, �û•£�¹‹B, �¼‰ªˆÀ•F. IFN-ƒÁ”½‰ž�«ƒPƒ‚ƒJƒCƒ“ŽY�¶�§Œä‹@�˜‚̉𖾂Æ�V‹K•¡�‡‚ª‚ñ–Ɖu—Ö@‚ւ̉ž—p. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‰¡•l. 2024”N11ŒŽ1“ú.

“ŒŒöˆê, –Ñ—˜“Ä�l, çÝŽ��L’m, âV“¡—Ç‘¾, �Ô�¼�O˜N, •Ä�ã�m—Y, —P–Ø�Ž•F, ’·“‡�L‘Š, �‚‹´‘�, “¡“c�¹Ž÷, �¼‰ªˆÀ•F, –ö’J“TŽq, “ñ‹{‹Mˆê˜N, �·Œ[‘¾, –k–쎠‹v, ‹Ê“c �kŽ¡, Še–±”Ž, ŽR–{�M”V, Œ·ŠÔ�º•F, Œõ•y“O�Æ. �Ø�œ•s”\IIIŠú”ñ�¬�×–E”xŠà‚ɑ΂·‚鉻Šw•úŽË�ü—Ö@ŒãDurvalumab‚̃oƒCƒIƒ}�[ƒJ�[Œ¤‹†�G’†ŠÔ‰ð�Í. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‰¡•l. 2024”N10ŒŽ31“ú.

Žç“c—º, ŒÃ‰®’¼Ž÷, ‹à’n�L‘ñ, ‰¡”öŒc‹I, –ö�ì�’, ŽR–{а, ûüŽR�_ˆê, ‰Í�£�¬•ä, �¼‰i˜a�l, •�“cŒ«ˆê, ’·“‡�L‘Š, �ã–{’q�G, –x“c�®�½, ‘êŒû—Tˆê, –ì�ì‚ЂƂÝ, �¼‰ªˆÀ•F, �¬—Ñ�‘•F, âE•”ˆÐ, ’Ã’[—R‰À—¢. �‚—îŽÒ‹@”\•]‰¿‚Æ�¶‘¶ŠúŠÔ‚¨‚æ‚Ñ–ò•¨—Ö@‚É‚¨‚¯‚é—LŠQŽ–�Û‚Ì—\‘ª”\‚ÉŠÖ‚·‚錟“¢�FENSURE-GA studyƒf�[ƒ^‚æ‚è. ‘æ65‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‰¡•l. 2024”N10ŒŽ31“ú.

’Ëú±—C‹M, ‰¬–ì�L˜a, ‰ª–ì‹`•v, Š`“à‘�Ži, –L“c—DŽq, �¼–{—˜‰ÁŽq, ”ö�è—Ì•F, �X“c—D, ŽO‹´“ÕŽu, –—m•½, �û•£�¹‹B, ’·’J‰Á—eŽq, ’|“à‰hŽ¡, —t‹v‹MŽi, �¼‰ªˆÀ•F. G-CSF ‚ª�i“WŒ^�¬�×–E”xŠà‚ɑ΂·‚鉻Šw–Ɖu—Ö@‚ÌŽ¡—ÃŒø‰Ê‚É‹y‚Ú‚·‰e‹¿‚ÉŠÖ‚·‚é‰ð�Í. ‘æ62‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. •Ÿ‰ª. 2024”N10ŒŽ24“ú.

—§‰Ô�®‘¾˜Y, �¬�씎‹v, �´�…�^—SŽq, �Ⓦ�OŠî, �²“¡�³‘å, �‚ŽR‘ì‘å, ˆä”V�ã�_ˆê, �¼‰ªˆÀ•F, �íŽR�Kˆê. –��«‹CŠÇŽxšb‘§‚É‚¨‚¯‚é”t�×–E‰ßŒ`�¬‚ɑ΂·‚éLPA1Žó—e‘̖̂ðŠ„. ‘æ73‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï. ‹ž“s. 2024”N10ŒŽ19“ú.

���ì�k‘¢, �²“¡�³‘å, �¬ŽRˆë–ç, ˆé‘º—S‘¾, —é�]—ÁŽq, ‘º�ã�s�l, �Ⓦ�OŠî, “yŽtŒbŽq, �¼‰ªˆÀ•F. ƒŠƒ“ƒp‹…“ÁˆÙ“Iƒ^ƒ“ƒpƒNŽ¿ƒ`ƒ�ƒVƒ“ƒLƒi�[ƒ[‘jŠQ‚É‚æ‚é�R�üˆÛ‰»�ì—p‚ÌŒŸ“¢. ‘æ4‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï. “Œ‹ž. 2024”N9ŒŽ29“ú.

�²“¡�³‘å, ŽR–{‘ìŽu, �X–{—FŽ÷, ˆé‘º—S‘¾, —é�]—ÁŽq, ‘º�ã�s�l, �Ⓦ�OŠî, “yŽtŒbŽq, ���ì�k‘¢, �¼‰ªˆÀ•F. Ž¿—Ê•ª�̓Cƒ��[ƒWƒ“ƒO‚ð—p‚¢‚½ƒjƒ“ƒeƒ_ƒjƒu‚Ì”x“à‹Ç�Ý•ª•z‚Ƒؗ¯ŽžŠÔ‚ÌŒŸ“¢. ‘æ4‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï. “Œ‹ž. 2024”N9ŒŽ29“ú.

ŽO‹´“ÕŽu, �¬ŽRˆë–ç, ‰¬–ì�L˜a, –—m•½, ”ö�è—Ì•F, ’Ë�è—C‹M, �X“c—D, ‹g“c•É�l, Œ¬Œ´�_, �û•£�¹‹B, �¼‰ªˆÀ•F. Fibrocyte �§Œä‚É‚æ‚邪‚ñ–Ɖu”r�œ�Ž•ž‚ÉŒü‚¯‚½Ž¡—Ã�í—ª. ‘æ83‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. •Ÿ‰ª. 2024”N9ŒŽ20“ú.

�¼žŠ“Ö˜Y, ‰¬–ì�L˜a, ‰ª“c�G•ä. ƒyƒvƒ`ƒhƒ�ƒNƒ`ƒ“ IMA950 ‚Æ varlilumab •¹—p—Ö@‚͒ራ�«“x�_ŒoäPŽîгŽÒ––�½ŒŒ‚É‚¨‚¢‚Ä effector memory T �×–E‚Ì•ª‰»‚ð‘£�i‚·‚é. ‘æ83‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. •Ÿ‰ª. 2024”N9ŒŽ19“ú.

‰¬–ì�L˜a, �¼žŠ“Ö˜Y, �¼‰ª ˆÀ•F, Nicholas A Butowski, Susan M Chang, Mitchel S Berger, ‰ª“c�G•ä. ’ራ�«“x�_ŒoäPŽî‚ɑ΂·‚éƒ}ƒ‹ƒ`ƒyƒvƒ`ƒhƒ�ƒNƒ`ƒ“IMA950‚Æ�RCD27ƒAƒSƒjƒXƒg�R‘Ìverlilumab•¹—p—Ö@‚̖ƉuŠw“IŒø‰Ê‚ɂ‚¢‚Ä. ‘æ28‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘�‰ï¥‘æ37‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠw�p�W‰ï‘�‰ï�‡“¯‘å‰ï. “Œ‹ž. 2024”N7ŒŽ12“ú.

‹{–{Œ›�Æ, �û•£�¹‹B, ˆé‘º—S‘¾, �X“c—D, ‘º�ã�s�l, �Ⓦ�OŠî, ”ö�è—Ì•F, ���ì�k‘¢, •Ä“c�_�l, ‰¬–ì�L˜a, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾Œã‚̌ċzŠíŠ´�õ�ǃnƒCƒŠƒXƒN�Ç—á‚É‚¨‚¯‚é—\–h“I�R‹Û–ò“Š—^‚̈Ӌ`‚ɂ‚¢‚Ă̌ã•ûŽ‹“IŒ¤‹†. ‘æ47‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. ‘å�ã. 2024”N6ŒŽ28“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, –—m•½, ”ö�è—Ì•F, Œ¬Œ´�_, �¼‰ªˆÀ•F. Fibrocyte •ª‰»‚ð•W“I‚Æ‚µ‚½–Ɖu”r�œ�Ž•ž‚Ö‚Ì�V‹KŽ¡—Ã’T�õ. ‘æ28‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. “Œ‹ž. 2024”N6ŒŽ20“ú.

‰¬–ì�L˜a, �¼žŠ“Ö˜Y, �¼‰ªˆÀ•F. ƒ}ƒ‹ƒ`ƒyƒvƒ`ƒhƒ�ƒNƒ`ƒ“ IMA950 ‚Æ�R CD27 ƒAƒSƒjƒXƒg�R‘Ì verlilumab ‚Ì•¹—p—Ö@‚͒ራ�«“x�_ŒoäPŽî‚É‚¨‚¯‚é T �×–E–Ɖu‰ž“š‚ð—U“±‚·‚é. ‘æ28‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. “Œ‹ž. 2024”N6ŒŽ20“ú.

ŽR‰º—Y–ç, ‰Í–ì�O, ˆÀ‘î�Ž”Ž, ‘º�ã�s�l, “à“¡�L�m, �²“¡�³‘å, �¼‰ªˆÀ•F. ƒŠƒEƒ}ƒ`ƒ‚ƒfƒ‹‚É‚¨‚¯‚éPLK‘jŠQ—Ö@‚ÌŽ¡—ÃŒø‰Ê. ‘æ68‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. �_ŒË. 2024”N4ŒŽ18“ú.

�²“¡�³‘å, ŽR–{‘ìŽu, �X–{—FŽ÷, �Ⓦ‹IŽq, ‘º�ã�s�l, �Ⓦ�OŠî, “yŽtŒbŽq, ���ì�k‘¢, �¼‰ªˆÀ•F. Ž¿—Ê•ª�̓Cƒ��[ƒWƒ“ƒOiMScope QT‚ð—p‚¢‚½ƒjƒ“ƒeƒ_ƒjƒu‚Ì”x“à‹Ç�Ý•ª•z‚Ƒؗ¯ŽžŠÔ‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‰¡•l. 2024”N4ŒŽ7“ú�D

‰¬–ì�L˜a, Nguyen Thi Na, ���¼”Ž”V, ŽO‹´“ÕŽu, ’Ëú±—C‹M, –—m•½, ”ö�è—Ì•F, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹¹•”Žîᇂɑ΂µ‚ĖƉuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Æ•¹—p‚·‚ׂ«ŽŠ“K�R‚ª‚ñ�܂̓¯’è‚ð–ÚŽw‚µ‚½–ƉuŠw“I‰ð�Í. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‰¡•l. 2024”N4ŒŽ7“ú�D

“yŽtŒbŽq, �²“¡�³‘å, �¬�씎‹v, ‘º�ã�s�l, �¬ŽRˆë–ç, Trang Thi Hong Phuong, ‰Í–ì�O, �¬—Ñ�Ž—˜, �”�¯�r˜Y, �¼‰ªˆÀ•F. ƒI�[ƒgƒ^ƒLƒVƒ“‘jŠQ�ì—p‚ð—L‚·‚é2ccPA‚Ì�R�üˆÛ‰»�ì—p‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‰¡•l. 2024”N4ŒŽ7“ú�D

Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yugo Matumura, Seiya Ichihara, Takeshi Imakura, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Yuko Toyoda, Kayoko Hase, Eiji Takeuchi, Takashi Haku, Yasuhiko Nishioka. The impacts of G-CSF on the therapeutic efficacy of chemo-immunotherapy for extensive-stage small cell lung cancer. ‘æ21‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. –¼ŒÃ‰®. 2024”N2ŒŽ24“ú.

Hirokazu Ogino, Nguyen Thi Na, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi, Yasuhiko Nishioka. Fluoropyrimidine has a potential to be an immunologically optimal partner ofimmunotherapy for thoracic malignancies. ‘æ21‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. –¼ŒÃ‰®. 2024”N2ŒŽ22“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
˜a“c’Ã�«–¤, ‘º�ã�s�l, �Ⓦ�OŠî, �Ⓦ‹IŽq, –—m•½, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒŒƒ“ƒoƒ`ƒjƒu‚ª‘tŒø‚µ‚½FGFR3•ψٗz�«‹¹‘BŠà‚Ì1—á. ‘æ131‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2024”N12ŒŽ15“ú.

ˆÉ“¡ˆê‹P, ‘º�ã�s�l, �Ⓦ�OŠî, ’†�¼Œk‰î, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �û•£�¹‹B, �¼‰ªˆÀ•F. ‘ÌŠOŽ®–ŒŒ^�l�H”x‚𓱓ü‚µ‚Ä‹~–½‚µ‚½ŠÖ�ßƒŠƒEƒ}ƒ`ŠÖ˜AŠÔŽ¿�«”x޾г‹}�«‘�ˆ«‚Ì1—á. ‘æ131‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2024”N12ŒŽ15“ú.

ŽO–Ø�^—�, �¼žŠ“Ö˜Y, ŽR‘º“ÄŽi˜Y, “¡’†—Yˆê, �¼‰ªˆÀ•F, ˆÉ�è•x—R”ü, ‘ê‘ò�GŒõ. “�«”xmycobacterium abscessusŠ´�õ�ǂɎè�p—Ö@‚ð�s‚¢•a�óƒRƒ“ƒgƒ��[ƒ‹‚𓾂½ˆê—á. ‘æ75‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï. �‚’m. 2024”N11ŒŽ30“ú.

ˆé‘º—S‘¾, ‘º�ã�s�l, �Ⓦ�OŠî, Š�–{’B–ç, ‹ß“¡Œ\‘å, “yŽtŒbŽq, •Ÿ‰Æ–ƒ”ü, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, ’Ò�½Žm˜Y, Œ´—Ï�¢, �¼‰ªˆÀ•F. •›�t•s‘S‚ð�‡•¹‚µ‚½ŒÇ”­�«‚Ì—¼‘¤•›�tŒ‹Šj‚̈ê—á. ‘æ75‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï. �‚’m. 2024”N11ŒŽ30“ú.

�X“c—D, ‘º�ã�s�l, �Ⓦ�OŠî, ‹{–{Œ›�Æ, ˆé‘º—S‘¾, Š�–{’B–ç, ‹ß“¡Œ\‘å, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾‚Å�f’f‚µ‚½”x“à�_Œo�âŽî‚̈ê—á. ‘æ33‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �‚’m. 2024”N11ŒŽ30“ú.

’†�¼éD“l, ‘º�ã�s�l, �Ⓦ�OŠî, ˆé‘º—T‘¾, Š�–{’B–ç, ‹ß“¡Œ\‘å, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒeƒ|ƒ`ƒjƒu“Š—^Œã‚É�‚“x‚ÈŒŒ�¬”ÂŒ¸�­‚Æ�D’†‹…Œ¸�­‚𗈂µ‚½MET exon14 skipping•ψٗz�«”x‘BŠà‚̈ê—á. ‘æ71‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �‚’m. 2024”N11ŒŽ29“ú.

Š�–{’B–ç, ‰Í–ì�O,‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. Rituximab‚É‚æ‚éinfusion-related reactions‚𗈂µ�A�WŠw“IŽ¡—Âð—v‚µ‚½‘½”­ŒŒŠÇ‰Š�«“÷‰èŽî�Ç‚Ì1—á. ‘æ35‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �L“‡. 2024”N11ŒŽ3“ú.

’†�¼éD“l, “à“¡�L�m, ‘º�ã�s�l, ŽR‰º—Y–ç, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �¼‰ªˆÀ•F. �_Œo�¶ŒŸ‚Å�f’f‚µ“¾‚½�A‹•ŒŒ�«––�½�_Œo�áŠQ‚ð’æ‚µ‚½�RƒŠƒ“Ž‰Ž¿�R‘Ì�ÇŒóŒQ‚Ì1—á. ‘æ35‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �L“‡. 2024”N11ŒŽ2“ú.

‹ß“¡Œ\‘å, ‘º�ã�s�l, �Ⓦ�OŠî, ’Ëú±—C‹M, ‰¬–ì�L˜a, �¼–{—˜‰ÁŽq, �X“c—D, ŽO‹´“ÕŽu, ”ö�è—Ì•F, –—m•½, �²“¡�³‘å, �û•£�¹‹B, ‰ª–ì‹`•v, Š`“à‘�Ži, –L“c—DŽq, ’·’J‰Á—eŽq, ’|“à‰hŽ¡, —t‹v‹MŽi, �¼‰ªˆÀ•F. �i“WŒ^�¬�×–E”xŠà‚É‚¨‚¢‚Äè÷—±‹…ƒRƒ�ƒj�[ŽhŒƒˆöŽq‚ª‰»Šw–Ɖu—Ö@‚ÌŽ¡—ÃŒø‰Ê‚É‹y‚Ú‚·‰e‹¿. ‘æ269‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2024”N7ŒŽ21“ú.

‰¬–ì�L˜a, �¼‰ªˆÀ•F. �p‘OŽ¡—ÂɂĔx‘S“E‚ð‰ñ”ð‚µ“¾‚½”ñ�¬�×–E”xŠà‚Ì2—á. ‘æ62‰ñ“ú–{”xŠàŠw‰ï ’†�‘�EŽl�‘Žx•”Šw�p�W‰ï(‰ï’·“Á•ÊŠé‰æ). •ÄŽq. 2024”N7ŒŽ19“ú.

ˆÉ“¡ˆê‹P, ‘º�ã�s�l, �Ⓦ�OŠî, ŽR–{�_�¶, ’Ë�è—C‹M, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. EGFR L858R •ψٗz�«”x‘BŠà‚ɑ΂µ‚Ä CBDCA�{nab-PTX�{Atezolizumab ‚ª pseudoprogression ‚𔺂Á‚Ä’˜Œø‚µ‚½ˆê—á. ‘æ70‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. •ÄŽq. 2024”N7ŒŽ19“ú.

˜a“c’Ã�«–¤, ‘º�ã�s�l, �Ⓦ�OŠî, “à“¡�L�m, �²“¡�³‘å, “Œ“�‘ã, �²“¡‰ë”ü, �û•£�¹‹B, ’†‘º–ÎŽ÷, �¶•ûŒöŽq, �‚“c”ü�²Žq, �¼‰ªˆÀ•F. COVID-19‚É�‡•¹‚µ‚½ŒŒ�´Œ^15A ”x‰Š‹…‹Û‚É‚æ‚é�d�Ç”x‰Š‚̈ê—á. ‘æ70‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. •ÄŽq. 2024”N7ŒŽ19“ú.

ŽR“c�‹G, ‘º�ã�s�l, �Ⓦ�OŠî, ’†�¼Œk‰î, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒ\ƒgƒ‰ƒVƒu‚ª‘tŒø‚µ‚½KRAS G12C•ψٗz�«‚Ì”xŒ´”­‘å�×–E�_Œo“à•ª”åŠà‚̈ê—á. ‘æ70‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. •ÄŽq. 2024”N7ŒŽ19“ú.

�Ⓦ‹IŽq, ‘º�ã�s�l, �Ⓦ�OŠî, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒvƒŒƒhƒjƒ]ƒ�ƒ“�AƒgƒVƒŠƒYƒ}ƒu�AƒŠƒcƒLƒVƒ}ƒu‚ÌŽO�Ü“¯Žž•¹—p—Ö@‚ª‘tŒø‚µ‚½Ž¡—Ã’ï�R�«TAFRO�ÇŒóŒQ‚Ì1—á. ‘æ130‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2024”N6ŒŽ16“ú.

’†�¼éD“l, ‘º�ã�s�l, �Ⓦ�OŠî, ‹{–{Œ›�Æ, �Ⓦ‹IŽq, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. •“IƒQƒmƒ€ƒvƒ�ƒtƒ@ƒCƒŠƒ“ƒOŒŸ�¸‚É‚ÄPD-L1ˆâ“`Žq‘�•�‚ð”F‚ß‚½‹¹�œŒ´”­•úŽË�üŠÖ˜A“÷Žî‚Ì1—á. ‘æ130‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2024”N6ŒŽ16“ú.

�Ⓦ‹IŽq, �Ⓦ�OŠî, “yŽtŒbŽq, ”ü”n�³�l, •Ÿ‰Æ–ƒ”ü, “à“¡�L�m, ”ö�è—Ì•F, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �âŒû‹Å, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é�d�Çšb‘§‚ɑ΂·‚é�¶•¨Šw“I�»�܂̎¡—ÃŒø‰Ê‚ÌŒŸ“¢. ‘æ268‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2024”N3ŒŽ10“ú.
2023”N‹Æ�Ñ
�y‰¢•¶Œ´’˜�z
Yabuki Y, Hanibuchi M, Takeuchi E, Haku T, Kanematsu T, Nishimura N, Toyoda Y, Mitsuhashi A, Otsuka K, Sato S, Goto H, Yoneda H, Ogino H, Nokihara H, Shinohara T, Nishioka Y. A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent non-squamous non-small-cell lung cancer. Thorac Cancer 14(32):3232-3239, 2023.

Takeuchi E, Kondo K, Okano Y, Ichihara S, Kunishige M, Kadota N, Machida H, Hatakeyama N, Naruse K, Ogino H, Nokihara H, Shinohara T, Nishioka Y. Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thorac Cancer 14(30):3042-3050, 2023.

Harada S, Imakura T, Sato S, Nokihara H, Nishioka Y. A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab: Case report. J Med Invest 70(3,4):516-520, 2023.

Sato S, Koyama K, Ogawa H, Murakami K, Imakura T, Yamashita Y, Kagawa K, Kawano H, Hara E, Nishioka Y. A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect. Respir Investig 61(6):781-792, 2023.

Takahashi T, Sato Y, Kashihara T, Miyata Y, Fujino Y, Mitsui Y, Okamoto K, Miyamoto H, Nishioka Y, Takayama T. Nintedanib-Induced Gastric Antral Vascular Ectasia in Patients With Idiopathic Pulmonary Fibrosis. ACG Case Rep J 10:e01107, 2023.

Takahashi H, Ogino H, Bando H, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Nishioka Y. FoundationOne CDx Detected an Uncovered Variant of EGFR Exon 19 Deletion by Omcomine Dx Target Test in a Patient with Lung Adenocarcinoma. Respir Med Case Rep 45:101893, 2023.

Takeuchi E, Kondo K, Okano Y, Kunishige M, Kondo Y, Kadota N, Machida H, Hatakeyama N, Naruse K, Ogino H, Nokihara H, Shinohara T, Nishioka Y. Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. J Cancer Res Clin Oncol 149(7):3139-3147, 2023.

Imakura T, Sato S, Koyama K, Ogawa H, Niimura T, Murakami K, Yamashita Y, Haji K, Naito N, Kagawa K, Kawano H, Zamami Y, Ishizawa K, Nishioka Y. A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis. Respir Res 24(1):148, 2023.

Yanagihara T, Tsubouchi K, Zhou Q, Chong M, Otsubo K, Isshiki T, Schupp JC, Sato S, Scallan C, Upagupta C, Revill S, Ayoub A, Chong SG, Dvorkin-Gheva A, Kaminski N, Tikkanen J, Keshavjee S, Pare G, Guignabert C, Ask K, Kolb MR. Vascular-Parenchymal Crosstalk Promotes Lung Fibrosis Through BMPR2 Signaling. Am J Respir Crit Care Med 207(11):1498-1514, 2023.

Nishioka Y, Homma S, Ogura T, Sato S, Arai N, Tomii K, Kamio K, Sakamoto S, Miyazaki Y, Tomioka H, Hisata S, Handa T, Azuma A. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis. Respir Investig 61(4):498-507, 2023.

Mitsuhashi A, Koyama K, Ogino H, Afroj T, Nguyen NT, Yoneda H, Otsuka K, Sugimoto M, Kondoh O, Nokihara H, Hanibuchi M, Takizawa H, Shinohara T, Nishioka Y. Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Rep 42(3):112162, 2023.

Hanibuchi M, Mitsuhashi A, Saijo A, Kajimoto T, Sato S, Kitagawa T, Nishioka Y. A case of atopic cough with aphonia showed a prominent response to a histamine H1 receptor antagonist. J Med Invest 70(1,2):281-284, 2023.

Nguyen N, Mitsuhashi A, Ogino H, Kozai H, Yoneda H, Afroj T, Sato S, Nokihara H, Shinohara, T, Nishioka Y. S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor. Cancer Sci 114(2):384-398, 2023.

Kuwana M, Bando M, Kawahito Y, Sato S, Suda T, Kondoh Y; CTD-ILD Delphi Collaborators (Nishioka Y). Identification and management of connective tissue disease-associated interstitial lung disease:evidence-based Japanese consensus statements. Expert Rev Respir Med 17(1):71-80, 2023.

Azuma M, Oishi K, Akeda Y, Morino S, Motoki Y, Hanibuchi M, Nishioka Y. Safety and immunogenicity of the sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naive adults �† 65 years of age: the comparison of booster effects by intervals of 0.5 year and 1.0 year. Vaccine 41(5):1042-1049, 2023.

Okuda R, Ogura T, Hisata S, Baba T, Kondoh Y, Suda T, Johkoh T, Iwasawa T, Tomioka H, Bando M, Azuma A, Inoue Y, Arai T, Nakamura Y, Miyamoto A, Miyazaki Y, Chiba H, Ishii H, Hamada N, Terasaki Y, Kuwahira I, Sato S, Kato S, Suzuki T, Sakamoto S, Nishioka Y, Hattori N, Hashimoto N, Morita S, Ichihara N, Miyata H, Hagiwara K, Nukiwa T, Kobayashi K. Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry. Respir Investig 61(1):95-102, 2023.

Hanibuchi M, Mitsuhashi A, Kajimoto T, Saijo A, Sato S, Kitagawa T, Nishioka Y. Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma. Respir Investig 61(1):16-22, 2023.

Ichihara S, Ogino H, Yoneda H, Haji K, Kagawa K, Murakami K, Mima M, Aoi Y, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Sato S, Nokihara H, Nishioka Y. Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody. Respir Med Case Rep 41:101797, 2023.

Numasaki M, Ito K, Takagi K, Nagashima K, Notsuda H, Ogino H, Ando R, Tomioka Y, Suzuki T, Okada Y, Nishioka Y, Unno M. Diverse and divergent functions of IL-32ƒÀ and IL-32ƒÁ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8. Cell Immunol 383:104652, 2023.
�y˜a•¶’˜�‘�z
�²“¡�³‘å, �¼‰ªˆÀ•F. �i�s�«�üˆÛ‰»‚𔺂¤ŠÔŽ¿�«”x޾г‚Ì�f’f‚ÆŽ¡—Ã. ŒÄ‹zŠí޾г�Å�V‚ÌŽ¡—Ã2023-2024, Œ·ŠÔ�º•F, �¼‰ªˆÀ•F, –˜a”Ž•Ò�W, pp31-34, 2023, “ì�]“°.

�¼‰ªˆÀ•F. “Á”­�«”x�üˆÛ�Ç. �¡“ú‚ÌŽ¡—ÃŽw�j2023”N”Å, •ŸˆäŽŸ–î, �‚–Ø�½, �¬Žºˆê�¬ ‘�•Ò�W, pp309-311, 2023, ˆãŠw�‘‰@.
�y˜a•¶‘��à�z
�²“¡�³‘å, ‘º�ã�s�l, �¼‰ªˆÀ•F. ”x�üˆÛ�ǂɂ¨‚¯‚éfibrocyte‚Ì–ðŠ„. ŒÄ‹zŠí“à‰È 44(3):336-341, 2023.

ŽO‹´“ÕŽu, �¼‰ªˆÀ•F. 1�×–E‰ð�͂ɂæ‚éŽîᇓàfibrocyte‚Ì“¯’è. �×–E 55(7):55-59, 2023.

�²“¡�³‘å, �¼‰ªˆÀ•F. PF-ILD‚Æ�R�üˆÛ‰»–ò‚ɂ‚¢‚Ä. “ú–{—Õଠ81(5):764-770, 2023.

�¼‰ªˆÀ•F, �²“¡�³‘å. “Á”­�«ŠÔŽ¿�«”x‰Š�iIIPs�j�E”x�üˆÛ�Ç. “ú–{ˆãŽ–�V•ñ 5157:42-43, 2023.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Atsushi Mitsuhashi, Kazuya Koyama, Tania Afroj, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka. The identification and analysis of fibrocyte regulating the tumor immune microenvironment. The 9th Joint Meeting 2023 (Tokushima Univ., Gifu Univ., SNU, and IBS-KAIST). Daejeon, South Korea. 2023”N10ŒŽ25“ú.

Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, NandinErdene Danzan, Hiroki Bando, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Eiji Hara, Yasuhiko Nishioka. A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ12“ú.

Hiroki Bando, Seidai Sato, Hirohisa Ogawa, Kazuya Koyama, Kojin Murakami, Yuya Yamashita, Nandin-Erdene Danzan, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. Anamorelin, a ghrelin receptor agonist, inhibited the allergic airway inflammation in mice. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ10“ú.

Yasuhiro Kondoh, Taiki Furukawa, Ryo Teramachi, Hironao Hozumi, Takafumi Suda, Tomoyuki Fujisawa, Ryoko Egashira, Takeshi Johkoh, Junya Fukuoka, Masataka Kuwana, Takashi Ogura, Yasunari Miyazaki, Masashi Bando, Yoshikazu Inoue, Hiromi Tomioka, Yasuhiko Nishioka, Hirofumi Chiba, Masahito Ebina, Kazuya Ichikado, Naozumi Hashimoto, Makoto Ishii. Diagnostic Criteria Arrangement in Nationwide All ILD Registry with Central MDD in Japan; PROMISE study. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ10“ú.

Taiki Furukawa, Yasuhiro Kondoh, Shintaro Oyama, Ryo Teramachi, Hironao Hozumi, Takafumi Suda, Tomoyuki Fujisawa, Ryoko Egashira, Takeshi Johkoh, Junya Fukuoka, Kensuke Kataoka, Hideya Kitamura, Osamu Nishiyama, Masaki Okamoto, Naoki Koshimizu, Nobuhisa Ishikawa, Satoshi Okamori, Yasunari Miyazaki, Masashi Bando, Yoshikazu Inoue, Takashi Ogura, Masataka Kuwana, Hiromi Tomioka, Yasuhiko Nishioka, Hirofumi Chiba, Masahito Ebina, Kazuya Ichikado, Yoichi Nakanishi, Naozumi Hashimoto, Yoshimune Shiratori, Yoshinori Hasegawa, Makoto Ishii: The Providing Multidisciplinary Ild Diagnoses [promise] Study Group. Nationwide All ILD registry with central MDD in Japan; Providing Multidisciplinary ILD diagnoses (PROMISE) study. ERS International Congress 2023. Milan, Italy. 2023”N9ŒŽ10“ú.

Kojin Murakami, Haruka Nishimura, Hiroshi Kawano, Nandin-Erdene Danzan, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kazuya Koyama, Seidai Sato, Yasuhiko Nishioka. Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model. ATS 2023. Washington, DC, USA. 2023”N5ŒŽ21“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
ŽO‹´“ÕŽu, ‰¬–ì�L˜a, •Ä“c�_�l, Œ¬Œ´�_, �¼‰ªˆÀ•F. ‹¹•”Žîᇂɂ¨‚¯‚éfibrocyte‚Ì“¯’è‚Æ�V‹KŽ¡—ÕW“I‚Æ‚µ‚Ă̓WŠJ. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). �ç—t. 2023”N11ŒŽ3“ú.

�¼‰ªˆÀ•F. “Á”­�«Ž÷Ž}�ó”x�œ‰»�Ç. ‘æ3‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). “Œ‹ž. 2023”N9ŒŽ30“ú.

�¼‰ªˆÀ•F. ”x�üˆÛ�ǂɑ΂·‚镪Žq•W“IŽ¡—Â̊J”­‚ð–ÚŽw‚µ‚Ä�`‘��BˆöŽq‚©‚ç fibrocyte ‚Ö�`. ‘æ3‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï(“Á•Ê�u‰‰). “Œ‹ž. 2023”N9ŒŽ30“ú.

ŽO‹´“ÕŽu, �¬ŽRˆë–ç, ƒAƒtƒ��[ƒY ƒ^ƒjƒA, �¼žŠ“Ö˜Y, ”ò”~—º, ‰¬–ì�L˜a, �™–{�³“¹, �ª“Œ��, Œ¬Œ´�_, �¼‰ªˆÀ•F. Žîᇓà fibrocyte ‚Ì“¯’è‚Æ�§Œä‚É‚æ‚é�V‹K‚ª‚ñŽ¡—ÊJ”­‚Ö‚Ì‹´“n‚µŒ¤‹†. ‘æ82‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï(“ú–{ŠàŠw‰ï�§—ã�ÜŽó�Ü�u‰‰). ‰¡•l. 2023”N9ŒŽ22“ú.

�¼‰ªˆÀ•F. Žîᇔ÷�¬ŠÂ‹«‚Ìfibrocyte�F‹@”\‰ð�Í‚©‚ç•W“IŽ¡—ÂÖ. ‘æ32‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï(ƒCƒuƒjƒ“ƒOƒZƒ~ƒi�[). �å‘ä. 2023”N7ŒŽ20“ú.

‰¬–ì�L˜a. •¡�‡‚ª‚ñ–Ɖu—Ö@‚Ì Up-To-Date. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï(Year in Review). �²‰ê. 2023”N6ŒŽ22“ú.

�¡‘qŒ’, �²“¡�³‘å, �¼‰ªˆÀ•F. ERS2022‚ÉŽQ‰Á‚µ‚Ä. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•ÊŠé‰æ). “Œ‹ž. 2023”N4ŒŽ28“ú�D

�¼‰ªˆÀ•F. “ú–{ŒÄ‹zŠíŠw‰ï�«—ˆŒv‰æˆÏˆõ‰ï•ñ��. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•Ê•ñ��). “Œ‹ž. 2023”N4ŒŽ28“ú�D

Yasuhiko Nishioka. Molecular pathogenesis of pulmonary fibrosis�Fupdate by novel technology. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(International Symposium). “Œ‹ž. 2023”N4ŒŽ28“ú�D
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
’Ë�è—C‹M, ”ò”~—º, ŽO‹´“ÕŽu, ”ö�è—Ì•F, –—m•½, •Ä“c�_�l, ‰¬–ì�L˜a, �û•£�¹‹B, �¬�씎‹v, ‘ê‘ò�GŒõ, �¼‰ªˆÀ•F. ”ñ�¬�×–E”xŠà�Ç—á‚É‚¨‚¯‚éŽîá‡�Z���üˆÛ�×–E‚Ì‘–‰»ˆöŽq‚ÆŽ¾Š³—\Œã‚Ƃ̊֘A�«‚ɂ‚¢‚Ẳð�Í. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. �ç—t. 2023”N11ŒŽ4“ú.

’|“à‰hŽ¡, ‰¬–ì�L˜a, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, �¼‘º—LŒå, ŽsŒ´�¹–ç, š �d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨�¶, Œ¬Œ´�_, ŽÂŒ´•×, �¼‰ªˆÀ•F. �DŽ_‹…‘�‰Á‚͖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽ¡—ÂðŽó‚¯‚½”ñ�¬�×–E”xŠàгŽÒ‚ÌŒø‰Ê—\‘ªƒoƒCƒIƒ}�[ƒJ�[. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. �ç—t. 2023”N11ŒŽ3“ú.

‰¬–ì�L˜a, ���¼”Ž”V, ŽO‹´“ÕŽu, ’Ë�è—C‹M, –—m•½, ”ö�è—Ì•F, •Ä“c�_�l, �û•£�¹‹B, Œ¬Œ´�_, �¼‰ªˆÀ•F. ƒtƒb‰»ƒsƒŠƒ~ƒWƒ“‚Í‹¹•”Žîᇂ̖ƉuŒ´�«�×–EŽ€‚ð—U“±‚µ–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŽŠ“K•¹—p–ò‚ƂȂ蓾‚é. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. �ç—t. 2023”N11ŒŽ3“ú.

”ö�è—Ì•F, Œ¬Œ´�_, ’Ë�è—C‹M, –—m•½, ŽO‹´“ÕŽu, •Ä“c�_�l, ‰¬–ì�L˜a, �¼‰ªˆÀ•F. �i“WŒ^�¬�×–E”xŠà‚É‚¨‚¢‚Ä2ŽŸŽ¡—ªŽó‚¯‚ç‚ê‚È‚¢Š³ŽÒ‚Ì—Õ�°“I”wŒi‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. �ç—t. 2023”N11ŒŽ3“ú.

�²“¡�³‘å, �û•£�¹‹B, ŽO‹´“ÕŽu, �¼‰ªˆÀ•F. ŠPšb‘§Ž¡—Âɂ¨‚¯‚éŒø‰Ê—\‘ªƒoƒCƒIƒ}�[ƒJ�[‚Ì’T�õ. ‘æ72‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï. “Œ‹ž. 2023”N10ŒŽ21“ú.

�Ⓦ�OŠî, �²“¡�³‘å, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L“ñ, �¬ŽRˆë–ç, ‰Í–ì�O, �¬�씎‹v, �¼‰ªˆÀ•F. ƒOƒŒƒŠƒ“Žó—e‘Ì�ì“®–òƒAƒiƒ‚ƒŒƒŠƒ“‚̃AƒŒƒ‹ƒM�[�«‹C“¹‰Š�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ72‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï. “Œ‹ž. 2023”N10ŒŽ20“ú.

�¬�씎‹v, �´�…�^—SŽq, •½�C, �Ⓦ�OŠî, �²“¡�³‘å, �íŽR�Kˆê, �¼‰ªˆÀ•F. ƒ�ƒ^ƒ{ƒ��[ƒ€‰ð�͂ɂæ‚é•¡�”�RŒ´Š´�ìšb‘§ƒ‚ƒfƒ‹‚É‚¨‚¯‚é“�«ˆöŽq‚Ì’T�õ. ‘æ72‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï. “Œ‹ž. 2023”N10ŒŽ20“ú.

”ö�è—Ì•F, �¬�ì‰l, Œ¬Œ´�_, ŽO‹´“ÕŽu, –—m•½, •Ä“c�_�l, ‰¬–ì�L˜a, �¼‰ªˆÀ•F. ALK—Z�‡ˆâ“`Žq—z�«”ñ�¬�×–E”xŠà‚ÌŒø‰Ê—\‘ªˆöŽq‚ÉŠÖ‚·‚錟“¢. ‘æ61‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‰¡•l. 2023”N10ŒŽ19“ú.

�²“¡�³‘å, �¬�씎‹v, ‘º�ã�s�l, ŽR‰º—Y–ç, “yŽtŒbŽq, ‰Í–ì�O, Œ´‰p“ñ, �¼‰ªˆÀ•F. BRD4 ‘jŠQ�Ü ARV825 ‚Ì�üˆÛ‰»ŠÖ˜Aˆâ“`Žq‚Ì”­Œ»—}�§‚ƘV‰»�×–E�œ‹Ž‚ð‰î‚µ‚½�R�üˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ3‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï. “Œ‹ž. 2023”N9ŒŽ30“ú.

“yŽtŒbŽq, �²“¡�³‘å, �¬�씎‹v, ‘º�ã�s�l, ŽR‰º—Y–ç, �¬ŽRˆë–ç, ‰Í–ì�O, �¬—Ñ�Ž—˜, �”�¯�r˜Y, �¼‰ªˆÀ•F. ƒI�[ƒgƒ^ƒLƒVƒ“‘jŠQ�ì—p‚ð—L‚·‚é 2ccPA ‚Ì”x�üˆÛ�ǂɂ¨‚¯‚é—LŒø�«‚ÌŒŸ“¢. ‘æ3‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï. “Œ‹ž. 2023”N9ŒŽ30“ú.

–—m•½, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, Na T. Nguyen, •Ä“c�_�l, ”ö�è—Ì•F, ’Ë�è—C‹M, �û•£�¹‹B, Œ¬Œ´�_, �¼‰ªˆÀ•F. HIF1A ‘jŠQ‚É‚æ‚éŽîá‡�×–E—R—ˆ CXCL10/11 �§Œä‚ð‰î‚µ‚½�R PDL1 �R‘̂ւ̑Ï�«�Ž•ž. ‘æ82‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‰¡•l. 2023”N9ŒŽ22“ú.

ŽO‹´“ÕŽu, �¬ŽRˆë–ç, ‰¬–ì�L˜a, �™–{�³“¹, �ª“Œ��, Œ¬Œ´�_, �¼‰ªˆÀ•F. Žîᇓà fibrocyte —V‘–�E•ª‰»�§Œä‚ª‚à‚½‚ç‚·ŽîᇖƉu”÷�¬ŠÂ‹«‚ւ̉e‹¿. ‘æ82‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‰¡•l. 2023”N9ŒŽ22“ú.

‰¬–ì�L˜a, Nguyen Na Thi, ���¼”Ž”V, ŽO‹´“ÕŽu, ’Ëú±—C‹M, –—m•½, ”ö�è—Ì•F, •Ä“c�_�l, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹¹•”ˆ«�«Žîᇂɂ¨‚¢‚ĖƉuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Æ•¹—p‚·‚ׂ«ŽŠ“KŽE�×–E�«�R‚ª‚ñ�܂̓¯’è‚ð–ÚŽw‚µ‚½–ƉuŠw“I‰ð�Í. ‘æ27‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘�‰ï. ŽO�d. 2023”N7ŒŽ21“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, Nguyen Na Thi, –—m•½, •Ä“c�_�l, �™–{�³“¹, �ª“Œ��, Œ¬Œ´�_, �¼‰ªˆÀ•F. Žîᇓàfibrocyte‚Ì“¯’è‚Æ‹@”\�§Œä‚É‚æ‚é�V‹K•¡�‡‚ª‚ñ–Ɖu—Ö@‚ÌŠJ”­. ‘æ32‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �å‘ä. 2023”N7ŒŽ21“ú.

•Ä“c�_�l, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, Œ¬Œ´�_, ˆ¢•”�^Ž¡, ‹àŽq”ü‰Ø, ‰Á“¡�K�¬, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘Ì‚¨‚æ‚Ñ�RCTLA-4�R‘̂ɂæ‚é•¡�‡‚ª‚ñ–Ɖu—Ö@‚ÌŒŸ“¢. ‘æ32‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �å‘ä. 2023”N7ŒŽ20“ú.

’Ë�è—C‹M, ŽO‹´“ÕŽu, ”ö�è—Ì•F, –—m•½, •Ä“c�_�l, ‰¬–ì�L˜a�A�¼‰ªˆÀ•F. ”xŠà‚É‚¨‚¯‚éŽîá‡�Z���üˆÛ�×–E‚Ì‘–‰»ˆöŽq‚Æ‚»‚ÌŽ¾Š³—\Œã‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ẳð�Í. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �²‰ê. 2023”N6ŒŽ23“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, Nguyen Na Thi, •Ä“c�_�l, –—m•½, �™–{�³“¹, �ª“Œ��, Œ¬Œ´�_, �¼‰ªˆÀ•F. Fibrocyte ‚Ì•ª‰»�§Œä‚É‚æ‚é•¡�‡‚ª‚ñ–Ɖu—Ö@‚Ö‚Ì“WŠJ. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �²‰ê. 2023”N6ŒŽ22“ú.

–—m•½, ŽO‹´“ÕŽu, Nguyen Na Thi, ‰¬–ì�L˜a, •Ä“c�_�l, ”ö�è—Ì•F, �¼‰ªˆÀ•F. IFN-g ”½‰ž�«ƒPƒ‚ƒJƒCƒ“ŽY�¶�§Œä‹@�˜‚̉𖾂Æ�V‹K•¡�‡‚ª‚ñ–Ɖu—Ö@‚ւ̉ž—p. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �²‰ê. 2023”N6ŒŽ22“ú.

‹g“c•É�l, ‰Á“¡�K�¬, �¼‰ªˆÀ•F, ˆ¢•”�^Ž¡. ‚ª‚ñ“ÁˆÙ“I�R podoplanin �R‘Ì chLpMab-2 ‚̃RƒAƒtƒR�[ƒX�œ‹Ž‚É”º‚¤ ADCC ‘�‹­‚ÆNK �×–EŠˆ�«‰»‚ÉŠÖ‚·‚錟“¢. ‘æ27‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �²‰ê. 2023”N6ŒŽ22“ú.

�Ⓦ�OŠî, �²“¡�³‘å, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, �¬ŽRˆë–ç, ‰Í–ì�O, �¬�씎‹v, �¼‰ªˆÀ•F. ƒOƒŒƒŠƒ“Žó—e‘Ì�ì“®–òƒAƒiƒ‚ƒŒƒŠƒ“‚̃AƒŒƒ‹ƒM�[�«‹C“¹‰Š�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ30“ú.

�²“¡�³‘å, �û•£�¹‹B, ŽO‹´“ÕŽu, �¼‰ªˆÀ•F. ŠPšb‘§‚É‚¨‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘f‚ÆŒŒ�´ƒyƒŠƒIƒXƒ`ƒ“‚Ì—Õ�°“IˆÓ‹`‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ30“ú.

�û•£�¹‹B, ŽO‹´“ÕŽu, �¼žŠ“Ö˜Y, �²“¡�³‘å, �¼‰ªˆÀ•F. ƒXƒNƒŠ�[ƒjƒ“ƒOŽ¿–â•[‚ð—p‚¢‚½COPDŒŸ�fƒVƒXƒeƒ€‚Ì—L—p�«‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ30“ú.

‘º�ã�s�l, �²“¡�³‘å, ŽR‰º—Y–ç, “yŽtŒbŽq, �Ⓦ�OŠî, “à“¡�L�m, �¬ŽRˆë–ç, ‰Í–ì�O, ˆî‘º“T�º, ˜@Œ©œ¨Ži, �¼‰ªˆÀ•F. �V‹K‰Â—n�«ƒGƒ|ƒLƒVƒqƒhƒ�ƒ‰�[ƒ[‘jŠQ–òSMTP-44D‚Ì”x�üˆÛ�ǂɑ΂·‚é—LŒø�«‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ29“ú.

ˆ¢•”‚ ‚©‚Ë, “Œ“�‘ã, �ò˜ÐŠó, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éClostridioides difficileŒŸ�¸‚ɑ΂·‚éDiagnostic stewardship‚ÌŽæ‚è‘g‚݂̌o‰ß•ñ��. ‘æ97‰ñ“ú–{Š´�õ�ÇŠw‰ï‘�‰ï�EŠw�p�u‰‰‰ï. ‰¡•l. 2023”N4ŒŽ29“ú.

�¼‰ªˆÀ•F, T M Maher, R G Jenkins, F Bonella, S Assassi, C Diefenbach, C Ittrich, K B Rohr, M Kolb. PF-ILDгŽÒ‚Ì�zŠÂƒoƒCƒIƒ}�[ƒJ�[‚ւ̃jƒ“ƒeƒ_ƒjƒu‚̉e‹¿. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ28“ú.

‰Í–ì�O, �¬˜H‹M�r, ˆÀ‘î�Ž”Ž, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. ƒŠƒ“ƒp‹…“ÁˆÙ“Iƒ`ƒ�ƒVƒ“ƒLƒi�[ƒ[‘jŠQ–òA-770041‚Í�§Œä�«T�×–E‚É‚æ‚éTGF-ƒÀsŽY�¶—}�§‚ð‰î‚µ‚Ä”x�üˆÛ�Ç‚ð‰ü‘P‚·‚é. ‘æ67‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. •Ÿ‰ª. 2023”N4ŒŽ26“ú�D

‰¬–ì�L˜a, ”ö�è—Ì•F, ‘åúœŒ›Ži, ŽO‹´“ÕŽu, ’Ëú±—C‹M, –—m•½, •Ä“c�_�l, Œ¬Œ´�_, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š‚ð�‡•¹‚·‚é�i�sŠú”xŠà‚ɑ΂·‚é“ñŽŸ‰»Šw—Ö@‚Ì—LŒø�«‚¨‚æ‚шÀ‘S�«‚ÉŠÖ‚·‚錟“¢. ‘æ120‰ñ“ú–{“à‰ÈŠw‰ï�u‰‰‰ï. “Œ‹ž. 2023”N4ŒŽ16“ú.

Yuki Tsukazaki, Ei Ogawa, Hiroshi Nokihara, Atsushi Mitsuhashi, Kensuke Kondo, Youhei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Yasuhiko Nishioka. The prognostic factors for the efficacy of anaplastic lymphoma kinase inhibitors in non-small cell lung cancer. ‘æ20‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. •Ÿ‰ª�D2023”N3ŒŽ18“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Yuki Tukazaki, Yohei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino, Yasuhiko Nishioka. Clinical factors of not receiving second-line chemotherapy in ED-SCLC patients. ‘æ20‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. •Ÿ‰ª�D2023”N3ŒŽ18“ú.

Hirokazu Ogino, Kensuke Kondo, Atsushi Mitsuhashi, Yuki Tsukazaki, Ryohiko Ozaki, Yohei Yabuki , Hiroto Yoneda, Hiroshi Nokihara, Yasuhiko Nishioka. The novel prognostic system for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. ‘æ20‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. •Ÿ‰ª�D2023”N3ŒŽ17“ú.

Eiji Takeuchi, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara, Yasuhiko Nishioka. Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. ‘æ20‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. •Ÿ‰ª�D2023”N3ŒŽ16“ú.

�²“¡�³‘å, ŽR–{‘ìŽu, �¼‰ªˆÀ•F. ƒCƒ��[ƒWƒ“ƒOŽ¿—ÊŒ°”÷‹¾iMScope TRIO‚É‚æ‚é�R�üˆÛ‰»–ò‚Ì�üˆÛ�«”x‘g�D“à‹Ç�Ý•ª•z‚ÌŒŸ“¢. ‘æ14‰ñŒÄ‹z‹@”\ƒCƒ��[ƒWƒ“ƒOŒ¤‹†‰ïŠw�p�W‰ï. ŽD–y. 2023”N1ŒŽ27“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
—é�]—ÁŽq, �Ⓦ�OŠî, “yŽtŒbŽq, ”ö�è—Ì•F, •Ä“c�_�l, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. �R‰¡–䋨�R‘Ì—z�«‚Ì�d�ÇirAE‹Ø‰Š�E�S‹Ø‰Š‚ɑ΂µ‚Ä‘�Šú‚Ì�WŠw“IŽ¡—ª‘tŒø‚µ‚½”x�G•½�ã”çŠà‚Ì1—á. ‘æ69‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

Ž›àV�‰, �Ⓦ�OŠî, “yŽtŒbŽq, •Ä“c�_�l, ‰¬–ì�L˜a, ‰ª“c’¼Žq, �ì’†�’, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒyƒvƒ`ƒhŽó—e‘Ì•úŽË�«ŠjŽí—Ö@‚ª‘tŒø‚µ‚½�¶‰º—tŒ´”­�i�sŠú”ñ’èŒ^ƒJƒ‹ƒ`ƒmƒCƒh‚Ì1—á. ‘æ69‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

�ˆä—D, �Ⓦ�OŠî, “yŽtŒbŽq, �‚‹´Œ[‹P, •Ä“c�_�l, ˆ¢•”‚ ‚©‚Ë, �²“¡�³‘å, “Œ“�‘ã, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾ŒŸ�¸‚Å�f’f‚µ‚½COVID-19ŠÖ˜A”xƒAƒXƒyƒ‹ƒMƒ‹ƒX�ǂ̂P—á. ‘æ32‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

’†�¼Œk‰î, �Ⓦ�OŠî, “yŽtŒbŽq, �¬‘q—Sˆê˜Y, ”ü”n�³�l, “à“¡�L“ñ, ˆ¢•”‚ ‚©‚Ë, �ì�^“c�ƒ, �™‰Y�G—S, �²“¡�³‘å, “Œ“�‘ã, �û•£�¹‹B, �¼—Ç�_ˆê, �¼‰ªˆÀ•F. Œ‹Šj�«�Ò’Å‰Š‚ÌŽ¡—Ã’†‚Éparadoxical response‚Æ‚µ‚Ĕ牺”^ᇂª�oŒ»‚µ‚½‚P—á. ‘æ74 ‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï. “¿“‡. 2023”N12ŒŽ17“ú.

‹{–{Œ›�Æ, �û•£�¹‹B, �Ⓦ�OŠî. •Ä“c�_�l. ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾Œã‚̌ċzŠíŠ´�õ�Ç‚ÌƒŠƒXƒNˆöŽq‚¨‚æ‚Ñ—\–h“I�R‹Û–ò“Š—^‚Ì—L—p�«‚ɂ‚¢‚Ă̌Ÿ“¢. ‘æ32‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. “¿“‡. 2023”N12ŒŽ16“ú.

ˆé‘º—S‘¾, �Ⓦ�OŠî, “yŽtŒbŽq, “à“¡�L�m, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ˆ«�«ƒŠƒ“ƒpŽî‚ÌŽ¡—ÃŒo‰ß’†‚É”­�Ç‚µ‚½ƒÀ-DƒOƒ‹ƒJƒ“‰A�«ƒjƒ…�[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Ì1—á.‘æ129‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2023”N12ŒŽ2“ú.

ŽR–{�_�¶, �Ⓦ�OŠî, “yŽtŒbŽq, ŽR‰º—Y–ç, “à“¡�L�m, �²“¡�³‘å, ‰Í–ì�O, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒXƒeƒ�ƒCƒh’ï�R�«‚Ì‹C“¹•a•ςɑ΂µ‚ăVƒNƒ�ƒzƒXƒtƒ@ƒ~ƒh‚ª’˜Œø‚µ‚½�Ä”­�«‘½”­“î�œ‰Š‚Ì‚P—á. ‘æ129‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2023”N12ŒŽ2“ú.

‰Í–ì�O, �ˆä—D, ˆÀ‘î�Ž”Ž, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. Œ°”÷‹¾“I‘½”­ŒŒŠÇ‰Š‚Ì�f’fŽž‚ÉEBV‚Ì�ÄŠˆ�«‰»‚ð’æ‚µ�AƒŠƒcƒLƒVƒ}ƒu‚ɂĊ°‰ð“±“ü—Ö@‚ð�s‚Á‚½1—á. ‘æ34‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ‰ªŽR. 2023”N12ŒŽ2“ú.

�ˆä—D, ‰Í–ì�O, ˆÀ‘î�Ž”Ž, ‘º�ã�s�l, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. ‹¹–Œ‰Š�AŠÔŽ¿�«”x޾г‚ð�æ�s‚µ�A”­”M�«�D’†‹…Œ¸�­�ǂƔx•a•ς̑�ˆ«‚Å”­�Ç‚µ‚½SLE‚Ì1—á. ‘æ34‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ‰ªŽR. 2023”N12ŒŽ2“ú.

Œ´“cŽÑŠó, �Ⓦ�OŠî, “yŽtŒbŽq, “à“¡�L�m, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¢‚ÄŠO‰ÈŽ¡—ÂðŽ{�s‚µ‚½”xMycobacterium avium complex‚ÌŒŸ“¢. ‘æ267‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2023”N8ŒŽ20“ú.

Ž›àV�‰�C�Ⓦ�OŠî�C“yŽtŒbŽq�C�¬˜H‹M�r�C•Ä“c�_�l�C�²“¡�³‘å�C‰Í–ì�O�C�û•£�¹‹B�C�¼‰ªˆÀ•F. ƒVƒNƒ�ƒXƒ|ƒŠƒ“‚ª—LŒø‚Å‚ ‚Á‚½ŒŒ�´IL-18�‚’l‚Ì�d�Ç�¬�l”­�ǃXƒeƒBƒ‹•a‚Ì1—á. ‘æ128‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2023”N7ŒŽ23“ú.

’†�¼Œk‰î�C�Ⓦ�OŠî�C“yŽtŒbŽq�C�¼‘º—LŒå�Cˆî—t���D�C•Ä“c�_�l�C‰¬–ì�L˜a�C�²“¡�³‘å�C�û•£�¹‹B�C�¼‰ªˆÀ•F. Carboplatin+etoposide‚â•úŽË�üŽ¡—Âɕs‰ž‚ànab-paclitaxel‚ª‘tŒø‚µ‚½”xŒ´”­‘å�×–E�_Œo“à•ª”åŠà‚Ì1—á. ‘æ128‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2023”N7ŒŽ23“ú.

ŽR–{�_�¶, �Ⓦ�OŠî, “yŽtŒbŽq, š �d“¹‘å, Š�–{’B–ç, �¬ŽRˆë–ç, ���ì�k‘¢, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. Ž©‘RŒo‰ß‚Å”X–E�«‰æ‘œ•ω»‚¨‚æ‚ьċz‹@”\‚̉ü‘P‚ð”F‚ß‚½�d�ÇCOVID-19‚Ì1—á. ‘æ68‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �‚�¼. 2023”N7ŒŽ15“ú�D

‘½“c—¢•ä, �Ⓦ�OŠî, “yŽtŒbŽq, �V‹����D, •Ä“c�_�l, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. �RPD-L1�R‘Ì“Š—^‚É‚æ‚èŽîá‡��”º�«�¬”]•Ï�«�Ç‚ªŒ°�݉»‚µ‚½�¬�×–E”xŠà‚Ì1—á. ‘æ61‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚�¼. 2023”N7ŒŽ15“ú�D

‰““¡—T”ü, �Ⓦ�OŠî, “yŽtŒbŽq, �‚‹´Œ[‹P, •Ä“c�_�l, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. •“IƒQƒmƒ€ƒvƒ�ƒtƒ@ƒCƒŠƒ“ƒO‚É‚æ‚è�f’f‚µ“¾‚½EGFR Exon19Œ‡Ž¸•ψٗz�«”x‘BŠà‚Ì1—á. ‘æ61‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚�¼. 2023”N7ŒŽ15“ú�D
2022”N‹Æ�Ñ
�y‰¢•¶Œ´’˜�z
Hanibuchi M, Saijo A, Mitsuhashi A, Kajimoto T, Kitagawa T, Nishioka Y. The efficacy of mass screening for chronic obstructive pulmonary disease by using screening questionnaires in a medical health check-up population. Respir Investig 60(6):815-821, 2022.

Ogura T, Suda T, Inase N, Nishioka Y, Azuma A, Okamoto M, Takizawa A, Ito T, Rohr KB, Inoue Y. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial. Respir Investig 60(6):787-797, 2022.

Otsuka K, Nokihara H, Mitsuhashi A, Ozaki R, Yabuki Y, Yoneda H, Ogino H, Nishioka Y. Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease. Thorac Cancer 13(21):2978-2984, 2022.

Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-center, randomized controlled trial. Rheumatology (Oxford) 61(11):4445-4454, 2022.

Kagawa K, Sato S, Koyama K, Imakura T, Murakami K, Yamashita Y, Naito N, Ogawa H, Kawano H, Nishioka Y. The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-ƒÀ production in regulatory T-cells. PLOS ONE 17(10):e0275987, 2022.

Nishioka Y, Toyoda Y, Egashira R, Johkoh T, Terasaki Y, Hebisawa A, Abe K, Baba T, Fujikura Y, Fujita E, Hamada N, Handa T, Hasegawa Y, Hidaka K, Hisada T, Hisata S, Honjo C, Ichikado K, Inoue Y, Izumi S, Kato M, Kishimoto T, Okamoto M, Miki K, Mineshita M, Nakamura Y, Sakamoto S, Sano M, Tsukada Y, Yamasue M, Bando Y, Homma S, Hagiwara K, Suda T, Inase N. Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype. BMJ Open Respir Res 9(1):e001337, 2022.

Tobiume M, Mitsuhashi A, Saijo A, Ogino H, Afroj T, Ogawa H, Goto H, Sato S, Abe A, Haji K, Ozaki R, Takizawa H, Nishioka Y. Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer. Oncol Lett 24(5):417, 2022.

Goto Y, Tamura A, Matsumoto H, Isobe K, Ozaki T, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Nokihara H. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan. JTO Clin Res Rep3(9):100397, 2022.

Ueno Y, Harada S, Sato K, Momota K, Sato H, Akimoto Y, Arai Y, Nunomura T, Ishihara M, Tane N, Itagaki T, Nishioka Y, Oto J. Independent lung ventilation for the management of acute allograft rejection after single-lung transplantation for end-stage emphysema. J Med Invest 69(3.4):323-327, 2022.

Tanaka T, Koyama K, Takahashi N, Morito K, Ali H, Azuma M, Kagawa K, Kawano H, Has RY, Aihara M, Nishioka Y. Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiopathic pulmonary fibrosis. J Med Invest 69(3.4):196-203, 2022.

Nokihara H, Kijima T, Yokoyama T, Kagamu H, Suzuki T, Mori M, Santorelli ML, Taniguchi K, Kamitani T, Irisawa M, Kanda K, Abe M, Burke T, Goto Y. Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan. Cancers (Basel)14(12):2846, 2022.

Kako J, Kobayashi M, Kajiwara K, Kimura Y, Oosono Y, Takegata M, Nakano K, Matsuda Y, Nakamura N, Kawashima N, Hirano Y, Kitae M, Yamaguchi K, Iwamoto H, Hattori N, Sawatari H, Shiono S, Ogino H, Nishioka Y, Amano K, Yorke J. Validity and Reliability of the Japanese Version of the Dyspnea-12 Questionnaire in Patients With Lung Cancer. J Pain Symptom Manage 64(2):e83-e89, 2022.

Ogawa H, Azuma M, Umeno A, Shimizu M, Murotomi K, Yoshida Y, Nishioka Y, Tsuneyama K. Singlet oxygen -derived nerve growth factor exacerbates airway hyperresponsiveness in a mouse model of asthma with mixed inflammation. Allergol Int 71:395-404, 2022.

Nokihara H, Ogino H, Mitsuhashi A, Kondo K, Ogawa E, Ozaki R, Yabuki Y, Yoneda H, Otsuka K, Nishioka Y. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion. BMC Cancer 22(1):597, 2022.

Yoshioka T, Daizumoto K, Tada K, Mima M, Kagawa K, Fukawa T, Yamaguchi K, Takahashi M, Nishioka Y, Kanayama H. Retroperitoneal hemorrhage in a patient with coronavirus disease 2019 (COVID-19):A case report. J Med Invest 69(1.2):148-151, 2022.

Sakurada T, Nokihara H, Koga T, Zamami Y, Goda M, Yagi K, Hamano H, Aizawa F, Ogino H, Sato S, Kirino Y, Goto H, Nishioka Y, Ishizawa K. Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study. Oncologist 27(7):e554-e560, 2022.

Nishijima H, Sugita M, Umezawa N, Kimura N, Sasaki H, Kawano H, Nishioka Y, Matsumoto M, Oya T, Tsuneyama K, Morimoto J, Matsumoto M. Development of organ-specific autoimmunity by dysregulated Aire expression. Immunol Cell Biol 100(5):371-377, 2022.

Morita Y, Saijo A, Nokihara H, Mitsuhashi A, Yoneda H, Otsuka K, Ogino H, Bando Y, Nishioka Y. Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer. Thorac Cancer 13(7):1079-1082, 2022.

Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco M, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim-Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas. J Clin Invest 132(3):e151239, 2022.

Enomoto N, Homma S, Inase N, Kondoh Y, Saraya T, Takizawa H, Inoue Y, Ishii H, Taguchi Y, Izumi S, Yamano Y, Tanino Y, Nishioka Y, Toyoshima M, Yokomura K, Imokawa S, Koshimizu N, Sano T, Akamatsu T, Mukae H, Kato M, Hamada N, Chiba H, Akagawa S, Muro S, Uruga H, Matsuda H, Kaida Y, Kanai M, Mori K, Masuda M, Hozumi H, Fujisawa T, Nakamura Y, Ogawa N, Suda T. Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. Thorax 77(2):143-153, 2022.

Sako M, Nokihara H, Kondo K, Mitsuhashi A, Ozaki R, Yabuki Y, Abe A, Yoneda H, Ogino H, Otsuka K, Uehara H, Nishioka Y. A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab. Thorac Cancer 13(1):129-132, 2022.

Ogino H, Tobiume M, Kagawa K, Kawano H, Sakaguchi S, Saijo A, Matsumoto D, Takizawa H, Morikawa Y, Bando Y, Goto H, Nokihara H, Nishioka Y. A case of radiation-associated angiosarcoma presenting as a massive pleural effusion. Intern Med 61(9):1393-1397, 2022.

Imakura T, Sato S, Tomonari T, Murakami K, Takahashi N, Naito N, Mima M, Kagawa K, Koyama K, Nishimura H, Kawano H, Nokihara H, Azuma M, Takayama T, Nishioka Y. A case of lenvatinib-induced interstitial pneumonia in a patient with hepatocellular carcinoma. Intern Med 61(8):1211-1217, 2022.

Sebe M, Tsutsumi R, Senoura S, Kishi J, Iuchi M, Mishima Y, Tsutsumi Y, Kuroda M, Harada N, Nakaya Y, Kinoshita S, Nishioka Y, Sakaue H. Saturated fatty acids intake is associated with muscle atrophy in rheumatoid arthritis. JCSM Rapid Commun 5:86-101, 2022.
�y˜a•¶’˜�‘�z
‰¬–ì�L˜a, Œ¬Œ´�_. CBDCA+nab-PTX/S-1. ”xŠà–ò•¨—Ö@ƒŒƒWƒ�ƒ“ Expert's Choice, ‘q“c•ó•Û�E‹g‰ª�O’Á•Ò�W�Fpp87-90, 2022, ƒ�ƒWƒJƒ‹ƒrƒ…�[ŽÐ.

�¼‰ªˆÀ•F. ŒÄ‹zŠí޾г‚̃oƒCƒIƒ}�[ƒJ�[�D“à‰ÈŠw�i‘æ12”Å�j‡U�Fpp353-355�C2022, ’©‘q�‘“X.
�y˜a•¶‘��à�z
–L“c—DŽq, �¼‰ªˆÀ•F. ‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX. ŒÄ‹zŠí“à‰È 42(6):616-621, 2022.

�¼‰ªˆÀ•F, ‘º�ã�s�l, �¬ŽRˆë–ç, �²“¡�³‘å. ”x�üˆÛ‰»‹@�˜. “ú–{—Õଠ80(9):1351-1355, 2022.

‘º�ã�s�l, �¼‰ªˆÀ•F. ‚т܂ñ�«”x޾г‚Ì•a‘Ô‚©‚ç�lŽ@‚·‚éMDD�f’f‚Ì�d—v�«‚ɂ‚¢‚Ä. ŒÄ‹zŠí“à‰È 42(2):142-148, 2022.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Kazuya Koyama, Seidai Sato, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa, Yasuhiko Nishioka. Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis. APSR 2022. Seoul, Korea. 2022”N11ŒŽ19“ú.

Yohei Yabuki, Kenji Otsuka, Hirokazu Ogino, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Masaki Hanibuchi, Atsushi Mitsuhashi, Yuki Tsukazaki, Ryohiko Ozaki, Hiroto Yoneda, Hiroshi Nokihara, Yasuhiko Nisihioka. A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer. APSR 2022. Seoul, Korea. 2022”N11ŒŽ19“ú.

Takeshi Imakura, Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka. Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis. ERS International Congress 2022. Barcelona, Spain. 2022”N9ŒŽ5“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Youhei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yasuhiko Nishioka. The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease. ERS International Congress 2022. Barcelona, Spain. 2022”N9ŒŽ4“ú.

Ryo Okuda, Takahi Ogura, Nobuhisa Ishikawa, Takafumi Suda, Naoki Arai, Takahisa Takihara, Megumi Hamaguchi, Yasuhiro Kondoh, Mikio Toyoshima, Keisuke Tomii, Mitsuhiro Abe, Motoyasu Kato, Michiko Kagajo, Yasuo Shimizu, Hiromi Tomioka, Kodai Kawamura, Kojiro Honda, Yasuhiko Nishioka, Motoaki Tanigawa, Hiroshi Chiba, Shinyu Izumi, Kazunori Tobino, Hiroyoshi Yamauchi, Tetsuharu Kawamura, Minoru Inomata, Kazuhiro Usui, Hirotsugu Ohkubo, Hidekaze Matsushima, Yoshitaka Oyamada, Takeshi Jokoh, Toru Arai, Tae Iwasawa, Fumikazu Sakai, Satoshi Morita, Naoaki Ichihara, Toshihiro Nukiwa, Kunihiko Kobayashi, Jips Registry Members. Nationwide prospective registry of idiopathic interstitial pneumonias with central multidisciplinary diagnosis in Japan (JIPS Registry): Analysis of disease progression. ERS International Congress 2022. Barcelona, Spain. 2022”N9ŒŽ4“ú.

Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko. Haji, Kozo Kagawa, Hiroshi Kawano, Eiji Hara, Yasuhiko Nishioka. A Novel Senolytic Agent, ARV-825, Ameliorates Bleomycin-InducedPulmonary Fibrosis in Mice. ATS 2022 International Conference. San Francisco, USA. 2022”N5ŒŽ17“ú.

Takeshi Imakura, Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka. Computational Drug Repositioning Approach Identifies Polo-Like KinaseInhibitors as Potential Therapeutics for Pulmonary Fibrosis. ATS 2022 International Conference. San Francisco, USA. 2022”N5ŒŽ15“ú.

Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Sato, Hirohisa Ogawa, Yasuhiko Nishioka. Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model. ATS 2022 International Conference. San Francisco, USA. 2022”N5ŒŽ15“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. �‰Šú—Õ�°Œ¤�CˆãƒZƒ~ƒi�[‚Ì�ÄŠJ‚Æ�¡Œã‚̉ۑè. ‘æ67‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï(�«—ˆŒv‰æˆÏˆõ‰ï•ñ��). ‰ªŽR. 2022”N12ŒŽ16“ú.

�û•£�¹‹B. ”x‚Ì�¶Šˆ�Kе•a "COPD(–��«•Â�Ç�«”x޾г)". ‘æ9‰ñ“¿“‡ŽsˆãŽt‰ïCOPDŽs–¯ŒöŠJ�u�À. ƒP�[ƒuƒ‹ƒeƒŒƒr“¿“‡. 2022”N12ŒŽ13,15,20,22“ú.

�¼‰ªˆÀ•F. ”x�üˆÛ�ǂɑ΂·‚éƒgƒ‰ƒ“ƒXƒŒ�[ƒVƒ‡ƒiƒ‹ƒŠƒT�[ƒ`�`PPF‚ɑ΂·‚é�R�üˆÛ‰»–ò‚ÌŠJ”­‚ÉŒü‚¯‚Ä�`. ‘æ122‰ñ“ú–{ŒÄ‹zŠíŠw‰ï“ŒŠC’n•û‰ï�i“Á•Ê�u‰‰�j. ’Ã�D2022”N11ŒŽ13“ú�D

Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara, Yasuhiko Nishioka. PD-1/PD-L1 blockade mediates antiangiogenic effects by tumorderived CXCL10/11 as a potential predictive biomarker. ‘æ81‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï(Cancer Science Young Scientists Award Lectures). ‰¡•l. 2022”N9ŒŽ30“ú�D

�¼‰ªˆÀ•F. ŠCŠO—¯Šw�•�¬‹à�§“x‚ÌŒ»�ó‚Æ–¢—ˆ. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�i“Á•ÊŠé‰æ). ‹ž“s. 2022”N4ŒŽ22“ú�D
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
�¬�ì‰l, Œ¬Œ´�_, ŽO‹´“ÕŽu, ‹ß“¡Œ’‰î, ’Ë�è—C‹M, –—m•½, ”ö�è—Ì•F, •Ä“c�_�l, ‰¬–ì�L˜a, �¼‰ªˆÀ•F. ALK—Z�‡ˆâ“`Žq—z�«”ñ�¬�×–E”xŠà‚ÌŒø‰Ê—\‘ªˆöŽq‚ÉŠÖ‚·‚錟“¢. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. •Ÿ‰ª. 2022”N12ŒŽ2“ú.

–Ñ—˜“Ä�l, Še–±”Ž, ŽO‰Y—�, �¼”ö�½�l, âV“¡—Ç‘¾, úå’J“TŽq, Œ¬Œ´�_, ˆäŒ`•¶•Û, �¼–ì˜a”ü, Œ·ŠÔ�º•F, ŽOŠp�r—T, ŠâàV�rˆê˜Y, ’‡�ì�T‘¾˜Y, Œõ•y“O�Æ. ƒAƒeƒ]ƒŠƒYƒ}ƒu‚Ì�RŽîᇌø‰Ê‚Æ––�½ŒŒT�×–Eƒvƒ�ƒtƒ@ƒCƒŠƒ“ƒO�F‘½Ž{�Ý‹¤“¯‘OŒü‚«ŠÏŽ@Œ¤‹†JTAIL•���Œ¤‹†. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. •Ÿ‰ª. 2022”N12ŒŽ2“ú.

Na T. Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara, Yasuhiko Nishioka. Eliminates MDSCs and enhances the efficacy of immune checkpoint inhibitor in thoracic tumors. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. •Ÿ‰ª. 2022”N12ŒŽ1“ú.

Œ¬Œ´�_, ‰¬–ì�L˜a, ŽO‹´“ÕŽu, ‹ß“¡Œ’‰î, �¬�ì‰l, ”ö�è—Ì•F, –—m•½, •Ä“c�_�l, �¼‰ªˆÀ•F. ‹¹�…‚𔺂¤EGFRˆâ“`Žq•ψٗz�«”ñ�¬�×–E”x‚ª‚ñ‚ɑ΂·‚éƒIƒVƒ�ƒ‹ƒ`ƒjƒu‚Ì—LŒø�«‚ÌŒŸ“¢. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. •Ÿ‰ª. 2022”N12ŒŽ1“ú.

’|“à‰hŽ¡, ‹ß“¡Œ’‰î, ‰ª–ì‹`•v, ŽsŒ´�¹–ç, š �d“¹‘å, –å“c’¼Ž÷, ’¬“c‹v“T, ”©ŽR’¨�¶, ‰¬–ì�L˜a, Œ¬Œ´�_, ŽÂŒ´•×, �¼‰ªˆÀ•F. �DŽ_‹…‚͖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽ¡—ÂðŽó‚¯‚½”ñ�¬�×–E”xŠàгŽÒ‚Ì—\Œã—\‘ªƒoƒCƒIƒ}�[ƒJ�[. ‘æ63‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. •Ÿ‰ª. 2022”N12ŒŽ1“ú.

”ö�è—Ì•F, Œ¬Œ´�_, ’Ë�è—C‹M, –—m•½, ŽO‹´“ÕŽu, •Ä“c�_�l, ‰¬–ì˜a�L, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�‡•¹�i“WŒ^�¬�×–E”xŠà‚É‚¨‚¯‚é2ŽŸ‰»Šw—Ö@‚Ì—LŒø�«‚¨‚æ‚шÀ‘S�«‚ɂ‚¢‚Ä. ‘æ60‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. �_ŒË�D2022”N10ŒŽ20“ú.

“à“¡�L�m, �¼‘º�t‰À, ŽR‰º—Y–ç, ‘º�ã�s�l, “yŽtŒbŽq, �¬ŽRˆë–ç, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚ð—p‚¢‚½JAK‘jŠQ–ò‚Ì�R�üˆÛ‰»Œø‰Ê‚ɂ‚¢‚Ă̌Ÿ“¢. ‘æ50‰ñ“ú–{—Õ�°–ƉuŠw‰ï‘�‰ï. “Œ‹ž. 2022”N10ŒŽ13“ú.

�¬�씎‹v, �´�…�^—SŽq, �²“¡�³‘å, �íŽR�Kˆê, �¼‰ªˆÀ•F. ƒŠƒ]ƒzƒXƒtƒ@ƒ`ƒWƒ“Ž_�iLPA�j‚ÍLPA1Žó—e‘Ì‚ð‰î‚µ‚Ä”S‰t�×–E‰ßŒ`�¬‚ð‘£�i‚·‚é. ‘æ71‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï. “Œ‹ž(ƒnƒCƒuƒŠƒbƒh) . 2022”N10ŒŽ9“ú�D

Atsushi Mitsuhashi, Hirokazu Ogino, Masamichi Sugimoto, Hiroshi Nokihara, Yasuhiko Nishioka. Fibrocyte drives antitumor immunity via T cell-costimulation in combination immunotherapy. ‘æ81‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‰¡•l. 2022”N9ŒŽ30“ú�D

Hirokazu Ogino, Atsuro Saijo, Yasuhiko Nishioka. Neoadjuvant vaccination with tumor-cell lysate induces CD8 T cell response in low-grade gliomas in randomized trial. ‘æ81‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‰¡•l. 2022”N9ŒŽ29“ú�D

Hirokazu Ogino, Jennie Taylor, Takahide Nejo, David Gibson, Payal Watchmaker, Atsuro Saijo, Meghan Tedesco, Jane Rabbitt, Michael Olin, Christopher Moertel, Andres Salazar, Annette Molinaro, Joanna Phillips, Nicholas Butowski, Jennifer Clarke, Philip Theodosopoulos, Susan Chang, Yasuhiko Nishioka, Mitchel Berger, Hideho Okada. Randomized trial of neoadjuvant vaccination with GBM6-AD tumor-cell lysate induces T cell response in low-grade gliomas. ‘æ26‰ñ“ú–{‚ª‚ñ–ƉuŠw‰ï‘�‰ï. “‡�ª. 2022”N7ŒŽ22“ú�D

‰¬–ì�L˜a, �¼žŠ“Ö˜Y, �¼‰ªˆÀ•F. Žîᇃ‰ƒCƒZ�[ƒg‚ð—p‚¢‚½�p‘O‚ª‚ñƒ�ƒNƒ`ƒ“—Ö@‚͒ራ�«“x�_ŒoäPŽî‚É‚¨‚¯‚éT�×–E–Ɖu‰ž“š‚ð—U“±‚·‚é. ‘æ26‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‹à‘ò. 2022”N6ŒŽ30“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, Nguyen Thi Na, •Ä“c�_�l, ‘å’ËŒ›Ži, �™–{�³“¹, �ª“Œ��, Œ¬Œ´�_, �¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇ�V�¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓàfibrocyte‚Ì‹@”\‰ð�Í. ‘æ26‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‹à‘ò. 2022”N6ŒŽ30“ú.

•Ä“c�_�l, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ”ö�è—Ì•F, –—m•½, Œ¬Œ´�_, ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘Ì‚¨‚æ‚Ñ�RCTLA-4�R‘̂ɂæ‚é•¡�‡‚ª‚ñ–Ɖu—Ö@‚ÌŒŸ“¢. ‘æ26‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‹à‘ò. 2022”N6ŒŽ30“ú.

ˆ¢•”‚ ‚©‚Ë, “Œ“�‘ã, ‰ª“c’¼�l, �²“¡‰ë”ü, �‚‹´�^—�, –î–ì—R”üŽq�C�¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚錌‰t”|—{�CClostridioides difficileŒŸ�¸‚ɑ΂·‚éDiagnostic stewardship‚ÌŽæ‚è‘g‚Ý. ‘æ70‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘�‰ï. Šò•Œ. 2022”N6ŒŽ5“ú.

“Œ“�‘ã, �¼‰ªˆÀ•F, �X–ìŽÑˆßŽq, ‘å�Θa“¿. 65�ΈÈ�ã‚Ì�¬�l‚ɑ΂·‚éPCV13-PPSV23˜A‘±�ÚŽí‚̈À‘S�«‚ƖƉuŒ´�«‚ÌŒŸ“¢. ‘æ70‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘�‰ï. Šò•Œ. 2022”N6ŒŽ5“ú.

‘º�ã�s�l, Œ´“cŽÑŠó, �¡‘qŒ’, ŽO‹´“ÕŽu, �¬�ì‰l, ’Ë�è—C‹M, ”ö�è—Ì•F, –—m•½, ���ì�k‘¢, •Ä“c�_�l, ˆ¢•”‚ ‚©‚Ë, ‰¬–ì�L˜a, �¬ŽRˆë–ç, �²“¡�³‘å, �âŒû‹Å, �¼‰ªˆÀ•F. �RGM-CSF�R‘Ì‘ª’肪‘�Šú�f’f‚É—L—p‚Å‚ ‚Á‚½Ž©ŒÈ–Ɖu�«”x–E’`”’�ǂ̈ê—á. ‘æ45‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. Šò•Œ(ƒIƒ“ƒfƒ}ƒ“ƒh). 2022”N5ŒŽ27-28“ú.

�¡‘qŒ’, �²“¡�³‘å, Œ´“cŽÑŠó, ŽO‹´“ÕŽu, �¬�ì‰l, ‘º�ã�s�l, ’Ë�è—C‹M, ”ö�è—Ì•F, –—m•½, ���ì�k‘¢, •Ä“c�_�l, ˆ¢•”‚ ‚©‚Ë, ‰¬–ì�L˜a, �âŒû‹Å, �¼‰ªˆÀ•F. ”x–å•”�E�cŠuƒŠƒ“ƒp�ߎî‘å‚ɑ΂µ‚ÄEBUS-TBNA‚ðŽÀŽ{‚µŽq‹{èòŠà�Ä”­‚Æ�f’f‚µ‚½1—á. ‘æ45‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. Šò•Œ(ƒIƒ“ƒfƒ}ƒ“ƒh). 2022”N5ŒŽ27-28“ú.

‰Í–ì�O, �¡‘qŒ’, ŽR‰º—Y–ç, ‘º�ã�s�l, “à“¡�L�m, �²“¡�³‘å, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éJAK‘jŠQ–ò‚Ì�R�üˆÛ‰»Œø‰Ê‚ÉŠÖ‚·‚錟“¢. ‘æ66‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. ‰¡•l(ƒnƒCƒuƒŠƒbƒh). 2022”N4ŒŽ25-27“ú.

Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Hiroshi Kawano, Eiji Hara, Yasuhiko Nishioka. Antifibrotic and senolytic activity of novel BRD4 degrader ARV825 in experimental model of lung fibrosis. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s�D2022”N4ŒŽ24“ú.

”ü”n�³�l, �²“¡�³‘å, Œ´“cŽÑŠó, —é�]—ÁŽq, ŽR‰º—Y–ç, ”ö�è—Ì•F, “yŽtŒbŽq, “à“¡�L�m, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. �RARS�R‘Ì—z�«ŠÔŽ¿�«”x޾г‚Ì‹¹•”‰æ‘œ�ŠŒ©‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s�D2022”N4ŒŽ24“ú.

�¬ŽRˆë–ç, ŽO‹´“ÕŽu, �¡‘qŒ’, ‘º�ã�s�l, ���ì�k‘¢, �²“¡�³‘å, ‰Í–ì�O, �¬�씎‹v, �¼‰ªˆÀ•F. ƒVƒ“ƒOƒ‹ƒZƒ‹‰ð�Í‚ð—p‚¢‚½”x�üˆÛ�ǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éfibrocyte‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s�D2022”N4ŒŽ24“ú.

‰Í–ì�O, �¡‘qŒ’, ‘º�ã�s�l, “à“¡�L�m, ���ì�k‘¢, �¬ŽRˆë–ç, �²“¡�³‘å, Œ¬Œ´�_, �¼‰ªˆÀ•F. ƒŒƒ|�[ƒ^�[ƒ}ƒEƒX‚ð—p‚¢‚½”x�üˆÛ�×–E‚Ì�V‹K“¯’è–@. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s�D2022”N4ŒŽ23“ú.

�¡‘qŒ’, �²“¡�³‘å, �¬ŽRˆë–ç, �V‘º‹M”Ž, ‘º�ã�s�l, ŽR‰º—Y–ç, “yŽtŒbŽq, ���ì�k‘¢, ‰Í–ì�O, �ÀŠÔ–¡‹`�l, �ÎàVŒ[‰î, �¼‰ªˆÀ•F. In silico‰ð�͂ɂæ‚蓯’肳‚ꂽPLK‘jŠQ�܂̃uƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŒø‰Ê‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s�D2022”N4ŒŽ23“ú.

Hirokazu Ogino, Taylor Jennie W, Takahide Nejo, Gibson David, Watchmaker Payal B, Kaori Okada, Atsuro Saijo, Tadesco Meghan, Rabbitt Jane, Olin Michael R, Moertel Christopher L, Salazar Andres M, Yasuhiko Nishioka, Molinaro Annette M, Phillips Joanna J, Butowski Nicholas A, Clarke Jennifer L, Chang Susan M, Berger Mitchel, Hideho Okada. Neoadjuvant vaccination with GBM6-AD, lysate of glioblastoma stem cell line, induces T-cell response in low-grade glioma. ‘æ19‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. ‹ž“s(ƒnƒCƒuƒŠƒbƒh). 2022”N2ŒŽ18“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Yohei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yasuhiko Nishioka. Second-line chemotherapy for extensive-disease small cell lung cancer with interstitial lung disease. ‘æ19‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. ‹ž“s(ƒnƒCƒuƒŠƒbƒh). 2022”N2ŒŽ17-19“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
�¼‘º—LŒå, “yŽtŒbŽq, —é�]—ÁŽq, •Ä“c�_�l, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �¬�씎‹v, �û•£�¹‹B, �¼‰ªˆÀ•F. ŒŒ�´Krebs von den Lungen-6 ‚ª�‚’l‚ðŽ¦‚µ‚½ˆ«�«‹¹–Œ’†”çŽî‚Ì1—á. ‘æ127‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2022”N12ŒŽ18“ú.

�V‹����D, “yŽtŒbŽq, �ˆä—D, ŽR‰º—Y–ç, “à“¡�L�m, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ŠÖ�ß‰Š‚ð’æ‚µ‚½ACTH ’P“ÆŒ‡‘¹�Ç‚Ì1—á. ‘æ127‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2022”N12ŒŽ18“ú.

‹{–{Œ›�Æ, “yŽtŒbŽq, Œ´“cŽÑŠó, —é�]—ÁŽq, ˆ¢•”‚ ‚©‚Ë, “Œ“�‘ã, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚é”xMAC�ǂɑ΂·‚éƒAƒWƒXƒ�ƒ}ƒCƒVƒ“•¹—p—Ö@‚Ì—LŒø�«�EˆÀ‘S�«‚ÌŒŸ“¢. ‘æ73‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

�X�ʉÔ, “yŽtŒbŽq, �ˆä—D, ‹{–{Œ›�Æ, ‘º�ã�s�l, ’Ë�è—C‹M, �Ⓦ�OŠî, ”ö�è—Ì•F, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–òŽg—pŒã‚É”x–E�oŒŒ‚ð‚«‚½‚µ‚½1—á. ‘æ31‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

Ž›àV�‰, “yŽtŒbŽq, ŽsŒ´�¹–ç, ŽR‰º—Y–ç, •Ÿ‰Æ–ƒ”ü, “à“¡�L�m, •Ä“c�_�l, ���ì�k‘¢, ‰¬–ì�L˜a, ‰Í–ì�O, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. �RPD-L1�R‘Ì“Š—^Œã‚ÉŒ°�݉»‚µ‚½�RARS�R‘Ì—z�«ŠÔŽ¿�«”x‰Š‚Ì1—á. ‘æ67‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

’†�¼éD“l, “yŽtŒbŽq, �¼‘º—LŒå, ŽO‹´“ÕŽu, �¬�ì‰l, �¡‘qŒ’, ”ü”n�³�l, ”ö�è—Ì•F, •Ä“c�_�l, ‰¬–ì�L˜a, �âŒû‹Å, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. “¯Žž‚ɈقȂé3‚‚̑g�DŒ^‚ð”F‚ß‚½‘½”­�«”xŠà‚Ì1—á. ‘æ67‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‰ªŽR. 2022”N12ŒŽ16“ú.

�¬˜H‹M�r, “à“¡�L�m, ‰Í–ì�O, ‘º�ã�s�l, ŽR‰º—Y–ç, ”ü”n�³�l, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. —¼‘¤�º‘Ñ–ƒáƒ‚ð’æ‚µ‚½‘½”­ŒŒŠÇ‰Š�«“÷‰èŽî�ǂɔº‚¤”ìŒú�«�d–Œ‰Š‚Ì1—á. ‘æ33‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ‰ºŠÖ�D2022”N12ŒŽ3“ú.

ˆÀ‘î�Ž”Ž, ‰Í–ì�O, �¬˜H‹M�r, ‘º�ã�s�l, ŽR‰º—Y–ç, ”ü”n�³�l, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. Œ€�Ç1Œ^“œ”A•a‚Æ“¯ŽžŠú‚É”­�Ç‚µ‚½—¼‘¤“Á”­�«ŠOŠá‹Ø‰Š‚Ì1—á. ‘æ33‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ‰ºŠÖ�D2022”N12ŒŽ3“ú.

’†�¼éD“l, “yŽtŒbŽq, –—m•½, �V‹����D, �‚ŠÛ—˜‰ÁŽq, •Ä“c�_�l, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒZƒ‹ƒyƒ‹ƒJƒ`ƒjƒu‚ª‘tŒ÷‚µ‚½RET—Z�‡ˆâ“`Žq—z�«”x‘BŠà‚Ì1—á. ‘æ265‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2022”N7ŒŽ31“ú.

�¬‘q—Cˆê˜N, “yŽtŒbŽq, ‹ß“¡Œ’‰î, ‘å’ËŒ›Ži, ‰¬–ì�L˜a, �¬ŽRˆë–ç, ‘º�ã�s�l, �Ⓦ�OŠî, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š‚Ö‚ÌŽ¡—Ô½‰ž�«‚©‚çŠÌ”x�ÇŒóŒQ‚Ì•¹‘¶‚ªŒ°�݉»‚µ‚½ˆê—á. ‘æ66‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ŽRŒû(ƒnƒCƒuƒŠƒbƒh). 2022”N7ŒŽ9“ú.

�¼‘º—LŒå, “yŽtŒbŽq, ”ü”n�³�l, –—m•½, ‘å’ËŒ›Ži, •Ä“c�_�l, Œ¬Œ´�_, ‰¬–ì�L˜a, ”ö�è—Ì•F, ’Ë�è—C‹M, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. �¬�×–E”xŠà‚Ö‚ÌŒ`Ž¿“]Š·‚ð”F‚ß‚½EGFRˆâ“`Žq•ψٗz�«”x‘BŠà‚Ì3—á. ‘æ60‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ŽRŒû(ƒnƒCƒuƒŠƒbƒh). 2022”N7ŒŽ9“ú.

�V‹����D, –—m•½, “yŽtŒbŽq, �‚ŠÛ—˜‰ÁŽq, •Ä“c�_�l, ‰¬–ì�L˜a, �²“¡�³‘å, �û•£�¹‹B, �¼‰ªˆÀ•F. ƒZƒ‹ƒyƒ‹ƒJƒ`ƒjƒu‚ª‘tŒø‚µ‚½RET—Z�‡ˆâ“`Žq—z�«”x‘BŠà‚Ì1—á. ‘æ60‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ŽRŒû(ƒnƒCƒuƒŠƒbƒh). 2022”N7ŒŽ9“ú.

“yŽtŒbŽq�C–—m•½�C”ü”n�³�l�C•Ä“c�_�l�C‰¬–ì�L˜a�C�²“¡�³‘å�C‰Í–ì�O�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. MET‘jŠQ–ò‚ª’˜Œø‚µ‚½METˆâ“`Žq exon14 skipping •ψٗz�«”x�G•½�ã”çŠà‚Ì1—á. ‘æ126‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2022”N6ŒŽ5“ú.

�‚‹´Œ[‹P�C–—m•½�CŽsŒ´�¹–ç�C‰¬–ì�L˜a�C�²“¡�³‘å�C‰Í–ì�O�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. �d“x‚Ìš‹‰º�áŠQ‚ð�‡•¹‚µ‚½�RRo52�R‘Ì—z�«”畆‹Ø‰Š‚Ì1—á. ‘æ126‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2022”N6ŒŽ5“ú.

–—m•½�C‘å’ËŒ›Ži�C’|“à‰hŽ¡�C—t‹v‹MŽi�CŒ“�¼‹M‘¥�C�¼‘º’¼Ž÷�C–L“c—DŽq�C�û•£�¹‹B�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D�‚—îŽÒ�i�s�E�Ä”­”ñ�¬�×–E”xŠà‚ɑ΂·‚éPemetrexed + Bevacizumab •¹—p—Ö@‚Ì—LŒø�«‚ƈÀ‘S�«‚ÌŒŸ“¢�D‘æ264‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2022”N2ŒŽ20“ú�D
2021”N‹Æ�Ñ
�y‰¢•¶Œ´’˜�z
Yoneda H, Nokihara H, Mitsuhashi A, Ozaki R, Yabuki Y, Ogino H, Otsuka K, Nishioka Y. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma. BMC Pulm Med 21(1):373, 2021.

Tezuka T, Azuma M, Ogawa H, Kondo M, Uehara H, Aono Y, Hanibuchi M, Nishioka Y. A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells. Exp Lung Res 47(9):451-463, 2021.

Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, Gono T, Harigai M, Ichiyasu H, Inoue Y, Johkoh T, Kameda H, Kataoka K, Katsumata Y, Kawaguchi Y, Kawakami A, Kitamura H, Kitamura N, Koga T, Kurasawa K, Nakamura Y, Nakashima R, Nishioka Y, Nishiyama O, Okamoto M, Sakai F, Sakamoto S, Sato S, Shimizu T, Takayanagi N, Takei R, Takemura T, Takeuchi T, Toyoda Y, Yamada H, Yamakawa H, Yamano Y, Yamasaki Y, Kuwana M; joint committee of Japanese Respiratory Society and Japan College of Rheumatology. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig, 59(6):709-740, 2021.

Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respir Med 187:106574, 2021.

Mitsuhashi A, Kondoh K, Horikawa K, Koyama K, Nguyen N, Afroj T, Yoneda H, Otsuka K, Ogino H, Nokihara H, Shinohara T, Nishioka Y. PD-1/PD-L1 blockade mediates anti-angiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker. Cancer Sci 112(12):4853-4866, 2021.

Nishioka Y, Homma S, Okubo T, Azuma A. Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis. Contemp Clin Trials Commun 23:100832, 2021.

Muraoka S, Yamada Z, Kawazoe M, Hirose W, Kono H, Yasuda S, Komano Y, Kawano H, Hidaka T, Nakashima S, Kasama T, Teramoto T, Nanki T, ABT-ATS study group. Abatacept is efficacious in the treatment of older patients with csDMARD-refractory rheumatoid arthritis: a prospective, multicenter, observational study. Rheumatol Ther 8(4):1585-1601, 2021.

Isshiki T, Homma S, Eishi Y, Yabe M, Koyama K, Nishioka Y, Yamaguchi T, Uchida K, Yamamoto K, Ohashi K, Arakawa A, Shibuya K, Sakamoto S, Kishi K. Usefulness of imunohistochemical detection of Propionibacterium acnes in granulomas for differentiating sarcoidosis from other garanulomatous diseases; comparison between manual and automated immunohistochemical detection methods. Microorganisms 9(8):1668, 2021.

Haji K, Sato S, Yoneda H, Nisisho T, Nokihara H, Nishioka Y. Multidisciplinary treatment of skeletal muscle metastasis from lung cancer: A case of triceps muscle metastasis of lung squamous cell cancer. Respir Med Case Rep 33:101470, 2021.

Nakasuka F, Tabata S, Sakamoto T, Hirayama A, Ebi H, Yamada T, Umetsu K, Ohishi M, Ueno A, Goto H, Sugimoto M, Nishioka Y, Yamada Y, Tomita M, Sasaki AT, Yano S, Soga T. TGF-ƒÀ-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. Commun Biol. 4(1):782, 2021.

Hisata S, Bando M, Homma S, Kataoka K, Ogura T, Izumi S, Sakamoto S, Watanabe K, Saito Y, Shimizu Y, Kato M, Nishioka Y, Hara H, Waseda Y, Tanino Y, Yatera K, Hashimoto S, Mukae H, Inase N; Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respir Investig 59(6):819-826, 2021.

Mukae H, Kaneko T, Obase Y, Shinkai M, Katsunuma T, Takeyama K, Terada J, Niimi A, Matsuse H, Yatera K, Yamamoto Y, Azuma A, Arakawa H, Iwanaga T, Ogawa H, Kurahashi K, Gon Y, Sakamoto H, Shibata Y, Tamada T, Nishioka Y, Haranaga S, Fujieda S, Miyashita N, Mochizuki H, Yokoyama A, Yoshihara S, Tamaoki J; JRS guidelines committee for the management of cough and sputum. The Japanese respiratory society guidelines for the management of cough and sputum (digest edition). Respir Investig 59(3):270-290, 2021.

Sato S, Chong SG, Upagupta C, Yanagihara T, Saito T, Shimbori C, Belleye PS, Nishioka Y, Kolb M. Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. Thorax 76(9):895-906, 2021.

Afroj T, Mitsuhashi A, Ogino H, Saijo A, Otsuka K, Yoneda H, Tobiume M, Nguyen TN, Goto H, Koyama K, Sugimoto M, Kondoh O, Nokihara H, Nishioka Y. Blockade of PD-1/PD-L1 pathway enhances the antigen-presenting capacity of fibrocytes. J Immunol 206(6):1204-1214, 2021.

Kawano H, Koyama K, Nishimura H, Toyoda Y, Kagawa K, Sato S, Naito N, Goto H, Inagaki Y, Nishioka Y. Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. Immun Inflamm Dis 9(1):120-127, 2021.

Kondo M, Tezuka T, Ogawa H, Koyama K, Bando H, Azuma M, Nishioka Y. Lysophosphatidic acid regulates the differentiation of Th2 cells and its antagonist suppresses allergic airway inflammation. Int Arch Allergy Immunol 182(1):1-13, 2021.

Naito N, Kawano H, Yamashita Y, Kondo M, Haji S, Miyamoto R, Toyoda Y, Kanematsu Y, Izumi Y, Bando Y, Nishioka Y. Neuropsychiatric systemic lupus erythematosus wihcerebellar vasculitis and obstructive hydrocephalus requiring decompressive craniectomy. Mod Rheumatol Case Rep 5(1):52-57, 2021.

Sakamoto S, Kataoka K, Kondo Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S, and the Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized trial. Eur Respir J 57(1):2000348, 2021.

Homma S, Ebina M, Kuwano K, Goto H, Sakai F, Sakamoto S, Johkoh T, Sugino K, Tachibana T, Terasaki Y, Nishioka Y, Hagiwara K, Hashimoto N, Hasegawa Y, Hebisawa A; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Intractable Diffuse Pulmonary Diseases: Manual for Diagnosis and Treatment. Respir Investig 59(1):8-33, 2021.
�y˜a•¶’˜�‘�z
�²“¡�³‘å, �¼‰ªˆÀ•F. “Á”­�«ŠÔŽ¿�«”x‰Š�DŒÄ‹zŠí�ÇŒóŒQ�i‘æ3”Å�j‡V�Fpp60-64�C2021, “ú–{—Õ଎Ð.

�²“¡�³‘å, �¼‰ªˆÀ•F. ŒÄ‹z�׋CŠÇŽx‰Š‚𔺂¤ŠÔŽ¿�«”x޾г(RB-ILD). Œ©‚é�f‚é‚í‚©‚é�I‹¹•”‰æ‘œ�f’f, ‘ë�ì“Þ‹`•v •Ò�W: pp145-149, 2021, ’†ŠOˆãŠwŽÐ.

�²“¡�³‘å, �¼‰ªˆÀ•F. ”ñ“ÁˆÙ�«ŠÔŽ¿�«”x‰Š(NSIP). Œ©‚é�f‚é‚í‚©‚é�I‹¹•”‰æ‘œ�f’f, ‘ë�ì“Þ‹`•v •Ò�W: pp139-144, 2021, ’†ŠOˆãŠwŽÐ.

�²“¡�³‘å, �¼‰ªˆÀ•F. “Á”­�«ŠíŽ¿‰»”x‰Š�iCOP�^BOOP�j.ŒÄ‹zŠí޾г�Å�V‚ÌŽ¡—Ã2021-2022, –å“c�~ˆê�EŒ·ŠÔ�º•F�E�¼‰ªˆÀ•F •Ò�W, pp293-295, 2021, “ì�]“°.
�y˜a•¶‘��à�z
‰¬–ì�L˜a�C�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�‡•¹”ñ�¬�×–E”xŠà‚ɑ΂·‚é–ò•¨—Ö@‚ɂ‚¢‚Ä�DBIO Clinica 36(11):41-47, 2021.

�¬ŽRˆë–ç, �¼‰ªˆÀ•F. ”x‚Ì�üˆÛ‰»�|”x�üˆÛ�Ç‚Æ�R�üˆÛ‰»–ò�|. —Õ�°–Ɖu�EƒAƒŒƒ‹ƒM�[‰È 76(2):139-146, 2021.

�²“¡�³‘å, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š. ƒŒƒWƒfƒ“ƒgƒm�[ƒg 23(8)(‘�Ч): 77-84, 2021.

�¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚邪‚ñˆã—Ã. “ú–{“à‰ÈŠw‰ïŽGŽ� 110(3):520-525, 2021.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Thi Na Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Kenji Otsuka, Hiroshi Nokihara, Yasuhiko Nishioka. S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Takeshi Imakura, Seidai Sato, Kazuya Koyama, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Naoki Takahashi, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka.Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Kojin Murakami, Naoki Takahashi, Seidai Sato, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Kazuaki Tanigawara, Wataru Toriumi, Yasuhiko Nishioka.Therapeutic effect of oligonucleotide therapeutics PK-7010 in mouse model of bleomycin-induced lung fibrosis. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, Kensuke Kondou, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka. The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Nobuhito Naito, Hiroshi Kawano, Takeshi Imakura, Yuya Yamashita, Kojin Murakami, Kozo Kagawa, Kazuya Koyama, Seidai Sato, Hiroshi Nokihara, Yutaka Inagaki, Yasuhiko Nishioka. Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka. Association of immune-related adverse events with therapeutic response to Nivolumab in patients with malignant pleural mesothelioma. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Takeshi Imakura, Kojin Murakami, Yuya Yamashita, Naoki Takahashi, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. A Lck-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF-b production in regulatory T cells. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hirokazu Ogino, Tania Afroj, Atsushi Mitsuhashi, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Na Thi Nguyen, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka. Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Seidai Sato. Novel senolytic drug ARV-825 promotes self-renewal of alveolar type 2 cells in lung. APSR 2021�iEmerging Talent Symposia). Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hiroshi Kawano, Haruka Nishimura, Takeshi Imakura, Yuya Yamashita, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Seidai Sato, Hiroshi Nokihara, Yasuhiko Nishioka. Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Masahiko Azuma, Hirohisa Ogawa, Toshifumi Tezuka, Mayo Kondo, Yasuhiko Nishioka. A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Yasuhiko Nishioka, Takashi Ogura, Naohiko Inase, Ayako Takizawa, Atsushi Taniguchi, Yoshikazu Inoue. Effects of nintedanib on forced vital capacity categorical changes and disease progression in Japanese patients with progressive fibrosing interstitial lung diseases: Subanalysis of INBUILD study. APSR 2021. Kyoto and online. 2021”N11ŒŽ20-21“ú.

Hiroshi Nokihara, Melissa L. Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, Kingo Kanda, Machiko Abe, Thomas Burke, Yasushi Goto. Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan. ESMO Congress 2021. Paris,France(Virtual). 2021”N9ŒŽ21“ú.

Yasushi Goto, Melissa L. Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, Kingo Kanda, Machiko Abe, Thomas Burke, Hiroshi Nokihara. Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS�†50%), advanced NSCLC in Japan. ESMO Congress 2021. Paris,France(Virtual). 2021”N9ŒŽ21“ú.

Ryo Toyozawa, Kota Itahashi, Yasushi Goto, Yutaka Fujiwara, Yusuke Okuma, Takayasu Kurata, Toshihide Yokoyama, Hiroshi Nokihara, Takashi Yokoi, Teppei Yamaguchi, Yoshimasa Shiraishi, Masayuki Takeda, Takaaki Tokito, Atsushi Nakamura, Yuki Hosomi, Yuishiro Ohe. Two single-arm, multicenter phase-‡Utrials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703). ESMO Congress 2021. Paris,France(Virtual). 2021”N9ŒŽ21“ú.

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Takeshi Imakura, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Haruka Nishimura, Hiroshi Kawano, Yasuhiko Nishioka. Anti-fibrotic efficacy of Lck inhibitor via the suppression of TGF-ƒÀ production in regulatory T cells. ERS International Congress 2021. WEB. 2021”N9ŒŽ7“ú�D

Antje Prasse, Toby M Maher, R Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Moises Selman, Jin Woo Song, Carina Ittrich, Claudia Diefenbach, Klaus B. Rohr, Susanne Stowasser, Eric S. White. Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. The 61st DGP Annual Congress�iDGP 2021 digital�j. 2021”N6ŒŽ2-5“ú.

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Klaus B Rohr, Daniel Wachtlin, Carina Ittrich, Claudia Diefenbach, R Gisli Jenkins: on behalf of the INMARK study investigators. Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study. The 61st DGP Annual Congress�iDGP 2021 digital�j. 2021”N6ŒŽ2-5“ú.

Naoki Takahashi, Seidai Sato, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Kazuaki Tanigawara, Wataru Toriumi, Yasuhiko Nishioka. Oligonucleotide therapeutics PK-7010 in combination with nintedanib ameliorates bleomycin-induced pulmonary fibrosis in mice. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.

Kazuya Koyama, Hiroshi Kawano, Yuya Yamashita, Takeshi Imakura, Naoki Takahashi, Nobuhito Naitoh, Seidai Sato, Yasuhiko Nishioka. Clinical Features of the Acute Exacerbation of Rheumatoid Arthritis-Associated Interstitial Lung Disease. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Naoki Takahashi, Haruka Nishimura, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Hiroshi Kawano, Yasuhiko Nishioka. The Lck-Specific Inhibitor A-770041 Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.

Takuma Isshiki, Sakae Homma, Matsuko Yabe, Kazuya Koyama, Yasuhiko Nishioka, Tetsuo Yamaguchi, Keisuke Uchida, Yoshinobu Eishi, KazutoshiShibuya, Susumu Sakamoto, Kazuma Kishi. Usefulness of Immunohistochemical detection of Propionibacterium acnes in granulomas for the differentiation of sarcoidosis and other granulomatous diseases. ATS 2021. WEB. 2021”N5ŒŽ14-19“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. With ƒRƒ�ƒiŽž‘ã‚̌ċzŠí�ê–åˆã‚Ì–ðŠ„ �`ŒÄ‹zŠí�ê–åˆã‚Ì–¢—ˆ�`. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�A‘æ30‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï�A‘æ72‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï (3Šw‰ï�‡“¯‰ï’·Šé‰æ). �¼�](WEB). 2021”N12ŒŽ5“ú�D

�¼‰ªˆÀ•F. PF-ILD‚Ì�f’f‚ÆŽ¡—Ã. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[). ‰¡•l. 2021”N11ŒŽ26“ú�D

Œá�ȉë•F�D’m‚Á‚Ä‚¨‚±‚¤�|”x‚Ì�¶Šˆ�Kе•aCOPD-�D‘æ8‰ñCOPDŽs–¯ŒöŠJ�u�À�DƒP�[ƒuƒ‹ƒeƒŒƒr“¿“‡�D2021”N10ŒŽ19�`31“ú�D

�¬ŽRˆë–ç�C‰Í–ì�O�C�¼‰ªˆÀ•F�D”x�üˆÛ‰»‚É‚¨‚¯‚éƒVƒ“ƒOƒ‹ƒZƒ‹‰ð�Í�D‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï(Šî‘bŒ¤‹†“Á•Ê�u‰‰)�D“Œ‹ž�D2021”N10ŒŽ3“ú.

–öŒ´–LŽj�C�²“¡�³‘å�CMartin Kolb�D”x�üˆÛ�ǂɂ¨‚¯‚é”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì•a‘Ô - ˆâ“`“I�ÆŽã�«‚Ì’T�õ“I‰ð�Í‚àŠÜ‚ß‚Ä-�D‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï(Šî‘bŒ¤‹†“Á•Ê�u‰‰)�D“Œ‹ž�D2021”N10ŒŽ3“ú.

�¼‰ªˆÀ•F�DTAS-115�D‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D“Œ‹ž�D2021”N10ŒŽ2“ú.

Œá�ȉë•F�D�¬�l‹CŠÇŽxšb‘§‚Ì�ŋ߂̎¡—Âɂ‚¢‚Ä�D“¿“‡‘åŠw•a‰@ƒtƒH�[ƒ‰ƒ€2021�t(Žs–¯ŒöŠJ�u�À). “¿“‡�D2021”N2ŒŽ28“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
ŽO‹´“ÕŽu, ‰¬–ì�L˜a, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. �RPD-1/PD-L1�R‘̂ɂæ‚錌ŠÇ�V�¶�§Œäƒ�ƒJƒjƒYƒ€‚̉ð�͂Ǝ¡—ÃŒø‰Ê—\‘ªƒoƒCƒIƒ}�[ƒJ�[‚Æ‚µ‚Ẳž—p. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‰¡•l. 2021”N11ŒŽ28“ú.

”ö�è—Ì•F, Œ¬Œ´�_, ŽO‹´“ÕŽu, ‹ß“¡Œ’‰î, –—m•½, •Ä“c�_�l, ‰¬–ì�L˜a, ‘å’ËŒ›Ži, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�‡•¹�¬�×–E”xŠà‚ɑ΂·‚é“ñŽŸ‰»Šw—Ö@‚Ì—LŒø�«‹y‚шÀ‘S�«‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‰¡•l. 2021”N11ŒŽ26“ú.

–—m•½, ‘å’ËŒ›Ži, ’|“à‰hŽ¡, —t‹v‹MŽi, Œ“�¼‹M‘¥, �¼‘º’¼Ž÷, –L“c—DŽq, �û•£�¹‹B, Œ¬Œ´�_, �¼‰ªˆÀ•F. �‚—îŽÒ�i�s�E�Ä”­”ñ�¬�×–E”xŠà‚ɑ΂·‚é Pemetrexed �{ Bevacizumab •¹—p—Ö@‚Ì—LŒø�«‚ƈÀ‘S�«‚ÌŒŸ“¢. ‘æ62‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‰¡•l. 2021”N11ŒŽ26“ú.

•Ä“c�_�l, Œ¬Œ´�_, ŽO‹´“ÕŽu, ”ö�è—Ì•F, –—m•½, ‰¬–ì�L˜a, ‘å’ËŒ›Ži, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽîгŽÒ‚É‚¨‚¯‚éƒjƒ{ƒ‹ƒ}ƒu‚̖ƉuŠÖ˜A—LŠQŽ–�Û‚ÆŽ¡—ÃŒø‰Ê‚Ì‘ŠŠÖ�«. ‘æ59‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‰¡•l(WEB)�D2021”N10ŒŽ22“ú.

‘å’ËŒ›Ži, ŽO‹´“ÕŽu, ”ö�è—Ì•F, –—m•½, •Ä“c�_�l, ‰¬–ì�L˜a, Œ¬Œ´�_, ’|“à‰hŽ¡, �™‰Y”ª�\�¶, ’m‰ÔŒ«Ž¡, “c‘ºŒú‹v, ˆÀ‘î�M“ñ, �¼‰ªˆÀ•F. �i“WŒ^�¬�×–E”xŠà‚É‚¨‚¯‚é—\Œã‹K’èˆöŽq. ‘æ59‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‰¡•l(WEB)�D2021”N10ŒŽ22“ú.

�¡‘qŒ’�C�²“¡�³‘å�C�¬ŽRˆë–ç�C�V‘º‹M”Ž�C‘º�ã�s�l�C�‚‹´’¼Šó�C���ì�k‘¢�C�ÀŠÔ–¡‹`�l�C�ÎàVŒ[‰î�C�¼‰ªˆÀ•F�DIn silico ‰ð�Í‚ð—p‚¢‚½”x�üˆÛ�ǂɑ΂·‚é�V‹KŽ¡—Öò‚Ì’T�õ�D‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï�D“Œ‹ž(WEB)�D2021”N10ŒŽ2“ú.

‘º�ã�s�l�C�‚‹´’¼Šó�C�²“¡�³‘å�C�¡‘qŒ’�CŽR‰º—Y–ç�C���ì�k‘¢�C�¬ŽRˆë–ç�C‰Í–ì�O�C’J�쌴–œŒ°�C’¹ŠC˜i�C�¼‰ªˆÀ•F�DƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é�V‹KŠjŽ_ˆã–ò‚Ì—LŒø�«‚ÌŒŸ“¢�D‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï�D“Œ‹ž(WEB)�D2021”N10ŒŽ2“ú.

�²“¡�³‘å�C�¼‰ªˆÀ•F�CMartin Kolb�D�üˆÛ‰»”x‘g�D‚Ì�×–EŠOŠîŽ¿‚ª�üˆÛ�×–E‚Ì�üˆÛ‰»‘£�i�«miRNA ”­Œ»‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢�D‘æ1‰ñ“ú–{‚т܂ñ�«”x޾гŒ¤‹†‰ï�D“Œ‹ž(WEB)�D2021”N10ŒŽ2“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, �¼žŠ“Ö˜Y�C‘å’ËŒ›Ži, �™–{�³“¹�CŒ¬Œ´�_, �¼‰ªˆÀ•F�D–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇ�V�¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éfibrocyte‚Ì–ðŠ„�D‘æ80‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï�D‰¡•l(WEB). 2021”N10ŒŽ2“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. ”x‚ª‚ñŠÌ“]ˆÚ‚É‚¨‚¯‚éspheroidŒ`�¬‚ª‚ñв�×–E—l•ª‰æ‚Ì–ðŠ„. ‘æ30‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. WEB. 2021”N7ŒŽ29“ú.

ŽO‹´“ÕŽu, Tania Afroj, Nguyen Thi Na, ‰¬–ì�L˜a, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. �RPD-1/PD-L1�R‘̂ɂæ‚éŽîᇌŒŠÇ�V�¶—}�§ƒ�ƒJƒjƒYƒ€‚̉ð�͂Ǝ¡—ÃŒø‰Ê—\‘ªƒoƒCƒIƒ}�[ƒJ�[‚Æ‚µ‚Ẳž—p. ‘æ25‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2021”N5ŒŽ28“ú.

Nguyen Thi Na, ŽO‹´“ÕŽu, ���¼”Ž”V, •Ä“c�_�l, Tania Afroj, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. TS-1‚É‚æ‚éŽîᇊ֘A�œ�‘—R—ˆ—}�§�×–E‚Ì�§Œä‚ð‰î‚µ‚½–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�܂Ƃ̕¹—pŒø‰Ê‚ÌŒŸ“¢. ‘æ25‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2021”N5ŒŽ26“ú.

ŽR‰º—Y–ç, �¡‘qŒ’, �‚‹´’¼Šó, “à“¡�L�m, �²“¡�³‘å, ‰Í–ì�O, �¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`‚É”º‚¤ŠÔŽ¿�«”x‰Š‹}�«‘�ˆ«‚Ì—Õ�°“I“Á’¥ �`“Á”­�«”x�üˆÛ�Ç‹}�«‘�ˆ«‚Ƃ̔äŠrŒŸ“¢�`. ‘æ65‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. WEB. 2021”N4ŒŽ26-28“ú.

�¼‰ªˆÀ•F, Valenzuela C, Maher T, Bonella F, Pesci A, Jouneau S, Patel N, Fernandez Perez E, Goeldner R, Cottin V. �i�s�«�üˆÛ‰»‚𔺂¤ŠÔŽ¿�«”x‰Š�iPF-ILD�j‚ł̃jƒ“ƒeƒ_ƒjƒu‚Ì—LŒø�«‚ɑ΂·‚éƒx�[ƒXƒ‰ƒCƒ“�“FVC•Ê•]‰¿�FINBUILDŽŽŒ±’ljÁ‰ð�Í. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

�¬ŽRˆë–ç, �û•£�¹‹B, –L“c—DŽq, ˆê�F‘ô–�, ŽO�DŽk�b, �â–{�W, ‰Á“¡Œ³�N, ûü‹´˜a‹v, •ЉªŒ’‰î, ‹ß“¡�N”Ž, �¼‰ªˆÀ•F, –{ŠÔ‰h. “Á”­�«”x�üˆÛ�ǂɂ¨‚¯‚éTOLLIPˆâ“`Žq‘½Œ^‚ÆN-ƒAƒZƒ`ƒ‹ƒVƒXƒeƒCƒ“‹z“ü—Ö@‚Ì—LŒø�«‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

‘º�ã�s�l, �²“¡�³‘å, �¡‘qŒ’, �¼‘º�t‰À, �‚‹´’¼Šó, “à“¡�L�m, ���ì�k‘¢, �¬ŽRˆë–ç, ‰Í–ì�O, Œá�ȉë•F, Œ¬Œ´�_, �¼‰ªˆÀ•F. �R�üˆÛ‰»–ò2�Ü‚ð�Ø‚è‘Ö‚¦‚ÄŽg—p‚µ‚½“Á”­�«”x�üˆÛ�Ç�Ç—á‚ÌŒã•ûŽ‹“IŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

‹ß“¡Œ’‰î, Œ¬Œ´�_, �²“¡�³‘å, ŽO‹´“ÕŽu, •Ä“c�_�l, ���¼”Ž”V, ‘å’ËŒ›Ži, �¼‰ªˆÀ•F. ”ñ�¬�×–E”xŠà‚ɑ΂·‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�܂̗\Œã—\‘ªˆöŽq‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

�rˆä’¼Ž÷, �Ö“¡•�•¶, �¬‘qûüŽu, •xˆäŒ[‰î, �_”ö�Fˆê˜Y, �â–{�W, ‹{�è‘×�¬, •y‰ª—mŠC, ‹v“c�C, ”¼“c’m�G, –{ŠÔ‰h, �¼‰ªˆÀ•F, Œá�ȈÀ—Ç‘¾. “Á”­�«”x�üˆÛ�ÇŠ³ŽÒ‚ð‘Î�Û‚Æ‚µ‚½‘æII‘Š—Õ�°ŽŽŒ±‚É‚¨‚¯‚éTAS-115‚Ì—LŒø�«‚ƈÀ‘S�«. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

���¼”Ž”V, ŽO‹´“ÕŽu, ”ö�è—Ì•F, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. –ƉuŒ´�«�×–EŽ€‚ð—U“±‚·‚é�×–E��ŠQ�«�RŠà�܂ɂ‚¢‚Ă̌Ÿ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

�¼‘º�t‰À, �²“¡�³‘å, �¡‘qŒ’, ‘º�ã�s�l, “à“¡�L�m, ���ì�k‘¢, �¬ŽRˆë–ç, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éJAK‘jŠQ�܂̌ø‰Ê‚ÉŠÖ‚·‚錟“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

�‚‹´’¼Šó, �²“¡�³‘å, �¡‘qŒ’, ‘º�ã�s�l, “à“¡�L�m, ���ì�k‘¢, �¬ŽRˆë–ç, ‰Í–ì�O, Œ¬Œ´�_, ’J�쌴–œŒ°, ’¹ŠC˜i, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŠjŽ_ˆã–òPK-7010‚Ænintedanib‚Ì•¹—pŒø‰Ê‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

ˆê�F‘ô–�, –{ŠÔ‰h, –î•”ƒ}ƒcŽq, �¬ŽRˆë–ç, �¼‰ªˆÀ•F, ŽRŒû“N�¶, “à“cŒ\‰î, �]�΋`�M, �a’J˜a�r, �â–{�W, ŠÝˆê”n. ƒTƒ‹ƒRƒCƒh�[ƒVƒX�f’f‚É‚¨‚¯‚éPAB�R‘̖Ɖu�õ�F‚Ì—L—p�«‚ÌŒŸ“¢. ‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž(WEB). 2021”N4ŒŽ23-25“ú.

”ö�è—Ì•F, ŽO‹´“ÕŽu, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F, ŸN“c�I, �ÎàVŒ[‰î. ƒyƒ�ƒgƒŒƒLƒZƒh“Š—^Œã‚Ì”ç�]‚ɑ΂·‚éƒfƒLƒTƒ�ƒ^ƒ]ƒ“—\–h“Š—^‚ÌŒø‰Ê‚ÌŒŸ“¢. ‘æ18‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. ‹ž“s(WEB). 2021”N2ŒŽ18-21“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
�Γc‘ì–ç, ‰Í–ì�O, �¡‘qŒ’, ‘º�ã�s�l, ŽR‰º—Y–ç, ”ü”n�³�l, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éäPŒ´•aŠÖ˜AŠÔŽ¿�«”x޾г‚ɑ΂·‚éƒjƒ“ƒeƒ_ƒjƒu‚ÌŽg—pŒoŒ±. ‘æ32‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �¼ŽR. 2021”N12ŒŽ11“ú.

ŽsŒ´�¹–ç�C‰Í–ì�O�C�¡‘qŒ’, ‘º�ã�s�l�CŽR‰º—Y–ç, ”ü”n�³�l, “à“¡�L�m, ‰¬–ì�L˜a, �²“¡�³‘å, �¼‰ªˆÀ•F. �Ä”­�«‘½”­“î�œ‰ŠŽ¡—Ã’†‚Ì•s–¾”M�¸�¸‚ÅUBA1ˆâ“`Žq‰ð�͂ɂæ‚è�f’f‚µ‚½VEXAS�ÇŒóŒQ‚Ì1—á. ‘æ32‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �¼ŽR. 2021”N12ŒŽ10“ú.

ŽsŒ´�¹–ç�C–—m•½�C‘º�ã�s�l�C���ì�k‘¢�C•Ä“c�_�l�C‰¬–ì�L˜a�C�²“¡�³‘å�C‰Í–ì�O�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. ˆŸ‹}�«‚É�i�s‚µ�A–I‘ƒ”x—l‚Ì�ŠŒ©‚ð’æ‚µ‚½–ò�Ü�«”x�áŠQ‚Ì1—á. ‘æ125‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2021”N12ŒŽ5“ú.

�Γc‘ì–ç�C–—m•½�C���ì�k‘¢�CŽR‰º—Y–ç�C‰¬–ì�L˜a�C�²“¡�³‘å�C‰Í–ì�O�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. �¬�lStill•a‚Ƃ̊ӕʂð—v‚µ‚½‰Æ‘°�«’n’†ŠC”M”ñ“TŒ^—á‚Ì1—á. ‘æ125‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2021”N12ŒŽ5“ú.

‘º�ã�®�Æ, –—m•½, ”ö�è—Ì•F, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. Sitafloxacin‚ª‘tŒø‚µ‚½”xMycobacterium abscessus subsp. massiliense �Ç‚Ì1—á. ‘æ72‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï. �¼�](WEB). 2021”N12ŒŽ5“ú.

�‚ŠÛ—˜‰ÁŽq, –—m•½, ˆé‘º—S‘¾, ���ì�k‘¢, ‘å’ËŒ›Ži, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. Ž©‘R‘Þ�k‚ð”F‚ß‚½‹CŠÇŽxŒ´”­‘Á‰t‘BŒ^ŽîᇂÌ1—á. ‘æ30‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �¼�](WEB). 2021”N12ŒŽ5“ú.

�¬�ì‰l, –—m•½, �ˆä—D, ���ì�k‘¢, �¬ŽRˆë–ç, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. —¼‘¤”x‚É‘½”­‚·‚é”Á�ó‰e‚ð’æ‚µ‚½Ž©ŒÈ–Ɖu�«”x–E’`”’�Ç‚Ì1—á. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �¼�](WEB). 2021”N12ŒŽ5“ú.

Œ´“c�ËŽq, –—m•½, ”ü”n�³�l, ”ö�è—Ì•F, ���ì�k‘¢, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. ”ñŒ‹Šj�«�RŽ_‹Û�ǂƂ̊ӕʂð—v‚µ�Aamikacin �{ minocycline‚ª‘tŒø‚µ‚½”xƒmƒJƒ‹ƒWƒA. ‘æ65‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �¼�](WEB). 2021”N12ŒŽ4“ú.

‰Ô–[�‰, –—m•½, �¡‘qŒ’, •Ä“c�_�l, ˆ¢•”‚ ‚©‚Ë, ”ü”n�³�l, ŽR‰º—Y–ç, “à“¡�L�m, ���ì�k‘¢, ‘å’ËŒ›Ži, �²“¡�³‘å, Œ¬Œ´�_, �¼‰ªˆÀ•F. ƒXƒeƒ�ƒCƒhƒpƒ‹ƒX—Ö@Œã‚É‘�ˆ«‚µ“ñ“x–ڂ̃pƒ‹ƒX—Ö@‚ª‘tŒø‚µ‚½COVID-19”x‰Š‚Ì1—á. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‰ªŽR. 2021”N8ŒŽ8“ú.

�âŒû‹Å, –—m•½, �¡‘qŒ’, •Ä“c�_�l, ‘º�ã�s�l, �¬ŽRˆë–ç, ���ì�k‘¢, �¬�ì‰l, ‰¬–ì�L˜a, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. �õ�ó‚Ì�¬—tŠÔŠu•ǂ̔ìŒú‚ð”F‚ß‹¹�o‹¾‰º”x�¶ŒŸ‚É‚Ä�f’f‚µ‚½ŠÔŽ¿�«”x‰Š‚Ì1—á. ‘æ63‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‰ªŽR. 2021”N8ŒŽ8“ú.

’†“à—F�‡�], –—m•½, “yŽtŒbŽq, •Ä“c�_�l, ŽO‹´“ÕŽu, �ˆä—D, �Γc‘ì–ç, ‘º�ã�®�Æ, ‰¬–ì�L˜a, �²“¡�³‘å, Œ¬Œ´�_, �¼‰ªˆÀ•F. Tepotinib‚ª’˜Œø‚µ‚½METˆâ“`Žqexon14 skipping•ψٗz�«”x‘BŠà‚Ì1—á. ‘æ59‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ‰ªŽR. 2021”N8ŒŽ7“ú.

ŽsŒ´�¹–ç, –—m•½, ”ö�è—Ì•F, ‹ß“¡Œ’‰î, •Ä“c�_�l, ‘å’ËŒ›Ži, •Ÿ‰Æ–ƒ”ü, �‚ŠÛ—˜‰ÁŽq, Œ´“c�ËŽq, ‰¬–ì�L˜a, �²“¡�³‘å, Œ¬Œ´�_, �¼‰ªˆÀ•F. Atezolizumab‚ÌImmune-Related Adverse Event‚É‚æ‚é‹}�«�t�áŠQ‚ð”F‚ß‚½”ñ�¬�×–E”xŠà‚Ì1—á. ‘æ59‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ‰ªŽR. 2021”N8ŒŽ7“ú.

�‚ŠÛ—˜‰ÁŽq�C“à“¡�L�m�CŒ´“cŽÑŠó�CŽR‰º—Y–ç�C”ö�è—Ì•F�C�‚‹´’¼Šó�C�²“¡�³‘å�C‰Í–ì�O�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX‚ɑ΂·‚éƒxƒŠƒ€ƒ}ƒu‚ÌŽg—pŒoŒ±. ‘æ124‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2021”N5ŒŽ9“ú.

�Γc‘ì–ç�C“à“¡�L�m�C�¡‘qŒ’�C���ì�k‘¢�C�²“¡�³‘å�C‰Í–ì�O�CŒ¬Œ´�_�C�‚ŽR“NŽ¡�C�¼‰ªˆÀ•F. ƒŒƒ“ƒoƒ`ƒjƒu‚É‚æ‚é–ò�Ü�«”x�áŠQ‚Ì1—á. ‘æ124‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2021”N5ŒŽ9“ú.

�ˆä—D, “à“¡�L�m, �¡‘qŒ’, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. Atezolizumab“Š—^Œã‚É’˜–¾‚ÈŒŒ�¬”ÂŒ¸�­�Ç‚ð‚«‚½‚µ‚½1—á. ‘æ262‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. WEB. 2021”N3ŒŽ7“ú.

�¡‘qŒ’, “à“¡�L�m, ŽR‰º—Y–ç, Œ´“cŽÑŠó, ���ì�k‘¢, •Ä“c�_�l, �²“¡�³‘å, ‰Í–ì�O, ’·’J‰Á—eŽq, Œ¬Œ´�_, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é�¬�l”­�ǃXƒeƒBƒ‹•a�Ç—á‚ÌŒŸ“¢. ‘æ262‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. WEB. 2021”N3ŒŽ7“ú.
2020”N‹Æ�Ñ
�y‰¢•¶Œ´’˜�z
Azuma M, Murakami K, Murata R, Kataoka K, Fujii H, Miyake Y, Nishioka Y. Clinical significance of carbapenem-tolerant Pseudomonas aeruginosa isolated in the respiratory tract. Antibiotics (Basel) 9(9):E626, 2020.

Morizumi S, Sato S, Koyama K, Okazaki H, Chen Y, Goto H, Kagawa K, Ogawa H, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y. Blockade of pan-fibroblast growth factor receptors mediates bidirectional effects in lung fibrosis. Am J Respir Cell Moll Biol 63(3):317-326, 2020.

Okuma Y, Goto Y, Ohyanagi F, Sunami K, Nakahara Y, Kitazono S, Kudo K, Tambo Y, Kanda S, Yanagitani N, Horiike A, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Nishio M, Ohe Y, Hosomi Y. Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma. Cancer Med 9(20):7418-7427, 2020.

Imakura T, Toyoda Y, Sato S, Koyama K, Nishimura H, Kagawa K, Takahashi N, Naito N, Murakami K, Kawano H, Azuma M, Shinohara T, Nishioka Y. Distinct improvement of pulmonary function, ground-1 glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment: a case report with a review of the literature. J Med Invest 67(3,4):358-361, 2020.

Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer:a single-institution retrospective study. K Sci Rep 10(1):13773, 2020.

Kanda S, Ohe Y, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Yamamoto T, Tamura T. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Cancer Sci 111(6):1933-1942, 2020.

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K. Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With DocetaxelMonotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3. Randomized Clinical Trial. JAMA Oncol 6(5):e196828, 2020.

Minegishi Y, Gemma A, Homma S, Kishi K, Azuma A, Ogura T, Hamada N, Taniguchi H, Hattori N, Nishioka Y, Tanizawa K, Johkoh T, Yokoyama T, Mori K, Taguchi Y, Ebina M, Inase N, Hagiwara K, Ohnishi H, Mukae H, Inoue Y, Kuwano K, Chiba H, Ohta K, Tanino Y, Sakai F, Sugiyama Y. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Res 6(2):00184-2019, 2020.

Otsuka K, Mitsuhashi A, Goto H, Hanibuchi M, Koyama K, Ogawa H, Ogino H, Saijo A, Kozai H, Yoneda H, Tobiume M, Kishuku M, Ishizawa K, Nishioka Y. Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Lung Cancer 146:86-96, 2020.

Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trialinvestigators(Nishioka Y). Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med: S2213-2600(20)30036-9, 2020.

Abe S, Sato S, Aono Y, Azuma M, Kishi M, Koyama K, Takahashi N, Kagawa K, Kawano H, Nishioka Y. Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects. J Med Invest 67:102-112, 2020.
�y˜a•¶’˜�‘�z
�²“¡�³‘å, �¼‰ªˆÀ•F. nintedanib‚ÌŽg‚¢•û‚Æ•›�ì—p‘Î�ô. ŠÔŽ¿�«”x޾г�f—Ã}ƒjƒ…ƒAƒ‹ ‰ü’ù‘æ3”Å, ‹v•Ûœ¨Žk ŠÄ�C, “¡“cŽŸ˜Y ŠìŽÉ�ê’©—Y •Ò�W, pp202-208, 2020.“ì�]“°.

–L“c—DŽq, �¼‰ªˆÀ•F. ƒXƒeƒ�ƒCƒh. äPŒ´•a‚É”º‚¤ŠÔŽ¿�«”x޾г �f’f�EŽ¡—ÃŽw�j2020 •Ò�W “ú–{ŒÄ‹zŠíŠw‰ï “ú–{ƒŠƒEƒ}ƒ`Šw‰ï�‡“¯ äPŒ´•a‚É”º‚¤ŠÔŽ¿�«”x޾г�f’f�EŽ¡—ÃŽw�j�ì�¬ˆÏˆõ‰ï(�¼‰ªˆÀ•F,–L“c—DŽq ‘¼), pp176-178, 2020. ƒ�ƒfƒBƒJƒ‹ƒŒƒrƒ…�[ŽÐ.

�²“¡�³‘å, �¼‰ªˆÀ•F. ƒTƒ‹ƒRƒCƒh�[ƒVƒX. �V—Õ�°“à‰ÈŠw ‘æ10”Å ŠÄ�C –îú±‹`—Y, pp1800-1801, 2020. ˆãŠw�‘‰@.

�¼‰ªˆÀ•F. ”x–E”÷�Î�Ç. �¡“ú‚Ì�f’fŽw�j ‘æ8”Å ‘�•Ò�W ‰iˆä—ÇŽO, pp995-996, 2020. ˆãŠw�‘‰@.
�y˜a•¶‘��à�z
‰Í–ì�O, �¼‰ªˆÀ•F. ƒOƒbƒhƒpƒXƒ`ƒƒ�[�ÇŒóŒQ. “ú–{ˆãŽt‰ïŽGŽ� 149(“Á•Ê�†2):244-246, 2020.

�¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�F�f’f‚ÆŽ¡—ÂÌ�Å‘O�ü. “ú–{“à‰ÈŠw‰ïŽGŽ� 109(9):1899-1905, 2020.

ŽO‹´“ÕŽu, �¼‰ªˆÀ•F. ŒŒŠÇ�V�¶‘jŠQ�܂ɑ΂·‚é‘Ï�«Šl“¾ƒ�ƒJƒjƒYƒ€�DŽÀŒ±ˆãŠw 38(15)(‘�):157-162, 2020.

Œ¬Œ´�_, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�‡•¹”ñ�¬�×–E”xŠà‚ÌŽ¡—Ã�í—ª. ”xŠà 60(2):74-80, 2020.

�²“¡�³‘å, �¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�ǂ̌Œ�´Šw“I�ŠŒ©�D–ò‹Ç 71(3):26-31, 2020.

�¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�ǂ̃KƒCƒhƒ‰ƒCƒ“‚̕ϑJ�D–ò‹Ç 71(3):16-20, 2020.

�²“¡�³‘å, �¼‰ªˆÀ•F, Martin Kolb. �üˆÛ‰»”x‘g�D‚Ì�×–EŠOŠîŽ¿‚ª�üˆÛ�×–E‚ÌmiR-21”­Œ»‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢. •ªŽqŒÄ‹zŠí•a 24(1):76-79, 2020.
�y˜a•¶Œ´’˜�z
•Ÿ‰Æ–ƒ”ü, ‰¬–ì�L˜a, ’؈䖢Šó, ‹ß“¡�^‘ã, ���ì�k‘¢, �û•£�¹‹B, ŽRú±”Ž‹P, ‹{–{—º‰î, –L“c—DŽq, �¼‰ªˆÀ•F�DƒGƒ^ƒ“ƒuƒg�[ƒ‹‚É‚æ‚é’E�‘�«––�½�_Œo�áŠQ‚É‚æ‚è‹}‘¬�i�s�«‚Ì•à�s�áŠQ‚ð’æ‚µ‚½Œ‹Šj�«‹¹–Œ‰Š‚Ì1—á�DŒ‹Šj95(2):73-77, 2020.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Jin Woo Song, R Gisli Jenkins, Imre Noth, Moises Selman, Vincent Cottin, Yasuhiko Nishioka, Antje Prasse, Eric S White, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Toby M Maher. Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. KATRD International Conference 2020. WEB. 2020”N11ŒŽ12-13“ú.

Jin Woo Song, Moises Selman, R Gisli Jenkins, Eric S White, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Antje Prasse, Benjamin Strobel, German Leparc, Carina Ittrich, Claudia Diefenbach, Klaus Rohr, Susanne Stowasser, Toby M Maher. Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK trial. KATRD International Conference 2020. WEB. 2020”N11ŒŽ12-13“ú.

Seidai Sato, Takushi Yamamoto, Kana Waki , Yuki Morimoto, Takeshi Imakura, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Koichi Tsuneyama, Yasuhiko Nishioka. Analysis of localization of nintedanib and cyclophosphamide in pulmonary fibrosisusing the iMScope TRIOS. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú-12ŒŽ30“ú.

Atsushi Mitsuhashi, Tania Afroj, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Yasuhiko Nishioka. The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú-12ŒŽ30“ú.

Naoki Takahashi, Seidai Sato, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Kazuaki Tanigawara, Wataru Toriumi, Yasuhiko Nishioka. The novel oligonucleotide therapeutics PK-7010 for TGF-ƒÀ1 ameliorates bleomycin-induced pulmonary fibrosis in micen. ERS International Congress 2020 Virtual. 2020”N9ŒŽ7“ú-12ŒŽ30“ú.

Kazuya Koyama, Susumu Sakamoto, Sakae Homma, Seidai Sato, Masaki Hanibuchi, Kiyoshi Masuda, Isei Imoto, Yuko Toyoda, Takuma Isshiki, Shion Miyoshi, Motoyasu Kato, Kazuhisa Takahashi, Kensuke Kataoka, Yasuhiro Kondoh, Yasuhiko Nishioka. The Relationship Between Single-Nucleotide Polymorphisms Within Tollip and the Efficacy of Inhaled N-Acetylcysteine Therapy in Idiopathic Pulmonary Fibrosis. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú-11ŒŽ10“ú.

Moises Selman, R Gisli Jenkins, Eric S White, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Antje Prasse, Jin Woo Song, Benjamin Strobel, German Leparc, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Toby M Maher on behalf of the INMARK trial investigators. Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK Trial. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú-11ŒŽ10“ú.

Naoki Arai, Takefumi Saito, Takashi Ogura, Keisuke Tomii, Koichiro Kamio, Susumu Sakamoto, Yasunari Miyazaki, Hiromi Tomioka, Shu Hisata, Tomohiro Handa, Sakae Homma, Yasuhiko Nishioka, Arata Azuma. Final Results of the Primary Endpoint and Other Supportive Analysis: TAS-115 Phase 2 Study in Patients with Idiopathic Pulmonary Fibrosis. ATS 2020 VIRTUAL. 2020”N8ŒŽ5“ú-11ŒŽ10“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚邪‚ñˆã—Ã. 2020”N“x“ú–{“à‰ÈŠw‰ï�¶ŠU‹³ˆç�u‰‰‰ï�@BƒZƒbƒVƒ‡ƒ“. WEB(‹à‘ò)�D2020”N11ŒŽ29“ú�D

Œ¬Œ´�_�DŠÌ“]ˆÚ‚̃}ƒlƒWƒ�ƒ“ƒg�D‘æ61‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D‰ªŽR�D2020”N11ŒŽ12“ú�D

Œ¬Œ´�_. ”x‚ª‚ñ‚Ì–ò•¨—Ö@‚Ì�i•à. —ߘa2”N“x“¿“‡‘åŠw‘åŠw‰@Žs–¯ŒöŠJ�u�À(’†�‘�EŽl�‘�Lˆæ‚ª‚ñƒvƒ�—{�¬ƒRƒ“ƒ\�[ƒVƒAƒ€).“¿“‡�D2020”N10ŒŽ17“ú.

�¼‰ªˆÀ•F, �²“¡�³‘å. �i�s�«�üˆÛ‰»�«ƒtƒFƒmƒ^ƒCƒv‚Ì•ªŽq•a‘Ô. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). WEB. 2020”N9ŒŽ21“ú.

�¼‰ªˆÀ•F, �¬ŽRˆë–ç, ŽO‹´“ÕŽu, Tania Afroji, ‰Í–ì�O. ”x�üˆÛ�ǃ‚ƒfƒ‹‚É‚¨‚¯‚éscRNA-Seq‚ð—p‚¢‚½�üˆÛ�×–E‚̉ð�Í. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). WEB. 2020”N9ŒŽ20“ú.

�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�F�f’f‚ÆŽ¡—ÂÌ�Å‘O�ü�D‘æ117‰ñ“ú–{“à‰ÈŠw‰ï�u‰‰‰ï(‹³ˆç�u‰‰). WEB(“Œ‹ž)�D2020”N8ŒŽ7“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
ŽO‹´“ÕŽu, ŸN“c�I, �‡“cŒõúª, �ÀŠÔ–¡‹`�l, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �ÎàVŒ[‰î, �¼‰ªˆÀ•F�Dƒyƒ�ƒgƒŒƒLƒZƒh“Š—^Œã‚Ì”ç�]‚ɑ΂·‚é’á—p—ʃfƒLƒTƒ�ƒ^ƒ]ƒ“—\–hŒø‰Ê‚ÌŒŸ“¢�D‘æ61‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D‰ªŽR�D2020”N11ŒŽ14“ú.

‘å’ËŒ›Ži, ŽO‹´“ÕŽu, •Ä“c�_�l, Œ¬Œ´�_, ’|“à‰hŽ¡, ’m‰ÔŒ«Ž¡, ˆÀ‘î�M“ñ, “c‘ºŒú‹v, �¼‰ªˆÀ•F�D�i“WŒ^�¬�×–E”xŠà‚Ì—\Œã‹K’èˆöŽq‚ÌŒŸ“¢�D‘æ61‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D‰ªŽR�D2020”N11ŒŽ12“ú�D

Œá�ȉë•F, –—m•½, �¼‰ªˆÀ•F. äPŒ´•a”x‚Ƃ̊ӕʂª–â‘è‚ɂȂÁ‚½’¹ŠÖ˜A‰ß•q�«”x‰Š‚Ì 1 —á. ‘æ51‰ñ“ú–{�E‹Æ�EŠÂ‹«ƒAƒŒƒ‹ƒM�[Šw‰ï‘�‰ï�EŠw�p‘å‰ï. ‰ªŽR�^WEB. 2020”N11ŒŽ6“ú�D

���¼”Ž”V, ŽO‹´“ÕŽu, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. �×–E�áŠQ�«�R‚ª‚ñ�܂ɂæ‚éŽîᇖƉuŒ´�«�×–EŽ€—U“±”\‚ÌŒŸ“¢. ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. WEB(‹ž“s). 2020”N10ŒŽ22-12ŒŽ25“ú.

ŸN“c�I, ŽO‹´“ÕŽu, •Ä“c�_�l, ‘å’ËŒ›Ži, �‡“cŒõа, �ÀŠÔ–¡‹`�l, �ÎàVŒ[‰î, Œ¬Œ´�_, �¼‰ªˆÀ•F. ƒyƒ�ƒgƒŒƒLƒZƒh“Š—^Œã‚Ì”ç�]‚ɑ΂·‚é’á—p—ʂ̃Xƒeƒ�ƒCƒh—\–h“Š—^‚Ì‘OŒü‚«—Õ�°ŽŽŒ±. ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. WEB(‹ž“s). 2020”N10ŒŽ22-24“ú.

‰Í–ì�O, ŽR‰º—Y–ç�C“à“¡�L�m�C�²“¡�³‘å�C–å“c�@”V�CˆÉ�¨�F”V�C”ª–Ø�G‰î�C�²“c�­—²�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. �‚ˆÀ“®–¬‰Š‚É‚æ‚é“�«”畆’×ᇂɑ΂µ‚Ă׃yƒ‹ƒ~ƒmƒQƒ“ ƒyƒ‹ƒvƒ‰ƒXƒ~ƒh�iƒqƒgŠÌ�×–E‘��BˆöŽqƒvƒ‰ƒXƒ~ƒhƒxƒNƒ^�[�j“Š—^‚ª‘tŒø‚µ‚½1—á. ‘æ48‰ñ“ú–{—Õ�°–ƉuŠw‰ï‘�‰ï. WEB. 2020”N10ŒŽ15-17“ú.

ŽO‹´“ÕŽu, ‰¬–ì�L˜a, �¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, �™–{�³“¹, Œ¬Œ´�_, �¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇ�V�¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓà fibrocyte-like cell ‚Ì‹@”\‰ð�Í. ‘æ79‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. WEB. 2020”N10ŒŽ1-31“ú.

�²“¡�³‘å, �X–{—FŽ÷, ŽR–{‘ìŽu, ŠÛ”ö•ü–ç, ˜e‰Ø�Ø, �¼‰ªˆÀ•F. ƒCƒ��[ƒWƒ“ƒOŽ¿—ÊŒ°”÷‹¾‚É‚æ‚éƒjƒ“ƒeƒ_ƒjƒu‚Ì�üˆÛ�«”x‘g�D“à‹Ç�Ý•ª•z‚ÌŒŸ“¢. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

���ì�k‘¢, �¬ŽRˆë–ç, �²“¡�³‘å, ûü‹´’¼Šó, �¼‘º�t‰À, ‰Í–ì�O, –L“c—DŽq, ŽÂŒ´•×, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“”x�üˆÛ�ǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éLck‘jŠQ‚Ì�R�üˆÛ‰»Œø‰Ê. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

ûü‹´’¼Šó, �²“¡�³‘å, �¬ŽRˆë–ç, ���ì�k‘¢, “à“¡�L�m, �¡‘qŒ’, –L“c—DŽq, ‰Í–ì�O, ’J�쌴–œŒ°, ’¹ŠC˜i, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŠjŽ_ˆã–òPK-7010‚Ì�R�üˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

–L“c—DŽq, �²“¡�³‘å, �¬ŽRˆë–ç, ���ì�k‘¢, �ã�b�„, �]“ª—æŽq, Ž›�è‘×�O, ŽÖàV�», ”‹Œ´�Oˆê, ˆî�£’¼•F, �¼‰ªˆÀ•F. “Á”­�«”x�œ‰»�Ç‘S�‘’²�¸�i’†ŠÔ•ñ���j. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

’J–]–¢, ‹g‘º�²�h, ŽR“c’‰–¾, ‘åŒF—T‰î, –k‘ä—¯ˆß, ’|“c—²”V, Œ“�¼‹M‘¥, Œã“Œ‹vŽk, •Ä“c�_�l, �¼‰ªˆÀ•F, Œ´“c‘åŽi, ŽR“c�’‰›, ˆÉ’B�h“ñ, ‰–’Ã�L‰î, ‰i“cˆê—m, �猴—C‰î, “à–ì�‡Ž¡, ûüŽR�_ˆê. ŠùŽ¡—Ôñ�¬�×–E”x‚ª‚ñ‚ð‘Î�Û‚Æ‚µ‚½ƒhƒZƒ^ƒLƒZƒ‹�{ƒ‰ƒ€ƒVƒ‹ƒ}ƒu•¹—p‚ÉŠÖ‚·‚鑽Ž{�Ý‹¤“¯Œã•ûŽ‹“IŒŸ“¢. ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. WEB. 2020”N9ŒŽ20-27“ú.

Hirohisa Ogawa, Masahiko Azuma, Aya Umeno, Mayuko Shimizu, Takaaki Tsunematsu, Mayo Kondo, Kazutoshi Murotomi, Koichi Tsuneyama, Yasuhiko Nishioka. Nerve growth factor exacerbates airway hyperresponsiveness via epithelial damage by neutrophils-derived singlet oxygen in a mouse model of asthma with mixed inflammation. ‘æ69‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï�iJSA/WAO Joint Congress 2020�j. WEB. 2020”N9ŒŽ17“ú-10ŒŽ20“ú.

���¼”Ž”V, ŽO‹´“ÕŽu, Nguyen Thi Na, Tania Afroj, •Ä“c�_�l, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. ”xŠà‚É‚¨‚¢‚Ä�×–E�áŠQ�«�RŠà�Ü‚ª–ƉuŒ´�«�×–EŽ€‚É—^‚¦‚é‰e‹¿‚ɂ‚¢‚Ă̌Ÿ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

ŽO‹´“ÕŽu, Tania Afroj, ‰¬–ì�L˜a, Nguyen Thi Na, •Ä“c�_�l, ���¼”Ž”V, ‘å’ËŒ›Ži, �™–{�³“¹, �ª“Œ��, Œ¬Œ´�_, �¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇ�V�¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓà fibrocyte-like cell ‚Ì‹@”\‰ð�Í. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

•Ä“c�_�l, ‹g‘º�²�h, Œã“Œ‹vŽk, �¼‰ªˆÀ•F, ŽR“c’‰–¾. ŠùŽ¡—Ôñ�¬�×–E”x‚ª‚ñ‚ð‘Î�Û‚Æ‚µ‚½ƒhƒZƒ^ƒLƒZƒ‹�{ƒ‰ƒ€ƒVƒ‹ƒ}ƒu•¹—p‚ÉŠÖ‚·‚鑽Ž{�Ý‹¤“¯Œã•ûŽ‹“IŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

‹ß“¡Œ’‰î, Œ¬Œ´�_, ŽO‹´“ÕŽu, •Ä“c�_�l, ���¼”Ž”V, ‘å’ËŒ›Ži, �¼‰ªˆÀ•F. ”ñ�¬�×–E”xŠà‚É‚¨‚¯‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�܂̗\Œã—\‘ªˆöŽq‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

Tania Afroj, ‰¬–ì�L˜a,ŽO‹´“ÕŽu, •Ä“c�_�l, ���¼”Ž”V, ‘å’ËŒ›Ži, Œ¬Œ´�_, ˆÀ”{�³”Ž, �¼‰ªˆÀ•F. ŽîᇖƉu‚É‚¨‚¯‚é�üˆÛ�×–E‚̖Ɖu’²�ß‹@”\‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

Nguyen Thi Na, ŽO‹´“ÕŽu, Tania Afroj, •Ä“c�_�l, ���¼”Ž”V, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. ƒ}ƒEƒX’†”çŽî�×–EŠ””牺ˆÚ�Aƒ‚ƒfƒ‹‚É‚¨‚¯‚é�×–E�áŠQ�«�RŠà�܂̎îᇊ֘A�œ�‘—R—ˆ—}�§�×–E‚ւ̉e‹¿. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

�¼žŠ“Ö˜Y, ���¼”Ž”V, Œã“Œ‹vŽk, ‘å’ËŒ›Ži, •Ä“c�_�l, ŽO‹´“ÕŽu, �¼‰ªˆÀ•F. ”ñ�¬�×–E”x‚ª‚ñ‚É�‡•¹‚µ‚½ˆ«�«‹¹�…‚ɑ΂·‚é bevacizumab ‚Ì—LŒø�«‚Æ‘Ï�«‰»‹@�˜‚̉ð�Í. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

‰ª“c’¼�l, �ÀŠÔ–¡‹`�l, ’†”n�^�K, �‡“cŒõа, �¼‰ªˆÀ•F, �ÎàVŒ[‰î. ”x‚ª‚ñгŽÒ‚É‚¨‚¯‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚éŠÔŽ¿�«”x޾г‚Ì”­Œ»ƒŠƒXƒNˆöŽq‚ÌŒŸ“¢�F’PŽ{�ÝŒã‚ëŒü‚«Œ¤‹†. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

�쌴ˆê‹P, ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚邪‚ñ“ÁˆÙ“I�R podoplanin �R‘Ì chLpMab-23f ‚Ì in vitro ‚É‚¨‚¯‚é�RŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. WEB. 2020”N9ŒŽ10“ú-10ŒŽ8“ú.

‰Í–ì�O, “à“¡�L�m, ˆÀ‘î�Ž”Ž, �¡‘qŒ’, ŽR‰º—Y–ç, �‚‹´’¼Šó, ‹ß“¡�^‘ã, �²“¡�³‘å, –L“c—DŽq, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚é�i�s�«�üˆÛ‰»‚𔺂¤äPŒ´•aŠÖ˜AŠÔŽ¿�«”x޾г‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. WEB. 2020”N8ŒŽ17“ú-9ŒŽ15“ú.

�²“¡�³‘å, ‘º�ã�s�l, –L“c—DŽq, �¬ŽRˆë–ç, �¼‘º�t‰À, ���ì�k‘¢, ûü‹´’¼Šó, ‰Í–ì�O, Œá�ȉë•F, �¼‰ªˆÀ•F. 2�Ü‚Ì�R�üˆÛ‰»–ò‚ðŽg—p‚µ‚½“Á”­�«”x�üˆÛ�Ç�Ç—á‚ÌŒŸ“¢. ‘æ117‰ñ“ú–{“à‰ÈŠw‰ï�u‰‰‰ï. Ž��ã�D2020”N8ŒŽ7-9“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
ŽR‰º—Y–ç, “à“¡�L�m, Œ´“cŽÑŠó, �¡‘qŒ’, ûü‹´’¼Šó, �²“¡�³‘å, ‰Í–ì�O, �¼‰ªˆÀ•F. ST�‡�܂ɂæ‚é–³‹Û�«�‘–Œ‰Š‚ð’æ‚µ‚½ƒVƒF�[ƒOƒŒƒ“�ÇŒóŒQ‚̈ê—á. ‘æ31‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. WEB. 2020”N12ŒŽ5“ú.

”ü”n�³�l, “à“¡�L�m, Œ´“cŽÑŠó, �¡‘qŒ’, ŽR‰º—Y–ç, ûü‹´’¼Šó, �²“¡�³‘å, ‰Í–ì�O, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é�RARS�R‘Ì—z�«�Ç—á‚ÌŒŸ“¢. ‘æ31‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. WEB. 2020”N12ŒŽ5“ú.

•Ä“c�_�l, “à“¡�L�m, ���¼”Ž”V, ‘å’ËŒ›Ži, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, Œá�ȉë•F, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鈫�«‹¹–Œ’†”çŽî‚ɑ΂·‚énivolumab“Š—^�Ç—á‚ÌŒŸ“¢. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

ˆ¢•”‚ ‚©‚Ë, “à“¡�L�m, ‘å’ËŒ›Ži, �ì�ã�sšõ, “¡ˆäŽu˜N, Šâ–{�½Ži, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. ”ñ�¬�×–E”xŠà‚É�‡•¹‚µ‚½Œã“V�«ŒŒ—F•aA‚Ì1—á. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

Œ´“cŽÑŠó, “à“¡�L�m, ‰ª–{—I—¢, ���ì�k‘¢, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. •s–¾”M‚Ì�¸�¸‚ÅMEFVˆâ“`Žq‰ð�͂ɂæ‚è�f’f‚µ‚½‰Æ‘°�«’n’†ŠC”M‚Ì1—á. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

“V–ì‰ë•¶, Š~Œ´�F“T, “¡–ì‘׋P, “c’†‹v”üŽq, ‰ª–{�kˆê, ‹{–{�OŽu, �²“¡�NŽj, ˜ZŽÔ’¼Ž÷, �¼‰ªˆÀ•F, �‚ŽR“NŽ¡. ƒjƒ“ƒeƒ_ƒjƒu‚É‚æ‚é“Á”­�«”x�üˆÛ�ÇŽ¡—ÃŒo‰ß’†‚É”­�Ç‚µ‚½‚т܂ñ�«ˆÝ‘O’ë•”–Ñ�׌ŒŠÇŠg’£�Ç‚Ì2—á. ‘æ123‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. WEB. 2020”N11ŒŽ22“ú.

š �d“¹‘å, “à“¡�L�m, Œ´“cŽÑ‹G, ŽR‰º—Y–ç, �‚‹´’¼Šó, ”ü”n�³�l, ���¼”Ž”V, �²“¡�³‘å, ‰Í–ì�O, �¼�¯�r•F, •l“c‘å•ã, Œ¬Œ´�_, �¼‰Y“N–ç, �¼—Ç�_ˆê, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é�œ�EŠÖ�ß•a•Ï‚ð’æ‚µ‚½”ñŒ‹Šj�«�RŽ_‹Û�ǂ̌Ÿ“¢. ‘æ71‰ñ“ú–{Œ‹Šj�E”ñŒ‹Šj�«�RŽ_‹Û�ÇŠw‰ï’†�‘Žl�‘Žx•”‰ï. WEB. 2020”N11ŒŽ21“ú�|12ŒŽ21“ú.

Š�–{’B–ç, “à“¡�L�m, “à“¡�m”ü, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, Œá�ȉë•F, �¼‰ªˆÀ•F. ‘S�g�«‹­”ç�ǂɔº‚¤ŠÔŽ¿�«”x‰Š‚Ì‘�ˆ«‚Ƃ̊ӕʂð—v‚µ‚½’¹ŠÖ˜A‰ß•q�«”x‰Š‚Ì1—á. ‘æ29‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. WEB. 2020”N11ŒŽ21“ú�|12ŒŽ21“ú.

ˆé‘º—S‘¾, “à“¡�L�m, ŽR‰º—Y–ç, •Ÿ‰Æ–ƒ”ü, �¬ŽRˆë–ç, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鋹�…’™—¯‚ð’æ‚µ‚½äPŒ´•a‚¨‚æ‚Ñ—Þ‰�޾г�Ç—á‚ÌŒŸ“¢. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. WEB. 2020”N11ŒŽ21“ú�|12ŒŽ21“ú.

�Ü–ìˆí�l, “à“¡�L�m, “à“¡�m”ü, ûü‹´’¼Šó, “c’†�G“T, �²“¡�³‘å, ‰Í–ì�O, �㌴‹v“T, Œ¬Œ´�_, �‚ŽR“NŽ¡, �¼‰ªˆÀ•F. ŠÌ�d•Ï‚ð�‡•¹‚µ�AŠÌ”x�ÇŒóŒQ‚É�i“W‚µ‚½ƒTƒ‹ƒRƒCƒh�[ƒVƒX‚Ì1—á. ‘æ64‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. WEB. 2020”N11ŒŽ21“ú�|12ŒŽ21“ú.

�ˆä—D�C���ì�k‘¢�C“à“¡�L�m�C�²“¡�³‘å�C‰Í–ì�O�CŽO�D�l�³�C�¼‰Y•ü”ü�C”�Œ´�G–ç�C‹g�ì�K‘¢�C–L“c—DŽq�C�Ⓦ—Ç”ü�CŒ¬Œ´�_�C�‚ŽR“NŽ¡�C“‡“cŒõ�¶�C�¼‰ªˆÀ•F�D�DŽ_‹…�«‘½”­ŒŒŠÇ‰Š�«“÷‰èŽî�ǂ̎¡—Ã’†‚ɉñ’°�oŒŒ‚ð‚«‚½‚µ�AŒŒŠÇ‰Š‚Ƃ̊ӕʂª�¢“ï‚Å‚ ‚Á‚½CMV’°‰Š‚Ì1—á�D‘æ260‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡�D2020”N2ŒŽ2“ú�D
2019”N‹Æ�Ñ
�y‰¢•¶Œ´’˜�z
Takezaki A, Tsukumo SI, Setoguchi Y, Ledford JG, Goto H, Hosomichi K, Uehara H, Nishioka Y, Yasutomo K. A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis. J Exp Med 216 (12):2724-2735, 2019.

Chong SG, Sato S, Kolb M, Gauldie J. Fibrocytes and fibroblasts-Where are we now. Int J Biochem Cell Biol 116:105595, 2019.

Yoshimura A, Yamada T, Okuma Y, Kitadai R, Takeda T, Kanematsu T, Goto H, Yoneda H, Harada T, Kubota Y, Yamada T, Date K, Shiotsu S, Nagata K, Chihara Y, Kaneko Y, Uchino J, Nishioka Y, Takayama K. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Transl Lung Cancer Res 8(4):450-460, 2019.

Yanagihara T, Sato S, Upagupta C, Kolb M. What have we learned from basic science studies on idiopathic pulmonary fibrosis? Eur Respir Rev 28(153):190029, 2019.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig 57(6):512-533, 2019.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG: on behalf of the INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib(INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 7(9):771-779, 2019.

Okazaki H, Sato S, Koyama K, Morizumi S, Abe S, Azuma M, Chen Y, Goto H, Aono Y, Ogawa H, Kagawa K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Kouji H,e Nishioka Y. The novel inhibitor PRI-724 for Wnt/ƒÀ-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice. Exp Lung Res 45(7):188-199, 2019.

Toyoda Y, Koyama K, Kawano H, Nishimura H, Kagawa K, Morizumi S, Naito N, Sato S, Yamashita Y, Takahashi N, Goto H, Azuma M, Nishioka Y. Clinical features of interstitial pneumonia associated with systemic lupus erythematosus. Respir Investig 57(5):435-443, 2019.

Shimbori C, Upagupta C, Bellaye PS, Ayaub EA, Sato S, Yanagihara T, Zhou Q, Ognjanovic A, Ask K, Gauldie J, Forsythe P, Kolb MRJ. Mechanical stress-induced mast cell degranulation activates TGF-ƒÀ1 signalling pathway in pulmonary fibrosis. Thorax 74(5):455-465, 2019.

Hanibuchi M, Kanoh A, Kuramoto T, Saito T, Tobiume M, Saijo A, Kozai H, Kondo M, Morizumi S, Yoneda H, Kagawa K, Ogino H, Sato S, Kawano H, Otsuka K, Toyoda Y, Nokihara H, Goto H, Nishioka Y. Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA. Oncotarget:10(38):3654-3666, 2019.

Koyama K, Goto H, Morizumi S, Kagawa K, Nishimura H, Sato S, Kawano H, Toyoda Y, Ogawa H, Homma S, Nishioka Y. The tyrosine kinase inhibitor TAS-115 attenuates bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 60(4):478-487, 2019.

Saijo A, Hanibuchi M, Ogino H, Otsuka K, Goto H, Nokihara H, Nishioka Y. Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias. Mol Clin Oncol 10(5):541-546, 2019.

Ueda S, Murakami T, Ogino H, Matsuura M, Tamaki M, Kishi S, Hann M, Toyoda Y, Nagai K, Bando Y, Abe H, Nishioka Y, Doi T. Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions. Intern Med 58(5):679-684, 2019.

Ogino H, Hanibuchi M, Sakaguchi S, Toyoda Y, Tezuka T, Kawano H, Kakiuchi S, Otsuka K, Saijo A, Azuma M, Nokihara H, Goto H, Nishioka Y. The clinical features of older patients with lung cancer in comparison with their younger counterparts. Respir Investig 57(1):40-48, 2019.

Sato S, Yanagihara T, Kolb MR. Therapeutic targets and early stage clinical trials for pulmonary fibrosis. Expert Opin Investig Drugs: 28(1):19-28, 2019.
�y˜a•¶’˜�‘�z
�¼žŠ“Ö˜Y, Œ¬Œ´�_. ALK-TKI‚É‚æ‚éˆêŽŸŽ¡—Âɂ©‚©‚í‚é”äŠrŽŽŒ±. ƒIƒ“ƒRƒ�ƒW�[ƒNƒŠƒjƒJƒ‹ƒKƒCƒh ”xŠà‰»Šw—Ö@ ‰ü’ù2”Å Œ·ŠÔ�º•F�E—¢“à”ü–íŽq•Ò�W pp215-217, 2019. “ìŽR“°.

Œ¬Œ´�_. CBDCA+PEM(�}BEV)(PEM’P�Ü). ”x‚ª‚ñ‰»Šw—Ö@•›�ì—pƒ}ƒlƒWƒ�ƒ“ƒg ƒvƒ�‚̃Rƒc�@‘q“c•ó•Û�E‹g‰ª�O’Á�E‹à“c�r•F•Ò�W pp55-58, 2019. ƒ�ƒWƒJƒ‹ƒrƒ…�[ŽÐ.

Œ¬Œ´�_. CDDP+PEM(�}BEV)(PEM’P�Ü). ”x‚ª‚ñ‰»Šw—Ö@•›�ì—pƒ}ƒlƒWƒ�ƒ“ƒg ƒvƒ�‚̃Rƒc�@‘q“c•ó•Û�E‹g‰ª�O’Á�E‹à“c�r•F•Ò�W pp51-54, 2019. ƒ�ƒWƒJƒ‹ƒrƒ…�[ŽÐ.

�²“¡�³‘å, �¼‰ªˆÀ•F�D“Á”­�«ŠÔŽ¿�«”x‰Š�i‚»‚Ì‘¼‚Ì”ñ“ÁˆÙ�«ŠÔŽ¿�«”x‰Š�CŠíŽ¿‰»”x‰Š�j�DŽ„‚ÌŽ¡—à 2019-20”N“x”Å ‰Ž“c‹�’j�E–k‘º‘yˆê˜Y ŠÄ�C “dŽqƒRƒ“ƒeƒ“ƒc�C2019�D“ú–{ˆãŽ–�V•ñŽÐ�D

�²“¡�³‘å, �¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�E‰ß•q�«”x‰Š�D–Ɖu�E‰Š�Ç•a‘Ô�~Ž¡—Ã�@Update, ŒFƒm‹½�~ •Ò�W pp77-87, 2019. “ìŽR“°�D

Œã“Œ‹vŽk�DŽîá‡�DŠPšu�Eš\á‚‚Ì�f—ÃKƒCƒhƒ‰ƒCƒ“2019�C“ú–{ŒÄ‹zŠíŠw‰ïŠPšu�Eš\á‚‚Ì�f—ÃKƒCƒhƒ‰ƒCƒ“2019�ì�¬ˆÏˆõ‰ï�i�¼‰ªˆÀ•F ‘¼�j•Ò�W pp88-89, 2019�Dˆê”ÊŽÐ’c–@�l“ú–{ŒÄ‹zŠíŠw‰ï�D

–L“c—DŽq�DŠÔŽ¿�«”x‰Š�iIP�j�DŠPšu�Eš\á‚‚Ì�f—ÃKƒCƒhƒ‰ƒCƒ“2019�C“ú–{ŒÄ‹zŠíŠw‰ïŠPšu�Eš\á‚‚Ì�f—ÃKƒCƒhƒ‰ƒCƒ“2019�ì�¬ˆÏˆõ‰ï�i�¼‰ªˆÀ•F ‘¼�j•Ò�W pp85-87, 2019�Dˆê”ÊŽÐ’c–@�l“ú–{ŒÄ‹zŠíŠw‰ï�D

‰Í–ì�O, �¼‰ªˆÀ•F�DäPŒ´•a‚Ì”x•a•Ï�DŒÄ‹zŠí޾г �Å�V‚ÌŽ¡—Ã2019-2020, –å“c�~ˆê�EŒ·ŠÔ�º•F�E�¼‰ªˆÀ•F •Ò�W pp384-387, 2019�D“ì�]“°�D

Œã“Œ‹vŽk, �¼‰ªˆÀ•F�DŒŒŠÇ�V�¶‘jŠQ–ò‘Ï�«‹@�\�DŒÄ‹zŠí޾г �Å�V‚ÌŽ¡—Ã2019-2020, –å“c�~ˆê�EŒ·ŠÔ�º•F�E�¼‰ªˆÀ•F •Ò�W pp54-57, 2019. “ì�]“°�D

�¼‰ªˆÀ•F�D�DŽ_‹…�«”x‰Š�D�¡“ú‚ÌŽ¡—ÃŽw�j2019”N”Å, •ŸˆäŽŸ–î, �‚–Ø�½, �¬Žºˆê�¬ ‘�•Ò�W, pp320-321, 2019.ˆãŠw�‘‰@�D
�y˜a•¶‘��à�z
–L“c—DŽq, �²“¡�³‘å, ‰Í–ì�O, �¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`Ž¡—Öò‚Æ”x•a•Ï. ŒÄ‹zŠí“à‰È 36(6):618-626, 2019.

Œã“Œ‹vŽk�CŒá�ȉë•F�C’†�£�Ÿ‘¥�C–Lú±ã•�C‰F“s‹{�³“o�C�¼‰ªˆÀ•F�DCOPD�E”x‚ª‚ñ‚ɂȂç‚È‚¢‚½‚ß‚É�DŽl�‘ˆãŠwŽGŽ� 75(1,2):23-30, 2019.

�¼‰ªˆÀ•F�D�Å�VçΛ{‚Ì•Ò�WˆÏˆõ‚ð’S“–‚µ‚Ä�D�Å�VçΛ{ 74(6):125, 2019.

�¼‰ªˆÀ•F�D”x‚ª‚ñŽîᇊ‹«‚É‚¨‚¯‚éfibrocyte-like cell‚Ì•a“IˆÓ‹`�D‰Š�ǂƖƉu 27(3):31-35, 2019.

ŽO‹´“ÕŽu�CŒ¬Œ´�_�D–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŒø‰Ê‚ð‘�‹­‚·‚镹—p—Ö@�D•ªŽqŒÄ‹zŠí•a 23(1):49-53, 2019.

‰Í–ì�O, �¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�E–��«•Â�Ç�«”x޾г�D–ò‹Ç 70(5):85-90, 2019.

�¼‰ªˆÀ•F�D”x‰Š‚ÆŠ´�õ‘Î�ô�DŠé‹Æ‚Æ‘åŠw 5:57, 2019.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Yasuhiko Nishioka. Update immunotherapy therapy for mesothelioma. Hanoi,Vietnam. APSR 2019(Symposium). 2019”N11ŒŽ16“ú�D

Yasuhiko Nishioka. Jin Woo Song, Yasuhiro Kondoh, Young Whan Kim, Osamu Nishiyama, Susanne Stowasser, Andreas Michael, Claudia Diefenbach, Klaus B Rohr, Toby M Maher. Biomarkers of Disease Progression in Asian Subjects with Idiopathic Pulmonary Fibrosis Treated with Nintedanib: Subgroup Analysis of the INMARK Trial. Hanoi,Vietnam. APSR 2019. 2019”N11ŒŽ15“ú�D

Kozo Kagawa, Kazuya Koyama, Seidai Sato, Naoki Takahashi, Haruka Nishimura, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda, Yasuhiko Nishioka. Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice. ERS International Congress 2019. Madrid, Spain. 2019”N10ŒŽ2“ú.

Kazuya Koyama, Susumu Sakamoto, Sakae Homma, Seidai Sato, Masaki Hanibuchi, Kiyoshi Masuda, Issei Imoto, Yuko Toyoda, Takuma Isshiki, Shion Miyoshi, Motoyasu Kato, Kazuhisa Takahashi, Kensuke Kataoka, Yasuhiro Kondoh, Yasuhiko Nishioka. Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

R Gisli Jenkins, Toby M Maher, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S White, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Moises Selman on behalf of the INMARK trial investigators. Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

Toby M Maher, R Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Moises Selman, Jin Woo Song, Antje Prasse, Carina Ittrich, Claudia Diefenbach, Klaus B Rohr, Susanne Stowasser, Eric S White. Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ30“ú.

Takashi Ogura, Yasuhiko Nishioka, Takefumi Saito, Keisuke Tomii, Koichiro Kamio, Hiromi Tomioka, Shu Hisata, Susumu Sakamoto, Tomohiro Handa, Yasunari Miyazaki, Sakae Homma, Arata Azuma. Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis. ERS International Congress 2019. Madrid, Spain. 2019”N9ŒŽ29“ú.

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ Kolb, Yasuhiko Nishioka. Expression of pro-fibrotic microRNA of fibrocytes in bronchoalveolar lavage fluid. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ21“ú�D

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Klaus B Rohr, Daniel Wachtlin, Carina Ittrich, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ20“ú�D

Kazyua Koyama, Nobuhito Naitoh, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma, Yasuhiko Nishioka. Acute Respiratory Failure in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease. ATS 2019 International Conference. Dallas,TX,USA. 2019”N5ŒŽ19“ú�D
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F�D‚ª‚ñ–ƉuƒTƒCƒNƒ‹‚©‚ç�l‚¦‚é”xŠà‚ɑ΂·‚é•¡�‡–Ɖu—Ö@�D‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). •Ÿ‰ª�D2019”N10ŒŽ25“ú�D

Œ¬Œ´�_�C‰ª–{—E�C—t�´—²�C�›Œ´�rˆê�C–x”V“à�G�m�C“ŒŒöˆê�C•Ä“ˆ�N�b�C‘º�ã�°‘×�C‘ʉê�°Žq�C�׌©�K�¶�CˆÀ‘î�M“ñ�C”ö�è’q”Ž�C–x’r“Ä�C“¡“cŒ‹‰Ô�C‰ª–{�_–¾�CˆÀ“¡�¹•F�C–쑺�®Œá�CŽR–{�M”V�C‘å�]—Tˆê�C’†�ì˜a•F. Phase III study of CBDCA/PEM followed by PEM versus DOC in elderly pts withadvanced non-sq NSCLC �iJCOG1210/WJOG7813L�j. ‘æ17‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï(Presidential Symposium). ‹ž“s�D2019”N7ŒŽ18“ú�D

�¼‰ªˆÀ•F�D‚ª‚ñ–ƉuƒTƒCƒNƒ‹‚ð�l—¶‚µ‚½•¡�‡‚ª‚ñ–Ɖu—Ö@�D2019”Nˆê”ÊŽÐ’c–@�l “ú–{�E‘½�‘ŠÔ—Õ�°ŽŽŒ±‹@�\ƒ��[ƒNƒVƒ‡ƒbƒv(‹³ˆç�u‰‰)�D–¼ŒÃ‰®�D2019”N6ŒŽ29“ú�D

�¼‰ªˆÀ•F, ‰¬–ì�L˜a, ŽO‹´“ÕŽu. ŒŒŠÇ�V�¶‘jŠQ–ò‘Ï�«‚Æ‚»‚Ì�Ž•ž. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘å�ã. 2019”N6ŒŽ13“ú�D

�¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�ÇUpdate -�R�üˆÛ‰»—Ö@‚ðŠî‘b‚Æ—Õ�°‚©‚ç�l‚¦‚é-�D‘æ234‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠÖ“Œ’n•û‰ï�@‹³ˆçƒZƒ~ƒi�[�D“Œ‹ž�D2019”N5ŒŽ25“ú�D

–L“c—DŽq. �À’k‰ï�u�—�«ˆã‹Ç’·‚É•·‚­�I�v�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒg�[ƒNƒZƒbƒVƒ‡ƒ“)�D“Œ‹ž�D2019”N4ŒŽ13“ú�D

�²“¡�³‘å�Dƒnƒ~ƒ‹ƒgƒ“Œ¤‹†•ú˜Q‹L�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•ÊŠé‰æ)�D“Œ‹ž�D2019”N4ŒŽ12“ú�D

�¼‰ªˆÀ•F�D“ú–{ŒÄ‹zŠíŠw‰ï‚ÌŠCŠO—¯ŠwŽx‰‡‚ÆŠCŠO—¯Šw�•�¬‹à�§“x�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•ÊŠé‰æ)�D“Œ‹ž�D2019”N4ŒŽ12“ú�D

�¼‰ªˆÀ•F�D”x‚ª‚ñŽîᇊ‹«‚É‚¨‚¯‚éfibrocyte-like cell‚Ì•a“IˆÓ‹`�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D“Œ‹ž�D2019”N4ŒŽ12“ú�D

Œá�ȉë•F�D‹CŠÇŽxšb‘§‚ɂ‚¢‚ÄŠw‚Ú‚¤�`ŒÄ‹zŠí“à‰Èˆã‚Ì—§�ê‚©‚ç�`�DŒ§–¯ŒöŠJ�u�À�@“¿“‡ƒAƒŒƒ‹ƒM�[ƒtƒH�[ƒ‰ƒ€2019�D“¿“‡�D2019”N2ŒŽ24“ú�D

Œã“Œ‹vŽk�DCOPD�E”x‚ª‚ñ‚ɂȂç‚È‚¢‚½‚ß‚É�D‘æ258‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ïŽs–¯ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€�D“¿“‡�D2019”N2ŒŽ3“ú�D
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
ŽO‹´“ÕŽu, ‰¬–ì�L˜a, –Ø�h�¹�r, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F�D–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇ�V�¶‘jŠQ–ò‚É‚æ‚é•¡�‡‚ª‚ñ–Ɖu—Ö@‚É‚¨‚¯‚éŽîᇓàfibrocytelike cell‚Ì‹@”\‰ð�Í�D‘æ32‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠw�p�W‰ï‘�‰ï�D‰ªŽR�D2019”N11ŒŽ28“ú�D

‘å’ËŒ›Ži, •Ä“c�_�l, ŽO‹´“ÕŽu, ‰¬–ì�L˜a, ���¼”Ž”V, ”ò”~—º, Œ¬Œ´�_, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�‡•¹”ñ�¬�×–E”xŠà‚É‚¨‚¯‚é2ŽŸ‰»Šw—Ö@‚̈À‘S�«‚Æ—LŒø�«‚ÌŒŸ“¢. ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. •Ÿ‰ª�D2019”N10ŒŽ24“ú�D

‘å’ËŒ›Ži�CŒã“Œ‹vŽk�C�û•£�¹‹B�C‰¬–ì�L˜a�C�¼žŠ“Ö˜Y�C���¼”Ž”V�C•Ä“c�_�l�C”ò”~—º�C�¼‰ªˆÀ•F�D‰»Šw—Ö@‚ÍŽîᇓà‚Ì�œ�‘—R—ˆ—}�§�×–E‚ðŒ¸�­‚³‚¹‚邱‚Ƃɂæ‚è�RPD-1�R‘Ì‚Ì�RŽîᇌø‰Ê‚ð‘�‹­‚·‚é. ‘æ28‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï�CŽ­Ž™“‡�D2019”N7ŒŽ26“ú�D

�¼‘º�t‰À, •Ä“c�_�l, ���ì�k‘¢, �¬ŽRˆë–ç, ”ò”~—º, ‰¬–ì�L˜a, �¼žŠ“Ö˜Y, ‹{–{Œ›�Æ, Œ´“cŽÑŠó, �Ⓦ‹IŽq, –L“c—DŽq, �¼‰ªˆÀ•F. Šà�«ƒŠƒ“ƒpŠÇ�Ç‚Ì�f’f‚ÉBAL ‚ª—L—p‚Å‚ ‚Á‚½‘½”­‚·‚èƒKƒ‰ƒX‰A‰e‚ð’æ‚µ‚½”x‘BŠà‚Ì1 —á. ‘æ42‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. “Œ‹ž. 2019”N7ŒŽ5“ú�D

•Ä“c�_�l, �¼‘º�t‰À, ���ì�k‘¢, ”ò”~—º, ‰¬–ì�L˜a, �¬ŽRˆë–ç, �¼žŠ“Ö˜Y, –L“c—DŽq, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾ŒŸ�¸‚É‚Ä�f’f‚µ“¾‚½ƒŠƒ“ƒp–¬ŠÇ‹ØŽî�Ç‚Ì1 —á. ‘æ42‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. “Œ‹ž. 2019”N7ŒŽ5“ú�D

�¬�씎‹v, Œá�ȉë•F, ”~–ì�Ê, Žº•x˜a�r, ‹ß“¡�^‘ã, �Ⓦ�OŠî, �íŽR�Kˆê, �¼‰ªˆÀ•F. ‹CŠÇŽxšb‘§‚É‚¨‚¯‚éˆê�d�€Ž_‘fŽ_‰»ƒXƒgƒŒƒX‚Í‹C“¹‰ß•q�«‚ð˜´�i‚³‚¹‚é. ‘æ68‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï. “Œ‹ž�D2019”N6ŒŽ15“ú�D

�¼žŠ“Ö˜Y, Œã“Œ‹vŽk, ���¼”Ž”V, ‰¬–ì�L˜a, ‘å’ËŒ›Ži, �¼‰ªˆÀ•F. ”ñ�¬�×–E”x‚ª‚ñ‚É�‡•¹‚µ‚½ˆ«�«‹¹�…‚ɑ΂·‚ébevacizumab‚Ì—LŒø�«‚Æ‘Ï�«‰»‹@�˜‚̉ð�Í. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‘å�ã. 2019”N6ŒŽ13“ú�D

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‰¬–ì�L˜a, ‘å’ËŒ›Ži, �™–{�³“¹, �ª“Œ��, �¼‰ªˆÀ•F. –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚¨‚æ‚ÑŒŒŠÇ�V�¶‘jŠQ–ò•¹—p—Ö@‚É‚¨‚¯‚éŽîᇓàfibrocyte-like cell‚Ì‹@”\‰ð�Í. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‘å�ã. 2019”N6ŒŽ13“ú�D

˜a�ò�r�q, ˆ¢•”�^Ž¡, Œã‰Í“à”üŽÑ, �¼ˆä•ü, Œã“Œ‹vŽk, ‰Á“¡�K�¬, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚邪‚ñ“ÁˆÙ“I�Rpodoplanin�R‘ÌchLpMab-2‚Ìin vitro‚É‚¨‚¯‚é�RŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‘å�ã. 2019”N6ŒŽ13“ú�D

�²“¡�³‘å�C�¼‰ªˆÀ•F�CMartin Kolb. �üˆÛ‰»”x‘g�D‚Ì�×–EŠOŠîŽ¿‚ª�üˆÛ�×–E‚ÌmiR-21”­Œ»‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢. ‘æ18‰ñ”xƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg•ªŽq•a‘ÔŒ¤‹†‰ï. ŽD–y�D2019”N6ŒŽ1“ú�D

Œá�ȉë•F�C’†�£�Ÿ‘¥�C–L�è“Z�C‰F“s‹{�³“o�C�¼‰ªˆÀ•F�D“¿“‡ŽsCOPDŒ[”­�„�iŽ–‹Æ‚Ì5”NŠÔ‚Ì�¬‰Ê�D‘æ116‰ñ“ú–{“à‰ÈŠw‰ï�u‰‰‰ï�D–¼ŒÃ‰®�D2019”N4ŒŽ26“ú�D

“à“¡�L�m, ‰Í–ì�O, ‹ß“¡�^‘ã, ‰¬–ì�L˜a, �²“¡�³‘å, –L“c—DŽq, Œã“Œ‹vŽk, �¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�‡•¹ŠÖ�ßƒŠƒEƒ}ƒ`‚ɑ΂·‚éJAK‘jŠQ–ò‚ÌŽg—pŒoŒ±�D‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï�D‹ž“s�D2019”N4ŒŽ16“ú�D

Tania Afroj, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Masatoshi Kisyuku, Atsuro Saijo, Atsushi Mitsuhashi, Kazuya Koyama, Hisatsugu Goto, Yasuhiko Nishioka�DAnalyses of immuno-modulatory function of fibrocytes in tumor immunity�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2019”N4ŒŽ14“ú�D

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ. Kolb, Yasuhiko Nishioka. Fibrotic extracellular matrix upregulates pro-fibrotic miRNA expression of fibrocytes�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2019”N4ŒŽ14“ú�D

‰|–{‹I”V, –{ŠÔ‰h, ˆî�£’¼•F, ‘êàVŽn, ˆä�ã‹`ˆê, �Έ䊰, “cŒû‘P•v, �ò�M—L, ŽR–ì‘וF, ’J–ìŒ÷“T, �¼‰ªˆÀ•F, –L“ˆŠ²�¶, ‰¡‘ºŒõŽi, –…�ìŽj˜N, �¬�´�…’¼Ž÷, �{“c—²•¶�DäPŒ´•a“I”wŒi‚ð—L‚·‚é“Á”­�«ŠÔŽ¿�«”x‰Š‚Ì—\Œã‚ÉŠÖ‚·‚錟“¢�F‘½Ž{�Ý‹¤“¯�C‘OŒü‚«ƒRƒz�[ƒgŒ¤‹†�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2019”N4ŒŽ14“ú�D

‰ªú±�O‘×, �²“¡�³‘å, �X�Z�r, �¬ŽRˆë–ç, �¬�씎‹v, ���ì�k‘¢, �¼‘º�t‰À, Yajuan Chen, �–ì�ƒ“T, ˆ¢•”�Gˆê, “Œ“�‘ã, Œã“Œ‹vŽk, ‰Í–ì�O, –L“c—DŽq, �㌴‹v“T, �¬˜H�O�s, �¼‰ªˆÀ•F�DƒuƒŒƒIƒ}ƒCƒVƒ“”x�üˆÛ�ǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éWnt/B-ƒJƒeƒjƒ“/CBPƒVƒOƒiƒ‹‘jŠQ–òPRI-724‚É‚æ‚é�R�üˆÛ‰»Œø‰Ê‚ÌŒŸ“¢�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2019”N4ŒŽ14“ú�D

Hiroshi Nokihara, Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto, Yasuhiko Nishioka�DA multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced NSCLC patients with interstitial lung disease�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2019”N4ŒŽ13“ú�D

�¬ŽRˆë–ç, “à“¡�L�m, ���ì�k‘¢, �¼‘º�t‰À, �²“¡�³‘å, ‰Í–ì�O, –L“c—DŽq, Œã“Œ‹vŽk, Œá�ȉë•F, �¼‰ªˆÀ•F�DŠÖ�ßƒŠƒEƒ}ƒ`�‡•¹ŠÔŽ¿�«”x‰ŠŠ³ŽÒ‚Ì‹}�«ŒÄ‹z•s‘S‚Ì—Õ�°“IŒŸ“¢�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2019”N4ŒŽ13“ú�D

�¼‰ªˆÀ•F, Toby Maher, Gisli Jenkins�DINMARKŽŽŒ±�FIPFгŽÒ‚Å‚ÌECM ƒ^�[ƒ“ƒI�[ƒo�[�\ƒoƒCƒIƒ}�[ƒJ�[‚ÆŽ¾Š³�i�s‚ÌŠÖ˜A‹y‚уjƒ“ƒeƒ_ƒjƒu‚ÌŒø‰Ê‚ð•]‰¿‚·‚鎎Œ±�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2019”N4ŒŽ13“ú�D
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
ˆÀ‘î�Ž”Ž�C‰Í–ì�O�C�¡‘qŒ’�C“à“¡�L�m�C‹ß“¡�^‘ã�C�²“¡�³‘å�C–L“c—DŽq�C�¼‰ªˆÀ•F�D’`”’àh�o�«ˆÝ’°�Ç�AƒNƒŠƒIƒOƒ�ƒuƒŠƒ“ŒŒ�ǂ𔺂Á‚½MCTD‚Ì1—á. ‘æ30‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D‰ªŽR�D2019”N12ŒŽ7“ú.

“à“¡�L�m�C‰Í–ì�O�C�¡‘qŒ’�C‹ß“¡�^‘ã�C�²“¡�³‘å�C–L“c—DŽq�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚éANCA—z�«ŠÔŽ¿�«”x‰Š�Ç—á‚ÌŒŸ“¢. ‘æ30‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D‰ªŽR�D2019”N12ŒŽ7“ú.

‰ª–{—I—¢, ���ì�k‘¢, ‘å’ËŒ›Ži, ‹{–{’¼‹P, ‹g“cŒõ‹P, •Ä“c�_�l, –L“c—DŽq, Œá�ȉë•F, �¼‰ªˆÀ•F�D‹¹�o“à‚É‘½”­‚µ‚½�ΊD‰»�üˆÛ�«ŽîᇂÌ1—á�D‘æ121‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼�D2019”N12ŒŽ1“ú�D

�Γc‘ì–ç, ���ì�k‘¢, •Ä“c�_�l, �¼‘ºŒ«“ñ, ŽR–{—y•½, �²“¡�³‘å, ‰Í–ì�O, Œ¬Œ´�_, �¼‰ªˆÀ•F. Œ°”÷‹¾“I‘½”­ŒŒŠÇ‰Š‚ÌŽ¡—Ã’†‚É�d�Njؖ³—Í�ǃNƒŠ�[ƒ[‚ð”­�Ç‚µ‚½1—á. ‘æ121‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼�D2019”N12ŒŽ1“ú�D

�²ŒÃ‰ë�G, ���ì�k‘¢, ”ò”~—º, ûü‹´’¼Šó, �¡‘qŒ’, “à“¡�L�m, ���¼”Ž”V, �²“¡�³‘å, –L“c—DŽq, Œ¬Œ´�_, Œá�ȉë•F, �¼‰ªˆÀ•F�DMycobacterium malmoense‚É‚æ‚é”xŠ´�õ�Ç‚Ì2—á�D‘æ70‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï. ŽRŒû�D2019”N11ŒŽ23“ú�D

ˆé‘º—S‘¾, ���ì�k‘¢, •Ä“c�_�l, Œ¬Œ´�_, ‘å’ËŒ›Ži, �²“¡�³‘å, ”ò”~—º, ���¼”Ž”V, �âŒû‹Å, Œá�ȉë•F, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鈫�«‹¹–Œ’†”çŽî‚Ì2ŽŸŽ¡—Â̌Ÿ“¢. ‘æ62‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ŽRŒû�D2019”N11ŒŽ23“ú�D

‘º�ã�s�l, ���ì�k‘¢, �¬ŽRˆë–ç, Œá�ȉë•F, �¼–{‘厑, ’؈äŒõ�O, �ì�ã�sšõ, ‹ß“¡˜a–ç, �²“¡�³‘å, ‘å’ËŒ›Ži, Œ¬Œ´�_, �¼‰ªˆÀ•F. ‘å—Ê‹¹�…‚¨‚æ‚Ñ‹¹–ŒŽîᎂðŒ_‹@‚É�f’f‚³‚ꂽ�b�ó‘Bàh–EŠà‚̈ê—á�D‘æ28‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï�DŽRŒû�D2019”N11ŒŽ23“ú�D

�Γc‘ì–ç�C���ì�k‘¢�C•Ä“c�_�l�C�Ⓦ‹IŽq�C“à“¡�L�m�C‰¬–ì�L˜a�C�²“¡�³‘å�C‰Í–ì�O�C�¼‘ºŒ«“ñ�CŽR–{—y•½�C–L“c—DŽq�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�DŒ°”÷‹¾“I‘½”­ŒŒŠÇ‰Š‚ÌŽ¡—Ã’†‚É�d�Njؖ³—Í�ǃNƒŠ�[ƒ[‚ð”­�Ç‚µ‚½1—á�D‘æ259‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2019”N8ŒŽ4“ú�D

���ì�k‘¢�C�¬ŽRˆë–ç�C�²“¡�³‘å�C�‚‹´’¼Šó�C�¼‘º�t‰À�C“à“¡�L�m�C‰Í–ì�O�C–L“c—DŽq�C�¼‰ªˆÀ•F�DƒuƒŒƒIƒ}ƒCƒVƒ“”x�üˆÛ�ǃ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éLck‘jŠQ‚Ì�R�üˆÛ‰»Œø‰Ê�D‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D“¿“‡�D2019”N7ŒŽ15“ú�D

‹ß“¡Œ’‰î�C�¼žŠ“Ö˜Y�C���ì�k‘¢�C‘å’ËŒ›Ži�C�²“¡�³‘å�C•Ä“c�_�l�C”ò”~—º�CŒã“Œ‹vŽk�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D––�½ŒŒŒŸ�¸’l‚ð—p‚¢‚½”ñ�¬�×–E”xŠà‚ɑ΂·‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�܂̌ø‰Ê—\‘ªˆöŽq‚ÌŒŸ“¢�D‘æ58‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D“¿“‡�D2019”N7ŒŽ15“ú�D

ˆÀ‘î�Ž”Ž�C���ì�k‘¢�C‹ß“¡�^‘ã�C�²“¡�³‘å�C•Ä“c�_�l�C‰¬–ì�L˜a�C”ò”~—º�C���¼”Ž”V�C‘å’ËŒ›Ži�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. Nivolumab“Š—^‚É‚æ‚è• �…‚Ì’˜–¾‚ÈŒ¸�­‚ð”F‚ß‚½ˆ«�«‹¹–Œ’†”çŽî‚Ì1—á�D‘æ58‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D“¿“‡�D2019”N7ŒŽ14“ú�D

‹ß“¡Œ\‘å�C���ì�k‘¢�C‹ß“¡�^‘ã�C‰¬–ì�L˜a�C”ò”~—º�C•Ä“c�_�l�C‘å’ËŒ›Ži�C�²“¡�³‘å�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚é‹Ç�Š�i�s”ñ�¬�×–E”xŠàгŽÒ‚ɑ΂·‚鉻Šw•úŽË�ü—Ö@Œã‚ÌDurvalumab‚É‚æ‚鎡—Â̗Õ�°“IŒŸ“¢�D‘æ58‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D“¿“‡�D2019”N7ŒŽ14“ú�D

“à“¡�m”ü�C���ì�k‘¢�C‹ß“¡�^‘ã�C�²“¡�³‘å�C“à“¡�L�m�C‰Í–ì�O�C–L“c—DŽq�CŒá�ȉë•F�CŒ¬Œ´�_�C�¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`‚ÅŽ¡—Ã’†‚É�RMDA5�R‘Ì—z�«‚ð‚݂Ƃß�A–³‹Ø�Ç�«”畆‹Ø‰Š‚Æ�f’f‚³‚ꂽŠÔŽ¿�«”x‰Š‚Ì2—á.‘æ61‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D“¿“‡�D2019”N7ŒŽ14“ú�D

•Ÿ‰Æ–ƒ”ü, –L“c—DŽq, ‰¬–ì�L˜a, ‰Í–ì�O, Œã“Œ‹vŽk, Œ¬Œ´�_, Œá�ȉë•F, �¼‰ªˆÀ•F. Stevens-Johnson�ÇŒóŒQŒã‚É�‡•¹‚µ‚½•Â�Ç�«�׋CŠÇŽx‰Š‚ɃXƒeƒ�ƒCƒh‚¨‚æ‚у^ƒNƒ�ƒŠƒ€ƒX‚ª—LŒø‚Å‚ ‚Á‚½1—á. ‘æ6‰ñ“ú–{ŒÄ‹zƒPƒA�EƒŠƒnƒrƒŠƒe�[ƒVƒ‡ƒ“Šw‰ï�@’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. “¿“‡�D2019”N6ŒŽ8“ú�D

ŽO‹´“ÕŽu, ”ò”~—º, ‰¬–ì�L˜a, ‹ß“¡�^‘ã, –L“c—DŽq, Œã“Œ‹vŽk, ‹g“cŒõ‹P, �¬�씎‹v, Œ¬Œ´�_, �¼‰ªˆÀ•F�D”x‘½Œ`Šà‚É‚¨‚¯‚é�ã”çŠÔ—t“]Š· (EMT)‚ÌŒŸ“¢�D‘æ120‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�‚’m�D2019”N5ŒŽ12“ú�D

ûü‹´’¼Šó, “à“¡�L�m, ‹ß“¡�^‘ã, ‰¬–ì�L˜a, ‰Í–ì�O, –L“c—DŽq, ŽO–Ø�_˜a, Œá�ȉë•F, Œ¬Œ´�_, �¼‰ªˆÀ•F�DŽ¡—Ã’ï�R�«‚ÌSLE‚É”º‚¤�ԉ苅ᔂɃVƒNƒ�ƒzƒXƒtƒ@ƒ~ƒhƒpƒ‹ƒX—Ö@‚ª’˜Œø‚µ‚½1—á�D‘æ120‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�‚’m�D2019”N5ŒŽ12“ú�D

ˆÀ‘î�Ž”Ž, ’†‘º�MŒ³, ‘å‰Y‰ë”Ž, ‘]‰ä•”ŒöŽq, Œ´“c•�Žu, “¡ˆäŽu˜N, ŽO–Ø�_˜a, ‰ê�ì‹v”üŽq, �¼‰ªˆÀ•F, ˆÀ”{�³”Ž�D’·Šú‚ɂ킽‚錌�¬”ÂŒ¸�­‚ª�æ�s‚µ‚½‰è‹…�«Œ`Ž¿�×–E—lŽ÷�ó�×–EŽîᇂÌ1—á�D‘æ120‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�‚’m�D2019”N5ŒŽ12“ú�D

�¬ŽRˆë–ç�C“à“¡�L�m�C���ì�k‘¢�C‹ß“¡�^‘ã�C�¼‘º�t‰À�C�²“¡�³‘å�C‰Í–ì�O�C–L“c—DŽq�CŒá�ȉë•F�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F. ƒ}ƒEƒX”x�üˆÛ�ǃ‚ƒfƒ‹‚É‚¨‚¯‚é�V‹Kmulti-tyrosine kinase inhibitor TAS-115‚Ì�R�üˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ258‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡�D2019”N2ŒŽ3“ú�D

‹ß“¡�^‘ã, �¬�씎‹v, Žè’Ë•qŽj, �Ⓦ�OŠî, Œá�ȉë•F, �¼‰ªˆÀ•F�D‹CŠÇŽxšb‘§‚É‚¨‚¯‚郊ƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_(LPA)‚Ì–ðŠ„‚Æ‚»‚Ì‘jŠQŒø‰Ê‚ɂ‚¢‚Ă̌Ÿ“¢�D‘æ1‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ï’†�‘�EŽl�‘Žx•”’n•û‰ï�D�L“‡�D2019”N2ŒŽ2“ú�D
2018”N‹Æ�Ñ
�y‰¢•¶’˜�‘�z
Hisatsugu Goto, Yasuhiko Nishioka. ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer? Clinical Relevance of Genetic Factors in Pulmonary Diseases, Takeshi Kaneko, Editor, pp295-315, 2018. Springer.
�y‰¢•¶‘��à“™�z
Goto H, Nishioka Y. Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression. Int J Mol Sci 19(1):98, 2018.
�y‰¢•¶Œ´’˜�z
Kishi M, Aono Y, Sato S, Koyama K, Azuma M, Abe S, Kawano H, Kishi J, Toyoda Y, Okazaki H, Ogawa H, Uehara H, Nishioka Y. Blockade of platelet-derived growth factor receptor-ƒÀ, not receptor-ƒ¿ ameliorates bleomycin-induced pulmonary fibrosis in mice. PLOS ONE 13(12):e0209786, 2018.

Ogawa H, Azuma M, Tsunematu T, Morimoto Y, Kondo M, Tezuka T, Nishioka Y, Tsuneyama K. Neutrophils induce smooth muscle hyperplasia via neutrophil elastase-induced FGF-2 in a mouse model of asthma with mixed inflammation. Clin Exp Allergy 48(12):1715-1725, 2018.

Mitsuhashi A, Okuma Y, Zenke Y, Hosomi Y. Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases. Mol Clin Oncol 9(5):561-565, 2018.

Hanibuchi M, Kakiuchi S, Atagi S, Ogushi F, Shimizu E, Haku T, Toyoda Y, Azuma M, Kondo M, Kawano H, Otsuka K, Sakaguchi S, Nokihara H, Goto H, Nishioka Y. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 125:93-99, 2018.

Chikugo M, Sebe M, Tsutsumi R, Iuchi M, Kishi J, Kuroda M, Harada N, Nishioka Y, Sakaue H. Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. J Med Invest 65(3,4):166-170, 2018.

Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP. Notch3-dependent ƒÀ-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat Commun 9(1):3198, 2018.

Kondo M, Ogino H, Ogawa H, Afroj T, Toyoda Y, Sakaguchi S, Tsuboi M, Bando Y, Goto H, Tsuneyama K, Nishioka Y. A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition. Respir Med Case Rep 25:119-121, 2018.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARKRtrial. BMJ Open Respir Res 5(1):e000325, 2018.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M. Macitentan reduces progression of TGF-ƒÀ1-induced pulmonary fibrosis and pulmonary hypertension. Eur Respir J 52(2): pii1701857, 2018.

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig 56(4):268-291, 2018.

Kishi S, Minato M, Saijo A, Murakami N, Tamaki M, Matsuura M, Murakami T, Nagai K, Abe H, Nishioka Y, Doi T. A Case of IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. Intern Med 57(9):1259-1263, 2018.

Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, Harada H, Kato Y. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget 9(32):22480-22497, 2018.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Toyoda Y, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI. Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells. Sci Rep 8(1):6760, 2018.

Kozai H, Toyoda Y, Goto H, Kishi J, Tobiume M, Yamashita Y, Nishimura H, Kondo M, Kawano H, Nishioka Y. A case of interstitial pneumonia associated with anti-PL-7 antibody in a patient with rheumatoid arthritis. J Med Invest 65(1,2):147-150, 2018.

Bellaye PS, Shimbori C, Upagupta C, Sato S, Shi W, Gauldie J, Ask K, Kolb M�DLysyl Oxidase-like 1 Protein Deficiency Protects Mice from AdTGF-ƒÀ1 induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol 58(4):461-470,2018.

Saijo A, Goto H, Nakano M, Mitsuhashi A, Aono Y, Hanibuchi M, Ogawa H, Uehara H, Kondo K, Nishioka Y. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. Cancer Lett 421:17-27, 2018.

Goto H, Okano Y, Machida H, Hatakeyama N, Ogushi F, Haku T, Kanematsu T, Urata T, Kakiuchi S, Hanibuchi M, Sone S, Nishioka Y. Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer. Respir Investig 56(1):80-86, 2018.

Bellaye PS, Shimbori C, Yanagihara T, Carlson DA, Hughes P, Upagupta C, Sato S, Wheildon N, Haystead T, Ask K, Kolb M. Synergistic role of HSP90ƒ¿ and HSP90ƒÀ to promote myofibroblast persistence in lung fibrosis. Eur Respir J 51(2):pii1700386, 2018.

Nishijima H, Kajimoto T, Matsuoka Y, Mouri Y, Morimoto J, Matsumoto M, Kawano H, Nishioka Y, Uehara H, Izumi K, Tsuneyama K, Okazaki IM, Okazaki T, Hosomichi K, Shiraki A, Shibutani M, Mitsumori K, Matsumoto M. Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). J Autoimmun 86:75-92, 2018.
�y˜a•¶’˜�‘�z
�¬ŽRˆë–ç, �¼‰ªˆÀ•F�Dƒeƒ�ƒ�ƒA�L’·‚Æ”x�üˆÛ�Ç�DŒÄ‹zŠí޾г�f’fŽ¡—ÃAƒvƒ��[ƒ`4�uŠÔŽ¿�«”x‰Š�E”x�üˆÛ�ǂƗމ�޾г�v ŽO“ˆ—��W ‘�•Ò�W, Œá�ȈÀ—Ç‘¾ �ê–å•Ò�W pp20-25�C2018�D’†ŽR�‘“X�D

�¼‰ªˆÀ•F�D‰ß•q�«”x‰Š�D�¡“ú‚ÌŽ¡—ÃŽw�j2018”N”Å�@•ŸˆäŽŸ–î, �‚–Ø�½, �¬Žºˆê�¬ ‘�•Ò�W, pp309-310, 2018. ˆãŠw�‘‰@�D
�y˜a•¶Œ´’˜�z
�X�Z�r�C‰Í–ì�O�C–L“c—DŽq�C�¬ŽRˆë–ç�C�¼‘º�t‰À�C���ì�k‘¢�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DƒuƒŒƒIƒ}ƒCƒVƒ“”x�üˆÛ�ǃ‚ƒfƒ‹‚É‚¨‚¯‚é�üˆÛ‰è�×–E‘��BˆöŽqŽó—e‘Ì‘jŠQ–ò‚Ì�R�üˆÛ‰»Œø‰Ê‚ÌŒŸ“¢�D•ªŽqŒÄ‹zŠí•a 22(1):96-98, 2018.
�y˜a•¶‘��à�z
Œá�ȉë•F�D‚º‚ñ‚»‚­‚ÌŽ¡—Âőå�؂Ȃ±‚Æ�DŽl�‘ˆãŠwŽGŽ� 74(5,6):159-162, 2018.

�¼‰ªˆÀ•F�Cûü‹´�Í�DŠª“ªŒ¾�DŽl�‘ˆãŠwŽGŽ� 74(5,6):125, 2018.

�¼‰ªˆÀ•F�D”x‚ª‚ñ–Ɖu—Ö@‚Ì�ŋ߂̘b‘è�D“¿“‡Œ§—Õ�°“à‰Èˆã‰ï‰ï•ñ 23:40-43, 2018�D

–L“c—DŽq�DŠÔŽ¿�«”x‰Š‚Ì�f’f‚ÆŽ¡—Ã�D“¿“‡Œ§—Õ�°“à‰Èˆã‰ï‰ï•ñ 23:36-39, 2018�D

�¬ŽRˆë–ç, �¼‰ªˆÀ•F�Dƒeƒ�ƒ�ƒA�L’·‚Æ”x�üˆÛ�Ç�DŒÄ‹zŠí“à‰È 34(3):300-303, 2018�D

‰¬–ì�L˜a, Œã“Œ‹vŽk, �¼‰ªˆÀ•F�DŠPšu‚ÌŒ´ˆö‚Æ‚µ‚ÄŒ©“¦‚µ‚Ă͂Ȃç‚È‚¢Žîá‡�DŒÄ‹zŠíƒWƒƒ�[ƒiƒ‹ 66(3):458-465, 2018�D

–L“c—DŽq, �¼‰ªˆÀ•F�D–ò�Ü�«”x�áŠQ�DŒÄ‹zŠí“à‰È 34(Suppl.1):454-461, 2018.

�¼žŠ“Ö˜Y, Œ¬Œ´�_. ALK—z�«”x‚ª‚ñ‚ÌŽ¡—ÃV�[ƒNƒGƒ“ƒX. Žîᇓà‰È 21(5):536-543, 2018.

�¼‰ªˆÀ•F�DŽ¿‹^‰ž“š ƒvƒ�‚©‚çƒvƒ�‚Ö�u‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX‚É‚¨‚¯‚é‚×ƒŠƒ€ƒ}ƒu�iƒxƒ“ƒŠƒXƒ^R�j‚ÌŽg—p–@�v�iŽ¿–âŽÒ�j�D“ú–{ˆãŽ–�V•ñ 4908:55, 2018.

–L“c—DŽq�C�¼‰ªˆÀ•F�Dƒjƒ“ƒeƒ_ƒjƒu’P“ƗÖ@�DŒÄ‹zŠíƒWƒƒ�[ƒiƒ‹ 66(2):229-235, 2018�D

�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š‚Ì�f’f‚ÆŽ¡—Ã�`�ŋ߂Ì�i•à�`�D“ú–{“à‰ÈŠw‰ïŽGŽ� 107(3):505-509, 2018.

Œã“Œ‹vŽk�C�¼žŠ“Ö˜Y�C�¼‰ªˆÀ•F�D‚ª‚ñ‚Ì�i“W‚É‚¨‚¯‚é�üˆÛ�×–E‚Ì‹@”\‚Æ–ðŠ„�`ŒŒŠÇ�V�¶‘jŠQ–ò‘Ï�«‚Æ‚ª‚ñв�×–E—l�×–E‚Ì—U“±�`�D•ªŽqŒÄ‹zŠí•a 22(1):49-51, 2018.

�¼‰ªˆÀ•F�DŽ¿‹^‰ž“š ƒvƒ�‚©‚çƒvƒ�‚Ö�u‹­”ç�Ç‚É�‡•¹‚µ‚½ŠÔŽ¿�«”x‰Š‚ÌŽ¡—Ö@�v�i‰ñ“šŽÒ�j�D“ú–{ˆãŽ–�V•ñ 4898:54-55, 2018.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hiroshi Nokihara, Hisatsugu Goto, Yasuhiko Nishioka. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. The IASLC 19th World Conference on Lung Cancer. Toronto,Canada. 2018”N9ŒŽ24“ú.

Toby Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moises Selman, Daniel Wachtlin, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ18“ú�D

Sakae Homma, Yasuhiro Kondoh, Motoyasu Kato, Tomoaki Hoshino, Hiroshi Mukae, Masashi Bando, Takafumi Suda, Takashi Kido, Yoshinori Tanino, Tomoo Kishaba, Noboru Hattori, Yoshio Taguchi, Takefumi Saitoh, Yasuhiko Nishioka, Kazuyoshi Kuwano, Kazuma Kishi, Naohiko Inase, Shinichi Sasaki, Hajime Takizawa, Takeshi Johkoh, Fumikazu Sakai, Susumu Sakamoto. Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ18“ú�D

Hiroshi Kawano, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Kozo Kagawa, Seidai Sato, Nobuhito Naito, Hisatsugu Goto, Yutaka Inagaki, Yasuhiko Nishioka. Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain. ERS International Congress 2018. Paris,France. 2018”N9ŒŽ16“ú�D

Hisatsugu Goto, Taito Yamago, Atsuro Saijo, Hirokazu Ogino, Makoto Tobiume, Kenji Otsuka, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara, and Yasuhiko Nishioka. Involvement of insulin-like growth factor in RANKL-targeted therapy in mouse model of lung cancer bone metastasis.�@ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ23“ú.

Seidai Sato, Chandak Upagupta, Toyoshi Yanagihara, Martin RJ Kolb. The fibrotic extracellular matrix induces exosomal pro-fibrotic miRNA production of fibrocytes. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ21“ú.

Kazuya Koyama, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Hirohisa Ogawa, Hisanori Uehara, Yasuhiko Nishioka. Novel Multi-tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Pulmonary Fibrosis In Mice. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ21“ú.

Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric White, Vincent Cottin, Imre Noth, Moises Selman, Daniel Wachtlin, Claudia Diefenbach, R Gisli Jenkins on behalf of the INMARK trial investigators. Investigating the effect of nintedanib on changes in biomarkers of ECM turnover in patients with IPF and limited FVC impairment: design of the INMARK study. ATS 2018 International Conference. San Diego,CA,USA. 2018”N5ŒŽ20“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F�D”xŠàŽ¡—Âɂ¨‚¯‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�܂̈ʒu‚¯‚Æ�V“WŠJ�D‘æ27‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[)�D�‚�¼�D2018”N12ŒŽ15“ú�D

Œã“Œ‹vŽk�D�üˆÛ�×–E�ifibrocytes�j‚ð•W“I‚Æ‚µ‚½ŒŒŠÇ�V�¶‘jŠQ–ò‘Ï�«ƒ�ƒJƒjƒYƒ€‚̉𖾂Ǝ¡—Âւ̓WŠJ�D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D“Œ‹ž�D2018”N11ŒŽ30“ú�D

�û•£�¹‹B, ˆÀ‘î�M“ñ, ‘勸•¶—², ŽR�è�Í, —t‹v‹MŽi, Œ¬Œ´�_, �¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�‡•¹–¢Ž¡—Ã�i�s”ñ�¬�×–E”xŠà‚ɑ΂·‚é TS-1+CBDCA •¹—p—Ö@‚Ì‘æ II ‘Š—Õ�°ŽŽŒ±�D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv)�D“Œ‹ž�D2018”N11ŒŽ30“ú�D

�¼‰ªˆÀ•F�D•ω»‚·‚é“Á”­�«”x�üˆÛ�ǂ̃}ƒl�[ƒWƒ�ƒ“ƒg�\޾г—�‰ð‚ÆŽ¡—Ã�í—ª�\�D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[)�D“Œ‹ž�D2018”N11ŒŽ29“ú�D

�¼‰ªˆÀ•F, ˆ¢•”�^Ž¡, ‹àŽq”ü‰Ø, ŽO‹´“ÕŽu, ‘å’ËŒ›Ži, Œã“Œ‹vŽk, ‰Á“¡�K�¬. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�V‹KŽ¡—Ö@ŠJ”­‚ð–ÚŽw‚µ‚½‘O—Õ�°Œ¤‹†. ‘æ56‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï(ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“). ‰¡•l�D2018”N10ŒŽ20“ú�D

�¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�Ç‚Ì�f’f‚ÆŽ¡—Ã�`�R�üˆÛ‰»–ò‚̈Ӌ`�`�D‘æ81‰ñ“ú–{ŒÄ‹zŠíŠw‰ï�E“ú–{Œ‹Šj•aŠw‰ï�E“ú–{ƒTƒ‹ƒRƒCƒh�[ƒVƒX�^“÷‰èŽî�«Ž¾Š³Šw‰ï‹ã�BŽx•”�H‹GŠw�p�u‰‰‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[)�D’·�è�D2018”N10ŒŽ6“ú�D

Œá�ȉë•F�D‚º‚ñ‚»‚­‚ÌŽ¡—Âőå�؂Ȃ±‚Æ�D‘æ257‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ïŽs–¯ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€�D“¿“‡�D2018”N8ŒŽ5“ú�D

�¼‰ªˆÀ•F�D”x‚ª‚ñ�i“W‚ÉŠÖ‚í‚é�üˆÛ�×–E‚Ì‹@”\‰ð�Í‚©‚玡—Âւ̓WŠJ�D‘æ27‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ï Šw�p�W‰ï�E‘�‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D‰¡•l�D2018”N7ŒŽ19“ú�D

�¼‰ªˆÀ•F�D”xŠàŽ¡—Âɂ¨‚¯‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�܂̈ʒu‚¯‚Æ�V“WŠJ�D‘æ108‰ñ“ú–{”xŠàŠw‰ïŠÖ�¼Žx•”Šw�p�W‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[)�D‘å�ã�D2018”N6ŒŽ30“ú�D

�¼‰ªˆÀ•F�D�i‰»‚·‚é”x‚ª‚ñ‚ÌŽ¡—à �`�i‚ÞƒQƒmƒ€ˆã—Â̌»�ê‚©‚ç�`�D‘æ31‰ñ“ú–{ŠàŠw‰ïŽs–¯ŒöŠJ�u�À�D“¿“‡�D2018”N5ŒŽ27“ú�D

Œã“Œ‹vŽk�DŒŒŠÇ�V�¶�D‘æ22‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï(‹³ˆçƒZƒ~ƒi�[)�D“Œ‹ž�D2018”N5ŒŽ17“ú�D

�û•£�¹‹B, ˆÀ‘î�M“ñ, ‘勸•¶—², �´�…‰pŽ¡, —t‹v‹MŽi, Œ¬Œ´�_, �¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�‡•¹–¢Ž¡—Ã�i�s”ñ�¬�×–E”xŠà‚ɑ΂·‚éTS-1+CBDCA•¹—p—Ö@‚Ì‘æII‘Š—Õ�°ŽŽŒ±. ‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€)�D‘å�ã�D2018”N4ŒŽ29“ú�D

�¼‰ªˆÀ•F�D”x‚ª‚ñ�f—ÂÌ�Å‘O�ü �`�i‚Þ•ªŽq�f’f‚ƌ•ʉ»ˆã—Ã�`�D‘æ17‰ñ“ú–{ŠàŽ¡—Êw‰ïŽs–¯ŒöŠJ�u�À�D“¿“‡�D2018”N4ŒŽ14“ú�D
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
‰¬–ì�L˜a�C‘å’ËŒ›Ži�CŽO‹´“ÕŽu�C–Ø�h�¹�r�C�¼‰ªˆÀ•F�D”xŠà�Eˆ«�«‹¹–Œ’†”çŽîƒ}ƒEƒXƒ‚ƒfƒ‹‚ð—p‚¢‚½–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Ɖ»Šw—Ö@‚Ì•¹—pŒø‰Ê‚ÉŠÖ‚·‚錟“¢�D‘æ31‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠw�p�W‰ï‘�‰ï�D“Œ‹ž�D2018”N12ŒŽ13“ú�D

•Ä“c�_�l, ‘å’ËŒ›Ži, ‰¬–ì�L˜a, �¼žŠ“Ö˜Y, Œã“Œ‹vŽk, Œ¬Œ´�_, �¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�‡•¹”ñ�¬�×–E”xŠà‚ɑ΂·‚é 2 ŽŸ‰»Šw—Ö@‚ÌŒŸ“¢�D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D“Œ‹ž�D2018”N12ŒŽ1“ú�D

�¼žŠ“Ö˜Y, ���¼”Ž”V, ‹ß“¡Œ’‰î, Œã“Œ‹vŽk, ‰¬–ì�L˜a, Œ¬Œ´�_, –L“c—DŽq, �¼‰ªˆÀ•F�D”ñ�¬�×–E”x‚ª‚ñ‚ɑ΂·‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�Ü‚Ì�¶‘¶ŠúŠÔ‚ÉŠÖ‚·‚é—\Œã•s—LjöŽq‚ÌŒŸ“¢�D‘æ59‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D“Œ‹ž�D2018”N11ŒŽ30“ú�D

•Ä“c�_�l�C‰¬–ì�L˜a�C–L“c—DŽq�C‰Í–ì�O�C‘å’ËŒ›Ži�C�¼žŠ“Ö˜Y�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F. �‚—î”xŠàгŽÒ‚ÌŽá”NŽÒ‚Æ”äŠr‚µ‚½—Õ�°“I“Á’¥. ‘æ56‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‰¡•l�D2018”N10ŒŽ18“ú�D

‘å’ËŒ›Ži, Œã“Œ‹vŽk, ‰¬–ì�L˜a, �¼žŠ“Ö˜Y, �¼‰ªˆÀ•F. ‰»Šw—Ö@‚ÍŽîᇓà‚ÌMDSCs‚ðŒ¸�­‚³‚¹‚邱‚Ƃɂæ‚è�RPD-1�R‘̂̌ø‰Ê‚ð‘�‹­‚·‚é. ‘æ77‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‘å�ã. 2018”N9ŒŽ27“ú.

ŽR“c�T“ñ, ‹àŽq”ü‰Ø, �‘“cŽéŽq, ˆ¢•”�^Ž¡, ”ˆä�r‰î, �[ŽR�³‹v, �¼‰ªˆÀ•F, ‰Á“¡�K�¬. ‚ª‚ñ“ÁˆÙ“Ipodoplanin‚ð”Fޝ‚·‚éƒqƒgƒLƒ�ƒ‰‰ü•σ‚ƒmƒNƒ��[ƒiƒ‹�R‘Ì�ichLpMab-23�j‚Ì�RŽîᇌø‰Ê‚¨‚æ‚шÀ‘S�«. ‘æ77‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‘å�ã. 2018”N9ŒŽ27“ú.

”ˆä�r‰î, ‘å�Î’qˆê, ‹àŽq”ü‰Ø, ŽR“c�T“ñ, ˆ¢•”�^Ž¡, �¼‰ªˆÀ•F, �ì“cŠw, Œ´“c�_”V, ‰Á“¡�K�¬. Œû�o�G•½�ã”çŠà‚É‚¨‚¯‚é�Rƒ|ƒhƒJƒŠƒLƒVƒ“�R‘Ì‚ÌADCC‚É‚æ‚é�RŽîᇌø‰Ê. ‘æ77‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‘å�ã. 2018”N9ŒŽ27“ú.

�XŒË�Ž–í, �´�…—Ç‘½, �‚‹´�®Žq, ‰ºàV�L�s, “Œ“�‘ã, ‰Í–ì�O, �¼‰ªˆÀ•F, •Ÿ“c’B–ç, �¬•錒‘¾˜N, “c’†•Û. ‘æ91‰ñ“ú–{�¶‰»Šw‰ï‘å‰ï. ‹ž“s�D2018”N9ŒŽ24-26“ú.

‰¬–ì�L˜a�C�û•£�¹‹B�CŠ`“à‘�Ži�CˆÀ‘î�M“ñ�C‘勸•¶—²�C�´�…‰pŽ¡�C—t‹v‹MŽi�C‘å’ËŒ›Ži�C�¼žŠ“Ö˜Y�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�‡•¹–¢Ž¡—Ã�i�s”ñ�¬�×–E”xŠà‚ɑ΂·‚éTS-1+CBDCA•¹—p—Ö@‚Ì‘æ‡U‘Š—Õ�°ŽŽŒ±�D‘æ16‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï�D�_ŒË�D2018”N7ŒŽ21“ú�D

Œá�ȉë•F�C–©‹`�²�C–؉º�Ÿ�O�C‹ß“¡�^‘ã�C�¼‰ªˆÀ•F�DƒNƒŠ�[ƒjƒ“ƒO‹Æ‚Ì•v•w‚É”­�Ç‚µ‚½‰ÄŒ^‰ß•q�«”x‰Š—á�D‘æ49‰ñ“ú–{�E‹Æ�EŠÂ‹«ƒAƒŒƒ‹ƒM�[Šw‰ï‘�‰ï�EŠw�p‘å‰ï�D‰¡•l�D2018”N7ŒŽ20“ú�D

�¼žŠ“Ö˜Y�CŒã“Œ‹vŽk�C���¼”Ž”V�C”ò”~—º�C‰¬–ì�L˜a�C•Ä“c�_�l�C�¼‰ªˆÀ•F�D”x‚ª‚ñ‚̈«�«‹¹�…‚ɑ΂·‚é bevacizumab ‚Ì—LŒø�«‚Æ‘Ï�«‰»‹@�˜‚̉ð�Í�D‘æ27‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ï Šw�p�W‰ï�E‘�‰ï�D‰¡•l�D2018”N7ŒŽ19“ú�D

‹ß“¡�^‘ã�CŽè’Ë•qŽj�C�¬�씎‹v�CŒá�ȉë•F�C�¼‰ªˆÀ•F�DƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚ð•W“I‚É‚µ‚½ƒAƒŒƒ‹ƒM�[�«‹C“¹‰Š�Ç�§Œä‚ɂ‚¢‚Ă̌Ÿ“¢�D‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï�D�ç—t�D2018”N6ŒŽ22“ú�D

�¬�씎‹v�CŒá�ȉë•F�C‹ß“¡�^‘ã�C�¼‰ªˆÀ•F. �_Œo�¬’·ˆöŽq�iNGF)‚̓�«šb‘§‚É‚¨‚¯‚é‹C“¹‰ß•q�«˜´�i‚ɑ΂·‚é–ðŠ„‚Æ‚»‚̃�ƒJƒjƒYƒ€. ‘æ67‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï�D�ç—t�D2018”N6ŒŽ22“ú�D

–L“c—DŽq�C�¬ŽRˆë–ç�C�¼‘º�t‰À�C���ì�k‘¢�C�¼žŠ“Ö˜Y�C”ò”~—º�C‰¬–ì�L˜a�C•Ä“c�_�l�C�¼‰ªˆÀ•F. “ûŠàгŽÒ‚Ì•úŽË�üŽ¡—ÃŒã‚É”­�Ç‚µ‚½•úŽË�ü”x‰Š‚É‚¨‚¯‚é‹CŠÇŽx”x–E�ô�ò‰t‚Ì—Õ�°“IŒŸ“¢. ‘æ41‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. “Œ‹ž. 2018”N5ŒŽ25“ú.

���ì�k‘¢�C–L“c—DŽq�C�¼žŠ“Ö˜Y�C”ò”~—º�C‰¬–ì�L˜a�C•Ä“c�_�l�C�¬ŽRˆë–ç�C�¼‘º�t‰À�C�¼‰ªˆÀ•F. EBUS-TBNAŒã‚É�cŠu‰Š‚ð”­�Ç‚µ‚½�Ç—á‚É‚¨‚¯‚éŠëŒ¯ˆöŽq‚ÌŒŸ“¢. ‘æ41‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. “Œ‹ž. 2018”N5ŒŽ24“ú.

‘å’ËŒ›Ži�CŒã“Œ‹vŽk�C‰¬–ì�L˜a�C�¼žŠ“Ö˜Y�C�û•£�¹‹B�C�¼‰ªˆÀ•F. ”xŠà�Eˆ«�«‹¹–Œ’†”çŽîƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Ɖ»Šw—Ö@‚Ì•¹—pŒø‰Ê. ‘æ22‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï�D“Œ‹ž�D2018”N5ŒŽ17“ú�D

‰¬–ì�L˜a�CŒã“Œ‹vŽk�C‘å’ËŒ›Ži�C�¼žŠ“Ö˜Y�C�û•£�¹‹B�C�¼‰ªˆÀ•F. �üˆÛ�×–E‚ªŽîᇖƉu‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ă̌Ÿ“¢. ‘æ22‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï�D“Œ‹ž�D2018”N5ŒŽ16“ú�D

”ò”~—º�C‰¬–ì�L˜a�CAfroj Tania�CŒã“Œ‹vŽk�CŒ¬Œ´�_�C‹g“cŒõ‹P�C�ì�ã�sšõ�C‘ê‘ò�GŒõ�C�¬�씎‹v�C�íŽR�Kˆê�C�¼‰ªˆÀ•F�D�ã”çŠÔ—t“]Š· (EMT)‚ª”x‘½Œ`Šà‚̈«�«‰»‚ÉŠñ—^‚·‚é‰Â”\�«‚ɂ‚¢‚Ă̌Ÿ“¢�D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D‘å�ã�D2018”N4ŒŽ28“ú�D

�¬ŽRˆë–ç�C–L“c—DŽq�C�¼‘º�t‰À�C���ì�k‘¢�C�X�Z�r�C‰Í–ì�O�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�Dƒ}ƒEƒX”x�üˆÛ�ǃ‚ƒfƒ‹‚É‚¨‚¯‚émulti-tyrosine kinase inhibitor TAS-115‚Ì�R�üˆÛ‰»Œø‰Ê‚ÌŒŸ“¢�D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D‘å�ã�D2018”N4ŒŽ28“ú�D

�¼‘º�t‰À�C�X�Z�r�C–L“c—DŽq�C—é�]—ÁŽq�C�¬ŽRˆë–ç�C���ì�k‘¢�C“à“¡�L�m�C‰Í–ì�O�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚é“Á”­�«”x�üˆÛ�ǂɑ΂·‚éNintedanib‚ÌŽ¡—Ã�Ç—á‚ÌŒŸ“¢�D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D‘å�ã�D2018”N4ŒŽ27“ú�D

“à“¡�L�m�C‰Í–ì�O�CŽR‰º—Y–ç�C‹ß“¡�^‘ã�C‰¬–ì�L˜a�C–L“c—DŽq�CŠÝ���CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DƒAƒUƒ`ƒIƒvƒŠƒ“•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½ŠÔŽ¿�«”x‰Š�‡•¹�RMDA5�R‘Ì—z�«”畆‹Ø‰Š‚Ì3—á�D‘æ62‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï�D“Œ‹ž�D2018”N4ŒŽ26“ú�D

–L“c—DŽq�C�û•£�¹‹B�CŠ`“à‘�Ži�CˆÀ‘î�M“ñ�C‘勸•¶—²�C�´�…‰pŽ¡�C—t‹v‹MŽi�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š�‡•¹–¢Ž¡—Ã�i�s”ñ�¬�×–E”xŠà‚ɑ΂·‚éTS-1+CBDCA•¹—p—Ö@‚Ì‘æ‡U‘Š—Õ�°ŽŽŒ±�D‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘�‰ï�E�u‰‰‰ï�D‹ž“s�D2018”N4ŒŽ14“ú�D

‰¬–ì�L˜a�C�û•£�¹‹B�C�¼žŠ“Ö˜Y�C‘å’ËŒ›Ži�C–L“c—DŽq�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@‚Ì”xŠà�Ç—á‚É‚¨‚¢‚Ä�‚—îŽÒ‚ÆŽá”NŽÒ‚ð”äŠr‚µ‚½Œã‚ëŒü‚«Œ¤‹†�D‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘�‰ï�E�u‰‰‰ï�D‹ž“s�D2018”N4ŒŽ14“ú�D
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
�²“¡�³‘å, –L“c—DŽq, “à“¡�L�m, •Ä“c�_�l, ���ì�k‘¢, �¼‘º�t‰À, ‹ß“¡�^‘ã, �¬ŽRˆë–ç, ‰Í–ì�O, Œã“Œ‹vŽk, �¼‰ªˆÀ•F�D‹CŠÇŽx”x–E�ô�ò‰t’†fibrocyte‚É‚¨‚¯‚émiR-21”­Œ»‚ÌŽ¾Š³•Ê�·ˆÙ‚ÉŠÖ‚·‚錟“¢�D‘æ27‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï�D�‚�¼�D2018”N12ŒŽ15“ú�D

�Ⓦ�OŠî, ‹ß“¡�^‘ã, ‹{�é—º, ‰¬–ì�L˜a, ”ò”~—º, ”ö–î�„Žu, �¬�씎‹v, ‰Í–ì�O, –L“c—DŽq, Œ¬Œ´�_, Œá�ȉë•F, Œã“Œ‹vŽk, �¼—Ç�_, �¼‰ªˆÀ•F�DƒGƒC‚ÌŽh‘nŒã‚É”­�Ç‚µ‚½”畆Mycobacterium massiliense�ǂ̈ê—á�D‘æ69‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï�D�‚�¼�D2018”N12ŒŽ15“ú�D

Œ´“cŽÑŠó, ‹ß“¡�^‘ã, �¼‘º�t‰À, “à“¡�L�m, ‰Í–ì�O, ‘å�è—T—º, �Ⓦ—Ç”ü, ûü‹´’¼Šó, ���ì�k‘¢, �¼‰ªˆÀ•F, ‰¬–ì�L˜a, ”ò”~—º, �¼žŠ“Ö˜Y, Œ¬Œ´�_, –L“c—DŽq, Œá�ȉë•F, Œã“Œ‹vŽk, �㌴‹v“T, Š�—´™Z�D–TŽîá‡�«�_Œo�ÇŒóŒQ‚ð�‡•¹‚µ‚½�¬�×–E”xŠà‚̈ê—á�D‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�‚�¼�D2018”N12ŒŽ15“ú�D

�Ⓦ‹IŽq, ‹ß“¡�^‘ã, ‰Í–ì�O, “¡–ì‘׋P, ‰ª‹v–«–ç, –L“c—DŽq, Œ¬Œ´�_, Œá�ȉë•F, Œã“Œ‹vŽk, �‚ŽR“NŽ¡, �¼‰ªˆÀ•F�D’×á‡�«‘å’°‰Š‰Á—Ã’†‚É”­�Ç‚µ�CŽ¡—Âɓï�a‚µ‚½ƒjƒ…�[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚̈ê—á�D‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�‚�¼�D2018”N12ŒŽ15“ú�D

‹{–{Œ›�Æ�C‹ß“¡�^‘ã�C“à“¡�L�m�CŽR�蔎‹P�C–L“c—DŽq�C‰¬–ì�L˜a�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠ�—´™Z�C�¼‰ªˆÀ•F�D–Ɖu‰î�Ý�«‰óŽ€�«ƒ~ƒIƒpƒ`�[‚Ì1—á�D‘æ119‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�¼ŽR�D2018”N12ŒŽ2“ú�D

‹àŽq—y—S�C‹ß“¡�^‘ã�Cûü‹´’¼Šó�C”ò”~—º�C‰¬–ì�L˜a�C�²“¡�³‘å�CŽO–Ø�_˜a�CŒã“Œ‹vŽk�CˆÀ”{�³”Ž�C�¼‰ªˆÀ•F�D‘½”­�¬Œ‹�߉e‚ð”F‚ß‚½HIV—z�«ƒjƒ…�[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Ì1—á�D‘æ119‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�¼ŽR�D2018”N12ŒŽ2“ú�D

ŽR‰º—Y–ç�C‰Í–ì�O�C�¡‘qŒ’�C“à“¡�L�m�C‹ß“¡�^‘ã�C‰¬–ì�L˜a�C�²“¡�³‘å�C–L“c—DŽq�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DTAFRO�ÇŒóŒQ‚Ì1—á�D‘æ29‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�‚�¼�D2018”N12ŒŽ1“ú�D

“à“¡�L�m�C‰Í–ì�O�C‹ß“¡�^‘ã�C‰¬–ì�L˜a�C�²“¡�³‘å�C–L“c—DŽq�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DEBƒEƒCƒ‹ƒX�ÄŠˆ�«‰»‚𔽕œ‚µ‚½�‚Ž¾Š³Šˆ“®�«ŠÖ�ßƒŠƒEƒ}ƒ`‚ɑ΂µ‚ăAƒoƒ^ƒZƒvƒg‚ª—LŒø‚Å‚ ‚Á‚½1—á�D‘æ29‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�‚�¼�D2018”N11ŒŽ30“ú�D

‹ß“¡�^‘ã�C�Ⓦ�OŠî�C���ì�k‘¢�C�¼‘º�t‰À�C�¬ŽRˆë–ç�C�²“¡�³‘å�C–L“c—DŽq�CŒá�ȉë•F�C�¬�씎‹v�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚ð•W“I‚É‚µ‚½ƒAƒŒƒ‹ƒM�[�«‹C“¹‰Š�Ç�§Œä‚ɂ‚¢‚Ă̌Ÿ“¢�D‘æ257‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2018”N8ŒŽ5“ú�D

ûü‹´’¼Šó�C‰¬–ì�L˜a�C�û•£�¹‹B�C�¼žŠ“Ö˜Y�C”ò”~—º�C���¼”Ž”V�C•Ä“c�_�l�C•Ÿ‰Æ–ƒ”ü�CŽO‹´“ÕŽu�C‹{–{Œ›�Æ�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚é�‚—îŽÒ”xŠà‚Ì—Õ�°“IŒŸ“¢�D‘æ257‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2018”N8ŒŽ5“ú�D

�X‚ ‚¸‚³�C“à“¡�L�m�CŽRú±”Ž‹P�C—Ñ—�Œb�C�Ⓦ‹IŽq�CŒ´“c�¹Šó�C‰Í–ì�O�C–L“c—DŽq�CŒã“Œ‹vŽk�CŠ�—´™Z�C‹v•Û‹X–¾�C�¼‰ªˆÀ•F�D–Ɖu‰î�Ý�«‰óŽ€�«ƒ~ƒIƒpƒ`�[‚Ì1—á. ‘æ257‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2018”N8ŒŽ5“ú�D

ŽO‹´“ÕŽu�C���ì�k‘¢�C•Ä“c�_�l�C�¼žŠ“Ö˜Y�C”ò”~—º�C‰¬–ì�L˜a�C‹ß“¡�^‘ã�Cûü‹´’¼Šó�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚É‚æ‚é–ò�Ü�«ŠÔŽ¿�«”x޾г‚ÌŒŸ“¢�B‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�^‘æ57‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï ŽáŽèŒü‚¯‚Ì‹³ˆçƒZƒ~ƒi�[. �o‰_�D2018”N7ŒŽ15“ú�D
�@
�X•¶���C•Ä“c�_�l�C‹ß“¡�^‘ã�C‰¬–ì�L˜a�C”ò”~—º�C�¼žŠ“Ö˜Y�C•Ÿ‰Æ–ƒ”ü�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D•¡Ž‹‚ð”­�Ç‚µ�AŽÎ‘ä•”ŽîᇂðŒ_‹@‚É�f’f‚³‚ꂽ”ñ�¬�×–E”xŠà‚Ì1—á�D‘æ57‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�o‰_�D2018”N7ŒŽ14“ú�D

š �d“¹‘å�C•Ä“c�_�l�C‰Í–ì�O�C�¼žŠ“Ö˜Y�C”ò”~—º�C‹ß“¡�^‘ã�C�Ⓦ�OŠî�C�¬�씎‹v�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D’°Œ^”x‘BŠà‚Ì1—á�D‘æ57‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�o‰_�D2018”N7ŒŽ14“ú�D

�Ⓦ‹IŽq�C–L“c—DŽq�C‰Í–ì�O�C�²“¡�³‘å�C�¬ŽRˆë–ç�C�¼‘º�t‰À�C���ì�k‘¢�C“à“¡�L�m�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D“–‰È‚ÅŒoŒ±‚µ‚½�RMDA5�R‘Ì—z�«”畆‹Ø‰Š�‡•¹ŠÔŽ¿�«”x‰Š‚Ì—Õ�°‘œ‚ÌŒŸ“¢�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�o‰_�D2018”N7ŒŽ14“ú�D

‘½”¦—Lä»”T�C‰¬–ì�L˜a�C�¼žŠ“Ö˜Y�C���¼”Ž”V�C‹ß“¡�^‘ã�C�Ⓦ—Ç”ü�C�¼–{‘厑�CŒã“Œ‹vŽk�C‘ê‘ò�GŒõ�C�¼‰ªˆÀ•F�Dˆ«�«‹¹�…‚ðŒ_‹@‚É�f’f‚³‚ꂽ•úŽË�ü—U”­ŒŒŠÇ“÷Žî‚Ì1—á�D‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�o‰_�D2018”N7ŒŽ14“ú�D

“à“¡�L�m�C�X“c—D�C���ì�k‘¢�C‹ß“¡�^‘ã�C�¼‘º�t‰À�C‰Í–ì�O�C–L“c—DŽq�CŠÝ���CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DTocilizumab ‚ª—LŒø‚Å‚ ‚Á‚½�d�Ç�¬�l”­�ǃXƒeƒBƒ‹•a‚Ì1—á�D‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D“¿“‡�D2018”N6ŒŽ3“ú�D

•Ä“c�_�l�C‰¬–ì�L˜a�C���¼”Ž”V�C‘å’ËŒ›Ži�C”ò”~—º�C�¼žŠ“Ö˜Y�C–L“c—DŽq�CŒã“Œ‹vŽk�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚é Pembrolizumab ‚ÌŽg—pŒoŒ±�D‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D“¿“‡�D2018”N6ŒŽ3“ú�D

”ü”n�³�l�C‰¬–ì�L˜a�C‹ß“¡�^‘ã�C���¼”Ž”V�C‘å’ËŒ›Ži�C”ò”~—º�C�²“¡�³‘å�C–L“c—DŽq�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D“Á”­�«”x�œ‰»�Ç‚Ì2—á�D‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D“¿“‡�D2018”N6ŒŽ3“ú�D

‹{–{ˆ»���C���¼”Ž”V�C‰¬–ì�L˜a�C‹ß“¡�^‘ã�C‘å’ËŒ›Ži�C�¬ŽRˆë–ç�C–L“c—DŽq�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D”xM.chelonae �ǂ̌o‰ß’†‚É�f’f‚³‚ꂽ”xM.massiliense �Ç‚Ì1—á. ‘æ118‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D“¿“‡�D2018”N6ŒŽ3“ú�D

“à“¡�L�m�C�X“c—D�C‘å’ËŒ›Ži�C‰Í–ì�O�C–L“c—DŽq�CŠÝ���CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DTocilizumab‚ª—LŒø‚Å‚ ‚Á‚½�d�Ç�¬�l”­�ǃXƒeƒBƒ‹•a‚Ì1—á�D‘æ256‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2018”N2ŒŽ11“ú.
2017”N‹Æ�Ñ
�y‰¢•¶‘��à“™�z
Sato S, Kolb MR. Personalised medicine for IPF: getting closer, but not there yet. Lancet Respir Med 5(11):836-837, 2017.
�y‰¢•¶Œ´’˜�z
Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Koyama K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 18(1):172, 2017.

Nagai K, Kishi J, Morizumi S, Minakuchi J, Bando Y, Nishioka Y, Doi T. Henoch-Schonlein purpura nephritis occurring postpartum in a patient with anti-PL-7 anti-synthetase syndrome. Mod Rheumatol 27(5):910-913, 2017.

Kaneko MK, Kunita A, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, Harada H, Kawada M, Nishioka Y, Fukayama M, Kato Y. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas. Monoclon Antib Immunodiagn Immunother 36(4):157-162, 2017.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI. Thymidine Catabolism as a Metabolic Strategy for Cancer Survival. Cell Rep 19(7):1313-1321, 2017.

Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity. Monoclon Antib Immunodiagn Immunother 36(3):104-112, 2017.

Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med 6(4):768-777, 2017.

Saijo A, Hanibuchi M, Goto H, Toyoda Y, Tezuka T, Nishioka Y. An analysis of the clinical features of lung cancer in patients with connective tissue diseases. Respir Investig 55(2):153-160, 2017.

Kakiuchi S, Hanibuchi M, Tezuka T, Saijo A, Otsuka K, Sakaguchi S, Toyoda Y, Goto H, Kawano H, Azuma M, Ogushi F, Nishioka Y. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: a feasibility of S-1. Respir Investig 55(2):145-152, 2017.

Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Monoclon Antib Immunodiagn Immunother 36(1):20-24, 2017.

Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain. Monoclon Antib Immunodiagn Immunother 36(1):25-29, 2017.

Oyama Y, Enomoto N, Suzuki Y, Kono M, Fujisawa T, Inui N, Nakamura Y, Kuroishi S, Yokomura K, Toyoshima M, Imokawa S, Oishi K, Watanabe S, Kasahara K, Baba T, Ogura T, Ishii H, Watanabe K, Nishioka Y, Suda T. Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE). Respir Med 123:63-70, 2017.

Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med 6(2):382-396, 2017.
�y˜a•¶’˜�‘�z
–L“c—DŽq, �¼‰ªˆÀ•F�Dƒ‰ƒ“ƒQƒ‹ƒnƒ“ƒX�×–E‘g�D‹…�Ç�D‹CŠÇŽx”x–E�ô�ò�uBAL�v–@‚ÌŽèˆø‚« ‰ü’ù‘æ3”Å�C“ú–{ŒÄ‹zŠíŠw‰ï‚т܂ñ�«”x޾гŠw�p•”‰ï, Œú�¶˜J“­�ȓ�«Ž¾Š³�Ž•žŒ¤‹†Ž–‹Æ‚т܂ñ�«”x޾г’²�¸Œ¤‹†”Ç •Ò, 2017. pp128-131�D�Ž�½“°�o”Å�D

�û•£�¹‹B�C�¼‰ªˆÀ•F�D•ªŽq�¶•¨Šw“I‚ɂ݂½ŠÔŽ¿�«”x‰Š‚¨‚æ‚Ñ”xŠà�DŠÔŽ¿�«”x‰Š�‡•¹�Ç”xŠà‚ÉŠÖ‚·‚éƒXƒe�[ƒgƒ�ƒ“ƒg�C“ú–{ŒÄ‹zŠíŠw‰ï Žîᇊw�p•”‰ï�E‚т܂ñ�«”x޾гŠw�p•”‰ï •Ò�W, 2017�Dpp13-18. “ì�]“°�D

Œã“Œ‹vŽk, �¼‰ªˆÀ•F�D”x–E”÷�Î�Ç�D“�«‚т܂ñ�«”x޾г�f—Ã‚ÌŽèˆø‚«�C“ú–{ŒÄ‹zŠíŠw‰ï ŠÄ�C, Œú�¶˜J“­�ȉȊwŒ¤‹†”ï•â�•‹à“�«Ž¾Š³�­�ôŒ¤‹†Ž–‹Æ�u‚т܂ñ�«”x޾г‚ÉŠÖ‚·‚é’²�¸Œ¤‹†�v”Ç “�«‚т܂ñ�«”x޾г�f—Ã‚ÌŽèˆø‚«�ì�¬ˆÏˆõ‰ï* •Ò�W, 2017. pp2-15�D“ì�]“°�D

�û•£�¹‹B�C�¼‰ªˆÀ•F�D‚¶‚ñ”x�Ç�iŒ]”x�CƒAƒXƒxƒXƒg”x�j�DŽ„‚ÌŽ¡—à 2017-18”N“x”Å, ‰Ž“c‹�’j�E–k‘º‘yˆê˜YŠÄ�C, 2017. pp242-243. “ú–{ˆãŽ–�V•ñŽÐ�D

�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š‚Ì‹}�«‘�ˆ«�D�¡“ú‚ÌŽ¡—ÃŽw�j2017”N”Å •ŸˆäŽŸ–î, �‚–Ø�½, �¬Žºˆê�¬ •Ò, 2017�Dpp308-309. ˆãŠw�‘‰@�D
�y˜a•¶Œ´’˜�z
‘ë‘q‹PŽÀ, �û•£�¹‹B, –L“c—DŽq, ‹ß“¡�^‘ã, ���¼”Ž”V, •Ÿ‰Æ–ƒ”ü, �¼‰ªˆÀ•F�D‹¹�…’†‚É‘½�”‚ÌLanghansŒ^‹��×–E‚ð”F‚ß‚½‹¹�…IL-6”Z“x‚ª�‚’l‚Å‚ ‚Á‚½Mycobacterium avium�ǂɔº‚¤‹¹–Œ‰Š‚̈ê—á�DŒ‹Šj 92(9):559-566, 2017�D
�y˜a•¶‘��à�z
‰¬–ì�L˜a, �¼‰ªˆÀ•F�D‚ª‚ñ“]ˆÚ‚Ì—Õ�°Œ¤‹†‚Ì—ðŽj‚Æ“W–]�D“ú–{—Õଠ75(‘�8):15-20, 2017.

ŠÝ���DäPŒ´•a‚Ì‘ŸŠí�Ç�ó‚Æƒ}ƒlƒWƒ�ƒ“ƒg‚Ì�i•à�@ŠÔŽ¿�«”x‰Š�E”x�üˆÛ�Ç�DƒAƒŒƒ‹ƒM�[ 66(9):1161-1164, 2017�D

–L“c—DŽq, �¼‰ªˆÀ•F. Precision Medicine�GƒRƒ“ƒpƒjƒIƒ“�f’f‚Æ“Á”­�«”x�üˆÛ�Ç. ŒÄ‹zŠí“à‰È 32(3):292-299, 2017.

�¼‰ªˆÀ•F, ˆ¢•”�^Ž¡�Dƒ|ƒhƒvƒ‰ƒjƒ“‚ð•W“I‚Æ‚µ‚½ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�V‹K�R‘̈ã–òŠJ”­�D�¶‰»Šw 89(4):564-567, 2017.

‘å’ËŒ›Ži�C�¼‰ªˆÀ•F�D”xŠà‚É‚¨‚¯‚é•W�€Ž¡—ÂƂµ‚Ă̖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò�DŠà‚Ɖ»Šw—Ö@ 44(8):655-660, 2017.

ŠÝ��, –L“c—DŽq�Dƒ‹�[ƒvƒX�t‰Š‚É‚¨‚¯‚é’·Šú—\Œã—\‘ª�DƒŠƒEƒ}ƒ`‰È58(1):102-108, 2017�D

‰¬–ì�L˜a, Œ¬Œ´�_�D–Ɖu—Ö@‚ÌŒ»�ó‚Æ�¡Œã‚Ì“W–]�D“ú–{—Õଠ75(7):1115-1120, 2017.

Œã“Œ‹vŽk�C�¼‰ªˆÀ•F�DŒŒŠÇ�V�¶‘jŠQ–ò‘Ï�«‚̃�ƒJƒjƒYƒ€�D“ú–{—Õଠ75(7):1039-1043�C2017.

“Œ“�‘ã�D•W�€—\–h�ô�E�´Œ‰‘€�ì(ƒKƒEƒ“ƒeƒNƒjƒbƒN‚È‚Ç)�D‹~‹}�E�W’†Ž¡—à 29(—Õ‘�):e1-e13, 2017�D

Œã“Œ‹vŽk�C�¼‰ªˆÀ•F�D�üˆÛ�×–E‚É‚æ‚é”x‚ª‚ñ‚ɑ΂·‚錌ŠÇ�V�¶‘jŠQ–ò‚Ì‘Ï�«ƒ�ƒJƒjƒYƒ€�D�Å�VˆãŠw 72(4):132-137�C2017.

Œã“Œ‹vŽk�CŽO‹´“ÕŽu�C�¼‰ªˆÀ•F�DŒŒŠÇ�V�¶‘jŠQ–ò‘Ï�«‚Æfibrocyte�D•ªŽqŒÄ‹zŠí•a 21(1):4-7�C2017�D
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
H. Goto. A. Mitsuhashi, Y. Nishioka. Mechanism of acquired resistance to anti-angiogenic therapy mediated by fibrocytes. The 22nd Congress of Asian Pacific Society of Respirology. Sydney, Australia�D2017”N11ŒŽ24“ú�D

H. Ogino, H. Goto, Y. Okano, H. Machida, N. Hatakeyama, F. Ogushi, T. Haku, T. Kanematsu, T. Urata, S. Kakiuchi, M. Hanibuchi, S. Sone, Y. Nishioka. Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer. ERS International Congress 2017. Milan,Italy. 2017”N9ŒŽ10“ú.

A. Saijo, H. Goto, M. Nakano, A.Mitsuhashi, H. Ogino, M. Tobiume, K. Otsuka, H. Yoneda, M.Hanibuchi, Y. Nishioka.Bone Marrow-Derived Fibrocytes Promote Stem Cell-Like Properties of Lung Cancer Cells. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ24“ú.

Y. Toyoda, S. Morizumi, S. Sato, H. Okazaki, Y. Chen, H.Goto, H. Ogawa, H. Nishimura, K. Koyama, H. Kawano, Y. Aono, H. Uehara, Y. Nishioka.Role of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Signal in Bleomycin-Induced Pulmonary Fibrosis in Mice. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ23“ú.

H. Goto, A.Mitsuhashi, A. Saijo, H. Ogino, K. Otsuka, M. Tobiume, H. Yoneda, M. Hanibuchi, Y. Nishioka. Fibrocytes as a Possible Cellular Biomarker for Anti-Angiogenic Therapy in Lung Cancer. ATS 2017 International Conference. Washington,DC, USA. 2017”N5ŒŽ21“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š‚Ì�f’f‚ÆŽ¡—Ã�`�ŋ߂Ì�i•à�`�D•½�¬29”N“x“ú–{“à‰ÈŠw‰ï�¶ŠU‹³ˆç�u‰‰‰ïBƒZƒbƒVƒ‡ƒ“(‘æ2‰ñ)�D•ÄŽq�D2017”N10ŒŽ29“ú�D

�¼‰ªˆÀ•F. ‚ª‚ñ–Ɖu—Ö@‚ÌŠî‘b‚Æ—Õ�°�`�ŋ߂̘b‘è�`�@‘æ56‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï�@’†�‘Žl�‘Žx•”Šw�p‘å‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[�D“¿“‡�D2017”N10ŒŽ22“ú�D

�¼‰ªˆÀ•F�DIIPs‚Ì•a‘Ô�EŽ¡—©‚çPM/DM‚É”º‚¤ŠÔŽ¿�«”x‰Š‚ð�l‚¦‚é. ‘æ9‰ñ‹Ø‰Šƒ��[ƒNƒVƒ‡ƒbƒv(‹³ˆç�u‰‰)�D“Œ‹ž�D2017”N10ŒŽ21“ú�D

�¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�ǂ̎¡—Ã�í—ª-�R�üˆÛ‰»Ž¡—Ã‚ð‚¢‚Â�A’N‚É“±“ü‚·‚é‚Ì‚©�H-�@‘æ58‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[�D‰¡•l�D2017”N10ŒŽ15“ú�D

Œã“Œ‹vŽk�C�¼‰ªˆÀ•F�Dˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�RŒŒŠÇ�V�¶—Ö@‚̉”\�«‚Æ‘Ï�«‹@�˜�D‘æ24‰ñ�ΖÈ�E’†”çŽîŒ¤‹†‰ï�D‘å�ã�D2017”N10ŒŽ7“ú�D

ˆ¢•”�^Ž¡�C‰Á“¡�K�¬�C�¼‰ªˆÀ•F�Dˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚éƒ|ƒhƒvƒ‰ƒjƒ“‚ð•W“I‚Æ‚µ‚½�R‘̗Ö@‚ÌŠJ”­�D‘æ24‰ñ�ΖÈ�E’†”çŽîŒ¤‹†‰ï�D‘å�ã�D2017”N10ŒŽ7“ú�D

Œã“Œ‹vŽk�CŽO‹´“ÕŽu�C�¼žŠ“Ö˜Y�C�û•£�¹‹B�C�¼‰ªˆÀ•F�D�üˆÛ�×–E(fibrocyte)‚ð•W“I‚Æ‚µ‚½‚ª‚ñ“]ˆÚ�E�i“Wƒ�ƒJƒjƒYƒ€‚̉𖾂ƌŒŠÇ�V�¶‘jŠQ–ò‘Ï�«�Ž•ž‚ÌŽŽ‚Ý�D‘æ26‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D‘å�ã. 2017”N7ŒŽ27“ú�D

�¼‰ªˆÀ•F. ”x�üˆÛ�Ç‚Ì�×–E•ªŽq•a‘Ô‚ÆŠÖ˜Aˆâ“`Žq. ‘æ38‰ñ“ú–{‰Š�Ç�E�Ä�¶ˆãŠw‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘å�ã. 2017”N7ŒŽ19“ú�D

�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š‚Ì�f’f‚ÆŽ¡—Ã�`�ŋ߂Ì�i•à�`�D•½�¬29”N“x“ú–{“à‰ÈŠw‰ï�¶ŠU‹³ˆç�u‰‰‰ïBƒZƒbƒVƒ‡ƒ“(‘æ1‰ñ)�D“Œ‹ž�D2017”N6ŒŽ11“ú�D

�¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�Ç�F‹´“n‚µŒ¤‹†‚̈Ӌ`‚Æ“W–]�D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•Ê�u‰‰)�D“Œ‹ž�D2017”N4ŒŽ22“ú�D

�¼‰ªˆÀ•F�DBlockade of growth factor signals in fibrogenesis of the lung�Ftherapeutic efficacy and mechanism of action�D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(International Symposium)�D“Œ‹ž�D2017”N4ŒŽ21“ú�D
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
�¼žŠ“Ö˜Y�C�û•£�¹‹B�C‰¬–ì�L˜a�CŒ¬Œ´�_�C–L“c—DŽq�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D�Ä”­�¬�×–E”xŠà‚ɑ΂·‚épaclitaxel—Ö@‚ÌŒŸ“¢�D‘æ58‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D‰¡•l�D2017”N10ŒŽ15“ú�D

ŽR“c�T“ñ�C‹àŽq”ü‰Ø�C�‘“cŽéŽq�C‘å�Î’qˆê�Cˆ¢•”�^Ž¡�C’£—s•¶�C”ˆä�r‰î�C�ì“cŠw�C�[ŽR�³‹v�C�¼‰ªˆÀ•F�C‰Á“¡�K�¬. ‚ª‚ñ“ÁˆÙ“Ipodocalyxin ‚ð”Fޝ‚·‚éƒqƒgƒLƒ�ƒ‰‰ü•σ‚ƒmƒNƒ��[ƒiƒ‹�R‘Ì�ichPcMab-6�j‚Ì�RŽîᇌø‰Ê‚¨‚æ‚шÀ‘S�«. ‘æ76‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï�D‰¡•l�D2017”N9ŒŽ30“ú�D

’£—s•¶�C�‘“cŽéŽq�C‹àŽq”ü‰Ø�C”ˆä�r‰î�CŽR“c�T“ñ�C‘å�Î’qˆê�Cˆ¢•”�^Ž¡�C�¼‰ªˆÀ•F�C�ì“cŠw�C�[ŽR�³‹v�C‰Á“¡�K�¬. ƒ|ƒhƒJƒŠƒLƒVƒ“‚ð•W“I‚Æ‚µ‚½ƒqƒgƒLƒ�ƒ‰Œ^�R‘ÌchPcMab-47 ‚É‚æ‚éƒqƒg‘å’°‚ª‚ñˆÚ�A•Ѓ‚ƒfƒ‹‚Å‚Ì�RŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ76‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï�D‰¡•l�D2017”N9ŒŽ30“ú�D

�¼žŠ“Ö˜Y�CŒã“Œ‹vŽk�C‰¬–ì�L˜a�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D�œ�‘—R—ˆ�üˆÛ�×–E(fibrocyte)‚Í”xŠà‚Ì‚ª‚ñв�×–E—l“Á�«‚ð‘£�i‚·‚é�D‘æ76‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï�D‰¡•l�D2017”N9ŒŽ28“ú�D

Œá�ȉë•F�C’·�@‰ë”ü�CŠâ“c‹M�C�ì“Y˜a‹`�C�ÎàVŒ[‰î�C’|’J–L�C�¼‰ªˆÀ•F�C�Ô’r‰ëŽj�D“¿“‡‘åŠw‚É‚¨‚¯‚é’S“–гŽÒ‚ð—p‚¢‚½‘½�EŽí˜AŒg‹³ˆç‚ÌŽæ‚è‘g‚Ý�D‘æ49‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ï�DŽD–y�D2017”N8ŒŽ19“ú�D

�¼žŠ“Ö˜Y�C‰¬–ì�L˜a�C‘å’ËŒ›Ži�CŽè’Ë•qŽj�CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DClinical efficacy of bevacizumab for non-squamous non-small cell lung cancer patients with malignant pleural effusion. ‘æ15‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï�D�_ŒË�D2017”N7ŒŽ29“ú�D

‰¬–ì�L˜a�C�û•£�¹‹B�C�¼žŠ“Ö˜Y�CŽè’Ë•qŽj�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D“¿“‡‘åŠw•a‰@‚É‚¨‚¯‚é�‚—îŽÒ”xŠà‚ÆŽá”NŽÒ”xŠà‚Ì—Õ�°“I“Á’¥‚ÉŠÖ‚·‚é”äŠrŒŸ“¢. ‘æ15‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï�D�_ŒË�D2017”N7ŒŽ29“ú�D

Œã“Œ‹vŽk�C�¼žŠ“Ö˜Y�C’†–ì–œ—L—¢�C”ò”~—º�C‘å’ËŒ›Ži�C•Ä“c�_�l�C�û•£�¹‹B�C�¼‰ªˆÀ•F�D‚ª‚ñв�×–E‰»‚Ì—U“±‚ð‰î‚µ‚½fibrocyte‚Ì”x‚ª‚ñ�i“W�E“]ˆÚ‘£�iƒ�ƒJƒjƒYƒ€�D‘æ26‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï�D‘å�ã. 2017”N7ŒŽ27“ú�D

�¬�씎‹v�CŒá�ȉë•F�C‹ß“¡�^‘ã�CŽè’Ë•qŽj�C�¼‰ªˆÀ•F�DIL-17/�D’†‹…‚Í‹C“¹”S–Œ�Ú’…•ªŽq‚ð�áŠQ‚µFGF-2ŽY�¶‚ð‰î‚µ‚½‹C“¹•½ŠŠ‹Ø”ìŒú‚ð—U“±‚·‚é�D‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï�D“Œ‹ž�D2017”N6ŒŽ17“ú�D

‹ß“¡�^‘ã�CŽè’Ë•qŽj�C�¬�씎‹v�CŒá�ȉë•F�C�¼‰ªˆÀ•F�DƒŠƒ]ƒtƒHƒXƒtƒ@ƒ`ƒWƒ“Ž_‚̓AƒŒƒ‹ƒM�[�«‹C“¹‰Š�ǂ̗U“±‚ÉŠÖ—^‚µ‚Ä‚¢‚é�D‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï�D“Œ‹ž�D2017”N6ŒŽ16“ú�D

˜a�ò�r�q�Cˆ¢•”�^Ž¡�C‰¬–ì�L˜a�CŒã“Œ‹vŽk�C�û•£�¹‹B�C‰Á“¡�K�¬�C�¼‰ªˆÀ•F�Dˆ«�«‹¹–Œ’†”çŽî“¯�ŠˆÚ�Aƒ}ƒEƒXƒ‚ƒfƒ‹‚ɑ΂·‚é�V‹Kƒ}ƒEƒX�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌLpMab-21‚É‚æ‚é�RŽîᇌø‰Ê‚ÌŒŸ“¢�D‘æ21‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŠw‰ïŠw�p�W‰ï�D•Ÿ‰ª�D2017”N6ŒŽ15“ú�D

ŽRŽq‘דl�CŒã“Œ‹vŽk�C�¼žŠ“Ö˜Y�C�û•£�¹‹B�C�¼‰ª ˆÀ•F�D”x‚ª‚ñ�œ“]ˆÚ‚É‚¨‚¯‚éRANKL•W“IŽ¡—Â̌ÀŠE‚Ɖ”\�«�D‘æ21‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŠw‰ïŠw�p�W‰ï�D•Ÿ‰ª�D2017”N6ŒŽ15“ú�D

‘å’ËŒ›Ži�C�û•£�¹‹B�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D”xŠà�Eˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�RPD-1�R‘Ì�A�RPD-L1�R‘̂Ɖ»Šw—Ö@‚Ì•¹—pŒø‰Ê‚ÌŠî‘b“IŒŸ“¢�D‘æ21‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŠw‰ïŠw�p�W‰ï�D•Ÿ‰ª�D2017”N6ŒŽ15“ú�D

Hirokazu Ogino, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa, Yasuhiko Nishioka. Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�‘�ÛƒtƒH�[ƒ‰ƒ€�D2017”N4ŒŽ23“ú�D

�û•£�¹‹B�C’†�£�Ÿ‘¥�C–L�è“Z�C–؉º�¬ŽO�C“‡“c‹v•v�C’ß”ö”ü•ä�CŒ´“c˜a‘ã�C�…ˆäŒ¤Ž¡�C—t‹v‹MŽi�C�¼‰ªˆÀ•F�D“¿“‡Žs‚É‚¨‚¯‚éCOPD‘�Šú”­Œ©‚ð–Ú“I‚Æ‚µ‚½ŒŸ�fƒVƒXƒeƒ€�D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2017”N4ŒŽ23“ú�D

Žè’Ë•qŽj�C�¬�씎‹v�C‹ß“¡�^‘ã�C–L“c—DŽq�C�²“¡�³‘å�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F�Dƒ_ƒj�RŒ´—U“±�«‚̃AƒŒƒ‹ƒM�[�«‹C“¹‰Š�Ç‚¨‚æ‚Ñ‹C“¹ƒŠƒ‚ƒfƒŠƒ“ƒO‚ÍPAR-2 antagonist‚Ì“Š—^‚É‚æ‚è—}�§‚³‚ê‚é�D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2017”N4ŒŽ23“ú.

–L“c—DŽq�CŠÝ���C‰Í–ì�O�C�X�Z�r�C�¬ŽRˆë–ç�C�¼‘º�t‰À�C���ì�k‘¢�CŽè’Ë•qŽj�CŒã“Œ‹vŽk�C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D“–‰@‚É‚¨‚¯‚é‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX�‡•¹ŠÔŽ¿�«”x‰Š‚Ì—Õ�°“IŒŸ“¢�D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2017”N4ŒŽ22“ú�D

Atsuro Saijo, Hisatsugu Goto, Mayuri Nakano, Atsushi Mitsuhashi, Hirokazu Ogino, Makoto Tobiume, Kenji Otsuka, Hiroto Yoneda, Masaki Hanibuchi, Yasuhiko Nishioka. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2017”N4ŒŽ22“ú�D

Shun Morizumi, Seidai Sato, Hiroyasu Okazaki, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Hiroshi Kawano, Yasuhiko Nishioka.Inhibition of pan-fibroblast growth factor receptor signaling in bleomycin-induced pulmonary fibrosis in mice. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2017”N4ŒŽ21“ú.

‘åŽR‹g�K�C‰|–{‹I”V�C—é–Ø—EŽO�C‰Í–ì‰ë�l�C’†‘º—S‘¾˜Y�C“¡àV•ü�K�CŠ£’¼‹P�C�•�Î�d�é�C‰¡‘ºŒõŽi�C–L“ˆŠ²�¶�C–…�ìŽj˜N�C‘å�ÎŒiŽm�C“n•Ó’mŽu�CŠ}Œ´Žõ˜Y�C”n�ê’q�®�C�¬‘q�‚Žu�C�Έ䊰�C“n•ÓŒ›‘¾˜N�C�¼‰ªˆÀ•F�C�{“c—²•¶. Pleuroparenchymal fibroelastosis‚É‚¨‚¯‚é”A’†ƒfƒXƒ‚ƒVƒ“‚Ì—L—p�«‚ÌŒŸ“¢. ‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D“Œ‹ž�D2017”N4ŒŽ21“ú.

‰Í–ì�O�C–L“c—DŽq�CŠÝ���C�X�Z�r�C‹ß“¡�^‘ã�CŽR‰º—Y–ç�CŽè’Ë•qŽj�CŒã“Œ‹vŽk�C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Š�‡•¹‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX�Ç—á‚Ì—Õ�°“IŒŸ“¢�D‘æ61‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï�D•Ÿ‰ª�D2017”N4ŒŽ20“ú�D

�û•£�¹‹B�C‰Á”[—º�C‘q–{‘ì�Æ�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�CŠàгŽÒŒŒŸ÷’†—V—£DNA‚ð—p‚¢‚½ˆâ“`Žq•ψٌŸ�¸‹Z�p‚Ì”äŠr�D‘æ114‰ñ“ú–{“à‰ÈŠw‰ï‘�‰ï�E�u‰‰‰ï�D“Œ‹ž�D2017”N4ŒŽ14“ú�D
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
•Ä“c�_�l�C‘å’ËŒ›Ži�C�¼žŠ“Ö˜Y�C”ò”~—º�C‰¬–ì�L˜a�C���¼”Ž”V�C–L“c—DŽq�CŒã“Œ‹vŽk�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚énivolumab‚Ì—LŠQŽ–�Û‚ÌŒŸ“¢�D‘æ117‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�‚�¼�D2017”N12ŒŽ3“ú�D

’Ò–{‰ê”ü�C“à“¡�L�m�C‹ß“¡�^‘ã�C���¼”Ž”V�C‰Í–ì�O�C‘å’ËŒ›Ži�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�¼‰ªˆÀ•F�D‘½”­’P�_Œo‰Š‚ð�‡•¹‚µ‚½�DŽ_‹…�«‘½”­ŒŒŠÇ‰Š�«“÷‰èŽî�Ç�iEGPA�j‚É‚¨‚¢‚ĖƉuƒOƒ�ƒuƒŠƒ“‘å—ʗÖ@�iIVIG�j‚ª—LŒø‚Å‚ ‚Á‚½3—á�D‘æ117‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�‚�¼�D2017”N12ŒŽ3“ú�D

‰Í–ì�O�C�¼–{–ž�C�¼‰ªˆÀ•F�D‚Ù‚Ú‚·‚ׂĂ̋¹‘B�‘Ž¿�ã”ç�×–E‚ª�¬�n‰ß’ö‚ÅAire‚ð”­Œ»‚·‚é‹@”\‚ð”õ‚¦‚Ä‚¢‚é�D‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D“¿“‡�D2017”N11ŒŽ25“ú�D

‰¬–ì�L˜a�C–L“c—DŽq�C‰Í–ì�O�CŠÝ���C‹ß“¡�^‘ã�C�X�Z�r�CŽR‰º—Y–ç�CŒã“Œ‹vŽk�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D“–‰@‚É‚¨‚¯‚é”x•a•Ï�‡•¹‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX�Ç—á‚Ì—Õ�°“IŒŸ“¢�D‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D“¿“‡�D2017”N11ŒŽ25“ú�D

�¡‘qŒ’�C“à“¡�L�m�CŽR‰º—Y–ç�C‰¬–ì�L˜a�CŠÝ���C‰Í–ì�O�C‹ß“¡�^‘ã�C�X�Z�r�C–L“c—DŽq�CŒã“Œ‹vŽk�CŒá�ȉë•F�C�¼‰ªˆÀ•F�Dƒ‹�[ƒvƒX�S‹Ø‰Š‚Ì2—á�D‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D“¿“‡�D2017”N11ŒŽ25“ú�D

ŽR‰º—Y–ç�C‰Í–ì�O�CŠÝ���C“à“¡�L�m�C‰¬–ì�L˜a�C‹ß“¡�^‘ã�C�X�Z�r�C–L“c—DŽq�CŒã“Œ‹vŽk�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D‘S�g�«‹­”ç�Ç‚ð”wŒi‚Éposterior reversible encephalopathy syndrome‚ð”­�Ç‚µ‚½ˆê—á�D‘æ28‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D“¿“‡�D2017”N11ŒŽ25“ú�D

”ò”~—º�C�X�Z�r�C—é�]—ÁŽq�C”ê“c“N–ç�C‰¬–ì�L˜a�C‘å’ËŒ›Ži�CŒã“Œ‹vŽk�C�㌴‹v“T�C‹v•Û‹X–¾�C�¼‰ªˆÀ•F�DBRAF —z�«”xŒ´”­ˆ«�«�•�FŽî‚Ì‚P—á�D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�L“‡�D2017”N10ŒŽ28“ú�D

�X“c—D�C–L“c—DŽq�C‘å’ËŒ›Ži�C�¼žŠ“Ö˜Y�C•Ä“c�_�l�C‹ß“¡�^‘ã�C���¼”Ž”V�CŒã“Œ‹vŽk�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D•úŽË�üŽ¡—ẪAƒuƒXƒRƒpƒ‹Œø‰Ê‚É‚æ‚éŽîá‡�k�¬‚ð”F‚ß‚½Œã‚É�Ä”­‚µ�Apembrolizumab ‚ª‘tŒ÷‚µ‚½”xŠà‚Ì‚P—á�D‘æ58‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�L“‡�D2017”N10ŒŽ28“ú�D

•Ÿ“c‹ª‘¾˜Y�C�X“c—D�C‘å’ËŒ›Ži�C�¼‘º�t‰À�C�X�Z�r�C���ì�k‘¢�C�¬ŽRˆë–ç�C�¡‘qŒ’�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�DBAL ‚É‚æ‚èŠà�«ƒŠƒ“ƒpŠÇ�Ç‚Æ�f’f‚µ‚¦‚½‘½”­ƒXƒŠƒKƒ‰ƒX‰e‚ð’æ‚µ‚½”x‘BŠà‚Ì‚P—á�D‘æ26‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï�D�L“‡�D2017”N10ŒŽ28“ú�D

”ü”n�³�l�C���¼”Ž”V�C”ò”~—º�C‘å’ËŒ›Ži�C“à“¡�L�m�C–L“c—DŽq�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�¼‰ªˆÀ•F�D�R IFN- ƒÁ�R‘Ì‚ª—z�«‚Å‚ ‚Á‚½”dŽí�«”ñŒ‹Šj�«�RŽ_‹Û�ǂ̂P—á�D‘æ68‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï�D�L“‡�D2017”N10ŒŽ28“ú�D

—é�]—ÁŽq�C�¼‘º�t‰À�C‰¬–ì�L˜a�C‘å’ËŒ›Ži�C”ò”~—º�C‰Í–ì�O�C•Ÿ‰Æ–ƒ”ü�CŽR‰º—Y–ç�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D�Sƒ^ƒ“ƒ|ƒi�[ƒf‚ð‚«‚½‚µ‚½Œ‹Šj�«�S–Œ‰Š‚Ì‚P—á�D‘æ68‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï�D�L“‡�D2017”N10ŒŽ28“ú�D

‘å�¼ˆê�C�X�Z�r�C”ê“c“N–ç�C�¼—§‹g�O�C‰¬–ì�L˜a�C‘å’ËŒ›Ži�C”ò”~—º�CŒã“Œ‹vŽk�C�㌴‹v“T�C‹v•Û‹X–¾�C�¼‰ªˆÀ•F�DBRAF—z�«”xŒ´”­ˆ«�«�•�FŽî‚Ì1—á�D‘æ255‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2017”N8ŒŽ6“ú�D

ŽR‰º‹M‰›�C�¼‘º�t‰À�C‰¬–ì�L˜a�C‘å’ËŒ›Ži�C”ò”~—º�C–L“c—DŽq�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D�Sƒ^ƒ“ƒ|ƒi�[ƒf‚ð‚«‚½‚µ‚½Œ‹Šj�«�S–Œ‰Š‚Ì1—á�D‘æ255‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2017”N8ŒŽ6“ú�D

—é�]—ÁŽq�C�X�Z�r�C‘å’ËŒ›Ži�C–L“c—DŽq�C‰Í–ì�O�C�¬ŽRˆë–ç�C���¼”Ž”V�C�¼‘º�t‰À�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�ǂɑ΂·‚énintedanib‚ÌŽg—pŒoŒ±�D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�‚’m�D2017”N7ŒŽ15“ú�D

”ü”n�³�l�CŒá�ȉë•F�C‘å’ËŒ›Ži�CŽR‰º—Y–ç�CŒã“Œ‹vŽk�CŠÝ���C‹g“cŒõ‹P�C�㌴‹v“T�C�¼‰ªˆÀ•F�DMinute Pulmonary Meningothelial-like Nodule‚Ì1—á�D‘æ57‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�‚’m�D2017”N7ŒŽ14“ú�D

�¡‘qŒ’�C‘å’ËŒ›Ži�C�¼žŠ“Ö˜Y�C”ò”~—º�C‰¬–ì�L˜a�C���¼”Ž”V�CŒã“Œ‹vŽk�CŒ¬Œ´�_�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ÌŽg—pŒoŒ±�D‘æ56‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚’m�D2017”N7ŒŽ14“ú�D

Šì“c—L‰À—¢�C���ì�k‘¢�C‘å’ËŒ›Ži�C‰¬–ì�L˜a�C”ò”~—º�C�¼žŠ“Ö˜Y�CŒ¬Œ´�_�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D�¬�×–E”xŠà‚Ö‚Ì“]‰»‚ð”F‚ß‚½EGFRˆâ“`Žq•ψٗz�«”x‘BŠà‚Ì1—á�D‘æ56‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚’m�D2017”N7ŒŽ14“ú�D

�X“c—D�C–L“c—DŽq�C�X�Z�r�C‘å’ËŒ›Ži�C‹ß“¡�^‘ã�C�¬ŽRˆë–ç�C�¼‘º�t‰À�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D•úŽË�üŽ¡—ẪAƒuƒXƒRƒpƒ‹Œø‰Ê‚É‚æ‚邯�l‚¦‚ç‚ê‚éŽîá‡�k�¬‚ð”F‚ß‚½”xŠà‚Ì1—á�D‘æ56‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚’m�D2017”N7ŒŽ14“ú�D

‹ß“¡�^‘ã�CŽè’Ë•qŽj�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�CŒá�ȉë•F�C“yŽt�³‘¾˜Y�CŠ�—´™Z�C�¼‰ªˆÀ•F�D�¬”]•‚Žî‚¨‚æ‚Ñ�…“ª�Ç‚ð”F‚ߊJ“ªŒ¸ˆ³�p‚ð—v‚µ‚½NPSLE‚Ì1—á�D‘æ116‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�‚’m�D2017”N5ŒŽ21“ú�D

�¼‘º�t‰À�CŽè’Ë•qŽj�C�¼žŠ“Ö˜Y�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���CŒ¬Œ´�_�C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D”x�G•½�ã”çŠàŽ¡—ÃŒã‚̋󓴕a•ςɔF‚ß‚½”xƒAƒXƒyƒ‹ƒMƒ‹ƒX�Ç‚Ì1—á�D‘æ116‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�D�‚’m�D2017”N5ŒŽ21“ú�D
2016”N‹Æ�Ñ
�y‰¢•¶’˜�‘�z
Yasuhiko Nishioka. Pathogenesis of IPF. Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease? In: Nakamura H, Aoshiba K (eds) Idiopathic Pulmonary Fibrosis, Springer, Tokyo, p43-58, 2016.
�y‰¢•¶‘��à�z
Nishioka Y. Cancer immunotherapy as a promising fourth standard therapy for lung canser: Beyond 20 years for the development of immunotherapy. Respir Investig 54:297, 2016.
�y‰¢•¶Œ´’˜�z
Toyoda Y, Ozaki R, Kishi J, Hanibuchi M, Kinoshita K, Tezuka T, Goto H, Ono H, Nagai K, Bando Y, Doi T, Nishioka Y.�@An autopsy case of aortic intimal sarcoma initially diagnosed as polyarteritis nodosa. Intern Med 55(21):3191-3195, 2016.

Toyoda Y, Hanibuchi M, Kishi J, Kawano H, Morizumi S, Sato S, Kondo M, Takikura T, Tezuka T, Goto H, Nishioka Y. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Invest 63(3,4):294-299, 2016.

Ogino H, Hanibuchi M, Kakiuchi S, Saojo A, Tezuka T, Toyoda Y, Tobiume M, Otsuka K, Sakaguchi S, Goto H, Arisawa K, Nishioka Y. Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. J Med Invest 63(3,4):286-293, 2016.

Hasegawa K, Tagawa M, Takagi K, Tsukamoto H, Tomioka Y, Suzuki T, Nishioka Y, Ohrui T, Numasaki M. Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-ă2 or IL-29/IFN-ă1. Cancer Gene Ther 23(8):266-277, 2016.

Numasaki M, Tsukamoto H, Tomioka Y, Nishioka Y, Ohrui T. A Heterodimeric Cytokine, Consisting of IL-17A and IL-17F, Promotes Migration and Capillary-Like Tube Formation of Human Vascular Endothelial Cells. Tohoku J Exp Med 240(1):47-56, 2016.

Abe S, Kato KM, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. Cancer Sci 107(9):1198-1205, 2016.

Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS, He J, Langley RR, Lehembre F, Regenass U, Fidler IJ. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro-Oncology 18(4):486-496, 2016.

Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Hommma S, Sugiyama Y;Japan Pirfenidone Clinical Study Group.Clinical Experience of the Long-tern Use of Pirfenidone for Idiopathic Pulmonary Fibrosis. Intern Med 55(5):443-448, 2016.

Sato S, Hanibuchi M, Takahashi M, Fukuda Y, Morizumi S, Toyoda Y, Goto H, Nishioka Y. A patient with idiopathic pleuroparenchymal fibroelastosis showing sustained pulmonary function due to treatment with pirfenidone. Intern Med 55(5):497-501�C2016.

Ogino H, Hanibuchi M, Takizawa H, Sakiyama S, Sumitomo H, Iwamoto S, Ikushima H, Nakajima K, Nagahiro H, Yamago T, Toyoda Y, Bando Y, Nishioka Y. Primary pulmonary synovial sarcoma showing prolonged survival with multimodality therapy. Intern Med 55(4):381-387�C2016.
�y˜a•¶’˜�‘�z
�¼‰ªˆÀ•F�D”ñ“ÁˆÙ�«ŠÔŽ¿�«”x‰Š(NSIP)�D“Á”­�«ŠÔŽ¿�«”x‰Š �f’f‚ÆŽ¡—Ã‚ÌŽèˆø‚«(‰ü’è‘æ3”Å), “ú–{ŒÄ‹zŠíŠw‰ï ‚т܂ñ�«”x޾г�f’f�EŽ¡—ÃKƒCƒhƒ‰ƒCƒ“�ì�¬ˆÏˆõ‰ï•Ò�W, 2016. pp61-68. “ì�]“°�D

�¼‰ªˆÀ•F�D“Á”­�«”x�üˆÛ�ǂ̊î‘b�DŒÄ‹zŠí޾г�Å�V‚ÌŽ¡—Ã2016-2018�D�™ŽR�K”äŒÃ�E–å“c�~ˆê,�EŒ·ŠÔ�º•F•Ò�D2016.pp57-60�D“ì�]“°

�¼‰ªˆÀ•F�D“Á”­�«ŠÔŽ¿”x‰Š�D�¡“ú‚ÌŽ¡—ÃŽw�j�D•ŸˆäŽŸ–î�C�‚–Ø�½�C�¬Žºˆê�¬‘�•Ò�W�D2016�Dpp355-356�DˆãŠw�‘‰@�D
�y˜a•¶‘��à�z
‰ªú±�O‘×�C�¼‰ªˆÀ•F�D‰Á—î‚Æ”x�üˆÛ‰»�DThe Lung perspectives 24(3):50-54�C2016�D

ŠÝ��, –L“c—DŽq�DRA‚É‚¨‚¯‚é‹CŠÇŽxŠg’£�ǂ͖��«Š´�õ�ǂŎ©ŒÈ–Ɖu‚ªŽä‹N‚³‚ê‚郂ƒfƒ‹‚Å‚ ‚é�DƒŠƒEƒ}ƒ`‰È56(1):86-91, 2016.

Œá�ȈÀ—Ç‘¾�C�¬‘q�‚Žu�C�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š Update �À’k‰ï �R�üˆÛ‰»–òŽž‘ã‚ÌŠÔŽ¿�«”x‰Š�f—Âð�l‚¦‚é�D�Å�VçΊw 71(7):1235-1248�C2016�D

�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š Update �˜˜_�D�Å�VçΊw 71(7):1233-1234�C2016�D

‰Í–ì�O�C�¼‰ªˆÀ•F�DäPŒ´•a‚É‚¨‚¯‚é”x•a•ςւ̃Aƒvƒ��[ƒ`�DƒŠƒEƒ}ƒ`‰È 55(4):345-352�C2016�D

�²“¡�³‘å, ‘å’J’¼Žq, Œ´‰p“ñ, �¼‰ªˆÀ•F�D‚ª‚ñ—}�§ˆâ“`Žq‚É‚æ‚é�×–E‚ƌ‘̘V‰»‚Ì�§Œä�D‚ª‚ñ•ªŽq•W“IŽ¡—Ã14(1):76-81, 2016.

Œã“Œ‹vŽk�CŽO‹´“ÕŽu�C�¼‰ªˆÀ•F�D�üˆÛ�×–E‚ª‚©‚©‚í‚錌ŠÇ�V�¶‘jŠQ–ò‚ɑ΂·‚éŠl“¾‘Ï�«ƒ�ƒJƒjƒYƒ€�D•ªŽqŒÄ‹zŠí•a 20(1):111-114�C2016�D

�¼‰ªˆÀ•F�C�²“¡�³‘å�Dƒjƒ“ƒeƒ_ƒjƒu�D•ªŽqŒÄ‹zŠí•a 20(1):100-102�C2016�D

Œã“Œ‹vŽk�C�–ì�ƒ“T�CŽO‹´“ÕŽu�C�¼‰ªˆÀ•F�D–��«‰Š�Ç‚Æfibrocyte�DŒÄ‹z‚Æ�zŠÂ 64(2):149-155�C2016�D
�y˜a•¶Œ´’˜�z
ŽRŽq‘דl�C�û•£�¹‹B�C‰¬–ì�L˜a�C‘º�ã‰i�®�CŠ�—´™Z�C�¼‰ªˆÀ•F�D‘½�Ê‚È�_Œo�Ç�ó‚ð’æ‚µ‚½�¬�×–E”xŠà‚É”º‚¤–TŽîá‡�«�_Œo�ÇŒóŒQ‚Ì1—á�D”xŠà 56(3):199-204�C2016�D
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Morizumi S, Sato S, Abe S, Okazaki H, Yanjuan C, Goto H, Hanibuchi M, Aono Y, Ogawa H, Hanibuchi M, Uehara H, Nishioka Y. Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity. ERS2016 International Conference, London, UK. 2016”N9ŒŽ4“ú�D

Yasuhiko Nishioka. Introduction of Session 152 - Repair pathways: from lung development to aging of the lung -. ERS2016 Internathional Conference(Invited lecture). London, UK. 2016”N9ŒŽ4“ú�D

Ogino H, Goto H, Kakiuchi S, Saijo A, Sakaguchi A, Tobiume M, Otsuka K, Hanibuchi M, Nishioka Y. Receptor tyrosine kinase-like orphan receptor 2, ROR2, regulates the proliferation of malignant pleural mesothelioma cells. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ17“ú

Sato S, Goto H, Morizumi S, Okazaki H, Yanjuan C, Kawano H, Toyoda Y, Hanibuchi M, Azuma M, Nishioka Y. Effect of blockade of fibroblast growth factor receptor signaling in experimental pulmonary fibrosis in mice. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ16“ú

Saijo A, Goto H, Mitsuhashi A, Nakano M, Ogino H, Aono Y, Sakaguchi S, Tobiume M, Otsuka K, Hanibuchi M, Nishioka Y. Bone marrow-derived fibrocytes maintain stem cell-like properties of lung cancer. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ15“ú

Goto H, Mitsuhashi A, Saijo A, Kuramoto T, Tabata T, Aono Y, Uehara H, Hanibuchi M, Nishioka Y�DFibrocytes mediate acquired resistance to anti-angiogenic therapy with bevacizumab in thoracic tumors. ATS 2016 International Conference. San Francisco, CA, USA. 2016”N5ŒŽ15“ú
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F�DŽîᇖƉuŠw‚ÌŠî‘b‚Æ”xŠà–Ɖu—Ö@‚Ì•à‚Ý�D‘æ57‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). •Ÿ‰ª. 2016”N12ŒŽ21“ú�D

Yasuhiko Nishioka. The mechanism of immunotherapy for lung cancer. JICS/KASLC symposium. ‘æ57‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(JLCS/KASLC Joint-Symposium). •Ÿ‰ª. 2016”N12ŒŽ19“ú�D

�¼‰ªˆÀ•F�DŒÄ‹zŠí޾г‚̃gƒ‰ƒ“ƒXƒŒ�[ƒVƒ‡ƒiƒ‹ƒŠƒT�[ƒ`�`ƒAƒJƒfƒ~ƒA”­‚Ì‘n–ò‚ð–ÚŽw‚µ‚½‘½�EŽí˜AŒg�`�D‘æ64‰ñˆã—ÖòŠwŒöŠJƒVƒ“ƒ|ƒWƒEƒ€�D“¿“‡�D2016”N11ŒŽ20“ú�D

Yasuhiko Nishioka�DAquired resistance to anti-angiogenic therapy and new insights toward the overcoming�DJASMO 2016 Annual Meeting�iInternational Symposium)�D�_ŒË�D2016”N7ŒŽ28“ú�D

Œã“Œ‹vŽk�C‰¬–ì�L˜a�CŽO‹´“ÕŽu�C�¼‰ªˆÀ•F�D�¬�×–E”xŠà‚É‚¨‚¯‚éŠÌ“]ˆÚ‚̈ʒu‚¯‚Æ‚ª‚ñв�×–E—l�×–E‚Ì–ðŠ„�D‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D•ÄŽq�D2016”N7ŒŽ22“ú�D

�¼‰ªˆÀ•F�D”x‚ª‚ñ‚ɑ΂·‚錌ŠÇ�V�¶‘jŠQ–ò‚Ì‘Ï�«‹@�\‚Æ‚»‚Ì�Ž•ž�D‘æ176‰ñ“ú–{”xŠàŠw‰ïŠÖ“ŒŽx•”Šw�p�W‰ï(ƒR�[ƒq�[ƒuƒŒƒCƒNƒZƒ~ƒi�[)�D“Œ‹ž�D2016”N7ŒŽ16“ú�D

ŠÝ���DŠÔŽ¿�«”x‰Š�E”x�üˆÛ�Ç�D‘æ65‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï(ƒVƒ“ƒ|ƒWƒEƒ€)�D“Œ‹ž�D2016”N6ŒŽ18“ú�D

�¼‰ªˆÀ•F�D”x�üˆÛ‰»‚Ì�×–E•ªŽq•a‘Ô‚ÆŽ¡–ü�í—ª�D‘æ37‰ñ“ú–{‰Š�Ç�E�Ä�¶ˆãŠw‰ï�D‹ž“s�D2016”N6ŒŽ16“ú�D

�¼‰ªˆÀ•F�DŒÄ‹zŠíŠw‰ï�‘�ۈψõ‰ï‚ÌŠˆ“®‚Æ—¯ŠwŽx‰‡�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•ÊŠé‰æ)�D‹ž“s�D2016”N4ŒŽ9“ú�D

�¼‰ªˆÀ•F�DRole of fibrocytes and growth factors in lung fibrosis and cancer�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(Inter-Assembly Symposium 2)�D‹ž“s�D2016”N4ŒŽ9“ú�D
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
�û•£�¹‹B�CŽè’Ë•qŽj�C�¼žŠ“Ö˜Y�C‰¬–ì�L˜a�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D“–‰È‚É‚¨‚¯‚é�‚—îŽÒ”xŠà‚ÌŽá”NŽÒ‚Ƃ̔äŠrŒŸ“¢�D‘æ57‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D•Ÿ‰ª�D2016”N12ŒŽ21“ú�D

�¼žŠ“Ö˜Y�CŽè’Ë•qŽj�C‰¬–ì�L˜a�C–L“c—DŽq�CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F�Dˆ«�«‹¹�…‚𔺂Á‚½”ñ�G•½�ã”ç”ñ�¬�×–E”xŠà‚ɑ΂·‚é Bevacizumab •¹—p‰»Šw—Ö@‚ÌŒŸ“¢�D‘æ57‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D•Ÿ‰ª�D2016”N12ŒŽ19“ú�D

‰¬–ì�L˜a�CŒã“Œ‹vŽk�C�¼žŠ“Ö˜Y�CŠ`“à‘�Ži�C�û•£�¹‹B�C�¼‰ªˆÀ•F�D“¿“‡‘åŠw•a‰@‚É‚¨‚¯‚é�i“WŒ^�¬�×–E”xŠàгŽÒ‚Ì—\ŒãˆöŽq‚ÉŠÖ‚·‚éŒã‚ëŒü‚«Œ¤‹†�D‘æ57‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï�D•Ÿ‰ª�D2016”N12ŒŽ19“ú�D

’†�h•¶ŠG, “c”¨�Ë, ŽR“c’‰–¾, Œã“Œ‹vŽk, –î–ì�¹“ñ, �¼‰ªˆÀ•F, ‘]‰ä•ü‹`, •y“c�Ÿ. ”ñ�¬�×–E”xŠà‚É‚¨‚¯‚é TGF-ƒÀ—U“±�«�ã”çŠÔ—t“]Š·‚Ì‘ãŽÓ“Á�«. ‘æ75‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‰¡•l. 2016”N10ŒŽ7“ú.

‰¬–ì�L˜a, �û•£�¹‹B�C‘å’ËŒ›Ži�C�¼žŠ“Ö˜Y�C�âŒû‹Å�CŽè’Ë•qŽj�CŠ`“à‘�Ži�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D“¿“‡‘åŠw•a‰@‚É‚¨‚¯‚é�i“WŒ^�¬�×–E”xŠàгŽÒ‚Ì—\ŒãˆöŽq‚ɂ‚¢‚Ă̌Ÿ“¢�D‘æ14‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï�D�_ŒË�D2016”N7ŒŽ28“ú�D

‘å’ËŒ›Ži�C�û•£�¹‹B�C‰¬–ì�L˜a�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F�D”xŠà�Cˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é–Æ‰uƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ�܂̗LŒø�«‚ÌŠî‘b“IŒŸ“¢�D‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï�D•ÄŽq�D2016”N7ŒŽ21“ú�D

�¼žŠ“Ö˜Y�CŒã“Œ‹vŽk�CŽO‹´“ÕŽu�C’†–ì–œ—L—¢�C‘å’ËŒ›Ži�C‰¬–ì�L˜a�C�âŒû‹Å�C�û•£�¹‹B�C�¼‰ªˆÀ•F�D�œ�‘—R—ˆ�üˆÛ�×–E(fibrocyte)‚Í”xŠà‚Ì‚ª‚ñв�×–E—l“Á�«‚ð‘£�i‚·‚é�D‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï�D•ÄŽq�D2016”N7ŒŽ21“ú�D

‰¬–ì�L˜a�CŒã“Œ‹vŽk�C�¼žŠ“Ö˜Y�C‘å’ËŒ›Ži�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DŽó—e‘ÌŒ^ƒ`ƒ�ƒVƒ“ƒLƒi�[ƒ[ROR2‚͈«�«‹¹–Œ’†”çŽî�×–E‚Ì‘��B‚ð�§Œä‚·‚é�D‘æ25‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï�D•ÄŽq�D2016”N7ŒŽ21“ú�D

ˆ¢•”�^Ž¡�C‰Á“¡�K�¬�CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F�Dƒ|ƒhƒvƒ‰ƒjƒ“‚ð•W“I‚Æ‚µ‚½�R‘̗Ö@‚ƃyƒ�ƒgƒŒƒLƒZƒh‚Ì•¹—p‚É‚æ‚鈫�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�RŽîᇌø‰Ê‚ÌŒŸ“¢�D‘æ20‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï�D•Ê•{�D2016”N5ŒŽ31“ú�D

‰Í–ì�O�C‹ß“¡�^‘ã�C�¼žŠ“Ö˜Y�C–L“c—DŽq�CŠÝ���C�¼‰ªˆÀ•F�D“–‰@‚É‚¨‚¯‚éäPŒ´•a‚É�‡•¹‚µ‚½”xŠà‚ÌŒŸ“¢�D‘æ60‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï�D‰¡•l�D2016”N4ŒŽ23“ú�D

‰¬–ì�L˜a�CŒã“Œ‹vŽk�C‘勸•¶—²�C—t‹v‹MŽi�CŒ“�¼‹M‘¥�C‰Y“c’m”V�C�û•£�¹‹B�C‘]�ªŽO˜Y�C�¼‰ªˆÀ•F�D�‚—îŽÒ�i�s”ñ�¬�×–E”xŠàгŽÒ‚ð‘Î�Û‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽS-1—Ö@‚Ì—Õ�°‘æ‡U‘ŠŽŽŒ±�D‘æ113‰ñ“ú–{“à‰ÈŠw‰ï‘�‰ï�E�u‰‰‰ï�D“Œ‹ž�D2016”N4ŒŽ15“ú�D

–L“c—DŽq�C�²“¡�³‘å�CŠÝ���C‰Í–ì�O�C�X�Z�r�CŠÝ�¹”ü�CŽè’Ë•qŽj�C�âŒû‹Å�CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F�D“–‰@‚É‚¨‚¯‚éäPŒ´•aŠÖ˜AŠÔŽ¿�«”x‰Š‚Ì‹}�«‘žˆ«‚ÉŠÖ‚·‚é—Õ�°“IŒŸ“¢�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D‹ž“s�D2016”N4ŒŽ10“ú�D

�û•£�¹‹B�C’†�£�Ÿ‘¥�C–L�è“Z�C–؉º�¬ŽO�C“‡“c‹v•v�C’ß”ö”ü•ä�CŒá�ȉë•F�C—t‹v‹MŽi�C�¼‰ªˆÀ•F�D“¿“‡Žs‚É‚¨‚¯‚éCOPDŒ’�f‚ÌŒ»�ó�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D‹ž“s�D2016”N4ŒŽ8“ú�D

Žè’Ë•qŽj�C�¬�씎‹v�C‹ß“¡�^‘ã�CŒá�ȉë•F�C–L“c—DŽq�C�²“¡ �³‘å�C‰ªú±�O‘×�C‰Í–ì�O�CŠÝ���CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DRAS‘jŠQ�Ü�iXRP44X�j‚ð—p‚¢‚½šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D‹ž“s�D2016”N4ŒŽ8“ú�D

ˆ¢•”�^Ž¡�C‰Á“¡�K�¬�C‹àŽq”ü‰Ø�CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F�Dˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�V‹K�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNE-12‚ÌŒø‰Ê�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�D‹ž“s�D2016”N4ŒŽ8“ú�D
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
Œ´—Ï�¢�CŽè’Ë•qŽj�C‹ß“¡�^‘ã�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DEB‚É‚æ‚é––�½�_Œo�áŠQ‚ð’æ‚µ‚½Œ‹Šj�«‹¹–Œ‰Š‚Ì1—á�D‘æ67‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï�D‰ªŽR�D2016”N12ŒŽ23“ú�D

�™•õ—D�l�CŽè’Ë•qŽj�C���ì�k‘¢�C•Ä“c�_�l�C‘å’ËŒ›Ži�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DEBUS-TBNAŒã‚É�cŠu‰Š‚ð”­�Ç‚µ‚½�cŠuŒ´”­ƒZƒ~ƒm�[ƒ}‚Ì1—á�D‘æ25‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï�D‰ªŽR�D2016”N12ŒŽ23“ú�D

‹e’r�‚Žj�CŽè’Ë•qŽj�C‹ß“¡�^‘ã�C‰¬–ì�L˜a�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DStevens-Johnson �ÇŒóŒQŒã‚É”­�Ç‚µ‚½•Â�Ç�«�׋CŠÇŽx‰Š‚ɃXƒeƒ�ƒCƒh‚¨‚æ‚у^ƒNƒ�ƒŠƒ€ƒX‚ª—LŒø‚Å‚ ‚Á‚½1—á�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D‰ªŽR�D2016”N12ŒŽ23“ú�D

�‚“‡‘ñ–ç�CŽè’Ë•qŽj�C‹ß“¡�^‘ã�C”ò”~—º�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DExon19‚Æexon21‚̈â“`Žq•ψق𓯎ž‚É”F‚ß‚½”x‘BŠà‚Ì1—á�D‘æ56‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D‰ªŽR�D2016”N12ŒŽ23“ú�D

–L“c—DŽq�CŽR‰º—Y–ç�C�X�Z�r�C‹ß“¡�^‘ã�C‰¬–ì�L˜a�C‰Í–ì�O�CŽè’Ë•qŽj�CŠÝ���CŒã“Œ‹vŽk�C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D“–‰@‚É‚¨‚¯‚éäPŒ´•aŠÖ˜AŠÔŽ¿�«”x‰Š‚Ì‹}�«‘žˆ«‚Ì—Õ�°“IŒŸ“¢�D‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�L“‡�D2016”N12ŒŽ3“ú�D

“c’†‚±‚±‚ë�C‰¬–ì�L˜a�C‹{“c�~–ç�CŽR‰º—Y–ç�C�X�Z�r�C‹ß“¡�^‘ã�C‰Í–ì�O�CŽè’Ë•qŽj�C–L“c—DŽq�CŠÝ���CŒã“Œ‹vŽk�C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D15”N‘O‚æ‚è”F‚ß‚é–��«�t‹@”\�áŠQ‚ɑ΂µ‚ăXƒeƒ�ƒCƒh‰Á—ª‘tŒ÷‚µ‚½�tƒTƒ‹ƒRƒCƒh�[ƒVƒX‚Ì1—á�D‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�L“‡�D2016”N12ŒŽ2“ú�D

ŽR‰º—Y–ç�C–L“c—DŽq�C‰¬–ì�L˜a�C‰Í–ì�O�CŽè’Ë•qŽj�CŠÝ���CŒã“Œ‹vŽk�C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F�D“–‰@‚É‚¨‚¯‚郋�[ƒvƒX�t‰Š‚ɑ΂·‚éIVCY‚ÆMMF‚ÌŽ¡—ÃŒoŒ±�D‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�L“‡�D2016”N12ŒŽ2“ú�D

‰¬–ì�L˜a�CŠÝ���C‰Í–ì�O�CŽè’Ë•qŽj�C–L“c—DŽq�CŒã“Œ‹vŽk�C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F�DŠÖ�ßƒŠƒEƒ}ƒ`‚Ì–ò•¨—Ö@‚É‚¨‚¯‚é‰h—{�ó‘Ԃ̕ω»‚ÌŒŸ“¢�D‘æ27‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï�D�L“‡�D2016”N12ŒŽ2“ú�D

���¼”Ž”V�CŽè’Ë•qŽj�CŽR‰º—Y–ç�C�¼žŠ“Ö˜Y�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F�DGefitinib“Š—^’†‚ÉAchromobacter Xylosoxidans‚É‚æ‚é‹ÛŒŒ�Ç‚ð”­�Ç‚µ‚½”x‘BŠà‚Ì‚P—á�D‘æ115‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�Dˆ¤•Q�D2016”N11ŒŽ27“ú�D

•Ä“c�_�l�CŽè’Ë•qŽj�C‰Í–ì�O�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F�D‘½”­�«ˆÝ�\“ñŽw’°’×ᇂ𔺂Á‚½MTXŠÖ˜AƒŠƒ“ƒp‘��B�«Ž¾Š³‚Ì‚P—á�D‘æ115‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï�Dˆ¤•Q�D2016”N11ŒŽ27“ú�D

ŽR–{�´�¬�CŽè’Ë•qŽj�C‰¬–ì�L˜a�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F. ‰ºŠ{Ž•“÷ŠàŽ¡—ÃŒã‚É”­�¶‚µ‚½•úŽË�ü—U”­ŒŒŠÇ“÷Žî‚Ì‚P—á. ‘æ253‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï�D“¿“‡�D2016”N7ŒŽ24“ú�D

���ì�k‘¢�CŽè’Ë•qŽj�C‘å’ËŒ›Ži�C�X�Z�r�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C�¼‰ªˆÀ•F. Crizotinib‚É‚æ‚éILD‚ð”­�ÇŒã‚ÉAlectinib‚Ì“Š—^‚ª‰Â”\‚Å‚ ‚Á‚½ALK—Z�‡ˆâ“`Žq—z�«”x‘BŠà‚Ì1—á. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�L“‡�D2016”N7ŒŽ9“ú.

‹ß“¡�^‘ã�CŽè’Ë•qŽj�C•Ä“c�_�l�C–L“c—DŽq�CŒã“Œ‹vŽk�CŠÝ���CŒá�ȉë•F�C�û•£�¹‹B�C‘º�㑾ˆê�C“yˆä�r•v�C‰Í–k’¼–ç�C‘ê‘ò�GŒõ�C�¼‰ªˆÀ•F. • �oƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚É‚æ‚è�f’f‚µ‰¡Šu–Œ–D�‡•Â�½�p‚ð�s‚Á‚½‰¡Šu–ŒŒð’Ê�Ç‚Ì1—á. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�D�L“‡�D2016”N7ŒŽ9“ú�D

ŽR‰º—Y–ç�C�¼žŠ“Ö˜Y�C�²“¡�³‘å�CŽè’Ë•qŽj�C�âŒû‹Å�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éäPŒ´•a�‡•¹”xŠà‚ÌŒŸ“¢. ‘æ114‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2016”N5ŒŽ22“ú.

�X�Z�r�C�²“¡�³‘å�C‰¬–ì�L˜a�C‰Í–ì�O�C�âŒû‹Å�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�CŒá�ȉë•F�C�¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éƒjƒ“ƒeƒ_ƒjƒu‚Ì“Á”­�«”x�üˆÛ�ǂɑ΂·‚éŽg—pŒoŒ±. ‘æ114‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2016”N5ŒŽ22“ú.
2015”N‹Æ�Ñ
�y‰¢•¶‘��à�z
Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 10: 89-98, 2015.
�y‰¢•¶Œ´’˜�z
Fukushima K, Nakamura S, Inoue Y, Higashiyama Y, Ohmichi M, Ishida T, Yoshimura K, Sawai T, Takayanagi N, Nakahama C, Kakugawa T, Izumikawa K, Aoki N, Nishioka Y, Kosaka O, Kohno S. Utility of a sputum antigen detection test in pneumococcal and lower respiratory infectious disease in adults. Intern Med 54(22):2843-2850, 2015.

Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Efficacy of perfenidone and disease severity of idiopathic pulmonary fibrosis: extended analysis of phase III trial in Japan. Respir Investig 53(6):279-287, 2015.

Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomisa H, Sakiyama S, Nishioka Y. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun 6:8792, 2015.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Konaka K, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Ishizawa K. Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids. Biol Pharm Bull 38(11):1752-1756, 2015.

Kawano H, Nishijima H, Morimoto J, Hirota F, Morita R, Mouri Y, Nishioka Y, Matsumoto M. Aire expression is inherent to most medullary thymic epithelial cells during their differentiation program. J Immunol 195(11):5149-5158, 2015.

Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget 6(34):36003-36018, 2015.

Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, Kameda H, Hara M, Kawaguchi Y, Tohma S, Takasaki Y, Dohi M, Nishioka Y, Yasuda S, Miyazaki Y, Kaneko Y, Nanki T, Watanabe K, Yamazaki H, Miyasaka N, Harigai M. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia. Mod Rheumatol. 25(4):609-614, 2015.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 49(4):398-404, 2015.

Sato S, Kawamata Y, Takahashi A, Imai Y, Hanyu A, Okuma A, Takasugi M, Yamakoshi K, Sorimachi H, Kanda H, Ishikawa Y, Sone S, Nishioka Y, Ohtani N, Hara E. Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice. Nat Commun 6:7035, 2015.

Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiyama H, Kohsaka H, Miyasaka N, Harigai M; PREVENT Study Group. Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study. J Rheumatol 42(4):614-622, 2015.

Tezuka T, Ogawa H, Azuma M, Goto H, Uehara H, Aono Y, Hanibuchi M, Yamaguchi Y, Fujikawa T, Itai A, Nishioka Y. IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators. PLoS One 10(3):e0121615, 2015.

Kawano H, Hanibuchi M, Yoshijima T, Toyoda Y, Kishi J, Tezuka T, Nishioka Y. A case of atypical Takayasu arteritis initially presenting with peripheral artery disease. Case Reports in Clinical Pathology 2(2):34-40, 2015.

Sato S, Hanibuchi M, Tobiume M, Kishi J, Toyoda Y, Kawano H, Takahashi M, Fukuda Y, Nishioka Y. A case of IgG4-related interstitial lung disease showing usual interstitial pneumonia pattern: Unusual case for histological features with pathological proof. Case Reports in Clinical Pathology 2(1):6-11, 2015.
�y˜a•¶’˜�‘�z
�¼‰ªˆÀ•F. �DŽ_‹…�«”x‰Š. �¡“ú‚ÌŽ¡—ÃŽw�j. •ŸˆäŽŸ–î, �‚–Ø�½, �¬Žºˆê�¬‘�•Ò�W. 2015. p330. ˆãŠw�‘‰@.

�²“¡�³‘å, �¼‰ªˆÀ•F. �×–E�¶•¨Šw�A•ªŽq•a‘Ô. �Å�VˆãŠw•Ê�û “Á”­�«”x�üˆÛ�ǂƂ»‚ÌŽü•ÓŽ¾Š³. Œá�ȈÀ—Ç‘¾•Ò�W. 2015. pp42-47. �Å�VˆãŠwŽÐ.

Œã“Œ‹vŽk�D”x‚ª‚ñ�D“¿“‡‘åŠw•a‰@‚Ì�Å�VŽ¡—ª‚í‚©‚é–{�C“¿“‡‘åŠw•a‰@•Ò’˜�D2015�Dpp30-31�DƒoƒŠƒ…�[ƒ�ƒfƒBƒJƒ‹�D

�¼‰ªˆÀ•F�D�‡–°Žž–³ŒÄ‹z�ÇŒóŒQ�D“¿“‡‘åŠw•a‰@‚Ì�Å�VŽ¡—ª‚í‚©‚é–{�C“¿“‡‘åŠw•a‰@•Ò’˜�D2015�Dpp32-33�DƒoƒŠƒ…�[ƒ�ƒfƒBƒJƒ‹�D

Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@ŒÄ‹zŠí�EäPŒ´•a“à‰È. ŒÄ‹zŠí޾г�f—ÂÌ�Å�æ’[. �™ŽR�K”äŒÃ, ‹ß“¡‹u, ’†�¼—mˆê, ‰œ‘º–¾”V�i, �‚‹´�O‹B, ˆêƒm�£�³˜a, ‹g–ìˆê˜Y, –{ŠÔ‰h, Œ·ŠÔ�º•F, ’r“c“¿•F, �{“c—²•¶, ˆÉ’B—mŽŠ, ‰iˆÀ•�, Ž›“c�OŽi•Ò�W. 2015. pp432-434. �æ’[ˆã—ËZ�pŒ¤‹†�Š.

�¼‰ªˆÀ•F. ”xŠà. �¡“ú‚Ì�f—Â̂½‚ß‚É ƒKƒCƒhƒ‰ƒCƒ“ŠO—ˆ�f—Ã2015. �ò�F‰p•Ò�W. 2015. pp570-572. “úŒoƒ�ƒfƒBƒJƒ‹ŠJ”­.
�y˜a•¶‘��à�z
–L“c—DŽq�C‰Í–ì�O�C�¼‰ªˆÀ•F�DŠÔŽ¿�«”x‰Š‚̖Ɖu—Ö@‚Í—L—p‚©�H�DŒÄ‹zŠí“à‰È 28(6):451-455�C2015.

�¼‰ªˆÀ•F. IPF‚Ì•aˆö˜_. THE LUNG perspective 23(3): 66-69, 2015.

ŽRŒû•�Žj, ”“Œ�_, �V’J•ÛŽÀ, —k‰Í�G�Í, �¼ˆä�®Žq, �d�´�r—Y, “c粕‘, �‚‰ª�§, ”ÑŠÔ“w, ‘å‰Y‰ë”Ž, Šì‘½�G�m, ŒË�ª�¹�D, –ì“c˜a�Ž, �X�Z�r�DˆÓޝ�áŠQгŽÒ‚ÌŠÓ•Ê�f’f‚É‚¨‚¯‚é�Ú�ׂȕa—ðŠm”F‚Ì�d—v�«�D“ú–{“à‰ÈŠw‰ïŽGŽ� 104(7):1495-1503, 2015.

�û•£�¹‹B, �¼‰ªˆÀ•F. Current topics from major journals-‰p•¶�´“lj‚ç ALK—z�«”ñ�¬�×–E”xŠà‚ɑ΂·‚é1ŽŸŽ¡—Âł̃NƒŠƒ]ƒ`ƒjƒu‚Ɖ»Šw—Ö@‚Ì”äŠrŽŽŒ±. “ú–{‹¹•”—Õ�° 74(6):717, 2015.

�¼‰ªˆÀ•F. –ò•¨Ž¡—Âɂ¨‚¯‚éƒXƒeƒ�ƒCƒh‚̈ʒu‚¯‚Æ‚Í�H. Modern Physician 6 35(6):766-768, 2015.

�¼‰ªˆÀ•F. ”x�üˆÛ�Ç. ŒÄ‹z‚Æ�zŠÂ 63(4): 315-322, 2015.

�¼‰ªˆÀ•F, ˆ¢•”�Gˆê, �²“¡�³‘å, Œã“Œ‹vŽk. Fibrocyte. Respiratory Medical Research 3(2):60-63, 2015.

�¼‰ªˆÀ•F. ‚ª‚ñ–Ɖu—Ö@‚Ì‰ß‹Ž‚Æ–¢—ˆ�FƒGƒrƒfƒ“ƒX‚ªŽ¦‚µ‚½�V‚½‚ȉ”\�«�D“ú–{Œû�o‰ÈŠw‰ïŽGŽ� 64(1):1-11, 2015.

“¿“‡‘åŠw‘åŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”�@ŒÄ‹zŠí�EäPŒ´•a“à‰ÈŠw•ª–ì. ŒÄ‹zŠí�´“ljï. ŒÄ‹z 34(2):233, 2015.

�û•£�¹‹B, �¼‰ªˆÀ•F. �R‚ª‚ñ�܂̕›�ì—p‚Ì—\–h“IŽ¡—Ã. “ú–{—Õଠ73(‘�2):93-97, 2015.

�¼‰ªˆÀ•F. ŒÄ‹zŠíŠ´�õ�Ç�|�ŋ߂̘b‘è�|. �¬�¼“‡ˆãŽt‰ï‰ï•ñ 49:26-27, 2015.

Œã“Œ‹vŽk, �¼‰ªˆÀ•F. ŒŒŠÇ�V�¶‘jŠQ�܂ɑ΂·‚é‘Ï�«ƒ�ƒJƒjƒYƒ€. ˆãŠw‚Ì‚ ‚ä‚Ý 252(7):814-818�C2015.

�û•£�¹‹B. COPD�|•a‘Ô‚Ì—�‰ð‚ƃ}ƒlƒWƒ�ƒ“ƒg‚ÌŽÀ�Û�|. �¬�¼“‡ˆãŽt‰ï‰ï•ñ 49:31-33, 2015.
�y˜a•¶Œ´’˜�z
’†–ì–œ—L—¢, ‹g“c�¬“ñ, ’†ŽR�³, ‘勸•¶—², �û•£�¹‹B, �¼‰ªˆÀ•F. ƒCƒ“ƒtƒ‹ƒGƒ“ƒU�iH1N1�j2009‚É”º‚¤ARDS‚ÉPMX-DHP—Ö@‚ª‘tŒø‚µ‚½1—á. Š´�õ�ÇŠwŽGŽ� 89(3):416-421, 2015.

�û•£�¹‹B, ‘å’ËŒ›Ži, ’Ëú±—C‹M, �≺’¼ŽÀ, Œ÷“�‚µ‚Ì‚Ô, •Ÿ“c—I, �¼‰ªˆÀ•F. Acute fibrinous and organizing pneumoniaƒpƒ^�[ƒ“‚Ì“Á”­�«ŠÔŽ¿�«”x‰Š‚ªŽ¦�´‚³‚ꂽ1—á. THE LUNG perspectives 23(2):2-5, 2015.

�²“¡�³‘å, Œã“Œ‹vŽk, ˆ¢•”�Gˆê, ’|ú±�²•v, ‰Í–ì�O, �–ì�ƒ“T, �¼‰ªˆÀ•F. ƒqƒgfibrocyte•ª‰»‚É‚¨‚¯‚éˆâ“`Žq”­Œ»‰ð�͂ƕªŽq•W“IŽ¡—Öò‚É‚æ‚镪‰»�§Œä‚ÌŒŸ“¢. •ªŽqŒÄ‹zŠí•a 19(1):135-139, 2015.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Yasuhiko Nishioka. Novel mechanisms in acquired resistance to anti-angiogenic therapy against lung cancer and mesothelioma. The 2nd Gene & Immunotherapy Conference Vietnam (Invited lecture). HCM City, Vietnam. 2015”N9ŒŽ25“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Yoshinori Aono, Hirokazu Ogino, Hirohisa Ogawa, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer. International Conference of Cancer Immunotherapy and Macrophages 2015. “Œ‹ž. 2015”N7ŒŽ9“ú.

Hirokazu Ogino, Atsushi Mitsuhashi, Hisatsugu Goto, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Hisanori Uehara, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. Characterization of Sphere-Forming Stem-Like Population of Lung Cancer Cell Line in Multi-Organ Metastasis Model. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ19“ú.

Yasuhiko Nishioka. What is a Role of Fibrocytes in Lung Fibrosis and Cancer? ATS 2015 International Conference (Invited lecture). Denver, CO. 2015”N5ŒŽ19“ú.

Seidai Sato, Hisatsugu Goto, Shuichi Abe, Terumi Yoshijima, Hiroyasu Okazaki, Akio Takezaki, Yoshinori Aono, Masaki Hanibuchi, Yasuhiko Nishioka. Effect of Kinase Inhibitors for Growth Factor Receptors on the Differentiation of Human Fibrocytes. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ17“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Yoshinori Aono, Hisanori Uehara, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. The Role of Fibrocytes in the Acquired Resistance to Anti-Angiogenic Therapy with Bevacizumab in Malignant Pleural Mesothelioma. ATS 2015 International Conference. Denver, CO. 2015”N5ŒŽ17“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F.�@‚ª‚ñ–Ɖu‚ð�l‚¦‚é�`�i•à‚·‚éŠî‘bŒ¤‹†‚ð—Õ�°‚Ö‚Ç‚¤Šˆ‚©‚·‚©�H�`.�@‘æ24‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[).�@�¼�]. 2015”N12ŒŽ20“ú.

�¼‰ªˆÀ•F.�@“Á”­�«”x�üˆÛ�Ç‚Ì�×–E•ªŽq•a‘ÔŒ¤‹†‚ÆŽ¡—ÂÌ�i•à.�@ ‘æ30‰ñ’·�èDDS�E�Ä�¶ˆã—ÃŒ¤‹†‰ï(“Á•Ê�u‰‰). ’·�è.�@2015”N12ŒŽ4“ú.

�¼‰ªˆÀ•F.�@‚ª‚ñ–Ɖu‚ÌABC�F”x‚ª‚ñ‚ɑ΂·‚é–Æ‰u—Ö@‚Ì—�‰ð‚ÉŒü‚¯‚Ä.�@‘æ56‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€).�@‰¡•l.�@2015”N11ŒŽ28“ú.

�¼‰ªˆÀ•F. “ú�í�f—Âɂ¨‚¯‚éäPŒ´•a”x‚ÌŠÓ•Ê–@. “ú–{ŒÄ‹zŠíŠw‰ï‘æ36‰ñ�¶ŠU‹³ˆç�u‰‰‰ï(‹³ˆç�u‰‰). –¼ŒÃ‰®. 2015”N11ŒŽ1“ú.

Yasuhiko Nishioka, Hisatsugu Goto. Mechanisms of acquired resistance to anti-angiogenic therapy and new insights toward the overcoming. ‘æ74‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï (Core Symposia 2). –¼ŒÃ‰®. 2015”N10ŒŽ8“ú.

‘å–Ø�OŽ¡, �¼‰ªˆÀ•F, ‰Á“¡�K�¬. �V‹K�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌLpMab-7‚Ì�RŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ19‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). �¼ŽR. 2015”N6ŒŽ11“ú.

“Œ“�‘ã. ‹ÛŒŒ�LjȊO‚ÌESBL Š´�õ�Ç‚àƒJƒ‹ƒoƒyƒlƒ€‚ÌŽg—p‚ð�„�§‚·‚é. ‘æ63‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘�‰ï(ƒ��[ƒNƒVƒ‡ƒbƒv). “Œ‹ž. 2015”N6ŒŽ5“ú.

Œã“Œ‹vŽk. Life in DUKE -DUKE‘åŠw—¯Šw‘ÌŒ±-. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•ÊŠé‰æ). “Œ‹ž. 2015”N4ŒŽ19“ú.

�¼‰ªˆÀ•F. �V‹K•ªŽq•W“I–ò‚Æ‚»‚̃^�[ƒQƒbƒg. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(‹³ˆç�u‰‰). “Œ‹ž. 2015”N4ŒŽ17“ú.

�¼‰ªˆÀ•F. “ú�í�f—Âɂ¨‚¯‚éäPŒ´•a”x‚ÌŠÓ•Ê–@. “ú–{ŒÄ‹zŠíŠw‰ï‘æ36‰ñ�¶ŠU‹³ˆç�u‰‰‰ï(‹³ˆç�u‰‰). “Œ‹ž. 2015”N4ŒŽ16“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
�û•£�¹‹B�C‰Á”[—º�C‘q–{‘ì�Æ�CŒã“Œ‹vŽk�C�âŒû‹Å�C–L“c—DŽq�CŽè’Ë•qŽj�C�¼žŠ“Ö˜Y�C�¼‰ªˆÀ•F.�@ŠàгŽÒŒŒŸ÷’†—V—£DNA‚ð—p‚¢‚½ˆâ“`Žq•ψٌŸ�¸‹Z�p‚Ì”äŠr.�@‘æ56‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï.�@‰¡•l.�@2015”N11ŒŽ27“ú.

�¼žŠ“Ö˜Y�C�âŒû‹Å�AŽè’Ë•qŽj�CŠ`“à‘�Ži�C–L“c—DŽq�CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F.�@“–‰@‚É‚¨‚¯‚éäPŒ´•a‚É�‡•¹‚µ‚½”xŠà‚ÌŒŸ“¢.�@‘æ56‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï.�@‰¡•l.�@2015”N11ŒŽ26“ú.

‰¬–ì�L˜a, ŽO‹´“ÕŽu, Œã“Œ‹vŽk, �¼žŠ“Ö˜Y, �²“¡�³‘å, �âŒû‹Å, Žè’Ë•qŽj, ‘q–{‘ì�Æ, “c”¨�Ë, �㌴‹v“T, �û•£�¹‹B, �¼‰ªˆÀ•F. Sphere Œ`�¬Šàв�×–E—l•ª‰æ‚̃qƒg”xŠà‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é–ðŠ„‚É‚Â‚¢‚Ẳð�Í. ‘æ74‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. –¼ŒÃ‰®. 2015”N10ŒŽ10“ú.

ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, ‹àŽq”ü‰Ø, ‘å’ËŒ›Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. �V‹KƒqƒgƒLƒ�ƒ‰Œ^�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘Ì NZ-12 ‚̈«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�RŽîᇌø‰Ê. ‘æ74‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. –¼ŒÃ‰®. 2015”N10ŒŽ9“ú.

‰¬–ì�L˜a, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, �¼žŠ“Ö˜Y, �²“¡�³‘å, Š`“à‘�Ži, �û•£�¹‹B, �㌴‹v“T, �¼‰ªˆÀ•F. Sphere Œ`�¬Šàв�×–E—l•ª‰æ‚Ì”xŠà‘½‘ŸŠí“]ˆÚ‚É‚¨‚¯‚é–ðŠ„‚É‚Â‚¢‚Ẳð�Í. ‘æ24‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. ‘å�ã. 2015”N7ŒŽ23“ú.

�¼žŠ“Ö˜Y, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ’†–ì–œ—L—¢, ŽRŽq‘דl, �âŒû‹Å, Š`“à‘�Ži, �û•£�¹‹B, �¼‰ªˆÀ•F. Fibrocyte ‚Í‚ª‚ñв�×–E�«ˆÛŽ�‚É‚æ‚è”xŠà�i“W‚ð‘£�i‚·‚é. ‘æ24‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. ‘å�ã. 2015”N7ŒŽ23“ú.

�âŒû‹Å, –L“c—DŽq, Žè’Ë•qŽj, ’|ú±�²•v, ’†–ì–œ—L—¢, ‘ë‘q‹P”ü, �²“¡�³‘å, ‰ªú±�O‘×, ‘å’ËŒ›Ži, Š`“à‘�Ži, Œã“Œ‹vŽk, ŠÝ��, �û•£�¹‹B, �¼‰ªˆÀ•F. ”x–E�oŒŒ‚ð‚«‚½‚µ‚½ 11 �Ç—á‚ÌŒŸ“¢. ‘æ38‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. “Œ‹ž. 2015”N6ŒŽ11“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, �¼žŠ“Ö˜Y, �û•£�¹‹B, �¼‰ªˆÀ•F. �üˆÛ�×–E�ifibrocytes�j‚ªŠÖ‚í‚錌ŠÇ�V�¶‘jŠQ�܂ɑ΂·‚éŠl“¾‘Ï�«ƒ�ƒJƒjƒYƒ€. ‘æ19‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �¼ŽR. 2015”N6ŒŽ11“ú.

‘å’ËŒ›Ži, �û•£�¹‹B, Œã“Œ‹vŽk, �¼‰ªˆÀ•F. ”xŠà‚ɑ΂·‚é�RPD-L1�R‘ÌŽ¡—Â̊î‘b“IŒŸ“¢. ‘æ19‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �¼ŽR. 2015”N6ŒŽ11“ú.

�¬�씎‹v, Žè’Ë•qŽj, �¼‰ªˆÀ•F. ƒ_ƒj�RŒ´Œo•@Š´�ì‚ÍIL-17‚ð‘�‰Á‚³‚¹•½ŠŠ‹Ø”ìŒú‚𔺂¤‹C“¹ƒŠƒ‚ƒfƒŠƒ“ƒO‚ð—U“±‚·‚é. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ïŠw�p‘å‰ï. “Œ‹ž. 2015”N5ŒŽ27“ú.

’}Œã“�Žq, ŠÝ��, –L“c—DŽq, ‰Í–ì�O, �¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`гŽÒ‚É‚¨‚¯‚é‰h—{•]‰¿–@‚ÌŒŸ“¢. ‘æ59‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. –¼ŒÃ‰®. 2015”N4ŒŽ24“ú.

–L“c—DŽq, ‘ë‘q‹PŽÀ, ‹ß“¡�^‘ã, �²“¡�³‘å, ”ö�è—Ì•F, ŠÝ��, Žè’Ë•qŽj, ‰Í–ì�O, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. äPŒ´•a‚É�‡•¹‚µ‚½ŒŒ‹…æÃ�H�«ƒŠƒ“ƒp‘g�D‹…�Ç‚Ì4�Ç—á. ‘æ59‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. –¼ŒÃ‰®. 2015”N4ŒŽ24“ú.

�²“¡�³‘å, Œã“Œ‹vŽk, �X�Z�r, ˆ¢•”�Gˆê, ‹g“ˆ‹PŽÀ, ‰ªú±�O‘×, �û•£�¹‹B, �¼‰ªˆÀ•F. ”x�üˆÛ‰è�×–E‚ɑ΂·‚éfibrocyte‚Ì�ì—p‚Ænintedanib‚Ì—}�§Œø‰Ê. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ19“ú.

�û•£�¹‹B, ’†�£�Ÿ‘¥, –L�é“Z, –؉º�¬ŽO, “‡“c‹v•v, ’ß”ö”ü•ä, Œá�ȉë•F, —t‹v‹MŽi, �¼‰ªˆÀ•F. “¿“‡Žs‚É‚¨‚¯‚éCOPDŒŸ�fƒVƒXƒeƒ€‚Ì�\’z. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ19“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Takuya Kuramoto, Sho Tabata, Yoshinori Aono, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka. Fibrocytes mediate acquired resistance to anti-angiogenic therapy with bevacizumab. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ18“ú.

’†‘º�MŒ³, “Œ“�‘ã, ‰F�‚Œ›Œá, ŽO–Ø�_˜a, ‰ê�ì‹v”üŽq, �¼‰ªˆÀ•F, ”nŒ´•¶•F, “¡“c”ŽŒÈ. “–‰@‚ÅŒoŒ±‚µ‚½�d�Ç”M�«ŒŒ�¬”ÂŒ¸�­�ÇŒóŒQ‚Ì3—á. ‘æ89‰ñ“ú–{Š´�õ�ÇŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s. 2015”N4ŒŽ17“ú.

Žè’Ë•qŽj, �¬�씎‹v, –L“c—DŽq, ’|ú±�²•v, �²“¡�³‘å, ‰ªú±�O‘×, ‹g“ˆ‹PŽÀ, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Plasminogen Activator Inhibitor-1 ‘jŠQ�Ü(IMD-4690)‚Ì–��«šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ17“ú.

Š`“à‘�Ži, ‰¬–ì�L˜a, ‘å’ËŒ›Ži, �âŒû‹Å, �¼žŠ“Ö˜Y, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Š�‡•¹”xŠà‚ÌŽ¡—Â̌»�ó. ‘æ55‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2015”N4ŒŽ17“ú.

“Œ “�‘ã, �¼‰ªˆÀ•F. ‘Ï�«—Δ^‹ÛŽ�‘±Š´�õ‚É‚¨‚¯‚é‘n•”‚ւ̃|ƒŠƒ~ƒLƒVƒ“ B —°Ž_‰–ŽU•z‚ÌŒŸ“¢. ‘æ89‰ñ“ú–{Š´�õ�ÇŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s. 2015”N4ŒŽ17“ú.

’†–ì–œ—L—¢, ‹g“ˆ‹PŽÀ, �û•£�¹‹B, ’†‘º�MŒ³, ŽO–Ø�_˜a, ‰ê�ì‹v”üŽq, �¼‰ªˆÀ•F. Pneumocystis jiroveci‚ɑ΂µST�‡�܂̒EŠ´�ì—Ö@‚ð�s‚Á‚½4�Ç—á‚ÌŒŸ“¢. ‘æ89‰ñ“ú–{Š´�õ�ÇŠw‰ïŠw�p�u‰‰‰ï. ‹ž“s. 2015”N4ŒŽ16“ú.

Šâ�â–ƒˆßŽq, �²“¡�³‘å, �âŒû‹Å, –L“c—DŽq, �¬�씎‹v, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Šƒ}�[ƒJ�[‚ÌŒŸ“¢. ‘æ112‰ñ“ú–{“à‰ÈŠw‰ï‘�‰ï. ‹ž“s. 2015”N4ŒŽ11“ú.

‰¬–ì�L˜a, –L“c—DŽq, ’†–ì–œ—L—¢, “Œ“�‘ã, �û•£�¹‹B, �¼‰ªˆÀ•F. ”畆‹Ø‰Š‚ɑ΂µ‚ăXƒeƒ�ƒCƒh‚¨‚æ‚іƉu—}�§�܂ɂæ‚é‰Á—Ã’†‚É”­�Ç‚µ‚½”dŽí�«Mycobacterium avium�Ç‚Ì1—á. ‘æ90‰ñ“ú–{Œ‹Šj•aŠw‰ï‘�‰ï. ’·�è. 2015”N3ŒŽ27“ú.

“Œ“�‘ã, ’†‘]ˆŸ�²”ü, “¡Œ´”ÍŽq, ”¨”ü’qŽq, ‰Á“¡�^‰î, �¼‰ªˆÀ•F. �uHYDRO AG�v‚ð—p‚¢‚½ƒ^ƒbƒ`ƒpƒlƒ‹‰t�»•ÛŒìƒtƒBƒ‹ƒ€‚̈ã—ÃŒ»�ê‚É‚¨‚¯‚é—L—p�«‚ÌŒŸ“¢. ‘æ30‰ñ“ú–{ŠÂ‹«Š´�õŠw‰ï‘�‰ï�EŠw�p�W‰ï. �_ŒË. 2015”N2ŒŽ20“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
Žl‹{—R‹M�C�²“¡�³‘å�C’|ú±�²•v�C‹ß“¡�^‘ã�C‘ë‘q‹PŽÀ�C�âŒû‹Å�A–L“c—DŽq�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�C�¼‰ªˆÀ•F.�@ƒTƒ‹ƒRƒCƒh�[ƒVƒXŒo‰ßŠÏŽ@’†‚É”­�Ç‚µ‚½Œ‹Šj�«‹¹–Œ‰Š‚Ì‚P—á.�@‘æ24‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï.�@�¼�]. 2015”N12ŒŽ20“ú.

•Ä“c�_�l�C�²“¡�³‘å�C���ì�k‘¢�C‰¬–ì�L˜a�C’|ú±�²•v�C�âŒû‹Å�C–L“c—DŽq�C“Œ“�‘ã�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�C�¼‰ªˆÀ•F.�@�œ�‘ˆÙŒ`�¬�ÇŒóŒQ‚É”dŽí�«Œ‹Šj�Ç‚ð�‡•¹‚µŽ¡—Âɓï�a‚µ‚½ˆê—á.�@‘æ66‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï. �¼�]. 2015”N12ŒŽ19“ú.

’–Žq–¢Šó�C‰¬–ì�L˜a�C’†–ì–œ—L—¢�C‰ªú±�O‘×�C‘å’ËŒ›Ži�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�C�Ⓦ—Ç”ü�C�íŽR�Kˆê�C�¼‰ªˆÀ•F.�@”]�AŒûŠW�‚�A�A“ª‚¨‚æ‚Ñ�¬’°‚ւ̉“Šu“]ˆÚ‚ðŒ`�¬‚·‚é‹H‚È—Õ�°Œo‰ß‚ð‚½‚Ç‚Á‚½‰E�ã—tŒ´”­‘½Œ`Šà‚̈ê–UŒŸ—á.�@ ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï.�@�¼�]. 2015”N12ŒŽ19“ú.

‘]‰ä•”—m•½�C�²“¡�³‘å�C�¼žŠ“Ö˜Y�C’†–ì–œ—L—¢�C‰Í–ì�O�C�âŒû‹Å�C–L“c—DŽq�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�C�¼‰ªˆÀ•F.�@Šà�«�‘–Œ‰Š‚ɑ΂µƒAƒtƒ@ƒ`ƒjƒu‚ª‘tŒø‚µ‚½2—á.�@‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï.�@�¼�]. 2015”N12ŒŽ19“ú.

‹ß“¡�^‘ã�C�²“¡�³‘å�CŽè’Ë•qŽj�C–L“c—DŽq�C”ò”~—º�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�C�¼‰ªˆÀ•F.�@‹¹–Œ‰Š�E�SŠO–Œ‰Š‚ðŒ_‹@‚É�f’f‚³‚ꂽ�¬�lStill•a‚Ì2—á.�@ ‘æ113‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼.�@2015”N12ŒŽ6“ú.

�X�Z�r�C�²“¡�³‘å�C‰¬–ì�L˜a�C‹ß“¡�^‘ã�CŽè’Ë•qŽj�C–L“c—DŽq�CŒã“Œ‹vŽk�CŠÝ���C�û•£�¹‹B�C�¼‰ªˆÀ•F.�@“–‰È‚ÅŽ{�s‚³‚ꂽ‹¹–Œ–ü’…�p‚É‚¨‚¯‚éƒ^ƒ‹ƒN�»�Ü‚ÆOK-432‚ÌŽg—p�¬�т̔äŠr.�@‘æ113‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2015”N12ŒŽ6“ú.

ŽR‰º—Y–ç�C‰¬–ì�L˜a�CŠÝ���C–L“c—DŽq�C�X�Z�r�C‹ß“¡�^‘ã�C‘ë‘q‹PŽÀ�C�²“¡�³‘å�C‰Í–ì�O�CŽè’Ë•qŽj�CŒã“Œ‹vŽk�C�û•£�¹‹B�A�¼‰ªˆÀ•F.�@‹¹–Œ‰Š�Aƒlƒtƒ��[ƒ[�ÇŒóŒQ‚¨‚æ‚Ñ�d�Ç‘m–X•Ù•Â�½•s‘S�Ç‚ð’æ‚µ‚½‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX‚̈ê—á.�@‘æ26‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï.�@‰ªŽR. 2015”N12ŒŽ5“ú.

Š�“cŒh‰î, �²“¡�³‘å, –L“c—DŽq, �âŒû‹Å, Žè’Ë•qŽj, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. PS•s—ÇALK—Z�‡ˆâ“`Žq—z�«‚ÌŽá”N”x‘BŠà‚ɑ΂µƒNƒŠƒ]ƒ`ƒjƒu‚ª‘tŒø‚µ‚½ˆê—á. ‘æ251‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2015”N8ŒŽ2“ú.

���ì�k‘¢, �âŒû‹Å, ’Ëú±—C‹M, �²“¡�³‘å, ”ò”~—º, •Ä“c�_�l, ’|ú±�²•v, Žè’Ë•qŽj, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Šà�«�‘–Œ‰Š‚Éafatinib‚ª‘tŒø‚µ‚½EGFR exon18 G719A•ψقð‚à‚”x‘BŠà‚̈ê—á. ‘æ54‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”‰ï. �¼ŽR. 2015”N7ŒŽ3“ú.

’–Žq–¢Šó, ‰¬–ì�L˜a, �âŒû‹Å, ŠÝ�¹”ü, –L“c—DŽq, ‹ß“¡�^‘ã, ’†–ì–œ—L—¢, ŠÝ��, �û•£�¹‹B, �¼‰ªˆÀ•F. Nocardia wallaceiŠ´�õ�Ç‚Ì1—á. ‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �¼ŽR. 2015”N7ŒŽ3“ú.

•�ˆä”ü‹MŽq�C‹ß“¡�^‘ã�C�²“¡�³‘å�C‰Í–ì�O�C–L“c—DŽq�C�û•£�¹‹B�C�¼‰ªˆÀ•F. �DŽ_‹…�«’_ŠÇ‰Š‚ð�‡•¹‚µ‚½‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX‚Ì‚P—á. ‘æ112‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2015”N6ŒŽ7“ú.

‘ë‘q‹PŽÀ�C�âŒû‹Å�C�X�Z�r�C‘å’ËŒ›Ži�CŠÝ�¹”ü�CŽè’Ë•qŽj�C�¼žŠ“Ö˜Y�CŠ`“à‘�Ži�C�û•£�¹‹B�C�¼‰ªˆÀ•F. N-acetylcysteine‹z“ü‚ª—LŒø‚Å‚ ‚Á‚½ƒsƒ‹ƒtƒFƒjƒhƒ“’ï�R�«“Á”­�«”x�üˆÛ�Ç‚Ì1—á. ‘æ112‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2015”N6ŒŽ7“ú.

”ö�è—Ì•F, �âŒû‹Å, Žè’Ë•qŽj, ‘å’ËŒ›Ži, �X�Z�r, ŠÝ��, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹¹–Œ’¼‰º‚É‘Ñ�ó‚É•ª•z‚·‚é‚·‚èƒKƒ‰ƒX‰A‰e‚Å”­�Ç‚µ‚½�AŽ©ŒÈ–Ɖu�«”x–E’`”’�ǂ̈ê—á. ‘æ23‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �‚’m. 2015”N2ŒŽ28“ú.

’†–ì–œ—L—¢, “Œ“�‘ã, ‘ë‘q‹PŽÀ, �âŒû‹Å, –L“c—DŽq, �ã‰ñŽÑ‘ã, ˆÀ•”�G�Ä, �û•£�¹‹B, “yˆä�r•v, �¼‰ªˆÀ•F. ’·ŠúŠÔƒXƒeƒ�ƒCƒh“Š—^‚ª”­�ǂ̌_‹@‚ƂȂÁ‚½�AMycobacterium intracellulare‚É‚æ‚éŠÖ�߉ЂÆ�œ�‘‰Š‚Ì2�Ç—á. ‘æ65‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï. �‚’m. 2015”N2ŒŽ28“ú.

–ì“c˜a�Ž, “Œ“�‘ã, �¼”—а—², •š’J�GŽ¡, �²“¡‰ë”ü, ”¨”ü’qŽq, �ÎàVŒ[‰î, �¼‰ªˆÀ•F. �^‹ÛŠ´�õBUNDLE‚Ì“¿“‡‘åŠw•a‰@‚ł̊ˆ—p‚ɂ‚¢‚Ä. ‘æ250‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2015”N2ŒŽ1“ú.

ˆîŠ_‘¾‘¢, ‰¬–ì�L˜a, �âŒû‹Å, –L“c—DŽq, ’†–ì–œ—L—¢, �X�Z�r, �²“¡�³‘å, �¬�씎‹v, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Šƒ}�[ƒJ�[‚ÌŒŸ“¢. ‘æ250‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2015”N2ŒŽ1“ú.

ŠÛ‹´•üŽq, ’†‘º�MŒ³, ‘]‰ä•”ŒöŽq, ”ª–؂Ђ©‚é, �‚‹´�^”üŽq, ‰F�‚Œ›Œá, “¡ˆäŽu˜N, ŽO–Ø�_˜a, ‰ê�ì‹v”üŽq, ˆÀ”{�³”Ž, �¼žŠ“Ö˜Y, ’†–ì–œ—L—¢, “Œ“�‘ã, �¼‰ªˆÀ•F, ‹ß“¡Œ›•Û, ˆä“à�V, “¡“c”ŽŒÈ, ”nŒ´•¶•F. “–‰@‚ÅŒoŒ±‚µ‚½�d�Ç”M�«ŒŒ�¬”ÂŒ¸�­�ÇŒóŒQ‚Ì‚R—á. ‘æ250‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2015”N2ŒŽ1“ú.
2014”N‹Æ�Ñ
�y‰¢•¶‘��à“™�z
Hanibuchi M, Kim SJ, Fidler IJ, Nishioka Y. The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Invest 61(3,4):241-253, 2014.

Nishioka Y. Physician scientists in respiratory medicine. Respir Investig 52(5):279, 2014.

Nishioka Y. New wave of immunotherapy against lung cancer rolls in to clinic. Transl Lung Cancer Res 3(1):1, 2014.

Goto H, Mitsuhashi A, Nishioka Y. Role of surfactant protein A in non-infectious lung diseases. J Med Invest 61(1,2):1-6, 2014.
�y‰¢•¶Œ´’˜�z
Matsuo T, Dat LT, Komatsu M, Yoshimaru T, Daizumoto K, Sone S, Nishioka Y, Katagiri T. Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes. PLoS ONE 9(11):e113606, 2014.

Ogawa H, Ledford JG, Mukherjee S, Aono Y, Nishioka Y, Lee JJ, Izumi K, Hollingsworth JW. Surfactant protein D attenuates sub-epithelial fibrosis in allergic airways disease through TGF-beta. Respir Res 15(1):143, 2014.

Sato S, Hanibuchi M, Fukuya A, Yabuki Y, Bando H, Yoshijima T, Goto H, Ogawa H, Nishioka Y. Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but Not Krebs von den Lungen-6. Lung 192(5):711-717, 2014.

Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, Sato S, Kawano H, Kishi J, Goto H, Uehara H, Izumi K, Nishioka Y. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol 51(6):793-801, 2014.

Yokoi K, Tanei T, Godin B, van de Ven AL, Hanibuchi M, Matsunoki A, Alexander J, Ferrari M. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Letters 345(1):48-55, 2014.

Toyoda Y, Tabata S, Kishi J, Kuramoto T, Mitsuhashi A, Saijo A, Kawano H, Goto H, Aono Y, Hanibuchi M, Horikawa H, Nakajima T, Furukawa T, Sone S, Akiyama S, Nishioka Y. Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum 66(3):560-568, 2014.
�y˜a•¶’˜�‘�z
ŠÝ��, ‰Í–ì�O, �¼‰ªˆÀ•F. ‹­”ç�Ç. �Å�VˆãŠw�E•Ê�û �V‚µ‚¢�f’f‚ÆŽ¡—ÂÌABC 85, �™ŽR�K”äŒÃ•Ò�W. 2014. pp34-41. �Å�VˆãŠwŽÐ.

�û•£�¹‹B. Œ‹Šj. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. p175. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

–L“c—DŽq. ƒVƒF�[ƒOƒŒƒ“�ÇŒóŒQ�Eƒx�[ƒ`ƒFƒbƒg•a. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp134-135. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

ŠÝ��. ‘S�g�«ƒGƒŠƒeƒ}ƒg�[ƒfƒX�E‘½”­�«‹Ø‰Š/”畆‹Ø‰Š�E‘S�g�«‹­”ç�Ç. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp132-133. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

ŠÝ��. äPŒ´•a�E–Ɖu޾г�EƒAƒŒƒ‹ƒM�[޾г‚Æ‚Í. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp128-129. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

Š`“à‘�Ži. ”x‚ª‚ñ�E‹Ö‰ŒŽw“±�E‹Ö‰ŒŽx‰‡. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp65-67. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

–L“c—DŽq. ‰ßŠ·‹C�ÇŒóŒQ. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp63-64. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

Š`“à‘�Ži. �‡–°Žž–³ŒÄ‹z�ÇŒóŒQ. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp61-62. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

Œã“Œ‹vŽk. ”x‰Š. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp59-60. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

Œã“Œ‹vŽk. –��«•Â�Ç�«”x޾г�EŠÔŽ¿�«”x‰Š. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp57-58. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

�û•£�¹‹B. ŠPšu�Eá‚. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. p29. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

�û•£�¹‹B. ”­”M. Ž•ŠE“W–] •Ê�û�EŽ•‰ÈˆãŽt‚Ì‚½‚߂̈ãŠwƒnƒ“ƒhƒuƒbƒN, ‹g–{�Ÿ•F, �Ô’r‰ëŽj, ‰ÕŒ´–«, Žs�ì“N—Y•Ò�W. 2014. pp11-12. ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

�¼‰ªˆÀ•F. �×–E�E•ªŽq�¶•¨. ŒÄ‹zŠí޾г•¶Œ£ƒŒƒrƒ…�[2014�`2015. ‹´–{�CŠÄ�C. 2014. pp12-25. Дޮ‰ïŽÐŠwŒ¤ƒ�ƒfƒBƒJƒ‹�G��ŽÐ.
�y˜a•¶‘��à�z
�¼‰ªˆÀ•F. COPD�f—Â̌»�ó‚Æ“¿“‡Œ§‚ł̎æ‚è‘g‚Ý. ˆ¢“ìˆã•ñ 175:20-21, 2014.

�¼‰ªˆÀ•F. ”x�üˆÛ�ǂƑ��BˆöŽqƒVƒOƒiƒ‹. ŒÄ‹z‚Æ�zŠÂ 62(9):873-878, 2014.

Œã“Œ‹vŽk, �¼‰ªˆÀ•F. �V–ò‚Ì�ŋ߂̘b‘è�uƒfƒmƒXƒ}ƒu�v. •ªŽqŒÄ‹zŠí•a 18(1):109-111, 2014.

�¼‰ªˆÀ•F. �V–òŽ¡—Öò‚ÌŠJ”­�󋵂Æ�«—ˆ“W–]. “ú–{ˆãŽt‰ïŽGŽ�143(5):1011, 2014.
�y˜a•¶Œ´’˜�z
–؉º�Ÿ�O, �–ì�ƒ“T, ’|ú±�²•v, ‰ªú±�O‘×, ‹g“ˆ‹PŽÀ, ŠÝ�¹”ü, “Œ“�‘ã, ŠÝ��, �òŒ[‰î, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“”x�üˆÛ�ǃ‚ƒfƒ‹‚É‚¨‚¯‚éFAKƒVƒOƒiƒ‹‘jŠQ–ò‚Ì�R�üˆÛ‰»Œø‰Ê. •ªŽqŒÄ‹zŠí•a 18(1):154-157, 2014.

’r’¼Žq, Š ’JƒAƒL, à_Œû�^—�, �H�X—eŽq, ���¼”Ž”V, ’†–ì–œ—L—¢, ’¬“c‹v“T, ”©ŽR’¨�¶, ‰ª–ì‹`•v,ŽÂŒ´•×, ‘勸•¶—². ”xŠà‰»Šw—Ö@гŽÒ‚ÌQOL/PRO•]‰¿‚É‹y‚Ú‚·Œ‡‘ª‚̉e‹¿. �‚’mŒ§ˆãŽt‰ïˆãŠwŽGŽ� 19(1):112-121, 2014.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Yasuhiko Nishioka, Shuichi Abe, Seidai Sato, Yoshinori Aono, Hisatsugu Goto, Masami Kishi, Terumi Yoshijima, Hiroyasu Okazaki, Masaki Hanibuchi. Role of human fibrocytes in regulating pulmonary fibrosis: comprehensive analysis of their gene expression profile and growth factor production. The 18th International Colloquium on Lung and Airway Fibrosis (ICLAF). Mont-Tremblant, Quebec Canada. 2014”N9ŒŽ23“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Atsuro Saijo, Trung The Van, Yoshinori Aono, Hirohisa Ogawa, Soji Kakiuchi, Masaki Hanibuchi, Seiji Yano, Keisuke Izumi, Yasuhiko Nishioka. The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer. ATS 2014 International Conference (Mini-symposium). San Diego, CA. 2014”N5ŒŽ21“ú.

Seidai Sato, Hisatsugu Goto, Shuichi Abe, Masami Kishi, Katsuhiro Kinoshita, Momoyo Azuma,Akio Takezaki, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi, Yasuhiko Nishioka. Effect of Nintedanib (BIBF1120) on fibrocyte-induced fibroblast activation. ATS 2014 International Conference. San Diego, CA. 2014”N5ŒŽ18“ú.

Hisatsugu Goto, Yasuhiko Nishioka.The role of surfactant protein A in the host defense of the lung. The 117th Conference of KATRD (Invited lecture). Buan, Korea. 2014”N4ŒŽ11“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
Œã“Œ‹vŽk�C�¼‰ªˆÀ•F. ‹}�«�EˆŸ‹}�«Œo‰ß‚ðŽ¦‚·ŠÔŽ¿�«”x‰Š‚Ì—Õ�°. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï(‹³ˆç�u‰‰�j. �‚�¼. 2014”N12ŒŽ13“ú.

�¼‰ªˆÀ•F. ‚ª‚ñ–Ɖu—Ö@‚Ì‰ß‹Ž‚Æ–¢—ˆ�FƒGƒrƒfƒ“ƒX‚ªŽ¦‚µ‚½�V‚½‚ȉ”\�«�D‘æ62‰ñ“ú–{Œû�oŠw‰ï ’†�‘�EŽl�‘’n•û•”‰ï(“Á•Ê�u‰‰). “¿“‡. 2014”N10ŒŽ25“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, �¼žŠ“Ö˜Y, ‘q–{‘ì�Æ, “c”¨�Ë, �û•£�¹‹B, Š`“à‘�Ži, �–ì�ƒ“T, �㌴‹v“T, �¼‰ªˆÀ•F. ƒxƒoƒVƒYƒ}ƒu‚ɑ΂·‚éŠl“¾‘Ï�«ƒ�ƒJƒjƒYƒ€‚Æ‚µ‚Ä‚Ì�üˆÛ�×–E�ifibrocytes�j‚Ì–ðŠ„. ‘æ18‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). �å‘ä. 2014”N6ŒŽ27“ú.

�¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š/”x�üˆÛ�Ç. ‘æ61‰ñ“ú–{–ƒ�Œ‰ÈŠw‰ïŠw�p�W‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‰¡•l. 2014”N5ŒŽ16“ú.

�¼‰ªˆÀ•F. ‰pŒê˜_•¶‚Ì�‘‚«•û‚ÆŽw“±ƒ|ƒCƒ“ƒg�`“–‰È‚É‚¨‚¯‚éŒoŒ±‚©‚ç�`. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(“Á•ÊŠé‰æ). ‘å�ã. 2014”N4ŒŽ27“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ˆ¢•”�Gˆê, �–ì�ƒ“T, �¼‰ªˆÀ•F. ŒÄ‹zŠí޾г‚É‚¨‚¯‚é–��«‰Š�Ç‚Æ fibrocyte. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘å�ã. 2014”N4ŒŽ27“ú.

�¼‰ªˆÀ•F. ”x‚ª‚ñ�E’†”çŽî‚É‚¨‚¯‚錌ŠÇ�V�¶‘jŠQ–ò‘Ï�«. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒVƒ“ƒ|ƒWƒEƒ€). ‘å�ã. 2014”N4ŒŽ26“ú.

�¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�‡•¹”xŠà‚ÌŽ¡—Ã�í—ª. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi�[). ‘å�ã. 2014”N4ŒŽ25“ú.

�¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“IŽ¡—Â̊î‘b‚Æ—Õ�°.•½�¬25”N“x“¿“‡—Õ�°�×–EŠw‰ï‘�‰ï‚¨‚æ‚ÑŠw�p�W‰ï(“Á•Ê�u‰‰). “¿“‡. 2014”N3ŒŽ6“ú.

�¼‰ªˆÀ•F. �‚—îŽÒ”x‰Š�f—ÂÌ�l‚¦•û. ‘æ25‰ñ“ú–{˜V”NˆãŠw‰ïŽl�‘’n•û‰ï(‹³ˆç�u‰‰). “¿“‡. 2014”N2ŒŽ23“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
Hitoshi Nishijima, Junko Morimoto, Yasuhiro Mouri, Hiroshi Kawano, Koichi Ikuta, Mitsuru Matsumoto. Approaches to identify Aire-regulated non-tissue-restricted antigen genes by the ectopic expression of Aire in thymic cortex. ‘æ43‰ñ“ú–{–ƉuŠw‰ïŠw�p�W‰ï. ‹ž“s. 2014”N12ŒŽ10“ú.

Hiroshi Kawano, Junko Morimoto, Yasuhiro Mouri, Hitoshi Nishijima, Yasuhiko Nishioka, Mitsuru Matsumoto. Unexpected disturbance of the development of medullary thymic epithelial cells at immature stages by the long-term ablation of mature Aire-expressing cells. ‘æ43‰ñ“ú–{–ƉuŠw‰ïŠw�p�W‰ï. ‹ž“s. 2014”N12ŒŽ10“ú.

Š`“à‘�Ži, ‘å’ËŒ›Ži, �²“¡�³‘å, �¼žŠ“Ö˜Y, �âŒû‹Å, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Š�‡•¹”xŠà‚ÌŽ¡—Â̌»�ó. ‘æ55‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‹ž“s. 2014”N11ŒŽ16“ú.

ŸN“cŒ÷, Š`“à‘�Ži, “c“‡‘sˆê˜Y, Ž›‰ª˜a•F, ’†‘º•qŒÈ, �ì“Y˜a‹`, �¼‰ªˆÀ•F, —k‰Í�G�Í, �…Œû˜a•v. ”xŠà–ò•¨—Ö@‚É‚¨‚¯‚é–ò�Ü�«ŠÔŽ¿�«”x‰Š‚Ì”­�ǂƂ»‚ÌƒŠƒXƒNˆöŽq‚̉ð�Í. ‘æ55‰ñ“ú–{”xŠàŠw‰ïŠw�p�W‰ï. ‹ž“s. 2014”N11ŒŽ15“ú.

‰Á“¡�K�¬, ‹àŽq”ü‰Ø, �¬Š}Œ´—@, �¼‰ªˆÀ•F. ‚ª‚ñ“ÁˆÙ“I�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘̂̎÷—§. ‘æ73‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‰¡•l. 2014”N9ŒŽ27“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, �¼žŠ“Ö˜Y, Š`“à‘�Ži, �û•£�¹‹B, �㌴‹v“T, –î–ì�¹“ñ, �¼‰ªˆÀ•F. ƒxƒoƒVƒYƒ}ƒu‚ɑ΂·‚éŠl“¾‘Ï�«ƒ�ƒJƒjƒYƒ€‚Æ‚µ‚Ä‚Ì�üˆÛ�×–E�ifibrocytes�j‚Ì–ðŠ„. ‘æ73‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ‰¡•l. 2014”N9ŒŽ27“ú.

�âŒû‹Å, Œã“Œ‹vŽk, ‘勸•¶—², —t‹v‹MŽi, Œ“�¼‹M‘¥, ‰Y“c’m”V, Š`“à‘�Ži, �û•£�¹‹B, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. �‚—îŽÒ�i�sNSCLCгŽÒ‚ð‘Î�Û‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽTS-1—Ö@‚Ì—Õ�°‘æ‡U‘ŠŽŽŒ±. ‘æ52‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‰¡•l. 2014”N8ŒŽ28“ú.

‘å’ËŒ›Ži�CŒã“Œ‹vŽk�C—t‹v‹MŽi, Œ“�¼‹M‘¥, ‰Y“c’m”V, Š`“à‘�Ži�C�û•£�¹‹B�C‘勸•¶—², ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. �‚—îŽÒ�i�s”ñ�¬�×–E”xŠàгŽÒ‚ð‘Î�Û‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽTS-1—Ö@‚Ì—Õ�°‘æ‡U‘ŠŽŽŒ±. ‘æ12‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. •Ÿ‰ª. 2014”N7ŒŽ18“ú.

‰Á“¡�K�¬, �¼‰ªˆÀ•F. ŒŒ�¬”‹Ã�WˆöŽqPodoplanin‚ɑ΂·‚邪‚ñ“ÁˆÙ“I�R‘̂̊J”­. ‘æ23‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. ‹à‘ò. 2014”N7ŒŽ11“ú.

ŽRŽq‘דl, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ‘q–{‘ì�Æ, “c”¨�Ë, �¼žŠ“Ö˜Y, Š`“à‘�Ži, �û•£�¹‹B, �¬�씎‹v, �㌴‹v“T, �¼‰ªˆÀ•F. ƒqƒg�¬�×–E”xŠà�œ“]ˆÚ‚ɑ΂·‚éRANKL•W“IŽ¡—Âɂ¨‚¯‚éIGF-1‚ÌŠÖ—^. ‘æ23‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. ‹à‘ò. 2014”N7ŒŽ10“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ‘q–{‘ì�Æ, “c”¨�Ë, �¼žŠ“Ö˜Y, Š`“à‘�Ži, �û•£�¹‹B, �㌴‹v“T, �¼‰ªˆÀ•F. ”xŠà‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚ésphereŒ`�¬Šàв�×–E—l•ª‰æ‚Ì–ðŠ„. ‘æ23‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. ‹à‘ò. 2014”N7ŒŽ10“ú.

‘å’ËŒ›Ži, ˆ¢•”�^Ž¡, �û•£�¹‹B, –Ø�h�¹�r, �ì“Y˜a‹`, ‰Á“¡�K�¬, �¼‰ªˆÀ•F. ‹¹–Œ’†”çŽî“¯�ŠˆÚ�Aƒ‚ƒfƒ‹‚É‚¨‚¯‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘Ì‚Ì�RŽîᇌø‰Ê. ‘æ18‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. �å‘ä. 2014”N6ŒŽ26“ú.

“Œ“�‘ã, �¼‰ªˆÀ•F. —Δ^‹ÛŠ´�õгŽÒ‚É‚¨‚¯‚éTolerance ‚ƃoƒCƒIƒtƒBƒ‹ƒ€Œ`�¬”\‚ÌŒŸ“¢. ‘æ88‰ñ“ú–{Š´�õ�ÇŠw‰ïŠw�p�u‰‰‰ï. •Ÿ‰ª. 2014”N6ŒŽ20“ú.

’†–ì–œ—L—¢, ûü‹´’¼Šó, ‹g“ˆ‹PŽÀ, �¼žŠ“Ö˜Y, Žè’Ë•qŽj, “Œ“�‘ã, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚ÅŒoŒ±‚µ‚½�d�Ç”M�«ŒŒ�¬”ÂŒ¸�­�ÇŒóŒQ(severe fever with thrombocytopenia syndrome: SFTS)‚Ì1—á. ‘æ88‰ñ“ú–{Š´�õ�ÇŠw‰ïŠw�p�u‰‰‰ï. •Ÿ‰ª. 2014”N6ŒŽ19“ú.

�²“¡�³‘å, ŠÝ�¹”ü, –؉º�Ÿ�O, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. ŒŒ�´ SP-D �ã�¸‚ð”F‚ß‚½ Idiopathic pleuroparenchymal fibroelastosis (IPPFE) �Ç—á‚ÌŒŸ“¢. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‘å�ã. 2014”N4ŒŽ27“ú.

ŠÝ�¹”ü, �–ì�ƒ“T, “Œ“�‘ã, –؉º�Ÿ�O, �²“¡�³‘å, ‹g“ˆ‹PŽÀ, ’|ú±�²•v, �¼‰ªˆÀ•F. PDGFƒŒƒZƒvƒ^�[-ƒ¿, ƒÀ‘jŠQ�R‘̂̃uƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é�R�üˆÛ‰»Œø‰Ê. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‘å�ã. 2014”N4ŒŽ26“ú.

Š`“à‘�Ži, ‘å’ËŒ›Ži, �²“¡�³‘å, �¼žŠ“Ö˜Y, �âŒû‹Å, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Š�‡•¹”xŠà‚ÌŽ¡—Â̌»�ó. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‘å�ã. 2014”N4ŒŽ26“ú.

–L“c—DŽq, ŠÝ��, ‰Í–ì�O, Œã“Œ‹vŽk, �û•£�¹‹B, ’†“‡—˜”Ž, �¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`гŽÒ—R—ˆ‚Ì�üˆÛ‰è�×–E—lŠŠ–Œ�×–E‚É‚¨‚¢‚Ä thymidine phosphorylase‚ÍCXCL10 ‚ð�§Œä‚·‚é. ‘æ58‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ïŠw�p�W‰ï. “Œ‹ž. 2014”N4ŒŽ26“ú.

ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, ‹àŽq”ü‰Ø, “Œ–ž”ü, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî“¯�ŠˆÚ�Aƒ‚ƒfƒ‹‚É‚¨‚¯‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘Ì‚Ì�RŽîᇌø‰Ê. ‘æ54‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. ‘å�ã. 2014”N4ŒŽ25“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
”“Œ’qŽq�C‰¬–ì�L˜a�C�âŒû‹Å�CŽè’Ë•qŽj�C�X�Z�r�C‹g“ˆ‹PŽÀ�CŠÝ���CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F. ’¹“ÁˆÙ“I�R‘Ì‚ª�‚’l‚ð’æ‚µ‚½’¹ŠÖ˜A‰ß•q�«”x‰Š‚̈ê—á. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �‚�¼. 2014”N12ŒŽ13“ú.

Šâ�²‚ ‚ä‚Ý�C�²“¡�³‘å�C�âŒû‹Å�C–L“c—DŽq�C“c“‡‘sˆê˜Y�CŸN“c�I�CŒã“Œ‹vŽk�CŠ`“à‘�Ži�C�û•£�¹‹B�C�¼‰ªˆÀ•F. UGT1A1ˆâ“`Žq‚̃wƒeƒ��Ú�‡‘Ì�i�–6‚Ü‚½‚Í�–28�j‚ðŽ�‚гŽÒ‚É‚¨‚¯‚鉖Ž_ƒCƒŠƒmƒeƒJƒ““Š—^‚ÉŠÖ‚·‚錟“¢. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �‚�¼. 2014”N12ŒŽ13“ú.

‹ß“¡�^‘ã, �²“¡�³‘å, –L“c—DŽq, ŠÝ��, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, ŠÝ�¹”ü, ‰Í–ì�O, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. ŒŒ�¬”ÂŒ¸�­‚ðŒ_‹@‚Æ‚µ‚Ä�f’f‚³‚ꂽ�‚—îŽÒ‚ÌSLE‚Ì2—á. ‘æ25‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �‚’m. 2014”N12ŒŽ6“ú.

�X�Z�r�C�²“¡�³‘å�C�âŒû‹Å�C–L“c—DŽq�CŠÝ�¹”ü�C�¬�씎‹v, Š`“à‘�Ži�CŒã“Œ‹vŽk�C�û•£�¹‹B�C�¼‰ªˆÀ•F. Idiopathic pleuroparenchymal fibroelastosis‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Šƒ}�[ƒJ�[‚ÌŒŸ“¢. ‘æ111‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2014”N11ŒŽ30“ú.

ŒIŒ´Œ’Žm, ‹g“ˆ‹PŽÀ, �âŒû‹Å, –L“c—DŽq, ’†–ì–œ—L—¢, ŠÝ��, Žè’Ë•qŽj, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Œo‰ß’†‚ÉŒŒ‹…æÃ�H�ÇŒóŒQ‚ð”­�Ç‚µ�AƒVƒNƒ�ƒzƒXƒtƒ@ƒ~ƒhŠÔŸ[‘å—Ê�Ã’�—Ö@‚ª‘tŒø‚µ‚½�d�ÇSLE‚Ì1—á. ‘æ111‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2014”N11ŒŽ30“ú.

ŽR‰º—Y–ç, ‰¬–ì�L˜a, ˆ¢‰Í�O˜a, ŠÝ�¹”ü, �âŒû‹Å, ‹g“ˆ‹PŽÀ, �²“¡�³‘å, Š`“à‘�Ži, Œã“Œ‹vŽk, ŠÝ��, �û•£�¹‹B, �¼‰ªˆÀ•F. ’¹“ÁˆÙ“I�R‘Ì‚ª�‚’l‚ð’æ‚µ‚½’¹ŠÖ˜A‰ß•q�«”x‰Š‚̈ê—á. ‘æ249‰ñ“¿“‡ˆãŠw‰ïŠw�p�W‰ï. “¿“‡. 2014”N7ŒŽ27“ú.

ˆ¢‰Í�O˜a, �²“¡�³‘å, ‹ß“¡�^‘ã, ’Ëú±—C‹M, Žè’Ë•qŽj, –L“c—DŽq, �âŒû‹Å, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚鈫�«‹¹�…’™—¯—á‚ɑ΂·‚éƒ^ƒ‹ƒN�»�܂̎g—pŒoŒ±. ‘æ53‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”‰ï. •ÄŽq. 2014”N7ŒŽ12“ú.

�¼–{�N•½, ”ö�è—Ì•F, –L“c—DŽq, ’†–ì–œ—L—¢, �X�Z�r, ‰Í–ì�O, ŠÝ��, Š`“à‘�Ži, �û•£�¹‹B, �¼‰ªˆÀ•F. �‚CaŒŒ�ǂɂĔ­�Ç‚µ‚½‘½‘ŸŠíƒTƒ‹ƒRƒCƒh�[ƒVƒX‚Ì1—á. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. •ÄŽq. 2014”N7ŒŽ12“ú.

’Ëú±—C‹M, ‘å’ËŒ›Ži, ŠÝ�¹”ü, ‹ß“¡�^‘ã, ‹g“ˆ‹PŽÀ, �²“¡�³‘å, ‰ªú±�O‘×, ’|ú±�²•v, “Œ“�‘ã, �û•£�¹‹B, �≺’¼ŽÀ, •Ÿ“c—I, �¼‰ªˆÀ•F. Acute Fibrinous and Organizing Pneumonia�iAFOP�j‚̈ê–UŒŸ—á. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. •ÄŽq. 2014”N7ŒŽ12“ú.

‰¬–ì�L˜a, �¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, �âŒû‹Å, Žè’Ë•qŽj, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Lambert-Eaton‹Ø–³—Í�ÇŒóŒQ‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ�¬�×–E”xŠà‚̈ê—á. ‘æ53‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”‰ï. •ÄŽq. 2014”N7ŒŽ11“ú.

”ö�è—Ì•F, –L“c—DŽq, ŠÝ��, –؉º�Ÿ�O, Žè’Ë•qŽj, ŠÝ�¹”ü, �²“¡�³‘å, Š`“à‘�Ži, �û•£�¹‹B, �¼‰ªˆÀ•F. �¶�t“®–¬•Â�Ç“™‚É‚æ‚茋�ß�«‘½”­“®–¬‰Š‚ª‹^‚í‚ꂽŒŒŠÇ“à–Œ“÷Žî‚Ì1–UŒŸ—á. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2014”N6ŒŽ8“ú.

‹ß“¡�^‘ã, �X�Z�r, �âŒû‹Å, �¼žŠ“Ö˜Y, ‹g“ˆ‹PŽÀ, ’†–ì–œ—L—¢, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Pemetrexed‚ÆBevacizumab‚Ì•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½�‚—îŽÒ”ñ�¬�×–E”xŠà‚Ì1—á. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2014”N6ŒŽ8“ú.

âV“¡—FŽq, ˆÉ�¨�F”V, ᢒm�~Žq, ŽRŒû�_Ži, Šâ�£�r, ŽR“c”Žˆû, “Y–Ø•�, Žá’ΓNŽO, Œã“Œ‹vŽk, �²“c�­—². �¶ŽºŽû�k•s‘S‚ÆŠÔŽ¿�«”x‰Š‚É”º‚¤”x�‚ŒŒˆ³�Ç‚ð�‡•¹‚µ‚½”畆‹Ø‰Š‚Ì1—á. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2014”N6ŒŽ8“ú.

ŽR–{�¹Žq, �û•£�¹‹B, �X�Z�r, ŠÝ�¹”ü, –؉º�Ÿ�O, ‰Í–ì�O, ’|ú±�²•v, –L“c—DŽq, “Œ“�‘ã, Œã“Œ‹vŽk, ŠÝ��, �¼‰ªˆÀ•F. �¶�ã—t–³‹C”x‚ð’æ‚µ‚½ƒAƒŒƒ‹ƒM�[�«‹CŠÇŽx”xƒAƒXƒyƒ‹ƒMƒ‹ƒX�ǂ̈ê—á. ‘æ248‰ñ“¿“‡ˆãŠw‰ï. “¿“‡. 2014”N2ŒŽ16“ú.

’ÕۗF��, �û•£�¹‹B, ‘ê‘ò�GŒõ, ‹g“cŒõ‹P, ‹g“ˆ‹PŽÀ, ‘å’ËŒ›Ži, �²“¡�³‘å, �¼žŠ“Ö˜Y, –L“c—DŽq, Žè’Ë•qŽj, Š`“à‘�Ži, Œã“Œ‹vŽk, �Ⓦ—Ç”ü, �æŽR�³“ñ, �¼‰ªˆÀ•F. ”xŒ´”­ŠŠ–Œ“÷Žî‚̈ê—á. ‘æ248‰ñ“¿“‡ˆãŠw‰ï. “¿“‡. 2014”N2ŒŽ16“ú.

”ö�è—Ì•F, ûü‹´’¼Šó, Œã“Œ‹vŽk, –L“c—DŽq, Žè’Ë•qŽj, ‘å’ËŒ›Ži, �¼žŠ“Ö˜Y, �âŒû‹Å, –؉º�Ÿ�O, Š`“à‘�Ži, �¬�씎‹v, �ì�ã�sšõ, �û•£�¹‹B, ‹ß“¡˜a–ç, �æŽR�³“ñ, �òŒ[‰î, �¼‰ªˆÀ•F. ‹CŠÇŽx‹¾’¼Ž‹‰º�¶ŒŸ‚É‚Ä�f’f‚ÉŽŠ‚Á‚½oncocytic carcinoid‚̈ê—á. ‘æ22‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. ‰ªŽR. 2014”N2ŒŽ15“ú.

�¥�¼–ƒ”ü, “à“¡�L�m, ŠÝ�¹”ü, ’†–ì–œ—L—¢, ‹g“cŒõ‹P, �ì�ã�sšõ, –؉º�Ÿ�O, “Œ“�‘ã, ‹g“ˆ‹PŽÀ, �²“¡�³‘å, ŠÝ��, �X‰Í—R—¢Žq, �¼ŽR—F—�Žq, �å”ü‰À, �Ⓦ—Ç”ü, “nç³�r‰î, �㌴‹v“T, �òŒ[‰î, �æŽR�³“ñ, �û•£�¹‹B, �¼‰ªˆÀ•F. ‹¹�…’†‚É‘½�”‚ÌLanghansŒ^‹��×–E‚ð”F‚ß‚½Mycobacterium avium�ǂɔº‚¤‹¹–Œ‰Š‚̈ê—á. ‘æ64‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï. ‰ªŽR. 2014”N2ŒŽ15“ú.
2013”N‹Æ�Ñ
�y‰¢•¶‘��à�z
Nishioka Y, Azuma M, Kishi M, Aono Y. Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis. J Med Invest 60(3,4):175-183, 2013.

�y‰¢•¶Œ´’˜�z
Honjo A, Ogawa H, Azuma M, Tezuka T, Sone S, Biragyn A, Nishioka Y. Targeted reduction of CCR4+ cells is sufficient to suppress allergic inflammation. Respir Investig 51(4):241-249, 2013.

Kinoshita K, Aono Y, Azuma M, Kishi J, Takezaki A, Kishi M, Makino H, Okazaki H, Uehara H, Izumi K, Sone S, Nishioka Y. Antifibrotic effects of focal adhesion klinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 49(4):536-543, 2013.

Okamoto T, Miyazaki Y, Ogura T, Chida K, Kohno N, Kohno S, Taniguchi H, Akagawa S, Mochizuki Y, Yamauchi K, Takahashi H, Johkoh T, Homma S, Kishi K, Ikushima S, Konno S, Mishima M, Ohta K, Nishioka Y, Yoshimura N, Munakata M, Watanabe K, Miyashita Y, Inase N. A nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51(3):191-199, 2013.

Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S. Akt kinase�@-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene 32(37):4427-4435, 2013.

Huang J, Tabata S, Kakiuchi S, The Van T, Goto H, Hanibuchi M, Nishioka Y. Identification of pregnancy -associated plasma protein A as a migration-promoting gene in malignant pleural�@mesothelioma cells: a potential therapeutic target. Oncotarget 4(8):1172-1184, 2013.

Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J. Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama SI, Sone S. Minakuchi K, Kato Y, Nishioka Y. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 190(12):6239-6249, 2013.

Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, Uehara H, Yano S, Ledford JG, Sone S, Nishioka Y. Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am J Pathol 182(5):1843-1853, 2013.

Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M, Iguratimod-Clinical Study Group (Kishi J). Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23(3):430-439, 2013.

Matsui S, Hebisawa A, Sakai F, Yamamoto H, Terasaki Y, Kurihara Y, Waseda Y, Kawamura T, Miyashita T, Inoue H, Hata N, Masubuchi H, Sugino K, Kishi J, Kobayashi H, Usui Y, Komazaki Y, Kawabata Y, Ogura T. Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respirology 18(3):480-487, 2013.

Sato S, Hanibuchi M, Kuramoto T, Yamamori N, Goto H, Ogawa H, Mitsuhashi A, Van TT, Kakiuchi S, Akiyama SI, Nishioka Y, Sone S. Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment. Clin Exp Metastasis 30(3):333-344, 2013.

Makino H, Aono Y, Azuma M, Kishi M, Yokota Y, Kinoshita K, Takezaki A, Kishi J, Kawano H, Ogawa H, Uehara H, Izumi K, Sone S, Nishioka Y. Antifibrotic effects of CXCR4 antagonist in bleomycin -induced pulmonary fibrosis in mice. J Med Invest 60(1-2):127-137, 2013.

Yuasa S, Yamaguchi H, Nakanishi Y, Kawaminami S, Tabata R, Shimizu N, Kohno M, Shimizu T, Miyata J, Nakayama M, Kishi J, Toyoda Y, Nishioka Y, Tani K. Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents. J Med Invest 60(1-2):77-90, 2013.
�y˜a•¶’˜�‘�z
�¼‰ªˆÀ•F, �–ì�ƒ“T. ˆÀ’èŠú‚Æ‘�ˆ«Šú‚̑Ήž. “Á”­�«ŠÔŽ¿�«”x‰Š‚ÌŽ¡—ÂƊǗ�, �™ŽR�K”äŒÃ•Ò�W. 2013. pp 177-184. �Ž�½“°�o”ÅŠ”Ž®‰ïŽÐ.

�¼‰ªˆÀ•F. “Á”­�«ŠíŽ¿‰»”x‰Š. “à‰ÈŠw ‘æ10”Å, –îú±‹`—Y‘�•Ò�W. 2013. pp 806-808. ’©‘q�‘“X.

�¼‰ªˆÀ•F. Fibrocyte‚ƌċzŠí޾г. •Ê�û�EˆãŠw‚Ì‚ ‚ä‚Ý ŒÄ‹zŠí޾г-state of arts Ver.6, –k‘º—@, ’F�_ˆê˜Y, �Έä–FŽ÷•Ò�W. 2013. pp 23-25, ˆãŽ•–ò�o”ÅŠ”Ž®‰ïŽÐ.

�¼‰ªˆÀ•F. �Ç�ó‚Æ•a‘Ô�¶—�. —Õ�°•a‘ÔŠw1Šª(‘æ2”Å), –k‘º�¹‘�•Ò�W. 2013. pp 231-233. ƒk�[ƒ”ƒFƒ‹ƒqƒ�ƒJƒ�.

�¼‰ªˆÀ•F. •›�t”玿ƒXƒeƒ�ƒCƒh–ò. ŒÄ‹zŠí޾г�Å�V‚ÌŽ¡—Ã2013-2015, ŠÑ˜a•q”Ž, �™ŽR�K”äŒÃ, –å“c�~ˆê•Ò�W. 2013. pp 97-101. “ì�]“°.

�¼‰ªˆÀ•F. ”x�üˆÛ‰»‚É‚¨‚¯‚éfibrocyte‚Ì–ðŠ„. Annual Review 2013 ŒÄ‹zŠí. ‰iˆäŒúŽu, ’F�_ˆê˜Y, ŒK–ì˜a‘P, �‚‹´˜a‹v•Ò�W. 2013. pp28-33. ’†ŠOˆãŠwŽÐ.
�y˜a•¶‘��à�z
�¼‰ªˆÀ•F, Œã“Œ‹vŽk. ”x–E�ã”ç�áŠQ‚Æ�C•œ. ŒÄ‹z‚Æ�zŠÂ 61(12):1146-1151, 2013.

Œã“Œ‹vŽk, �¼‰ªˆÀ•F. •úŽË�ü”x‘Ÿ‰Š. “ú–{—Õଠ71(‘�6):526-529, 2013.

�¼‰ªˆÀ•F, �–ì�ƒ“T. Fibrocyte‚Ì–ðŠ„. “ú–{‹¹•”—Õ�° 72(‘�):S186-189, 2013.

�¼‰ªˆÀ•F. “¿“‡‘åŠw‘åŠw‰@ƒwƒ‹ƒXƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†•”ŒÄ‹zŠí�EäPŒ´•a“à‰ÈŠw•ª–ì‚Ì‚²�Љî. “¿“‡Œ§ˆãŽt‰ï•ñ 508:32-33, 2013.

�¼‰ªˆÀ•F. •ªŽq•W“IŽ¡—ÂƖƉu—Ö@. Šà‚Ɖ»Šw—Ö@ 40(8):1004-1008, 2013.

�²“¡�³‘å, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. ƒqƒg”xŠà‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚Æmacrophage stimulatuing protein. THE LUNG perspectives 21(3):72-77, 2013.

�¼‰ªˆÀ•F. IPF‚Ì—Õ�°ŽŽŒ±‚ð�l‚¦‚é(Šª“ªŒ¾). ŒÄ‹z‚Æ�zŠÂ 61(7):603, 2013.

Œã“Œ‹vŽk, Š`“à‘�Ži, �¼‰ªˆÀ•F. ”x‚ª‚ñ�×–E‚Ì�œ“]ˆÚ‚ÉŠÖ—^‚·‚éˆâ“`Žq‚Ì’T�õ. �¶‘̂̉Ȋw 64(3):279-282, 2013.

�¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š‚Ì�f’f‚ÆŽ¡—Ã:�ŋ߂Ì�i•à. “ú–{—Õ�°“à‰Èˆã‰ï‰ïŽ� 28(1):46-50, 2013.

�¼‰ªˆÀ•F,�–ì�ƒ“T. ŠÔŽ¿�«”x‰Š‚Æ‘��BˆöŽq. ƒAƒŒƒ‹ƒM�[‚Ì—Õ�° 443(33):421-424, 2013.

�¼‰ªˆÀ•F. “�«ŒÄ‹zŠí޾г‚Ì•ªŽq•a‘ԉ𖾂Æ�V‹KŽ¡—Ö@‚ÌŠJ”­. Žl�‘ˆãŠwŽGŽ� 69(1,2):52-56, 2013.

Š`“à‘�Ži, �¼‰ªˆÀ•F. mTOR‘jŠQ–ò‚É‚æ‚é”x�áŠQ‚Æ‚»‚̑Ήž. •ªŽqŒÄ‹zŠí•a 17(1):42-45, 2013.

ŠÝ��, ‰Í–ì�O, �¼‰ªˆÀ•F. ŠÖ�ßƒŠƒEƒ}ƒ`‚ÆŠÔŽ¿�«”x•a•Ï.ƒŠƒEƒ}ƒ`‰È 49(2):161-165, 2013.

�¼‰ªˆÀ•F, �–ì�ƒ“T, ˆ¢•”�Gˆê.�@”x�üˆÛ�ǂɂ¨‚¯‚é�üˆÛ‰è�×–E‚Ì—R—ˆ.�@ŒÄ‹zŠí“à‰È 23(1):20-24, 2013.
�y˜a•¶Œ´’˜�z
“Œ“�‘ã, ’†‘]ˆŸ�²”ü, �¼–삳‚¨‚è, �‚ŠJ“o–ÎŽq, �æŽR�³“ñ, ‰Á“¡�^‰î, �¼‰ªˆÀ•F. ˆã—Ã�]Ž–ŽÒ‚É‚¨‚¯‚é–A�óƒAƒ‹ƒR�[ƒ‹�«ŽèŽw�Á“Å�܂̎E‹ÛŒø‰Ê, “h•z–Ê�Ï‹y‚ÑŽg—pŠ´‚ÉŠÖ‚·‚錟“¢. “ú–{ŠÂ‹«Š´�õŠw‰ïŽ� 28(6):342-347, 2013.

�–ì�ƒ“T, ŠÝ�¹”ü, ‰ªú±�O‘×, ’|ú±�²•v, �¼‰ªˆÀ•F. ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”x�üˆÛ�ǃ‚ƒfƒ‹‚É‚¨‚¯‚éPDGFƒŒƒZƒvƒ^�[ƒ¿�CƒÀ‘jŠQ�R‘Ì‚Ì�R�üˆÛ‰»Œø‰Ê. •ªŽqŒÄ‹zŠí•a 17(1):136-139, 2013.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Yoshinori Aono, Shuichi Abe, Katsuhiro Kinoshita, Masami Kishi, Yasuhiko Nishioka. Fibrocyte regulates lung fibroblast acivation via producing growth factors.�@18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G Ledford, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. 18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Masaki Hanibuchi, Sun-Jin Kim, Kenji Otsuka, Atsushi Mitsuhashi, Hisatsugu Goto, Yasuhiko Nishioka, Isaiah J. Fidler. Therapeutic efficacy of endothelin receptor blockade on experimental brain metastases of human non-small cell lung cancer.�@18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Hisatsugu Goto, Fumitaka Ogushi, Takashi Haku, Tomoyuki Urata, Takanori Kanematsu, Soji Kakiuchi, Masaki Hanibuchi, Saburo Sone, Yasuhiko Nishioka. Phase ‡U study of S-1 with patient-reported outcome evaluation in elderly patients with advanced non-small cell lung cancer.�@18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ13“ú.

Katsuhiro Kinoshita, Yoshinori Aono, Hisatsugu Goto, Momoyo Azuma, Akio Takezaki, Terumi Yoshijima, Masami Kishi, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Shuichi Abe, Toshifumi Tezuka, Hisanori Uehara, Keisuke Izumi, Yasuhiko Nishioka. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. 18th Congress of the Asian Pacific Society of Respirology. ‰¡•l. 2013”N11ŒŽ12“ú.

Momoyo Azuma, Keiji Murakami, Katuhiko Hirota, Tsuneko Ono, Yoichiro, Miyake, Yasuhiko Nishioka. The relationship between antibiotic tolerance and severity of clinical isolated Pseudomonas aeruginosa in respiratory disease patients. The28th International Congress of Chemotherapy and Infection and the 14th Asia-pacific Society of Clinical Microbiology and Infection. ‰¡•l. 2013”N6ŒŽ7“ú.

Yasuhiko Nishioka, Shuichi Abe, Yoshinori Aono, Katsuhiro Kinoshita, Hideki Makino, Masami Kishi, Masaki Hanibuchi. Fibrocytes regulate function of lung fibroblasts by producing profibrotic growth factors.�@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ22“ú.

Hirohisa Ogawa, J.G. Ledford, S. Mukherjee, Yoshinori Aono, Yasuhiko Nishioka, Keisuke Izumi, J.W. Hollingsworth. Surfactant protein D attenuates sub-epithelial fibrosis in a model of allergic airways disease trough regulation of TGF-ƒÀ.�@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ21“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, and Yasuhiko Nishioka. Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.�@ATS 2013 Conference. Philadelphia, PA. 2013”N5ŒŽ21“ú.

Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka. Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice.�@AACR Annual Meeting 2013. Washington, DC. 2013”N4ŒŽ7“ú.

Yasuhiko Nishioka. Application of dendritic cells and antibodies in cancer treatment. The first Gene & Immunotherapy Conference (Invited lecture). HCM City, Vietnam. 2013”N3ŒŽ21“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Trung The Van, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Saburo Sone, Yasuhiko Nishioka. Acquired resistance to anti-VEGF therapy via angiogenic switch in orthotopically implanted human malignant pleural mesothelioma in SCID mice.�@Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research. Maui, HI. 2013”N2ŒŽ24“ú.

Sawaka Yukishige, Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Sho Tabata, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijyo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses lung cancer progression by regulating tumor-associated macrophage polarization.�@Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research. Maui, HI. 2013”N2ŒŽ24“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. “Á”­�«ŠÔŽ¿�«”x‰Š‚Ì�f’f‚ÆŽ¡—Ã-�ŋ߂̘b‘è-. ‘æ49‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘Žx•”�¶ŠU‹³ˆç�u‰‰‰ï�i‹³ˆç�u‰‰�j. �‚�¼. 2013”N12ŒŽ1“ú.

�¼‰ªˆÀ•F. ”xŠà‚É‚¨‚¯‚éƒxƒoƒVƒYƒ}ƒu‚ð—p‚¢‚½�RŒŒŠÇ�V�¶—Ö@‚ɑ΂·‚éŠl“¾‘Ï�«ƒ�ƒJƒjƒYƒ€.�@‘æ72‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï�iInternational Session�j. ‰¡•l. 2013”N10ŒŽ3“ú.

�¼‰ªˆÀ•F. Translational Research.�@‘æ11‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï�i‹³ˆç�u‰‰�j. �å‘ä. 2013”N8ŒŽ30“ú.

�¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“IŽ¡—Â̊î‘b‚Æ—Õ�°.�@“ú–{•úŽË�üŽîᇊw‰ï�@‘æ15‰ñ•úŽË�üŽîᇊw‰Ä‹GƒZƒ~ƒi�[(‹³ˆç�u‰‰). “¿“‡. 2013”N8ŒŽ3“ú.

ˆ¢•”�Gˆê, �–ì�ƒ“T, ‰ªú±�O‘×, ŠÝ�¹”ü, ’|ú±�²•v, –؉º�Ÿ�O, “Œ“�‘ã, ŠÝ��, �¼‰ªˆÀ•F. ”x�üˆÛ�ǂɂ¨‚¯‚é‘��BˆöŽqŽY�¶‚ð‰î‚µ‚½fibrocyte‚Ì–ðŠ„‚ÆŒŸ“¢.�@‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€�j. “Œ‹ž. 2013”N4ŒŽ20“ú.

�–ì�ƒ“T. ˆ¢•”�Gˆê, ’|ú±�²•v, ‰ªú±�O‘×, ŠÝ�¹”ü, �¼‰ªˆÀ•F. DNAƒ}ƒCƒNƒ�ƒAƒŒƒC–@‚ð—p‚¢‚½Fibrocyte‚Æ’P‹…‚̈â“`Žq”­Œ»‰ð�͂̌Ÿ“¢.�@‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€�j. “Œ‹ž. 2013”N4ŒŽ20“ú.

�¬�씎‹v�C�–ì�ƒ“T�CŽè’Ë•qŽj�CŒã“Œ‹vŽk�C�¼‰ªˆÀ•F. Surfactant Protein D‚̓_ƒj�RŒ´–��«–\˜I‚É‚æ‚é‹C“¹�üˆÛ‰»‚ð—}�§‚·‚é�D‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€�j. “Œ‹ž. 2013”N4ŒŽ20“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu�C�–ì�ƒ“T�C�¼‰ªˆÀ•F. ”xŠà�i“W‚É‚¨‚¯‚éSP-A‚ÆŽîᇊ֘Aƒ}ƒNƒ�ƒtƒ@�[ƒW.�@‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iƒVƒ“ƒ|ƒWƒEƒ€�j. “Œ‹ž. 2013”N4ŒŽ19“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
Žè’Ë•qŽj, �¬�씎‹v, –؉º�Ÿ�O, �û•£�¹‹B, �¼‰ªˆÀ•F. Calpain inhibitor�iCalpeptin�j‚Ìšb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢. ‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ï�H‹GŠw�p‘å‰ï. “Œ‹ž. 2013”N11ŒŽ30“ú.

‰ª–ì‹`•v, Œã“Œ‹vŽk, —t‹v‹MŽi, Œ“�¼‹M‘¥, ‰Y“c’m”V, Š`“à‘�Ži, �û•£�¹‹B, ‘勸•¶—², ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. �‚—îŽÒ�i�s”ñ�¬�×–E”xŠàгŽÒ‚ð‘Î�Û‚Æ‚µ‚ÄPRO•]‰¿‚ðŽæ‚è“ü‚ꂽTS-1—Ö@‚Ì—Õ�°‘æ‡U‘ŠŽŽŒ±. ‘æ54‰ñ“ú–{”xŠàŠw‰ï‘�‰ï. “Œ‹ž. 2013”N11ŒŽ21“ú.

Žè’Ë•qŽj, –L“c—DŽq, Š`“à‘�Ži, ‘å’ËŒ›Ži, �¼žŠ“Ö˜Y, –؉º�Ÿ�O, Œã“Œ‹vŽk, ŸN“c�I, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰È‚Ì”xŠà‰»Šw—Ö@‚É‚¨‚¯‚éshort-hydration Cisplatin‚Ì”E—e�«‚ÉŠÖ‚·‚錟“¢. ‘æ51‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‹ž“s. 2013”N10ŒŽ25“ú.

�¼žŠ“Ö˜Y, Š`“à‘�Ži, Žè’Ë•qŽj, Œã“Œ‹vŽk, ŽRŽq‘דl, ‘å’ËŒ›Ži, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éBevacizumab’·ŠúˆÛŽ�“Š—^�Ç—á‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{ŠàŽ¡—Êw‰ïŠw�p�W‰ï. ‹ž“s. 2013”N10ŒŽ25“ú.

Š`“à‘�Ži, ‘å’ËŒ›Ži, �¼žŠ“Ö˜Y, Žè’Ë•qŽj, –L“c—DŽq, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Š�‡•¹”xŠà‚ÌŽ¡—Â̌»�ó. ‘æ11‰ñ“ú–{—Õ�°Žîᇊw‰ïŠw�p�W‰ï. �å‘ä. 2013”N8ŒŽ31“ú.

�¼žŠ“Ö˜Y, Œã“Œ‹vŽk, “c”¨�Ë, ŽO‹´“ÕŽu, –L“c—DŽq, �û•£�¹‹B, Š`“à‘�Ži, �HŽR�Lˆê, �¼‰ªˆÀ•F. ‚ª‚ñ�×–E‚Ì—V‘–‚É‚¨‚¯‚éthymidine phosphorylase‚ÆCXCL11‚Ì–ðŠ„. ‘æ22‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �¼–{. 2013”N7ŒŽ11“ú.

Œã“Œ‹vŽk, ŽO‹´“ÕŽu, ‘q–{‘ì�Æ, “c”¨�Ë, �¼žŠ“Ö˜Y, �û•£�¹‹B, Š`“à‘�Ži, �–ì�ƒ“T, �㌴‹v“T, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. ”xsurfactant protein A (SP-A) ‚Ì”xŠà�i“W‚É‚¨‚¯‚é‹@”\‰ð�Í. ‘æ22‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �¼–{. 2013”N7ŒŽ11“ú.

‹ß“¡ˆç”ü, ‘剺�’Žj, Œ³–Ø—R”ü, �û•£�¹‹B, •�‹v—mŽO. –��«Šú•a‰@‚ł̈ã—ÃNƒ‰�[ƒN‚Ì–ðŠ„‚É‚Â‚¢‚Ä.‘æ63‰ñ“ú–{•a‰@Šw‰ï. �VŠƒ. 2013”N6ŒŽ28“ú.

‘å�¼�O—S, ‘厭•Û��, ˆ¢•”“ú“o”ü, Œ³–Ø—R”ü, �û•£�¹‹B, •�‹v—mŽO. –��«Šú•a“�‚ł̚\á‚‹zˆøƒJƒe�[ƒeƒ‹ŠÇ—�•û–@‚ɂ‚¢‚Ä. ‘æ63‰ñ“ú–{•a‰@Šw‰ï. �VŠƒ. 2013”N6ŒŽ28“ú.

Œ³–Ø—R”ü, ‘厭•Û��, ˆ¢•”“ú“o”ü, ’·”ö—DŽq, �û•£�¹‹B, •�‹v—mŽO. ˆÝᑉh—{гŽÒ‚É‚¨‚¯‚é“œŽ¿�§ŒÀ�H‚Ì—LŒø�«‚ɂ‚¢‚Ä. ‘æ63‰ñ“ú–{•a‰@Šw‰ï. �VŠƒ. 2013”N6ŒŽ27“ú.

�û•£�¹‹B, ‘å’ËŒ›Ži, Œã“Œ‹vŽk, ‘q–{‘ì�Æ, ŽO‹´“ÕŽu, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, ƒtƒBƒhƒ‰�[ ƒCƒUƒCƒA�[ J. EndothelinŽó—e‘Ì�h�R�܂ɂæ‚é”xŠà”]“]ˆÚ—}�§Œø‰Ê‚ÌŒŸ“¢. ‘æ17‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‹ž“s. 2013”N6ŒŽ13“ú.

‰©�r, “c”¨�Ë, �û•£�¹‹B, �¼‰ªˆÀ•F. ˆ«�«’†”çŽî‚É‚¨‚¯‚éPAPPA‚Ì‹@”\‰ð�͂ƕªŽq•W“IŽ¡—Ö@ŠJ”­‚ÌŒŸ“¢. ‘æ17‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‹ž“s. 2013”N6ŒŽ13“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, �¼žŠ“Ö˜Y, ‘q–{‘ì�Æ, “c”¨�Ë, �û•£�¹‹B, –î–ì�¹“ñ, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî“¯�ŠˆÚ�Aƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚é�RVEGFŽ¡—ÑÏ�«‰»ƒ�ƒJƒjƒYƒ€‚ÌŒŸ“¢. ‘æ17‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. ‹ž“s. 2013”N6ŒŽ13“ú.

ŠÝ��, ’†�ì–ƒ–ë, ‰Í–ì�O, �¼”ö�i, •½“c—L‹I�Ø, ŽR“c”Žˆû, �²“c�­—², �¼‰ªˆÀ•F. äPŒ´•a‚ÌŠÖ�߉Ђɂ¨‚¯‚éãüâ|ƒŠƒ“ƒp�߂̒´‰¹”g�«�ó‚ÉŠÖ‚·‚錟“¢. ‘æ86‰ñ“ú–{’´‰¹”gˆãŠw‰ïŠw�p�W‰ï. ‘å�ã. 2013”N5ŒŽ25“ú.

ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, ‹àŽq”ü‰Ø, –Ø�h�¹�r, �ì“Y˜a‹`, “Œ–ž”ü, �û•£�¹‹B, �…Œû˜a�¶, �¼‰ªˆÀ•F. ƒqƒgNK�×–E‚ð‰î‚µ‚½�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-8‚̈«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�RŽîᇌø‰Ê. ‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ21“ú.

Jun Huang, Dai-Shun Liu, Soji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi, Yasuhiko Nishioka. Therapeutic efficacy of RNA interference targeting focal adhesion kinase against orthotropic xenograft of human malignant pleural mesothelioma in SCID mice. ‘æ53‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ21“ú.

‹g“ˆ‹PŽÀ, ‰Í–ì�O, Žè’Ë•qŽj, –L“c—DŽq, ŠÝ��, �¼‰ªˆÀ•F. Œ´ˆö•s–¾‚Ì––�½•Â�Ç�«“®–¬Ž¾Š³‰Á—Ã’†‚ÉŠ¥“®–¬áŽ‚ª”­Šo‚µ�‚ˆÀ“®–¬‰Š‚Æ�f’f‚µ‚½1—á. ‘æ57‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. ‹ž“s. 2013”N4ŒŽ20“ú.

�û•£�¹‹B, Œã“Œ‹vŽk, ‹ß“¡�^‘ã, ŽRŽq‘דl, ‰ªú±�O‘×, Žè’Ë•qŽj, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éIdiopathic pleuroparenchymal fibroelastosis(IPPFE)�Ç—á‚ÌŒŸ“¢-IgG4ŠÖ˜A޾г‚Ƃ̊֘A�«-. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ï�u‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ13“ú.

Š`“à‘�Ži, ‘å’ËŒ›Ži, ŽRŽq‘דl, �¼žŠ“Ö˜Y, Žè’Ë•qŽj, Œã“Œ‹vŽk, �–ì�ƒ“T, �û•£�¹‹B, �¼‰ªˆÀ•F.“–‰@‚É‚¨‚¯‚éŠÔŽ¿�«”x‰Š�‡•¹”xŠà‚ÌŽ¡—Â̌»�ó. ‘æ110‰ñ“ú–{“à‰ÈŠw‰ï�u‰‰‰ï. “Œ‹ž. 2013”N4ŒŽ12“ú.

Œã“Œ‹vŽk. �¬—t’†�S�«�¬—±�ó‰A‰e‚Æ‹­‚¢•Â�Ç�«Š·‹C�áŠQ‚ð’æ‚µ‚½–��«‰ß•q�«”x‰Š‚̈ê—á. ‘æ5‰ñŒÄ‹z‹@”\ƒCƒ��[ƒWƒ“ƒOŒ¤‹†‰ïŠw�p�W‰ï. “¿“‡. 2013”N1ŒŽ13“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
“à“¡�L�m, ‰Í–ì�O, ‘å’ËŒ›Ži, –L“c—DŽq, ŠÝ��, Žè’Ë•qŽj, –؉º�Ÿ�O, ‹g“ˆ‹PŽÀ, ŠÝ�¹”ü, �û•£�¹‹B, �¼‰ªˆÀ•F. • •”‘å“®–¬ŽüˆÍ‰Š‚𔺂Á‚½‘½”­ŒŒŠÇ‰Š�«“÷‰èŽî�Ç‚Ì2—á. ‘æ24‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. •ÄŽq. 2013”N12ŒŽ7“ú.

ŽR–{�¹Žq, �û•£�¹‹B, �X�Z�r, ŠÝ�¹”ü, –؉º�Ÿ�O, ‰Í–ì�O, ’|ú±�²•v, –L“c—DŽq, “Œ“�‘ã, Œã“Œ‹vŽk, ŠÝ��, �¼‰ªˆÀ•F. �¶�ã—t–³‹C”x‚ð’æ‚µ‚½ƒAƒŒƒ‹ƒM�[�«‹CŠÇŽx”xƒAƒXƒyƒ‹ƒMƒ‹ƒX�ǂ̈ê—á. ‘æ50‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �L“‡. 2013”N12ŒŽ7“ú.

’ÕۗF��, �û•£�¹‹B, ‘ê‘ò�GŒõ, ‹g“cŒõ‹P, ‹g“ˆ‹PŽÀ, ‘å’ËŒ›Ži, �²“¡�³‘å, �¼žŠ“Ö˜Y, –L“c—DŽq, Žè’Ë•qŽj, Š`“à‘�Ži, Œã“Œ‹vŽk, �Ⓦ—Ç”ü, �æŽR�³“ñ, �¼‰ªˆÀ•F. ”xŒ´”­ŠŠ–Œ“÷Žî‚̈ê—á. ‘æ50‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �L“‡. 2013”N12ŒŽ7“ú.

–—m•½, �¼žŠ“Ö˜Y, –؉º�Ÿ�O, ŠÝ�¹”ü, ‘å’ËŒ›Ži, �û•£�¹‹B, �¼‰ªˆÀ•F, ˆä“à�V, �–ì�ƒ“T. “¿“‡Œ§‚Å”­�¶‚µ‚½�d�Ç”M�«ŒŒ�¬”ÂŒ¸�­�ÇŒóŒQ�isevere fever with thrombocytopenia syndrome: SFTS�j‚Ì1—á. ‘æ109‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2013”N12ŒŽ1“ú .

�Ⓦ�OŠî, �û•£�¹‹B, –L“c—DŽq, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, Œã“Œ‹vŽk, Š`“à‘�Ži, ŠÝ��, �¼‰ªˆÀ•F, �â–{�K—T. ‹CŠÇŽxŠg’£�Ç‚ð’æ‚µ‚½Œ´”­�«�ü–щ^“®•s‘S�Ç‚Ì1—á. ‘æ109‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï.�‚�¼. 2013”N12ŒŽ1“ú.

’·�£ŽÑ‹G, –L“c—DŽq, ˆ¢•”�Gˆê, ŠÝ��, ‰Í–ì�O, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, �û•£�¹‹B, ’r“c�^—R”ü, �æŽR�³“ñ, �¼‰ªˆÀ•F. ƒTƒ‹ƒRƒCƒh�[ƒVƒX‚ÌŒo‰ßŠÏŽ@’†‚É”x‘BŠà‚ð�‡•¹‚µ‚½1—á. ‘æ49‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �‚�¼. 2013”N7ŒŽ20“ú.

�¥�¼–ƒ”ü, ŠÝ�¹”ü, �–ì�ƒ“T, ’|ú±�²•v, “Œ“�‘ã, –؉º�Ÿ�O, ˆ¢•”�Gˆê, �û•£�¹‹B, ‹g“cŒõ‹P, �æŽR�³“ñ, •Ÿ“c—I, �¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@‚É‚¨‚¯‚鋹�o‹¾�iVATS�j‰º”x�¶ŒŸ�Ç—á‚ÌŒŸ“¢. ‘æ49‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. �‚�¼. 2013”N7ŒŽ19“ú.

”ö�è—Ì•F, Š`“à‘�Ži, Žè’Ë•qŽj, �¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, ŽRŽq‘דl, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@‚É‚¨‚¯‚éBevacizumab ’·ŠúˆÛŽ�“Š—^—á‚ÌŒŸ“¢. ‘æ52‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”‰ï. �‚�¼. 2013”N7ŒŽ19“ú.

�‚‹´’¼Šó, �û•£�¹‹B, �–ì�ƒ“T, –؉º�Ÿ�O, “Œ“�‘ã, ŠÝ�¹”ü, ’|ú±�²•v, �¼žŠ“Ö˜Y, Œã“Œ‹vŽk, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éidiopathic pleuroparenchymal fibroelastosis(IPPFE)�Ç—á‚ÌŒŸ“¢. ‘æ108‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2013”N6ŒŽ9“ú.

�X�Z�r, ‘å’ËŒ›Ži, –L“c—DŽq, ‰Í–ì�O, ŠÝ��, Žè’Ë•qŽj, ‹g“ˆ‹PŽÀ, Š`“à‘�Ži, �û•£�¹‹B, �¼‰ªˆÀ•F. ”]‰Š‚Æ• •”‘å“®–¬áŽ‚ð�‡•¹‚µ‚½‘½”­ŒŒŠÇ‰Š�«“÷‰èŽî�Ç‚Ì1—á. ‘æ108‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2013”N6ŒŽ9“ú.

•Ä“c�_�l, Žè’Ë•qŽj, �–ì�ƒ“T, ���ì�k‘¢, �¼žŠ“Ö˜Y, ŽRŽq‘דl, ‘å’ËŒ›Ži, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �òŒ[‰î, �¼‰ªˆÀ•F. ‹¹�o‹¾‰º‹¹–Œ�¶ŒŸ‚Å�f’f‚µ‚¦‚½�tá±Šà‹¹–Œ“]ˆÚ‚Ì1—á. ‘æ21‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. “¿“‡. 2013”N2ŒŽ16“ú.

‹g“ˆ‹PŽÀ, �û•£�¹‹B, “Œ“�‘ã, –L“c—DŽq, ‰Í–ì�O, ŠÝ��, ’|ú±�²•v, ‰ªú±�O‘×, ’·”ö‘½”üŽq, —é–Ø—íŽq, �‚ŠJ“o–ÎŽq, �æŽR�³“ñ, �¼‰ªˆÀ•F. “¿“‡‘åŠw•a‰@�Eˆõ‚É‚¨‚¯‚é�ö�Ý�«Œ‹ŠjŠ´�õ�ǂ̌»�ó. ‘æ63‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”‰ï. “¿“‡. 2013”N2ŒŽ16“ú.
2012”N‹Æ�Ñ
�y‰¢•¶‘��à�z
Nishioka Y. Malignant pleural effusion: further translational research is crucial. Transl Lung Cancer Res 1(3):167-169, 2012.
�y‰¢•¶Œ´’˜�z
Kuramoto T, Goto H, Mitsuhashi A, Tabata S, Ogawa H, Uehara H, Saijo A, Kakiuchi S, Maekawa Y, Yasutomo K, Hanibuchi M, Akiyama SI, Sone S, Nishioka Y. Dll4-Fc, an inhibitor of Dll4-Notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-kappa-B activity. Mol Cancer Ther 11(12):2578-2587, 2012.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci 103(11):1913-1919, 2012.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol 181(3):1034-1043, 2012.

Tabata S, Ikeda R, Yamamoto M, Furukawa T, Kuramoto T, Takeda Y, Yamada K, Haraguchi M, Nishioka Y, Sone S, Akiyama S. Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells. Oncol Rep 28(3):895-902, 2012.

Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat le T, Nishioka Y, Akiyama S, Sone S. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology 17(6):984-990, 2012.

Dat le T, Matsuo T, Yoshimaru T, Kakiuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S, Katagiri T. Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice. Int J Oncol 40(5):1455-1469, 2012.

Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takeuchi M, Kudoh S; Japan NAC Clinical Study Group. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 17(3):467-477, 2012.

Ogawa H, Azuma M, Uehara H, Takahashi T, Nishioka Y, Sone S, Izumi K. Nerve growth factor derived from bronchial epithelium after chronic mite antigen exposure contributes to airway hyperresponsiveness by inducing hyperinnervation, and is inhibited by in vivo siRNA. Clin Exp Allergy 42(3):460-470, 2012.

Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW, Wright JR. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185(5):525-536, 2012.

Gabr AG, Goto H, Hanibuchi M, Ogawa H, Kuramoto T, Suzuki M, Saijo A, Kakiuchi S, Trung VT, Sakaguchi S, Moriya Y, Sone S, Nishioka Y. Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis 29(3):207-216, 2012.

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18(6):1663-1671, 2012.

Tezuka T, Azuma M, Goto H, Nishioka Y, Sone S. Psychiatric symptoms in a patient with Churg-Strauss syndrome. Intern Med 51(3):301-303, 2012.

Miyake K,, Tani K, Kakiuchi S, Suzuka C, Toyoda Y, Kishi J, Tezuka T, Yuasa S, Hanibuchi M, Aono Y, Nishioka Y, Sone S. Epidermal growth factor tyrosine kinase inhibitor (gefitinib) augments pnumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest 59(1-2):174-185, 2012.
�y˜a•¶’˜�‘�z
�¼‰ªˆÀ•F.�@–ò•¨—Ö@. ŠÔŽ¿�«”x‰Š‚ð‹†‚ß‚é, ‘êàVŽn•Ò�W. 2012. pp86-95. Дޮ‰ïŽÐƒ�ƒWƒJƒ‹ƒrƒ…�[ŽÐ.

ŠÝ��. �^‹ÛŠ´�õ�Ç. äPŒ´•a‚Ì”x�‡•¹�Ç �f—Ã}ƒjƒ…ƒAƒ‹, ‹{�â�M”V•Ò. 2012. pp147-153.�@ˆã–òƒWƒƒ�[ƒiƒ‹ŽÐ.

�¼‰ªˆÀ•F.�@äPŒ´•a‚Ì”x�‡•¹�Ç�|ŒŸ�¸‚ÌŠî–{�|. äPŒ´•a‚Ì”x�‡•¹�Ç �f—Ã}ƒjƒ…ƒAƒ‹, ‹{�â�M”V•Ò. 2012. pp43-51.�@ˆã–òƒWƒƒ�[ƒiƒ‹ŽÐ.
�y˜a•¶‘��à�z
Œã“Œ‹vŽk. –ڂł݂éƒgƒŒ�[ƒjƒ“ƒO. Medicina 49(8):1434,1437, 2012.

�–ì�ƒ“T, �¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“I–ò‚É�‡•¹‚·‚éŠÔŽ¿�«”x‰Š. Medical Science Digest 38(9):396-399, 2012.

�¼‰ªˆÀ•F. ‚ª‚ñ•ªŽq•W“IŽ¡—Âɂ¨‚¯‚éˆê‘̉»ŠJ”­‚ÌŒ»�ó‚Æ“W–]. ‚ª‚ñ•ªŽq•W“IŽ¡—à 10(4):267-275, 2012.

�¼‰ªˆÀ•F. “�«ŒÄ‹zŠí޾г‚ÌŽ¡—Ö@‚ÌŠJ”­‚ð–ÚŽw‚µ‚Ä. ŒÄ‹z 31(7):587-588, 2012.

�¼‰ªˆÀ•F, ‘]�ªŽO˜Y.�@ŒÄ‹zŠí޾г‚É‚¨‚¯‚éƒgƒ‰ƒ“ƒXƒŒ�[ƒVƒ‡ƒiƒ‹ƒŠƒT�[ƒ`:Œ»�ó‚Æ�«—ˆ“W–]. ŒÄ‹zŠí“à‰È 21(6):483-484, 2012.

�–ì�ƒ“T, Jo Rae Wright, �¼‰ªˆÀ•F. ”x�üˆÛ�ǂɂ¨‚¯‚éSP-D‚Ì–hŒä“I–ðŠ„. •ªŽqŒÄ‹zŠí•a 16(1):147-150, 2012.

ŠÝ��, �¼‰ªˆÀ•F. ƒTƒ‹ƒRƒCƒh�[ƒVƒXƒ‚ƒfƒ‹‚Æ�V‹KŽ¡—ÕW“I. •ªŽqŒÄ‹zŠí•a 16(1):56-58, 2012.

�û•£�¹‹B, �¼‰ªˆÀ•F. ”x‚ª‚ñ‚ƉŠ�Ç. �Å�VˆãŠw 67(3):479-484, 2012.

Œã“Œ‹vŽk. ”x‚Ì�¶‘Ì–hŒä‹@�\‚É‚¨‚¯‚éƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’‚`‚Ì–ðŠ„. ŒÄ‹z 31(1):79-89, 2012.
�y˜a•¶Œ´’˜�z
�â–{�Wˆê, Š�‰Y�kˆê˜Y, ‘ê‘ò�GŒõ, ’†�ì–õŽm, ’r“c�^—R”ü, ŒÃ�쑸Žq, �X–{‰ë”ü, �¼–ì�‹Žu, Œã“¡�³˜a, ’†�ì”ü�»Žq, ŽR–{—m‘¾, ŒÃ–k—R�m, •�’m�_˜a, ‹g“cŒõ‹P, �ì�ã�sšõ, “c�Š—R‹IŽq, �æŽR�³“ñ, ‹ß“¡˜a–ç, �Ⓦ—Ç”ü, ‰ª�è�O‘×, Œã“Œ‹vŽk, �¼‰ªˆÀ•F, ’O�•�Í. Erlotinib ‚Åinduction therapy ‚ð�s‚Á‚½‡VAŠú”ñ�¬�×–E”xŠà‚Ì1Žè�p—á. Žl�‘ˆãŽ� 68(5,6):251-256, 2012.

Œã“Œ‹vŽk, �–ì�ƒ“T, �¼‰ªˆÀ•F�D”x‚Ì�¶‘Ì–hŒä‹@�\‚É‚¨‚¯‚éƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’A‚Ì–ðŠ„. “ú–{”xƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg�EŠE–ʈãŠw‰ïŽGŽ� 43:9-15, 2012.

–î–ì‘c, �¼žŠ“Ö˜Y, ‹ß“¡�^‘ã, ‰Í–ì�O, –L“c—DŽq, Š`“à‘�Ži, ŠÝ��, �û•£�¹‹B, ŒÃ�ì‹M‘å, “¡“c�_Ži, �¼‰ªˆÀ•F. �_Œo�ª�áŠQ‚Å”­�Ç‚µ‚½�_ŒoƒTƒ‹ƒRƒCƒh�[ƒVƒX‚̈ê—á. Žl�‘ˆãŽ� 68(3,4):153-158, 2012.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Sho Tabata, Sawaka Yukishige, Shinji Abe, Masaki Hanibuchi, Soji Kakiuchi, Atsuro Saijo, Yoshinori Aono, Hisanori Uehara, Seiji Yano, Julie G. Ledford, Saburo Sone, Yasuhiko Nishioka Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. Tokushima University-Seoul National University-KAIST joint meeting, Seoul, Korea. 2012”N12ŒŽ20“ú.

Masaki Hanibuchi, Sun-Jin Kim, Kenji Otsuka, Sho Tabata, Takuya Kuramoto, Hisasugu Goto, Yasuhiko Nishioka, Isaiah J Fidler. Eradication of experimental brain metastases of human non-small cell lung cancer by macitentan, a dual antagonist of the endothelin A and B receptor, combined with paclitaxel. Markers in Cancer 2012 : A Joint Meeting by ASCO, EORTC and NCI. Hollywood, FL. 2012”N10ŒŽ12“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Soji Kakiuchi, Sho Tabata, Atsuro Saijo, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model.14th International Biennial Congress of the Metastasis Research Society, Brisbane, Australia. 2012”N9ŒŽ4“ú.

Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Atsuro Saijo, Soji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone, Yasuhiko Nishioka. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity.14th International Biennial Congress of the Metastasis Research Society. Brisbane, Australia. 2012”N9ŒŽ4“ú.

Yasuhiko Nishioka, Shinji Abe, Yuki Morita, Mika Kato Kaneko, Masaki Hanibuchi, Hisatsugu Goto, Soji Kakiuchi, Yoshinori Aono, Jun Huang, Atsushi Mitsuhashi, Seidai Sato, Kazuo Minakuchi, Yukinari Kato. Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma.�@14th International Biennial Congress of the Metastasis Research Society. Brisbane, Australia. 2012”N9ŒŽ3“ú.

Hisatsugu Goto, Atsushi Mitsuhashi, Takuya Kuramoto, Masaki Hanibuchi, Soji Kakiuchi, Sho Tabata, Atsuro Saijo, Shin-ichi Akiyama, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model.�@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ23“ú.

Yasuhiko Nishioka, Shinji Abe, M.K. Kaneko, Yoshinori Aono, Jun Huang, Hisatsugu Goto, Masatoshi Kishuku, Masaki Hanibuchi, Saburo Sone, Kazuo Minakuchi, Yukinari Kato. Antitumor effects of anti-podoplanin antibody NZ-1 against malignant mesothelioma via ADCC.�@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ23“ú.

Shuichi Abe, Hiroyasu Okazaki, Masami Kishi, Akio Takezaki, Katsuhiro Kinoshita, Momoyo Azuma, Jun Kishi, Yoshinori Aono, Yasuhiko Nishioka. Fibrocyte regulates lung fibroblast function. ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ22“ú.

Yoshinori Aono, Masami Kishi, Yasuhiko Nishioka. Different functions of PDGF receptor-alpha and beta in lung fibrosis.�@ATS 2012 International Conference. San Francisco, CA. 2012”N5ŒŽ22“ú.

Takuya Kuramoto, Hisatsugu Goto, Atsushi Mitsuhashi, Sho Tabata, Hirohisa Ogawa, Hisanori Uehara, Seidai Sato, Soji Kakiuchi, Masaki Hanibuchi, Yoichi Maekawa, Koji Yasutomo, Shin-ichi Akiyama, Saburo Sone, Yasuhiko Nishioka. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through down-regulation of NF-kappa-B activity. AACR Annual Meeting 2012. Chicago, IL. 2012”N4ŒŽ2“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š‚Ì�f’f‚ÆŽ¡—Ã�F�ŋ߂Ì�i•à.�@‘æ26‰ñ“ú–{—Õ�°“à‰ÈˆãŠw‰ï(‹³ˆç�u‰‰). “¿“‡. 2012”N10ŒŽ7“ú.

�¼‰ªˆÀ•F. ŠÔŽ¿�«”x‰Š�f—Â̌»�ó‚Æ‰Û‘è.�@‘æ47‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï�iŒÄ‹zŠíƒZƒ~ƒi�[�j.‰ºŠÖ. 2012”N7ŒŽ21“ú.

“c”¨�Ë, ’r“c—´“ñ, ŽR–{‰ë’B, ŒÃ�ì—´•F, ‘q–{‘ì�Æ, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, �HŽR�Lˆê. ƒqƒgŠà�×–E‚ÌROSŽY�¶‚¨‚æ‚Ñ�¶‘¶‚É‚¨‚¯‚éƒ`ƒ~ƒWƒ“ˆÙ‰»�ì—p‚Ì–ðŠ„.�@‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï�iƒ��[ƒNƒVƒ‡ƒbƒv�j. –k‹ã�B. 2012”N6ŒŽ28“ú.

Jun Huang, Shinji Abe, Yuki Morita, Shuji Ozaki, Masatoshi Kishuku, Kazuo Minakuchi, Masaki Hanibuchi, Toshio Matsumoto, Saburo Sone, Yasuhiko Nishioka. Antibody-dependent cellular cytotoxicity against mesothelioma cells mediated by anti-HM 1.24 antibodies.�@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iEnglish Mini-Symposium�j. �_ŒË. 2012”N4ŒŽ22“ú.

�–ì�ƒ“T, Jo Rae Wright, Œã“Œ‹vŽk, �¼‰ªˆÀ•F. ”x‘¹���E�C•œ‚ÆSP-D:�R�üˆÛ‰»‚ÌŽ‹“_‚©‚ç. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iƒVƒ“ƒ|ƒWƒEƒ€�j. �_ŒË. 4ŒŽ22“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, Syo Tabata, Hirohisa Ogawa, Hisanori Uehara, Shin-ichi Akiyama, Jo Rae Wright, Saburo Sone, Yasuhiko Nishioka. Surfactant protein A suppresses progression of human lung adenocarcinoma in nude mice via modulating host immune response. ‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï(English Mini-Symposium). �_ŒË. 2012”N4ŒŽ21“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, ‹àŽq”ü‰Ø, ‰©�r, �û•£�¹‹B, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚éƒqƒgƒLƒ�ƒ‰Œ^�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘̗Ö@‚ÌŒŸ“¢.�@‘æ25‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠw�p�W‰ï‘�‰ï. ‰ªŽR. 2012”N12ŒŽ14“ú.

“c“‡‘sˆê˜Y, ŸN“c�I, Š`“à‘�Ži, �ã�¼‘ì, •Г‡‚é‚Ý, Ž›‰ª˜a•F, ‹vŽŸ•Ä•q�G, �ì“Y˜a‹`, �¼‰ªˆÀ•F, —k‰Í�G�Í, �…Œû˜a�¶. UGT1A1ˆâ“`Žq‚̃wƒeƒ��Ú�‡‘Ì(*6‚Ü‚½‚Í*28)‚ðŽ�‚ƒCƒŠƒmƒeƒJƒ““Š—^гŽÒ‚É‚¨‚¯‚鎡—ÈÀ‘S�«‚È‚ç‚тɌp‘±�«‚ÉŠÖ‚·‚錟“¢.�@‘æ33‰ñ“ú–{—Õ�°–ò—�Šw‰ïŠw�p‘�‰ï . ‰«“ê. 2012”N11ŒŽ29“ú.

�û•£�¹‹B, ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, ‹àŽq”ü‰Ø, –Ø�h�¹�r, �ì“Y˜a‹`, ‰©�r, ŽO‹´“ÕŽu, �…Œû˜a�¶, �¼‰ªˆÀ•F. �Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-1‚̈«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�R‘̈ˑ¶�«�×–E�áŠQŠˆ�«‚Æ�RŽîᇌø‰Ê.�@‘æ53‰ñ“ú–{”xŠàŠw‰ï‘�‰ï. ‰ªŽR. 2012”N11ŒŽ9“ú.

–L“c—DŽq, Š`“à‘�Ži, �û•£�¹‹B, Žè’Ë•qŽj, Œã“Œ‹vŽk, �¼‰ªˆÀ•F. Patient-Reported-Outcome(PRO)‚É‚æ‚é”xŠà–ò•¨—Ö@‚Ì—LŒø�«‚ÌŒŸ“¢.�@‘æ53‰ñ“ú–{”xŠàŠw‰ï‘�‰ï. ‰ªŽR. 2012”N11ŒŽ8“ú.

Œ³–Ø—R”ü, ˆ¢•”“ú“o”ü, ’–“à�G˜a, �û•£�¹‹B, •�‹v—mŽO. “–‰@‚ł̑Ï�«‹Û‚ɑ΂·‚éŽæ‚è‘g‚Ý.�@‘æ20‰ñ“ú–{–��«Šúˆã—Êw‰ï. •Ÿˆä. 2012”N11ŒŽ8“ú.

Œ³–Ø—R”ü, ˆ¢•”“ú“o”ü, ’–“à�G˜a, �û•£�¹‹B, •�‹v—mŽO. “–‰@‚ł̑Ï�«‹Û‚ɑ΂·‚éŽæ‚è‘g‚Ý.�@‘æ54‰ñ‘S“ú–{•a‰@Šw‰ï. ‰¡•l. 2012”N9ŒŽ21“ú.

“c”¨�Ë, ’r“c—´“ñ, ŽR–{‰ë’B, ŒÃ�ì—´•F, ‘q–{‘ì�Æ, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, �HŽR�Lˆê. ƒqƒgŠà�×–E‚Ì�¶‘¶‚É‚¨‚¯‚éƒ`ƒ~ƒWƒ“ˆÙ‰»�ì—p‚Ì–ðŠ„.�@‘æ71‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ŽD–y. 2012”N9ŒŽ20“ú.

�¼‰ªˆÀ•F, ˆ¢•”�^Ž¡, –Ø�h�¹�r, �ì“Y˜a‹`, ‰©�r, �û•£�¹‹B, �…Œû˜a�¶, ‘]�ªŽO˜Y, ‰Á“¡�K�¬. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚郉ƒbƒg�]ƒqƒgƒLƒ�ƒ‰Œ^�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-8‚Ì�RŽîᇌø‰Ê.�@‘æ71‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ŽD–y. 2012”N9ŒŽ19“ú.

‰Á“¡�K�¬, �‘“cŽéŽq, �¼‰ªˆÀ•F. �Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘̂ɂæ‚é“]ˆÚ—}�§Œø‰Ê‚ÌŒŸ“¢.�@‘æ71‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ŽD–y. 2012”N9ŒŽ19“ú.

ƒŒ�@ƒ^ƒ“ƒ_�[, �¼”ö‘×—C, ‹gŠÛ“N˜Y, Š`“à‘�Ži, Œã“Œ‹vŽk, ‘q–{‘ì�Æ, ŽO‹´“ÕŽu, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F, •Ћ˖L‰ë. ”xŠà‚Ì�œ“]ˆÚ‚ð�§Œä‚·‚é�V‹K“]ŽÊˆöŽqLBMTF‚Ì‹@”\‰ð�Í.�@‘æ71‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. ŽD–y. 2012”N9ŒŽ19“ú.

’Ò–{—Y‘¾, �‘“cŽéŽq, �¼‰ªˆÀ•F, ‰Á“¡�K�¬. ƒqƒgƒLƒ�ƒ‰Œ^�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘̂ɂæ‚é“]ˆÚ—}�§Œø‰Ê‚ÌŒŸ“¢.�@‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �L“‡. 2012”N7ŒŽ12“ú.

‘å’ËŒ›Ži, �û•£�¹‹B, Œã“Œ‹vŽk, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, Fidler Isaiah J. Endothelin Žó—e‘Ì�h�R�܂ɂæ‚é”xŠà”]“]ˆÚ—}�§Œø‰Ê‚ÌŒŸ“¢. ‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �L“‡. 2012”N7ŒŽ12“ú.

‘q–{‘ì�Æ, Œã“Œ‹vŽk, ŽO‹´“ÕŽu, “c”¨�Ë, �㌴‹v“T, �¼žŠ“Ö˜Y, Š`“à‘�Ži, �û•£�¹‹B, ‘O�ì—mˆê, ˆÀ—F�N“ñ, �HŽR�Lˆê, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. �¬�×–E”x‚ª‚ñ“]ˆÚ‚É‚¨‚¯‚éDll4-NotchƒVƒOƒiƒ‹‚Ì‘ŸŠí“ÁˆÙ�«‚ÉŠÖ‚·‚錟“¢. ‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �L“‡. 2012”N7ŒŽ12“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‘q–{‘ì�Æ, “c”¨�Ë, �¬�씎‹v, �㌴‹v“T, �HŽR�Lˆê, Wright Jo Rae, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. ”xsurfactant protein A�iSP-A�j‚Ì”xŠà�i“W‚É‚¨‚¯‚é‹@”\‰ð�Í.�@‘æ21‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�E‘�‰ï. �L“‡. 2012”N7ŒŽ12“ú.

�¼‰ªˆÀ•F, ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, –Ø�h�¹�r, �ì“Y˜a‹`, ‰©�r, �û•£�¹‹B, �…Œû˜a�¶, ‘]�ªŽO˜Y. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚éƒqƒgƒLƒ�ƒ‰Œ^�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-8‚Ì�RŽîᇌø‰Ê. ‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. –k‹ã�B. 2012”N6ŒŽ28“ú.

‰Á“¡�K�¬, ˆ¢•”�^Ž¡, �…Œû˜a�¶, �¼‰ªˆÀ•F. ƒqƒgƒLƒ�ƒ‰Œ^�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘̂ɂæ‚é“]ˆÚ—}�§‹@�˜‚̉ð–¾.�@‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. –k‹ã�B. 2012”N6ŒŽ28“ú.

‘q–{‘ì�Æ, Œã“Œ‹vŽk, �²“¡�³‘å, ŽO‹´“ÕŽu, “c”¨�Ë, �¼žŠ“Ö˜Y, �㌴‹v“T, Welm Alana, �û•£�¹‹B, �HŽR�Lˆê, ‘]�ªŽO˜Y, �¼‰ª ˆÀ•F. ƒqƒg”x‚ª‚ñ‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚éMacrophage-stimulating protein ‚Ì–ðŠ„‚ÉŠÖ‚·‚錟“¢.�@‘æ16‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. –k‹ã�B. 2012”N6ŒŽ28“ú.

–L“c—DŽq, �û•£�¹‹B, Š`“à‘�Ži, ŸN“c�I, Œã“Œ‹vŽk, Žè’Ë•qŽj, ŠÝ��, �–ì�ƒ“T, �¼‰ªˆÀ•F. “–‰È‚É‚¨‚¯‚é�I––Šú‚Ì’Á�Âɂ‚¢‚Ă̌Ÿ“¢.�@‘æ17‰ñ“ú–{ŠÉ˜aˆã—Êw‰ïŠw�p‘å‰ï. �_ŒË. 2012”N6ŒŽ23“ú.

�¼žŠ“Ö˜Y, Š`“à‘�Ži, ���¼”Ž”V, ‘å’ËŒ›Ži, ŽRŽq‘דl, Žè’Ë•qŽj, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F. Cycleave–@‚ÆPCR-Clamp–@‚É‚æ‚éEGFRˆâ“`Žq•ψّª’茋‰Ê‚ÆEGFRƒ`ƒ�ƒVƒ“ƒLƒi�[ƒ[‘jŠQ�܂̎¡—ÃŒø‰Ê‚Æ‚Ì‘ŠŠÖ.�@‘æ35‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠw�p�W‰ï. “Œ‹ž. 2012”N5ŒŽ31“ú.

‰Í–ì�O, ŠÝ�¹”ü, Žè’Ë•qŽj, –L“c—DŽq, ŠÝ��, �¼‰ªˆÀ•F. • •”‘å“®–¬ŽüˆÍ‰Š‚𔺂Á‚½granulomatosis with polyangiitis‚Ì1—á.�@‘æ56‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘�‰ï�EŠw�p�W‰ï. “Œ‹ž. 2012”N4ŒŽ27“ú.

‘�ˆî“c—DŽq, �¼ˆä�ËŽq, ŽR–{—m, “¡‘º�­Ž÷, —L“c�^’mŽq, �Έ䊰, ‹î�è‹`—˜, �™ŽR�K”äŒÃ, “n•Ó�³Ž÷, ‰Pˆä—T, ‰Í‘º“NŽ¡, �¬—щp•v, �¼‰ªˆÀ•F, –{ŠÔ‰h, �¬‘q�‚Žu. IgG4ŠÖ˜A޾г(IgG4RD)‚̌ċzŠí•a•ςɂ¨‚¯‚é—Õ�°‰æ‘œ•a—�Šw“IŒŸ“¢.�@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2012”N4ŒŽ22“ú.

ˆ¢•”�Gˆê, ‰ªú±�O‘×, ŠÝ�¹”ü, ’|ú±�²•v, –؉º�Ÿ�O, “Œ“�‘ã, ŠÝ��, �–ì�ƒ“T, �¼‰ªˆÀ•F. Fibrocyte‚Ì”x�üˆÛ‰è�×–E‹@”\‚É‹y‚Ú‚·Œø‰Ê‚ÌŒŸ“¢.�@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2012”N4ŒŽ20“ú.

ŠÝ�¹”ü, �–ì�ƒ“T, ’|�è�²•v, “Œ“�‘ã, ŠÝ��, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚éƒsƒ‹ƒtƒFƒjƒhƒ““Š—^�Ç—á‚ÌŒŸ“¢.�@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2012”N4ŒŽ20“ú.

ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, ‹àŽq”ü‰Ø, –Ø�h�¹�r, �ì“Y˜a‹`, “Œ–ž”ü, �…Œû˜a�¶, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-1‚Ì�RŽîᇌø‰Ê‚ÉŠÖ‚·‚錟“¢.�@‘æ52‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. �_ŒË. 2012”N4ŒŽ20“ú.

Š`“à‘�Ži, �û•£�¹‹B, “c‰ª—²�¬, �¼žŠ“Ö˜Y, Žè’Ë•qŽj, –L“c—DŽq, Œã“Œ‹vŽk, �‚‹´�³�K, ‹àŽR”Ž�b,�¼‰ªˆÀ•F. mTOR‘jŠQ�ܓЗ^�Ç—á‚É‚¨‚¯‚éŠÔŽ¿�«”x�áŠQ‚Ì—Õ�°“I“Á’¥.�@‘æ109‰ñ“ú–{“à‰ÈŠw‰ï‘�‰ï�E�u‰‰‰ï. ‹ž“s. 2012”N4ŒŽ15“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
‘º�ã‰i�®, “‡’J‰ÀŒõ, ŽRŽq‘דl, ‘å�è—T—º, ‹{�鈤, �X“ÖŽq, –쎛—T”V, ˜a�ò—B�M, �¼‰ªˆÀ•F, Š�—´™Z. ‘½�Ê‚È�_Œo�Ç�ó‚ð’æ‚µ‚½�¬�×–E”xŠà‚Ì1—á. ‘æ107‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2012”N12ŒŽ8“ú.

���ì�k‘¢, ‰Í–ì�O, “¡“c�_Ži, ‘º�ã‰i�®, Žè’Ë•qŽj, ŠÝ��, �û•£�¹‹B, Š�—´™Z, �¼‰ªˆÀ•F. MPO-ANCAŠÖ˜A”ìŒú�«�d–Œ‰Š‚Ì1—á. ‘æ107‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2012”N12ŒŽ2“ú.

•Ä“c�_�l, ‘å’ËŒ›Ži, �–ì�ƒ“T, –L“c—DŽq, �¼–ì�‹Žu, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F.“�«‚Ì�t�«�EŠÌ�«‹¹�…‚ɑ΂µ‚Ä‹¹�o�|• �oƒVƒƒƒ“ƒg‚ª‘tŒø‚µ‚½1—á. ‘æ107‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �¼ŽR. 2012”N12ŒŽ2“ú.

‰Í–ì�O, –L“c—DŽq, ŠÝ��, �û•£�¹‹B, �¼‰ªˆÀ•F. �RCCP�R‘Ì�‚’l‚ð’æ‚µ�AŠÖ�ß‰Š‚ð”º‚í‚¸‚É”­�Ç‚µ‚½ƒXƒeƒ�ƒCƒh’ï�R�«ŠíŽ¿‰»”x‰Š‚Ì1—á. ‘æ23‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. ‰F•”. 2012”N10ŒŽ20“ú.

�û•£�¹‹B, ’·”ö‘½”üŽq, —é–Ø—íŽq, �‚ŠJ“o–ÎŽq, “Œ“�‘ã, �¼‰ªˆÀ•F. �ö�Ý�«Œ‹ŠjŠ´�õ�Ç(latent tuberculosis infection: LTBI)‚ɑ΂·‚鎡—Â̌»�ó‚Æ–â‘è“_. ‘æ6‰ñ“ú–{Œ‹Šj•aŠw‰ï’†�‘Žl�‘Žx•”Œ¤‹†‰ï. ‰ªŽR. 2012”N9ŒŽ29“ú.

’†�¼‰ÃŒ›, ‰Í–ì�O, ˆ¢•”�Gˆê, ’|ú±�²•v, Œã“Œ‹vŽk, �–ì�ƒ“T, �û•£�¹‹B, �æŽR�³“ñ, •Ÿ“c—I, �¼‰ªˆÀ•F. “Á”­�«”x�œ‰»�Ç‚Ì1—á. ‘æ47‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‰ºŠÖ. 2012”N7ŒŽ21“ú.

���ì�k‘¢, �¼žŠ“Ö˜Y, Š`“à‘�Ži, ‘å’ËŒ›Ži, ŽRŽq‘דl, Žè’Ë•qŽj, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F.‘ª’è–@‚É‚æ‚èEGFR•ψق̑ª’茋‰Ê‚ɉ𗣂ª‚Ý‚ç‚ꂽ”ñ�¬�×–E”xŠà‚Ì3—á. ‘æ51‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”‰ï. ‰ºŠÖ. 2012”N7ŒŽ20“ú.

•Ä“c�_�l, �–ì�ƒ“T, ŠÝ�¹”ü, –L“c—DŽq, ‹ß“¡�^‘ã, ‰ªú±�O‘×, ŠÝ��, �û•£�¹‹B, ŠÄ�è�Fˆê˜Y, •Ÿ“c—I, �¼‰ªˆÀ•F. �‚IgGŒŒ�ǂ̒·ŠúŠÔ‚ÌŒo‰ßŠÏŽ@’†‚É‘½’†�S�«ƒLƒƒƒbƒXƒ‹ƒ}ƒ“•a‚Ì�f’f‚ÉŽŠ‚Á‚½ˆê—á. ‘æ47‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‰ºŠÖ. 2012”N7ŒŽ20“ú.

‘å’ËŒ›Ži, –L“c—DŽq, ŠÝ��, �–ì�ƒ“T, �û•£�¹‹B, �¼‰ªˆÀ•F, Œ´’m–ç, ŽRŒû�_Ži, �²“c�­—². �S‹Ø‰Š‚ð�‡•¹‚µ‚½Churg-Strauss�ÇŒóŒQ‚Ì1—á. ‘æ106‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2012”N6ŒŽ17“ú.

“c‰ªŽu•Û, ‰Í–ì�O, Žè’Ë•qŽj, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, �¼‰ªˆÀ•F, ‰ª–{�kˆê, �‚ŽR“NŽ¡. FDG-PET/CT‚É‚æ‚è�¬’°“]ˆÚ‚ð”­Œ©‚µ‚½”xŠà‚Ì2�Ç—á. ‘æ106‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. “¿“‡. 2012”N6ŒŽ17“ú.

‹ß“¡�^‘ã, –L“c—DŽq, ˆ¢•”�Gˆê, ‰Í–ì�O, ŠÝ�¹”ü, ’|ú±�²•v, “Œ“�‘ã, Š`“à‘�Ži, Œã“Œ‹vŽk, �–ì�ƒ“T, �û•£�¹‹B, �¼‰ªˆÀ•F. •a�¨‚ÉŠÖ˜A‚µ‚ÄCA19-9‚̕ϓ®‚ð”F‚ß‚½”ñŒ‹Šj�«�RŽ_‹Û�Ç‚Ì1—á. ‘æ20‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �o‰_. 2012”N3ŒŽ3“ú.

���¼”Ž”V, Žè’Ë•qŽj, ‰Í–ì�O, ’|ú±�²•v, “Œ“�‘ã, Š`“à‘�Ži, Œã“Œ‹vŽk, ŠÝ��, �–ì�ƒ“T, �û•£�¹‹B, �¼‰ªˆÀ•F. ”ñŒ‹Šj�«�RŽ_‹Û�Ç‚ð�‡•¹‚µ‚½ƒTƒ‹ƒRƒCƒh�[ƒVƒX‚Ì1—á. ‘æ20‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �o‰_. 2012”N3ŒŽ3“ú.

’|ú±�²•v, �¼žŠ“Ö˜Y, ‘å’ËŒ›Ži, ŠÝ�¹”ü, Žè’Ë•qŽj, Š`“à‘�Ži, Œã“Œ‹vŽk, ŠÝ��, �–ì�ƒ“T, �û•£�¹‹B, �¼‰ªˆÀ•F. “–‰È‚ÅŒoŒ±‚µ‚½”x–E�oŒŒ4�Ç—á‚Ì—Õ�°“IŒŸ“¢. ‘æ20‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �o‰_. 2012”N3ŒŽ3“ú.
2011”N‹Æ�Ñ
�y‰¢•¶‘��à�z
Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S.�@Antiangiogenic therapies for malignant pleural mesothelioma. Front Biosci 16:740-748, 2011.

Nishioka Y, Aono Y, Sone S. Role of tyrosine kinase inhibitors in tumor immunology. Immunotherapy 3:107-116, 2011.
�y‰¢•¶Œ´’˜�z
Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci 102:2157-2163, 2011.

Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T, Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 12:143-153, 2011.

Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine Nnetwork. Am J Pathol 179:1483-1493, 2011.

Goto H, Hanibuchi M, Sakaguchi S, Kanematsu T, Kakiuchi S, Tomimoto H, Azuma M, Tezuka T, Tada H, Miki Y, Nakamura T, Sone S, Nishioka Y. Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital. J Med Invest 58:219-226, 2011.

Batmunkh R, Nishioka Y, Aono Y, Azuma M, Kinoshita K, Kishi J, Makino H, Kishi M, Takezaki A, Sone S. CCN6 as a profibrotic mediator that stimulates the proliferation of lung fibroblasts via the integrin ƒÀ1/focal adhesion kinase pathway. J Med Invest 58:188-196, 2011.

Van TT, Hanibuchi M, Kakiuchi S, Sato S, Kuramoto T, Goto H, Mitsuhashi A, Nishioka Y, Akiyama SI, Sone S. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemother Pharmacol 68:497-504, 2011.

Kishi J, Nishioka Y, Kuwahara T, Kakiuchi S, Azuma M, Aono Y, Makino H, Kinoshita K, Kishi M, Batmunkh R, Uehara H, Izumi K, Sone S. Blockade of Th1 chemokine receptors ameriolates pulmonary granulomatosis in mice. Eur Respir J 38:415-424, 2011.

Ogino H, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther 10:1218-1228, 2011.

Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T. Pirfenidone Clinical Study Group in Japan. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12:93-101, 2011.

Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, Yamamoto A, Takeuchi E, Yamamoto A, Azuma M, Tada H, Kanematsu T, Kakiuchi S, Goto H, Yano S, Nishioka Y, Sone S. A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Lett 2:465-470, 2011.

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17:2260-2269, 2011.

Yokoi K, Hawke D, Oborn CJ, Jang JY, Nishioka Y, Fan D, Kim SW, Kim SJ, Fidler IJ. Identification and validation of Src and phospho-Src family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer. Transl Oncol 4:83-91, 2011.

Sakai T, Furoku S, Nakamoto M, Shuto E, Hosaka T, Nishioka Y, Sone S. Soy isoflavone equol perpetuates dextran sulfate sodium-induced acute colitis in mice. Biosci Biotechnol Biochem 75:593-595, 2011.

Ogawa H, Azuma M, Muto S, Nishioka Y, Honjo A, Tezuka T, Uehara H, Izumi K, Itai A, Sone S. IkB kinase b inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus -sensitized mouse model of chronic asthma. Clin Exp Allergy 41:104-115, 2011.
�y˜a•¶’˜�‘�z
�¼‰ªˆÀ•F.�@ƒxƒoƒVƒYƒ}ƒu�@•ªŽq•W“IŽ¡—Öò�|�Å�V‚Ì‘I‚Ñ•û�EŽg‚¢•û�|.�@‚ª‚ñ�f—ÃŒƒNƒ`ƒƒ�[ 2, �Ήª�ç‰ÁŽj•Ò. 2011. pp262-263. ‘��‡ˆãŠwŽÐ.

–؉º�Ÿ�O, �¼‰ªˆÀ•F.�@•¶Œ£ŒŸ�õ‚ÌŽd•û, ˆãŠw˜_•¶‚̓ǂݕû�E�‘‚«•û, Šw‰ï‚Ö‚ÌŽæ‚è‘g‚Ý•û, ‘åŠw‰@�EˆãŠw”ŽŽm�E—¯Šw‚ɂ‚¢‚Ä, ŒÄ‹zŠí‰Èˆã‚ɂƂÁ‚ÄŒ¤‹†‚Ƃ͉½‚©? ŒÄ‹zŠí Œ¤�Cƒm�[ƒg, ˆ°àV˜a�l, ‘å�ò‘�Žj, ‰«‰i‘sŽ¡, •ž•”“o, �¯�ì�N•Ò. 2011. pp82-93. �f’f‚ÆŽ¡—ÃŽÐ.
�y˜a•¶‘��à�z
�–ì�ƒ“T, �¼‰ªˆÀ•F.�@äPŒ´•a‚ÆŠÖ˜A‚µ‚½‚т܂ñ�«”x޾г.�@‘��‡—Õ�° 60:2463-2469, 2011.

�¼‰ªˆÀ•F.�@Gremlin‚Æ“Á”­�«ŠÔŽ¿�«”x‰Š.�@ŒÄ‹z 30:955-958, 2011.

‘]�ªŽO˜Y.�@ˆãŠwŒ¤‹†‚É‚¨‚¯‚éCOIƒ}ƒl�[ƒWƒ�ƒ“ƒg.�@Š´�õ�ÇŠw‰ïŽGŽ� 85:396-397, 2011.

�û•£�¹‹B. QOL•]‰¿–@‚Æ‚µ‚Ä‚Ìpatient-reported outcome(PRO)‚Æ‚Í.�@CLITICAL EYES on Clinical Oncology 40:11, 2011.

ŠÝ�¹”ü, ‘]�ªŽO˜Y. ‹¹–Œ‰Š, ”^‹¹.�@Medical Practice 28(‘�):334-338, 2011.

–؉º�Ÿ�O, �¼‰ªˆÀ•F.�@–ò�Ü�«”x�áŠQ‚Ì�Å�V‚Ì’mŒ©. •ªŽqŒÄ‹zŠí•a 15(1):66-68, 2011.

Œã“Œ‹vŽk, Julie G Ledford, Sambuddho Mukherjee, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, Jo Rae Wright. ‹}�«”x‘¹��‚É‚¨‚¯‚éSurfactant Protein A‚Ì–ðŠ„. •ªŽqŒÄ‹zŠí•a15:74-76, 2011.
�y˜a•¶Œ´’˜�z
“¡‰ªŒ[‰î, �¼žŠ“Ö˜Y, –L“c—DŽq, Š`“à‘�Ži, �û•£�¹‹B, Œá�ȉë•F, ’|“à‹±Žq, “¡ˆäŽu˜N, ’†‘º�MŒ³, ‰F�‚Œ›Œá, ‰ê�ì‹v”üŽq, ˆÀ”{�³”Ž, �…’J—F�Æ, �¼‰ªˆÀ•F.�@”畆ƒ‰ƒ“ƒ_ƒ€�¶ŒŸ‚ª�f’f‚É—LŒø‚Å‚ ‚Á‚½ŒŒŠÇ“àƒŠƒ“ƒpŽî‚̈ê—á. Žl�‘ˆãŠwŽGŽ� 67:257-262, 2011.

Œ“�¼‹M‘¥, –L“c—DŽq, Œã“Œ‹vŽk, ˆ¢•”�Gˆê, ‰Í–k’¼–ç, �æŽR�³“ñ, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y.�@”x‘½”­Œ‹�ß•a•Ï‚ð’æ‚µ‚½Œ´”­�«”x•½ŠŠ‹Ø“÷Žî‚Ì1—á. “ú–{ŒÄ‹zŠíŠw‰ïŽGŽ� 49:167-171, 2011.

–؉º�Ÿ�O, �¼‰ªˆÀ•F, ŠÝ�¹”ü, ’|�è�²•v, �–ì�ƒ“T, “Œ“�‘ã, ŠÝ��, �㌴‹v“T, �òŒ[‰î, ‘]�ªŽO˜Y. ޾гŒ`�¬‚É‚¨‚¯‚é•W“I•ªŽq‚Ì–ðŠ„ FAKƒVƒOƒiƒ‹‚Ì”x�üˆÛ‰»‚É‚¨‚¯‚é–ðŠ„ ƒuƒŒƒIƒ}ƒCƒVƒ“”x�üˆÛ�ǃ‚ƒfƒ‹‚ł̌Ÿ“¢. •ªŽqŒÄ‹zŠí•a 15:124-127, 2011.
�yŠw‰ï”­•\-�‘�ÛŠw‰ï�z
Masaki Hanibuchi, Shinji Abe, Masatoshi Kisyuku, Soji Kakiuchi, Kasuyoshi Kawazoe, Kazuo Minakuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka. Targeted therapy for mesothelioma using anti-podoplanin antibody NZ-1 via ADCC. 5th EORTC-NCI-ASCO Annual Meeting on 'Molecular Markers in Cancer'. Brussels, Belgium. 2011”N10ŒŽ27“ú.

Saburo Sone, Seiji Yano. Role of hepatocyte growth factor in resistance acquisition to EGFR-TK inhibitor (Gefitinib/Erlotinib) in EGFR mutant lung cancer patients. The 19th Catholic allergic and Respiratory Workshop. Seoul, Korea. 2011”N6ŒŽ26“ú.

Yasuhiko Nishioka. Novel targets for treatment of pulmonary fibrosis: lessons from animal study for the clinic. The 19th Catholic allergic and Respiratory Workshop. Seoul, Korea. 2011”N6ŒŽ26“ú.

Katsuhiro Kinoshita, Yasuhiko Nishioka, Masami Kishi, Momoyo Azuma, Yoshinori Aono, Hisanori Uehara, Akio Takezaki, S. Hatakeyama, E. Kawahara, Saburo Sone. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ18“ú.

Yoshinori Aono, J.G. Ledford, Yasuhiko Nishioka, Saburo Sone, M.F. Beers, J.R. Wright. SP-D attenuates bleomycin induced lung fibrosis via regulating recruitment and activation of macrophages and fibrocytes.ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ18“ú.

Atsushi Mitsuhasi, Hisatsugu Goto, Takuya Kuramoto, Soji Kakiuchi1, Seidai Sato, Van The Trung, Atsuro Saijo, Makoto Tobiume, Kenji Otsuka, Yasuhiko Nishioka, Jo Rae Wright, Saburo Sone. Surfactant protein A suppresses progression of human lung adenocarcinoma in an experimental lung metastasis model. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ17“ú.

Momoyo Azuma, Yasuhiko Nishioka, Reham Mohammed El-morshedy, Jun Kishi, Masami Kishi, Katsuhiro Kinoshita, Hisanori Uehara, Keisuke Izumi, Saburo Sone. The role of sphingosine 1-phospate (SIP) signaling in pulmonary fibrosis. ATS 2011 International Conference. Denver, CO. 2011”N5ŒŽ15“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�i“Á•Ê�u‰‰�EƒVƒ“ƒ|ƒWƒEƒ€�Eƒ��[ƒNƒVƒ‡ƒbƒv�j�z
�¼‰ªˆÀ•F. •ªŽq•W“IŽ¡—Âɂ¨‚¯‚éˆê‘̉»ŠJ”­‚Ö‚ÌŠú‘Ò. JAMTTC�EJSGDT�‡“¯ƒVƒ“ƒ|ƒWƒEƒ€ “Œ‹ž. 2011”N12ŒŽ9“ú.

Œã“Œ‹vŽk, �–ì�ƒ“T, �¼‰ªˆÀ•F. ”x‚Ì�¶‘Ì–hŒä‹@�\‚É‚¨‚¯‚éƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’A‚Ì–ðŠ„. “ú–{”xƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg�EŠE–ʈãŠw‰ï‘æ47‰ñŠw�pŒ¤‹†‰ï(‹³ˆç�u‰‰). “¿“‡. 2011”N10ŒŽ29“ú.

�¼‰ªˆÀ•F, ’Ò–{—Y‘¾, ‰Á“¡�K�¬, ‘]�ªŽO˜Y. ƒqƒgƒLƒ�ƒ‰Œ^�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘̂̊ˆ�«•]‰¿. ‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï�iƒ��[ƒNƒVƒ‡ƒbƒv�j. �ɪ. 2011”N6ŒŽ30“ú.

‰Á“¡�K�¬, �¼‰ªˆÀ•F, ˆ¢•”�^Ž¡, �…Œû˜a•v, ‘]�ªŽO˜Y. ˆ«�«ƒOƒŠƒI�[ƒ}‚ɑ΂·‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-1‚ÌŠˆ�«•]‰¿. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï�iƒ��[ƒNƒVƒ‡ƒbƒv�j. “Œ‹ž. 2011”N6ŒŽ24“ú.

‘q–{‘ì�Æ, Œã“Œ‹vŽk, Š`“à‘�Ži, �¬�씎‹v, ŽO‹´“ÕŽu, “c”¨�Ë, �²“¡�³‘å, ‘O�ì—mˆê, ˆÀ—F�N“ñ, �¼‰ªˆÀ•F, �HŽR�Lˆê, ‘]�ªŽO˜Y. �¬�×–E”x‚ª‚ñ“]ˆÚ‚É‚¨‚¯‚éDLL4-NotchƒVƒOƒiƒ‹‚Ì‘ŸŠí“ÁˆÙ�«‚ÉŠÖ‚·‚錟“¢. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï�iƒ��[ƒNƒVƒ‡ƒbƒv�j. “Œ‹ž. 2011”N6ŒŽ24“ú.

“Œ“�‘ã. —Õ�°–ò�ÜŽt‚ÆTDM�`ˆãŽt‚Ƃ̃Rƒ~ƒjƒ…ƒP�[ƒVƒ‡ƒ“‚Ì�d—v�«�`. ‘æ28‰ñ“ú–{TDMŠw‰ï�EŠw�p‘å‰ï�iƒVƒ“ƒ|ƒWƒEƒ€�j. �L“‡. 2011”N6ŒŽ18“ú.

–؉º�Ÿ�O, �¼‰ªˆÀ•F, ŠÝ�¹”ü, “Œ“�‘ã, �–ì�ƒ“T, ’|�è�²•v, �㌴‹v“T, ”©ŽR�T“ñ, ‰ÍŒ´‰pŽ¡, ‘]�ªŽO˜Y. ƒuƒŒƒIƒ}ƒCƒVƒ“”x�üˆÛ�ǃ‚ƒfƒ‹‚É‚¨‚¯‚éFAK‘jŠQ�ÜTAE226‚Ì�R�üˆÛ‰»Œø‰Ê‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iƒ|ƒXƒ^�[ƒVƒ“ƒ|ƒWƒEƒ€�j. “Œ‹ž. 2011”N4ŒŽ24“ú.

Shinji Takeuchi�CWei Wang�CQi Li�CTadaaki Yamada�CHitomi Koizumi�CIvan S Donev�CYasuhiko Nishioka�CSaburo Sone�CToshimitsu Uenaka. E7050, A Dual MET/VEGFR-2 Kinase Inhibitor, Circumvents EGFR-TKIs Resistance in EGFR Mutant Lung Cancer cells Induced by HGF. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iEnglish�@Mini-symposium�j. “Œ‹ž. 2011”N4ŒŽ24“ú.

Atsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto�CSoji Kakiuchi�CSeidai Sato�CVan The Trung�CMakoto Tobiume�CKenji Otsuka�CYasuhiko Nishioka. SP-A suppresses lung cancer progression and pleural effusion of human lung cancer cells in experimental mice model. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï�iEnglish�@Mini-symposium�j. “Œ‹ž. 2011”N4ŒŽ23“ú.
�yŠw‰ï”­•\-�‘“àŠw‰ï�iˆê”ʉ‰‘è�j�z
ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, ‹àŽq”ü‰Ø, ‰©�r, �û•£�¹‹B, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘̗Ö@‚ÌŒŸ“¢.�@‘æ24‰ñ“ú–{ƒoƒCƒIƒZƒ‰ƒsƒBŠw‰ïŠw�p�W‰ï‘�‰ï. ˜a‰ÌŽR. 2011”N12ŒŽ1“ú.

Žè’Ë•qŽj, �¬�씎‹v, Œá�ȉë•F, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. Plasminogen Activator Inhibitor-1‘jŠQ�Ü�iIMD-4690)‚Ì–��«šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢.�@‘æ61‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ï�H‹GŠw�p‘å‰ï. “Œ‹ž. 2011”N11ŒŽ10“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‘q–{‘ì�Æ, Š`“à‘�Ži, �²“¡�³‘å, Ttung The Van, �¼žŠ“Ö˜Y, “c”¨�Ë, �¬�씎‹v, �㌴‹v“T, �HŽR�Lˆê, �¼‰ªˆÀ•F, Jo Rae Wright, ‘]�ªŽO˜Y. ”xƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’SP-A”x‚ª‚ñ�i“W‚É‚¨‚¯‚é‹@”\‰ð�Í.�@“ú–{”xƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg�EŠE–ʈãŠw‰ï‘æ47‰ñŠw�pŒ¤‹†‰ï. “¿“‡. 2011”N10ŒŽ29“ú.

�–ì�ƒ“T, �¼‰ªˆÀ•F. ”x�üˆÛ�ǂɂ¨‚¯‚éSP-D‚Ì–hŒä“I–ðŠ„.�@“ú–{”xƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg�EŠE–ʈãŠw‰ï‘æ47‰ñŠw�pŒ¤‹†‰ï. “¿“‡. 2011”N10ŒŽ29“ú.

�¼‰ªˆÀ•F, ‰Á“¡�K�¬, �û•£�¹‹B, ‘]�ªŽO˜Y. ˆ«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-1‚Ì�RŽîᇌø‰Ê.�@‘æ70‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. –¼ŒÃ‰®. 2011”N10ŒŽ5“ú.

“c”¨�Ë, ŽR–{‰ë’B, ’r“c—´“ñ, ŒÃ�ì—´•F, ‘q–{‘ì�Æ, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, �HŽR�Lˆê. ƒ`ƒ~ƒWƒ“ƒzƒXƒzƒŠƒ‰�[ƒ[‚É‚æ‚Á‚ă`ƒ~ƒWƒ“‚©‚ç”h�¶‚µ‚½“œ‚̉𓜌n‚ւ̈Ú�s.�@‘æ70‰ñ“ú–{ŠàŠw‰ïŠw�p‘�‰ï. –¼ŒÃ‰®. 2011”N10ŒŽ3“ú.

ƒŒ�@ƒ^ƒ“ƒ_�[, �¼”ö‘×—C, ‹gŠÛ“N˜Y, ‘q–{‘ì�Æ, �û•£�¹‹B, Œã“Œ‹vŽk, Š`“à‘�Ži, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, •Ћ˖L‰ë. ƒqƒg”ñ�¬�×–E”xŠà‚Ì‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹ƒ}ƒEƒX‚ð—p‚¢‚½�œ“]ˆÚŠÖ˜Aˆâ“`Žq‚Ì–Ô—…“I‰ð�Í.�@“ú–{ŠàŠw‰ïŠw�p‘�‰ï. –¼ŒÃ‰®. 2011”N10ŒŽ3“ú.

�²“¡�³‘å, Œã“Œ‹vŽk, ‘q–{‘ì�Æ, �¬�씎‹v, ŽO‹´“ÕŽu, ƒeƒoƒ“ ƒ`ƒ…ƒ“, Š`“à‘�Ži, “c”¨�Ë, �HŽR�Lˆê, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. ƒqƒg”x‚ª‚ñ‘½‘ŸŠí“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚éMacrophage Stimulationg Protein‚Ì–ðŠ„‚ÉŠÖ‚·‚錟“¢.�@‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï. �ɪ. 2011”N6ŒŽ30“ú.

Œã“Œ‹vŽk, ƒAƒfƒ‹ ƒKƒuƒ‹, �û•£�¹‹B, ‘q–{‘ì�Æ, Š`“à‘�Ži, �²“¡�³‘å, “c”¨�Ë, ƒeƒoƒ“ ƒ`ƒ…ƒ“, �¬�씎‹v, �HŽR�Lˆê, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. ƒqƒg”xŠà“]ˆÚƒ‚ƒfƒ‹‚É‚¨‚¯‚éerlotinib‚Ì�hŽå‰î�Ý�«�RŽîᇌø‰Ê‚ÌŒŸ“¢. ‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï. �ɪ. 2011”N6ŒŽ30“ú.

ŽO‹´“ÕŽu, Œã“Œ‹vŽk, ‘q–{‘ì�Æ, Š`“à‘�Ži, �²“¡�³‘å, ƒeƒoƒ“ ƒ`ƒ…ƒ“, �¼žŠ“Ö˜Y, “c”¨�Ë, �HŽR�Lˆê, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. ”xƒT�[ƒtƒ@ƒNƒ^ƒ“ƒg’`”’SP-A‚Ì”xŠà�i“W‚É‚¨‚¯‚é‹@”\‰ð�Í.�@‘æ20‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠw�p�W‰ï. �ɪ. 2011”N6ŒŽ30“ú.

�²“¡�³‘å,�@�¼‰ªˆÀ•F, ‘]�ªŽO˜Y, ‘å’J’¼Žq. ‚ª‚ñƒ}ƒCƒNƒ�RNAƒNƒ‰ƒXƒ^�[Mir17-92”­Œ»‚Ì�¶‘Ì“àƒCƒ��[ƒWƒ“ƒO‚Æ‚ª‚ñŽ¡—Âւ̉ž—p.�@‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. “Œ‹ž. 2011”N6ŒŽ24“ú.

�¼‰ªˆÀ•F, ˆ¢•”�^Ž¡, ‰Á“¡�K�¬, –Ø�h�¹�r, �ì“Y˜a‹`, ‰©�r, �û•£�¹‹B, �…Œû˜a•v, ‘]�ªŽO˜Y. �Rƒ|ƒhƒvƒ‰ƒjƒ“�R‘ÌNZ-1‚̈«�«‹¹–Œ’†”çŽî‚ɑ΂·‚é�R‘̈ˑ¶�«�×–E�áŠQŠˆ�«‚Æ�RŽîᇌø‰Ê.�@‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. “Œ‹ž. 2011”N6ŒŽ24“ú.

ƒŒ ƒ^ƒ“ ƒ_�[, �¼”ö‘×—C, Œã“Œ‹vŽk, Š`“à‘�Ži, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, •Ћ˖L‰ë. ”xŠà‚Ì�œ“]ˆÚ‚ð�§Œä‚·‚é�V‚½‚È“]ŽÊˆöŽq‚Ì“¯’è‚Æ‚»‚Ì‹@”\‰ð�Í. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. “Œ‹ž. 2011”N6ŒŽ24“ú.

“c”¨�Ë, ŽR–{‰ë’B, ’r“c—´“ñ, ŒÃ�ì—´•F, ‘q–{‘ì�Æ, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y, �HŽR�Lˆê. ƒ`ƒ~ƒWƒ“ƒzƒXƒzƒŠƒ‰�[ƒ[‚É‚æ‚Á‚ă`ƒ~ƒWƒ“‚©‚ç”h�¶‚µ‚½“œ‚̉𓜌n‚ւ̈Ú�s. ‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. “Œ‹ž. 2011”N6ŒŽ23“ú.

ƒoƒ“ ƒe ƒ`ƒ…ƒ“, �û•£�¹‹B, Œã“Œ‹vŽk, Š`“à‘�Ži, ‘q–{‘ì�Æ�@ƒŒ ƒ^ƒ“ ƒ_�[, –î–ì�¹“ñ, �HŽR�Lˆê, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. ŒŒŠÇ�V�¶‘jŠQ�ÜTSU-68‚̈«�«‹¹–Œ’†”çŽî“¯�ŠˆÚ�Aƒ‚ƒfƒ‹‚É‚¨‚¯‚é�RŽîᇌø‰Ê‚ÌŒŸ“¢.‘æ15‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠw�p�W‰ï. “Œ‹ž. 2011”N6ŒŽ23“ú.

Œá�ȉë•F, –{ŸÄ�WŽj, Žè’Ë•qŽj, �¬�씎‹v, •Ä“c˜a•v, —t‹v‹MŽi, �™“c–¾”ü, –©‹`�², �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. “¿“‡Œ§‚É‚¨‚¯‚é‹CŠÇŽxšb‘§Š³ŽÒ‚̃Rƒ“ƒgƒ��[ƒ‹‚ÉŠÖ‚·‚éŽÀ‘Ô’²�¸‘æ2•ñ. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM�[Šw‰ï�t‹G—Õ�°‘å‰ï. �ç—t. 2011”N5ŒŽ14“ú.

’|�è�²•v, “Œ“�‘ã, –؉º�Ÿ�O, Œã“Œ‹vŽk, ‘½“c�_–ç, Œá�ȉë•F, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. “–‰@‚É‚¨‚¯‚é–��«‰óŽ€�«”xƒAƒXƒyƒ‹ƒMƒ‹ƒX�ǂɑ΂·‚éƒAƒ€ƒrƒ]�[ƒ€‚ÌŽg—pŒoŒ±. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2011”N4ŒŽ24“ú.

“Œ“�‘ã, �¼‰ªˆÀ•F, Mohammed Elmorshedy Reham, ŠÝ��, ŠÝ�¹”ü, –؉º�Ÿ�O, ’|�è�²•v, Jun Huang, �㌴‹v“T, �òŒ[‰î, �HŽR�Lˆê, ‘]�ªŽO˜Y. ”x�üˆÛ�ǂɂ¨‚¯‚éƒXƒtƒBƒ“ƒSƒVƒ“-1-ƒŠƒ“Ž_ƒVƒOƒiƒ‹‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2011”N4ŒŽ23“ú.

Žè’Ë•qŽj, �¬�씎‹v, Œá�ȉë•F, –{�ò�WŽj, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ì�RŒ´Š´�ì‚É‚¨‚¯‚éIKKƒÀ-NF-ƒÈBŒo˜H‚̉e‹¿‚ɂ‚¢‚Ä. ‘æ51‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠw�p�u‰‰‰ï. “Œ‹ž. 2011”N4ŒŽ22“ú.
�yŠw‰ï”­•\-�‘“à’n•ûŠw‰ï�z
‰ªú±�O‘×, –L“c—DŽq, ŠÝ��, ‰Í–ì�O, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, Œá�ȉë•F, �å”ü‰À, �¼‰ªˆÀ•F. ‘g�D�f’f‚ª“¾‚ç‚ꂽŠÌƒTƒ‹ƒRƒCƒh�[ƒVƒX‚Ì2�Ç—á. ‘æ22‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï’†�‘�EŽl�‘Žx•”Šw�p�W‰ï. �¼ŽR. 2011”N12ŒŽ10“ú.

‘å’ËŒ›Ži, –L“c—DŽq, Š`“à‘�Ži, Œã“Œ‹vŽk, �û•£�¹‹B, Œá�ȉë•F, �¼‰ªˆÀ•F, ŠÄú±�Fˆê˜Y, •Ÿ�X’mŽ¡, �Ⓦ—Ç”ü. ‘½”­Œ‹�߉e‚ð’æ‚µ‚½Langerhans cell histiocytosis‚Ì1—á. ‘æ105‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2011”N11ŒŽ6“ú.

‹ß“¡�^‘ã, ‰Í–ì�O, Š`“à‘�Ži, ŠÝ��, �û•£�¹‹B, Œá�ȉë•F, ‹ß“¡ŠG—¢, �‡“c�³˜a, �Ίے¼�Ÿ, �¼‰ªˆÀ•F. IgG4ŠÖ˜A‰º�‚‘Ì‰Š‚Ì1—á. ‘æ105‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚�¼. 2011”N11ŒŽ6“ú.

�‚‹´’¼Šó, ”ò”~—º, Žè’Ë•qŽj, –L“c—DŽq, “Œ“�‘ã, Œã“Œ‹vŽk, Š`“à‘�Ži, ŠÝ��, �–ì�ƒ“T, �û•£�¹‹B, Œá�ȉë•F, ‘]�ªŽO˜Y, �¼‰ªˆÀ•F, �‚‹´”ü‹IŽq, •Ÿ“c—I. ŠÔŽ¿�«”x‰Š‚Ì�¸�¸‚É‚æ‚è�f’f‚³‚ꂽIgG4ŠÖ˜A޾г‚Ì1—á. ‘æ46‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‘q•~. 2011”N7ŒŽ16“ú.

���¼”Ž”V, –L“c—DŽq, Š`“à‘�Ži, ’|ú±�²•v, ŠÝ�¹”ü, ‘å’ËŒ›Ži, Žè’Ë•qŽj, Œã“Œ‹vŽk, �û•£�¹‹B, Œá�ȉë•F, �¼‰ªˆÀ•F. ‹C‹¹‚ð�‡•¹‚µ‚½”xŠà10—á‚ɂ‚¢‚Ă̌Ÿ“¢. ‘æ50‰ñ“ú–{”xŠàŠw‰ï’†�‘�EŽl�‘Žx•”‰ï. ‘q•~. 2011”N7ŒŽ15“ú.

“c‰ª—²�¬, ŠÝ�¹”ü, ’|ú±�²•v, –؉º�Ÿ�O, –L“c—DŽq, Š`“à‘�Ži, �û•£�¹‹B, ˆäú±”Ž•¶, �‚‹´�³�K, •Ÿ�X’mŽ¡, ‹àŽR”Ž�b, �¼‰ªˆÀ•F. “–‰@‚É‚¨‚¯‚émTOR‘jŠQ–ò“Š—^гŽÒ‚É”­�Ç‚µ‚½ŠÔŽ¿�«”x‰Š‚Ì—Õ�°“IŒŸ“¢. ‘æ46‰ñ“ú–{ŒÄ‹zŠíŠw‰ï’†�‘�EŽl�‘’n•û‰ï. ‘q•~. 2011”N7ŒŽ15“ú.

‘¾“c—�ŠG, Šâ�£�r, ‹v‰ª”’—z‰Ô, ŽR“c”Žˆû, �¼‰ªˆÀ•F, �‚”ö�³ˆê˜Y, �Ⓦ�²’mŽq, ”\�¨”¹�l, “í�£Œ«–ç, �m–Ø•q”V, •y“c‹IŽq, �ã“c—R‰À, ŽRŒû�_Ži, ’|’J‘P—Y, “Y–Ø•�, Žá’ΓNŽO, �Ô’r‰ëŽj, ‘]�ªŽO˜Y, �²“c�­—². �SŽºŒÅ—L’²—¥‚ª�S•a•Ï�f’f‚Ì‚«‚Á‚©‚¯‚ƂȂÁ‚½ƒTƒ‹ƒRƒCƒh�[ƒVƒX‚Ì1—á. ‘æ98“ú–{�zŠÂŠíŠw‰ï ’†�‘�EŽl�‘�‡“¯’n•û‰ï. “¿“‡. 2011”N5ŒŽ13“ú.

ˆÀ�Ï–ƒˆß, Šâ�£�r, �m–Ø•q”V, Žá’ΓNŽO, �²“c�­—², �Ô’r‰ëŽj, �‚”ö�³ˆê˜Y, Œ´“c‰ëŽj, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. Šá, ”x, ‹Ø•a•ςɑ±‚¢‚ÄŒo‰ß’†‚É�V•a•ς̌°�݉»‚ð”F‚ß‚½ƒTƒ‹ƒRƒCƒh�[ƒVƒX‚̈ê—á. ‘æ104‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2011”N5ŒŽ8“ú.

–؉º�Ÿ�O, �²“¡�³‘å, Œã“Œ‹vŽk, Š`“à‘�Ži, �û•£�¹‹B, Œá�ȉë•F, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. ƒxƒoƒVƒYƒ}ƒu‚ª‘tŒ÷‚µ‚½”ñ�¬�×–E”xŠà‚Ì2�Ç—á. ‘æ104‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2011”N5ŒŽ8“ú.

ŠÝ�¹”ü, �¼‰ªˆÀ•F, –L“c—DŽq, ŠÝ��, Œã“Œ‹vŽk, Œá�ȉë•F, ‘]�ªŽO˜Y. �R�b�ó‘B–ò•ž—p’†‚ÉMPO-ANCAŠÖ˜AŒŒŠÇ‰Š�ÇŒóŒQ‚ð”­�Ç‚µ‚½2—á. ‘æ104‰ñ“ú–{“à‰ÈŠw‰ïŽl�‘’n•û‰ï. �‚’m. 2011”N5ŒŽ8“ú.

�m–Ø�¹“¿, �¼žŠ“Ö˜Y, Œã“Œ‹vŽk, –{ŸÄ�WŽj, –؉º�Ÿ�O, “Œ“�‘ã, ‘½“c�_–ç, Œá�ȉë•F, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. Clarithromycin�AAmikacin�AImipenem/cilastatin�AMoxifloxacin‚Ì•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚½”xMycobacterium abscessusŠ´�õ�Ç‚Ì1—á. ‘æ19‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �V‹�•l. 2011”N1ŒŽ22“ú.

”ò”~—º, �²“¡�³‘å, –L“c—DŽq, Œã“Œ‹vŽk, ‘½“c�_–ç, �¼‰ªˆÀ•F, ‘]�ªŽO˜Y. ˆÙ‚È‚éEGFRˆâ“`Žq•ψقð—L‚·‚鑽”­”x‘BŠà‚̈ê—á. ‘æ19‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ï’†�‘Žl�‘Žx•”‰ï. �V‹�•l. 2011”N1ŒŽ22“ú.
“¿“‡‘åŠw‘åŠw‰@ˆãŽ•–òŠwŒ¤‹†•”ŒÄ‹zŠí�EäPŒ´•a“à‰ÈŠw•ª–ì
�§770-8503“¿“‡Œ§“¿“‡Žs‘ –{’¬‚R’š–Ú‚P‚W”Ô’n‚Ì‚P‚T
TEL:088-633-7127�@FAX:088-633-2134
Copyright Department of Respiratory Medicine and Rheumatology
Graduate School of Biomedical Sciences
Tokushima University